introduct
next
clinic
import
mycobacterium
tuberculosi
complex
mtc
nontuberculosi
mycobacteria
ntm
pathogen
especi
immunocompromis
senior
peopl
speci
identif
import
diagnosi
optim
treatment
malditof
identif
mycobacterium
strain
hamper
low
qualiti
acquir
mass
spectra
sampl
process
standard
procedur
therefor
new
prepar
method
mycobacteria
establish
influenc
addit
preced
heat
inactiv
step
evalu
method
mycobacterium
strain
prepar
use
standard
ethanolform
acid
extract
procedur
new
establish
mycobacteria
bead
prepar
protocol
test
addit
strain
extend
protocol
name
inactiv
mycobacteria
bead
prepar
method
test
strain
mass
spectra
record
microflex
lt
malditof
mass
spectromet
identif
done
appli
maldi
biotyp
softwar
bruker
daltonik
germani
result
mycobacterium
spp
strain
test
data
shown
strain
hard
analys
malditof
therefor
select
studi
consequ
standard
ethanolform
acid
extract
procedur
fail
acquir
mass
spectra
strain
signific
improv
qualiti
mass
spectra
achiev
use
mycobacteria
bead
prepar
method
glass
bead
cell
suspens
disrupt
mycobacterium
strain
result
good
qualiti
mass
spectra
three
one
averag
qualiti
addit
mycobacterium
strain
process
accord
new
protocol
result
good
qualiti
spectra
addit
heat
inactiv
step
introduc
safeti
reason
mass
spectra
mycobacterium
spp
strain
process
mycobacteria
bead
prepar
method
without
heat
inactiv
step
compar
mass
spectra
reveal
minor
differ
higher
peak
intens
obtain
gener
heat
inactiv
procedur
conclus
fast
secur
easi
perform
method
develop
mycobacteri
protein
extract
extract
highli
access
malditof
analysi
good
qualiti
mass
spectra
precondit
identif
mycobacteria
techniqu
new
prepar
method
success
test
differ
strain
repres
speci
supplement
heat
inactiv
step
introduc
minim
hazard
handl
live
mtc
cell
main
mechan
bacteri
resist
antibiot
expressionoverexpress
destroy
ring
antibiot
hydrolysi
reaction
result
mass
shift
plu
da
easili
detect
mass
spectrometri
rapid
malditof
ms
base
assay
set
detect
resist
bacteria
blood
cultur
method
blood
cultur
bottl
inocul
differ
e
coli
klebsiella
pneumonia
strain
incub
indic
posit
subsequ
ml
fresh
posit
blood
cultur
process
accord
slightli
modifi
protocol
maldi
sepsityp
kit
wash
step
repeat
subsequ
bacteria
incub
correspond
antibiot
solut
h
agit
ampicillin
test
e
coli
strain
ertapenem
test
klebsiella
pneumonia
strain
incub
bacteria
correspond
antibiot
subsequ
centrifug
supernat
directli
appli
maldi
sampl
carrier
dri
spot
overlaid
maldi
matrix
hcca
malditof
ms
spectra
acquir
microflex
lt
benchtop
mass
spectromet
inhibit
hydrolysi
perform
presenc
respect
inhibitor
result
ms
spectrum
correspond
reveal
molecular
peak
ampicillin
da
respect
sodium
adduct
spectra
deriv
produc
strain
show
peak
da
correspond
hydrolyz
form
sodium
adduct
hydrolyz
decarboxyl
form
ampicillin
respect
slight
spontan
hydrolysi
also
observ
spectra
success
inhibit
ampicillin
hydrolysi
demonstr
incub
presenc
calvulan
acid
incub
ertapenem
klebsiella
pneumonia
strain
reveal
clear
differ
carbapenem
sensit
strain
carbapenamas
posit
strain
carbapenem
sensit
strain
molecular
peak
ertapenem
mh
da
clearli
detect
incub
ertapenem
carbapenemas
posit
strain
result
disappear
molecular
peak
ertapenem
contrast
ampicillin
hydrolyz
form
ertapenem
instabl
immedi
broke
therefor
decreas
molecular
peak
ertapenem
employ
indic
resist
carbapenem
moment
addit
peak
appear
spectra
carbapenemas
posit
strain
directli
correspond
hydrolyz
form
ertapenem
identifi
far
discuss
develop
approach
provid
rapid
method
detect
betalactamas
activ
bacteria
within
less
h
posit
blood
cultur
object
purpos
studi
investig
genotyp
distribut
maltophilia
isol
patient
cystic
fibrosi
cf
repetit
sequencebas
pcr
reppcr
use
diversilab
system
method
sputum
sampl
cf
patient
inocul
onto
select
medium
improv
isol
maltophilia
period
two
year
suspect
isol
identifi
convent
standard
method
well
sequenc
total
maltophilia
isol
cf
patient
detect
genotyp
dna
extract
perform
ultracleantm
microbi
dna
isol
kit
mo
bio
laboratori
carlsbad
ca
usa
accord
instruct
diversilab
bacteri
dna
fingerprint
kit
marci
franc
use
type
follow
protocol
manufactur
related
determin
cluster
analysi
use
correl
coeffici
isol
similar
consid
clinic
relat
isol
similar
consid
indistinguish
result
reppcr
demonstr
maltophilia
isol
cf
patient
exhibit
high
rate
genet
divers
small
proport
isol
clonal
relat
suggest
either
crosstransmiss
common
sourc
exposur
conclus
maltophilia
cf
patient
show
wide
variat
molecular
profil
epidemiolog
studi
sourc
track
requir
elucid
rout
colonizationinfect
cf
patient
object
studi
determin
whether
photochem
inactiv
virus
could
accomplish
high
effici
preserv
molecular
integr
viral
target
allow
subsequ
diagnost
test
perform
lower
level
contain
cost
studi
effect
either
ina
amotosalen
amo
also
known
known
target
either
viral
protein
viral
nucleic
acid
found
vaccinia
viru
vacv
orthopox
viru
dna
genom
pixuna
viru
pixv
alphaviru
rna
genom
stabl
irradi
uva
alon
expos
either
ina
amo
dark
amo
follow
uva
exposur
least
onethousandfold
virucid
inauva
vacv
pixv
treat
similar
condit
photoinactiv
either
ina
amo
condit
abolish
viral
infect
result
minim
impair
subsequ
elisa
pcr
test
present
data
could
assist
develop
method
inactiv
field
environment
forens
sampl
suspect
contamin
high
virul
viru
thu
limit
need
costli
secur
safeti
oper
accident
intent
viral
releas
system
symptom
diphtheria
caus
toxencod
diphtheria
toxin
dt
produc
toxigen
corynebacterium
spp
recent
year
emerg
zoonot
pathogen
c
ulceran
replac
c
diphtheria
major
agent
diphtheria
sever
industri
western
countri
reliabl
detect
toxigen
corynebacterium
spp
substanti
diphtheria
surveil
public
health
sector
clinic
workup
patient
diphtherialik
symptom
sinc
respect
tox
gene
c
diphtheria
c
ulceran
differ
dna
amino
acid
sequenc
tox
gene
cover
novel
realtim
pcr
method
describ
develop
valid
lightcycl
pcr
assay
reliabl
recogn
tox
gene
c
diphtheria
c
ulceran
differenti
respect
target
gene
fluoresc
reson
energi
transfer
fret
hybrid
probe
melt
curv
analysi
background
detect
enterobacteriacea
carri
carbapenemas
challeng
sinc
mic
suscept
rang
differenti
carbapenem
resist
due
carbapenemas
mechan
possibl
routin
suscept
test
method
enterobacteriacea
elev
carbapenem
mic
sent
german
nation
refer
laboratori
multidrugresist
gramneg
bacteria
studi
strain
use
carbapenemas
exclud
bioassay
base
cellfre
extract
specif
pcr
addit
strain
carbapenemas
character
sequenc
studi
strain
mic
carbapenem
determin
etest
modifi
hodgetest
mht
perform
differ
media
combin
disk
test
edta
boron
acid
perform
result
collect
compris
k
pneumonia
n
e
coli
n
e
cloaca
n
e
aerogen
n
enterobacteriacea
speci
strain
n
n
n
n
n
n
n
n
n
includedth
sensit
mht
muellerhinton
agar
oxoid
imipenem
meropenem
ertapenem
respect
wherea
specif
subgroup
metallobetalactamas
n
mht
perform
four
differ
agar
media
lowest
sensit
mht
meropenem
perform
mh
agar
merck
addit
mm
zinc
disk
increas
sensit
sensit
mbl
etest
wherea
combin
disk
test
edta
sensit
conclus
contrast
recommend
clsi
mht
also
perform
imipenem
despit
lower
specif
import
carbapenemas
detect
justifi
higher
sensit
caution
use
choos
test
media
sinc
huge
differ
metallobetalactamas
detect
seen
due
better
sensit
combin
disk
test
edta
substitut
mbl
etest
enterobacteriacea
introduct
urinari
tract
infect
uti
common
nosocomi
infect
worldwid
standard
procedur
identif
uropathogen
base
cultiv
agar
plate
subsequ
biochem
differenti
eg
etc
often
requir
one
day
initi
antibiot
treatment
nonspecif
speci
develop
protocol
fast
min
direct
identif
speci
pathogen
urin
sampl
base
matrixassist
laser
desorptionion
time
flight
mass
spectrometri
malditofm
method
analys
urin
sampl
inpati
sent
institut
medic
microbiolog
routin
diagnost
separ
uropathogen
sediment
consist
leucocyt
erythrocyt
cell
detritu
protein
cylind
centrifug
filtrat
protocol
filter
residu
eluat
transfer
onto
spot
metal
plate
inactiv
acid
organ
matrix
protein
spectra
acquir
malditofmass
spectromet
str
appliedbiosystem
identif
spectra
compar
databas
anagnostec
whole
process
complet
within
minut
result
direct
identif
uropathogen
alreadi
success
unidentifi
sampl
intens
peak
triplet
occur
correspond
human
alphadefensin
interf
factor
mz
valu
around
da
protein
produc
natur
bodi
remov
simpli
wash
filter
residu
close
interact
bacteri
membran
therefor
improv
protocol
purif
separ
bacteria
tick
differ
pathogen
found
may
caus
seriou
infect
human
domest
anim
reliabl
detect
pathogen
pcr
isol
nucleic
acid
one
import
prerequisit
influenc
whole
diagnost
procedur
therefor
optim
protocol
dna
isol
tick
requir
sinc
question
regard
optim
dna
extract
tick
poorli
address
far
present
studi
compar
differ
method
isol
dna
tick
materi
method
four
differ
method
dna
extract
fieldcollect
unf
tick
compar
dnaquantif
experi
done
nanodropspectromet
quantit
pcr
measur
tick
betaactin
experi
dna
isol
singl
homogen
nymph
per
method
highsalt
dna
isol
protocol
peqlab
germani
b
magbead
dna
extract
protocol
carlroth
germani
c
columnbas
dna
extract
protocol
peqlab
germani
modifi
tripureisol
protocol
peqlab
germani
experi
ac
done
accord
manufactur
instruct
experi
best
dna
extract
method
experi
use
addit
enrich
dna
singl
nymph
per
treatment
use
pretreat
e
liquid
nitrogen
f
without
pretreat
prior
dna
isol
experiment
run
combin
differ
addit
step
proteinas
k
treatment
prior
experi
e
f
base
differ
treatment
durat
final
best
method
experi
use
dnaisol
adult
tick
comparison
method
ac
result
experi
highest
dnayield
obtain
modifi
tripur
dna
isol
protocol
time
higher
dnaamount
p
experi
pretreat
proteinas
k
overnight
combin
addit
liquid
nitrogen
treatment
show
highest
dna
recoveri
p
final
find
transfer
dna
isol
result
adult
tick
p
fig
discuss
detect
differ
pathogen
tick
reliabl
repeat
method
dnaisol
import
prerequisit
experi
clearli
show
signific
differ
perform
variou
dna
extract
method
appli
tick
furthermor
modif
clearli
enhanc
quantiti
isol
dna
use
optim
method
studi
new
qualit
quantit
pcr
way
measur
amount
borrelia
singl
tick
germani
lactamasesproduc
esbl
enterobacteriacea
show
resist
variou
lactamantibiot
like
penicillin
cephalosporin
aztreonam
minim
inhibitori
concentr
mic
strain
increas
standard
clsibreakpoint
confirmatori
test
requir
studi
compar
esblscreenig
result
micdetermin
disk
diffus
confirmatori
test
growth
onto
chromogen
esbldetect
agar
program
e
coli
diseas
fooddeliv
companion
anim
collect
mic
determin
broth
microdilut
lactamantibiot
penicillin
g
cefotaxim
cefoperazon
cefquinom
ceftiofur
disk
diffus
confirmatori
test
esbl
ceftazidin
ceftazidineclavulan
acid
cefotaxim
cefotaximeclavulan
acid
perform
accord
clsi
document
brillianc
esbl
chromogen
agar
oxoid
appli
correspond
manufactur
construct
esblsuspici
strain
verifi
detect
blactxm
blaoxa
blatem
blashvgen
result
broth
microdilut
test
e
coli
exhibit
mic
valu
mgl
cefotaxim
clsi
esblscreen
concentr
simultan
perform
disk
diffus
test
screen
onto
chromogen
agar
result
esblsuspici
strain
respect
pcr
esblposit
e
coli
could
confirm
strain
character
mic
valu
mgl
cefotaxim
increas
zone
diamet
disk
diffus
esbl
confirmatori
test
blue
growth
onto
chromogen
esbldetect
agar
conclus
overal
disk
diffus
esbl
confirmatori
test
well
chromogen
esbldetect
agar
suitabl
detect
esblposit
e
coli
test
show
sensit
chromogen
agar
result
specif
wherea
disk
diffus
test
one
falseposit
strain
detect
howev
use
disk
diffus
test
often
staffand
timeintens
background
enterobacteriacea
resist
carbapenem
grow
problem
increas
number
countri
worldwid
germani
carbapenemas
resist
still
rare
appear
rise
sever
hospit
outbreak
describ
mani
infect
carbapenem
resist
strain
acquir
abroad
special
precaut
undertaken
control
infect
local
spread
rapid
isol
type
cornerston
infect
control
outbreak
descript
result
institut
carbapenemas
produc
enterobacteriacea
isol
previous
januari
russian
patient
admit
screen
multiresist
microorgan
reveal
colon
klebsiella
pneumonia
strain
increas
mic
imipenem
meropenem
carbapenemas
product
demonstr
modifi
hodg
test
confirm
genotyp
type
carbapenemas
subsequ
four
addit
patient
found
colon
k
pneumonia
strain
ident
resist
pattern
later
produc
suspect
transmiss
occur
time
span
admiss
initi
infect
control
measur
index
patient
random
pcr
rapd
attempt
prove
clonal
origin
isol
yet
case
k
pneumonia
isol
method
discrimin
altern
rapid
type
malditof
spectra
isol
compar
yield
excel
spectrum
ident
outbreak
strain
good
discrimin
toward
unrel
isol
yet
autom
calcul
dendrogram
biotyp
softwar
applic
intraspeci
differenti
result
subsequ
confirm
pulsedfield
gel
electrophoresi
pfge
conclus
conjunct
instead
rapid
type
method
eg
rapd
diagnost
use
malditof
spectra
may
help
preliminari
epidemiolog
analysi
clinic
outbreak
within
hour
valu
limit
method
need
valid
differ
microorgan
standard
procedur
eg
pfge
mlst
yet
eas
applic
low
run
cost
make
mass
spectra
analysi
promis
tool
first
line
clinic
outbreak
analysi
mycoplasma
pneumonia
mp
third
frequent
pathogen
respons
communityacquir
pneumonia
cap
infect
preval
children
young
adult
show
epidem
peak
everi
year
mp
infect
often
diagnos
pcr
mainli
serolog
clinic
routin
laboratori
studi
evalu
recombin
mpspecif
protein
develop
serolog
lineimmunoassay
line
seven
protein
prove
use
detect
specif
igg
iga
igm
antibodi
addit
iprotein
human
erythrocyt
autoantigen
induc
cold
agglutinin
igmtyp
acut
mp
infect
includ
furthermor
integr
genotypespecif
conserv
region
main
adhesin
enabl
us
differenti
infect
two
common
mp
subtyp
estim
preval
specif
igg
establish
line
test
sera
sera
possibl
mp
infect
blood
donor
bordetella
pertussi
legionella
pneumophila
posit
sera
sera
patient
acut
nonrespiratori
infect
sera
children
sera
pretest
elisa
western
blot
use
whole
mp
antigen
prepar
line
compar
consensu
result
elisa
western
blot
follow
sensit
specif
found
igg
iga
igm
addit
determin
mpspecif
iggpreval
sera
panel
posit
pcr
result
refer
test
confirm
mp
infect
well
establish
therefor
analys
sera
network
communityacquir
pneumonia
capnet
posit
mp
pcr
result
correspond
respiratori
specimen
furthermor
sera
mp
pcrneg
healthi
person
sera
patient
suffer
cap
caus
agent
mp
analys
sensit
specif
refer
pcr
result
line
achiev
sensit
igg
iga
igm
respect
accumul
result
iga
igm
igg
iga
igm
sensit
obtain
result
demonstr
practic
use
new
line
blot
base
select
protein
highli
specif
sensit
tool
serodiagnosi
mp
infect
bittner
kd
j
buer
aw
rettenmei
f
mosel
essen
institut
hygien
und
arbeitsmedizin
essen
deutschland
essen
institut
medizinisch
mikrobiologi
essen
deutschland
background
standard
procedur
identif
bacteria
base
detect
distinct
metabol
properti
biochem
test
system
api
vitek
addit
ga
chromatograph
determin
speciesspecif
pattern
longchain
fatti
acid
use
laboratori
bacteria
isol
tissu
fluid
patient
antibiot
treatment
specif
viscou
bronchial
mucu
respiratori
tract
patient
cystic
fibrosi
often
chang
characterist
metabol
properti
therefor
elud
identif
convent
procedur
examin
whether
analysi
bacteri
protein
pattern
malditofm
matrixassist
laser
desorptionion
time
flight
mass
spectrometri
result
unequivoc
identif
case
method
isol
obtain
tissu
fluid
patient
clinic
routin
could
unambigu
identifi
api
vitek
ga
chromatographi
respect
analyz
malditofm
small
number
bacteri
cell
cultur
plate
directli
deposit
onto
sampl
plate
bacteria
inactiv
intracellular
mostli
ribosom
protein
liber
exposur
acid
use
organ
matrix
spectra
protein
compar
entri
databas
sarami
anagnostec
germani
whole
process
sampl
prepar
measur
databas
match
take
minut
result
use
malditofm
analysi
could
identifi
nearli
isol
previous
given
clear
result
standard
identif
procedur
appli
case
bacteria
could
identifi
speci
level
case
genu
level
dna
adult
tick
per
treatment
isol
differ
extract
protocol
highsalt
dna
isol
protocol
b
magbead
dna
extract
protocol
c
columnbas
dna
extract
protocol
modifi
tripureisol
protocol
rapid
detect
toxin
produc
clostridium
difficil
essenti
cdad
patient
studi
compar
perform
new
pcr
assay
bd
genohm
cdiff
assay
convent
elisa
ridascreen
c
difficil
toxin
ab
rapid
detect
toxinproduc
c
difficil
strain
directli
stool
stool
sampl
obtain
patient
suspect
cdad
singl
centr
analys
realtim
pcr
elisa
sampl
accord
criteria
diarrheal
stool
bristol
score
elig
studi
anaerob
cultur
also
perform
agar
studi
approv
institut
review
board
use
elisa
analyt
gold
standard
pcr
yield
concord
posit
result
concord
neg
result
stool
sampl
assay
show
discrep
result
includ
cultur
result
discrep
analysi
pcr
result
true
posit
true
neg
one
fals
posit
fals
neg
pcr
test
observ
yield
analyt
sensit
specif
respect
compar
elisa
posit
neg
predict
valu
pcr
test
respect
although
studi
deal
cost
effect
pcr
manag
cdad
patient
spars
bd
genohm
cdiff
assay
pcr
greater
analyt
sensit
convent
toxin
elisa
maintain
compar
specif
sampl
cada
patient
halfmann
u
geipel
l
von
herrmann
univers
hospit
saarland
institut
medic
microbiolog
hygien
homburg
deutschland
background
univers
screen
methicillinresist
staphylococcu
aureu
mrsa
valuabl
tool
estim
mrsa
preval
yet
singl
institut
laboratori
challeng
larg
campaign
requir
qualityassur
handl
process
sampl
enorm
twomonth
univers
mrsa
admiss
preval
screen
project
sampl
need
analyz
reduc
manual
burden
process
addit
specimen
workdaili
walk
away
specimen
processor
wasp
copan
itali
fulli
autom
robotbas
instrument
manag
step
tube
handl
vortex
medium
inocul
plate
label
use
report
experi
use
wasp
set
parallel
use
process
routin
sampl
method
sampl
collect
eswab
copan
mrsa
project
modifi
eswab
system
consist
two
flock
collect
swab
throat
nare
respect
one
liquid
ami
mediumcontain
tube
use
sampl
inocul
chromogen
aureu
mrsa
biplat
mast
germani
incub
read
routin
sampl
like
urin
process
accord
standard
procedur
use
differ
univers
select
media
plate
result
initi
pilot
phase
mrsa
screen
sampl
plate
parallel
wasp
manual
initi
import
differ
recoveri
rate
method
appear
manual
inocul
plate
yield
ten
time
elev
coloni
count
compar
parallel
plate
inocul
wasp
subsequ
sever
modif
wasp
specimen
process
protocol
variou
vortex
time
quantiti
medium
plate
streak
pattern
carri
support
readili
avail
wasp
technic
team
onlin
onsit
specif
optim
streak
pattern
found
crucial
optim
coloni
count
optim
wasp
protocol
addit
test
specimen
process
either
wasp
manual
reveal
even
low
coloni
number
sensit
wasp
compar
manual
plate
readili
achiev
wasp
connect
li
mlab
dorner
germani
allow
process
varieti
differ
sampl
type
time
basi
fast
reliabl
work
flow
streak
qualiti
yield
singl
coloni
consist
high
qualiti
especi
urin
use
one
quadrant
streak
pattern
allow
easi
fast
semiquantit
estim
coloni
count
show
fir
tree
like
growth
pattern
agar
plate
conclus
integr
wasp
laboratori
procedur
larg
univers
screen
program
process
routin
sampl
allow
consider
reduct
manual
workload
qualityconform
specimen
process
fals
posit
candida
cryptococc
antigen
detect
serum
result
cross
reactiv
differ
therapeut
iv
solut
epstein
barr
viru
ebv
viru
herp
famili
one
common
virus
human
peopl
becom
infect
ebv
earli
age
often
asymptomat
may
caus
infecti
mononucleosi
symptom
infecti
mononucleosi
fever
sore
throat
swollen
lymph
gland
although
symptom
infecti
mononucleosi
usual
resolv
month
ebv
dormant
latent
cell
throat
blood
life
period
viru
reactiv
commonli
found
saliva
infect
individu
reactiv
usual
occur
without
symptom
ill
novel
recomwel
ebv
test
system
combin
confirmatori
assay
recomlin
ebv
igg
avid
igm
effect
tool
comprehens
ebv
serodiagnost
system
base
four
separ
elisa
enzym
link
immunosorb
assay
recomwel
ebv
ebna
igg
recomwel
ebv
vca
igg
recomwel
ebv
ea
igg
recomwel
ebv
igm
standard
concept
design
eia
test
kit
enabl
implement
assay
use
singl
sampl
dilut
standard
incub
time
system
perform
evalu
four
sampl
collect
healthi
blood
donor
ebv
seroneg
sampl
und
sampl
repres
acut
subsid
ebv
infect
assay
character
high
specif
sensit
compar
commerci
avail
ebv
eia
test
system
recomwel
ebv
test
show
consider
advantag
compar
assay
test
primari
ebv
infect
detect
earli
phase
infect
due
high
sensit
recomwel
ebv
vca
igg
recomwel
ebv
ea
igg
ebv
igm
assay
addit
due
high
specif
recomwel
ebna
igg
assay
fals
posit
antiebna
igg
find
among
acut
infect
utterli
exclud
high
specif
anti
ebna
igg
assay
import
aspect
ebv
diagnost
different
primari
recent
infect
subsid
past
infect
primarili
achiev
detect
anti
ebna
igg
antibodi
screen
measur
avid
igg
antibodi
confirm
final
result
obtain
compar
recent
publish
evalu
studi
four
commerci
system
diagnost
ebv
primari
infect
de
ori
et
al
clinic
vaccin
immunolog
evalu
four
commerci
system
diagnosi
epstein
barr
viru
primari
infect
sever
studi
publish
claim
identifi
oxacillin
resist
staphylococcu
aureu
whole
cell
matrix
assist
laser
desorpt
time
flight
malditof
mass
spectrometri
studi
select
methicillin
suscept
aureu
isol
compar
select
methicillin
resist
aureu
mrsa
isol
nevertheless
studi
design
studi
suitabl
achiev
goal
mecasccmec
isogen
strain
could
discrimin
strain
specificand
meca
sccmecdepend
peak
variat
also
describ
strain
specif
peak
exist
within
speci
aureu
identifi
studi
mecasccmec
isogen
strain
aureu
analys
peak
profil
malditof
ms
larg
mrsa
strain
collect
contain
strain
molecular
diverg
background
use
meca
gene
found
isol
cultur
freez
cultur
loss
meca
gene
freez
cultur
previous
describ
singl
coloni
isol
identifi
cefoxitin
resist
phenotyp
meca
pcr
result
bacteria
freez
cultur
submit
lb
media
contain
increas
oxacillin
concentr
order
select
correspond
meca
contain
strain
two
sampl
could
select
meca
contain
strain
correspond
isogen
strain
lack
meca
gene
two
pair
molecularli
characteris
strain
submit
whole
cell
malditof
ms
order
increas
express
oxacillin
resist
strain
also
cultur
lb
medium
contain
nacl
oxacillin
correspond
oxacillin
suscept
strain
cultur
lb
medium
found
evid
differ
peak
profil
masstochargeratio
da
da
two
mecaisogen
pair
aureu
strain
cultur
blood
agar
plate
protein
peak
profil
meca
posit
strain
cultur
oxacillin
contain
media
also
virtual
ident
compar
meca
neg
correspond
isol
contrast
sever
report
literatur
could
show
first
time
whole
cell
malditof
msderiv
peak
profil
suitabl
discrimin
meca
posit
aureu
strain
masstochargeratio
da
rapid
identif
mixedand
singl
bacteri
fungal
infect
pcr
coupl
electrosprayion
timeofflight
mass
spectrometri
pcresitof
ms
c
tiemann
hartmann
knoop
labor
krone
molek
diagnostik
bad
salzuflen
deutschland
identif
bacteria
yeast
blood
cultur
time
consum
step
shorten
benefit
patient
sever
technolog
develop
replac
second
incub
step
agar
plate
biochem
character
promin
analysi
mass
spectrometri
howev
resolut
complex
mixtur
detect
antibiot
resist
marker
still
unmet
need
order
overcom
limit
new
molecular
technolog
pcr
coupl
mass
spectrometri
develop
allow
detect
identif
multipl
pathogen
select
antibiot
resist
marker
virul
factor
singl
test
pcr
differ
broad
rang
specif
primer
cover
bacteria
candida
key
antibiot
resist
marker
base
composit
amplicon
determin
mass
spectrometri
abbott
plexid
analyz
follow
bioinformat
identif
genotyp
clinic
sampl
posit
neg
blood
cultur
well
spike
blood
cultur
analyz
plexid
instrument
bac
spectrum
bc
assay
result
compar
tradit
microbiolog
techniqu
discord
result
addit
confirm
rrna
gene
sequenc
plexid
technolog
display
high
specif
superior
tradit
molecular
techniqu
also
abl
demonstr
resolut
mixtur
sever
clinic
sampl
resolut
differ
bacteria
yeast
singl
primer
pair
evalu
pseudintermediu
differenti
use
molecular
marker
analysi
maldi
tof
ms
function
analysi
two
type
ii
nadh
dehydrogenas
isoform
toxoplasma
gondii
ss
lin
u
w
bohn
institut
medizinisch
mikrobiologi
deutschland
nadh
dehydrogenas
play
import
role
energi
metabol
transfer
electron
nadh
mobil
electron
carrier
ubiquinon
sever
bacteria
fungi
protozoa
possess
call
type
ii
nadh
dehydrogenas
structur
function
differ
common
complex
mammalian
cell
thu
consid
put
drug
target
compos
singl
subunit
involv
proton
transloc
apicomplexan
parasit
toxoplasma
gondii
possess
two
isoform
target
mitochondrion
type
ii
nadh
dehydrogenas
occur
either
intern
enzym
util
mitochondri
nadh
extern
enzym
util
cytosol
nadh
determin
orient
isoform
appli
split
gfp
complement
approach
could
demonstr
isoform
intern
enzym
face
activ
site
mitochondri
matrix
intern
orient
confirm
proteas
protect
assay
select
membran
permeabil
digitonin
obtain
function
data
contribut
individu
isoform
gondii
energi
metabol
gener
singl
knockout
mutant
isoform
mutant
viabl
display
decreas
replic
rate
sever
mutant
function
complement
possibl
ectop
express
delet
gene
express
heterolog
isoform
suggest
two
enzym
possess
nonredund
isotypespecif
function
develop
toxoplasma
gondii
skelet
muscl
cell
depend
differenti
host
cell
ij
swierzi
cgk
institut
medic
microbiolog
deutschland
toxoplasma
gondii
apicomplexan
parasit
protozoan
infect
almost
everi
nucleat
mammalian
avian
cell
includ
skelet
muscl
cell
skmc
replic
parasit
differenti
dormant
bradyzoit
stage
skmc
consid
crucial
foodborn
transmiss
human
via
undercook
cure
meat
previou
result
laboratori
indic
skmc
promot
spontan
differenti
tachyzoit
bradyzoit
vitro
readili
fibroblast
therefor
identif
celltyp
specif
factor
regul
parasit
develop
skmc
major
interest
studi
cell
typespecif
interact
investig
use
perman
mousederiv
skelet
muscl
cell
fibroblast
control
myoblast
differenti
polynucl
contractil
myotub
vitro
immunoblot
immunofluoresc
microscopi
quantit
rtpcr
valid
differenti
effici
cell
measur
express
myosin
heavi
chain
intriguingli
infect
gondii
parasit
replic
clearli
lower
differenti
myotub
undifferenti
myoblast
control
fibroblast
day
infect
parasitophor
vacuol
pv
contain
averag
parasit
myoblast
respect
wherea
parasit
found
pv
differenti
addit
parasiteinduc
cell
lysi
could
observ
differenti
contrast
nondifferenti
quantif
toxoplasma
realtim
pcr
confirm
reduc
replic
parasit
differenti
myotub
compar
undifferenti
myoblast
mitogen
activ
protein
kinas
mapk
erk
well
aktpkb
regul
differenti
skmc
therefor
also
investig
whether
mapk
might
control
gondii
develop
differenti
undifferenti
skmc
first
result
use
immunoblot
show
consider
increas
erk
aktpkb
phoshoryl
within
differenti
furthermor
phosphoryl
aktpkb
protein
enhanc
postinfect
gondii
differenti
compar
undifferenti
experi
impact
map
kinas
differenti
well
infect
process
progress
togeth
result
suggest
host
cell
type
differenti
skmc
regul
gondii
replic
vitro
might
also
explain
differ
effici
gondii
persist
differenti
tissu
host
candida
albican
factor
h
bind
molecul
also
function
complement
receptor
hiv
bind
molecul
caenorhabd
elegan
host
model
system
screen
novel
antifung
benzimidazol
deriv
singh
w
abu
rayyan
dietsch
h
eickhoff
kh
k
institut
mikrobiologi
und
infektionsmedizin
deutschland
emc
microcollect
gmbh
deutschland
candida
albican
commens
microorgan
caus
agent
opportunist
oral
genit
infect
human
infect
c
albican
account
invas
mycos
treatment
invas
fungal
infect
problemat
due
sever
persist
therapeut
drawback
particular
develop
resist
current
avail
drug
toxic
side
effect
patient
variou
approach
develop
screen
new
antifung
drug
activ
previous
nematod
caenorhabd
elegan
success
use
model
host
human
pathogen
screen
novel
antimicrobi
drug
shown
c
albican
colon
intestin
tract
c
elegan
establish
persist
lethal
infect
accompani
deep
tissu
invas
entir
organ
screen
seri
novel
benzimidazol
deriv
antifung
activ
variou
candida
isol
use
standard
eucast
european
committe
antimicrobi
suscept
test
protocol
one
compound
benzimidazol
show
auspici
result
therefor
studi
detail
analyz
antifung
activ
variou
candida
speci
abil
inhibit
biofilm
format
c
albican
determin
activ
vivo
use
c
elegan
anim
model
show
highest
antifung
activ
set
variou
clinic
isol
includ
c
albican
c
glabrata
c
parapsilosi
c
krusei
furthermor
show
signific
reduct
c
albican
biofilm
format
vitro
condit
addit
found
toxic
effect
c
elegan
effect
inhibitori
concentr
vivo
infect
studi
could
demonstr
inhibit
filament
c
albican
prolong
surviv
c
albican
infect
nematod
identifi
screen
potenti
use
effect
antifung
agent
investig
activ
fungal
speci
also
murin
model
studi
activ
system
candidiasi
hexa
protein
aspergillu
fumigatu
role
stress
resist
virul
j
beck
b
echtenach
f
ebel
bakteriologi
deutschland
institut
immunologi
regenburg
regensburg
deutschland
mycelium
filament
fungi
consist
interwoven
network
multinucl
hypha
individu
cell
within
hypha
separ
septa
howev
intern
wall
contain
central
pore
allow
exchang
molecul
nutrient
even
organel
enabl
mycelium
respond
function
entiti
chang
environ
drawback
organ
local
damag
cell
wall
potenti
threat
whole
syncytium
prevent
uncontrol
bleed
cytoplasm
filament
fungi
develop
uniqu
organel
woronin
bodi
abl
seal
septal
pore
sever
fungi
hexa
protein
identifi
major
essenti
compon
woronin
bodi
mutant
gener
neurospora
crassa
aspergillu
oryza
show
uncontrol
loss
cytoplasm
local
damag
loss
magnaporth
grisea
impair
virul
plant
pathogen
data
yet
avail
role
hex
protein
filament
fungi
caus
infect
human
studi
analyz
import
woronin
bodi
particular
hexa
protein
stress
resist
virul
human
pathogen
mold
aspergillu
fumigatu
phenotyp
fumigatu
delta
hexa
mutant
less
dramat
compar
n
crassa
mutant
standard
condit
growth
fumigatu
delta
hexa
mutant
compar
wild
type
presenc
stressor
like
congo
red
sd
growth
mutant
clearli
impair
also
analyz
local
hexa
use
fluoresc
fusion
protein
wherea
gfphexa
fusion
target
organel
show
typic
characterist
woronin
bodi
hexagfp
fusion
show
strike
local
septal
wall
investig
consequ
loss
hexa
analyz
virul
delta
hexa
mutant
murin
model
infect
studi
phenotyp
confront
assay
use
human
murin
immun
cell
function
analysi
c
albican
infectionassoci
gene
unknown
function
interact
host
cell
complex
infect
model
jacobsen
wilson
f
mayer
b
hube
mikrobiel
jena
deutschland
introduct
candida
albican
common
fungal
pathogen
human
abl
caus
varieti
clinic
infect
hypothes
c
albican
unknown
function
gene
transcript
upregul
infect
infect
associ
gene
might
contribut
infect
process
aim
methodolog
aim
determin
whether
c
albican
infect
associ
gene
contribut
virul
therefor
base
transcript
profil
oral
infect
liver
invas
incub
human
blood
select
subset
infectionassoci
gene
unknown
function
analysi
isogen
delet
mutant
construct
subsequ
test
extens
vitro
screen
interact
epitheli
endotheli
cell
complex
infect
model
result
twentyfour
isogen
delet
mutant
construct
subsequ
analyz
vitro
infect
model
increas
complex
sixteen
mutant
impair
abil
damag
monolay
human
endotheli
andor
epitheli
cell
within
subset
seven
mutant
addit
display
decreas
stress
resist
vitro
two
mutant
show
filament
defect
determin
whether
delet
gene
influenc
virul
complex
infect
model
mutant
test
ovo
abil
kill
chicken
embryo
infect
chorioallanto
membran
recent
show
mortal
model
depend
fungal
abil
invad
membran
proinflammatori
host
respons
like
contribut
pathogenesi
surprisingli
seven
mutant
attenu
model
five
also
attenu
damag
epitheli
cell
vitro
three
mutant
attenu
ovo
one
mutant
attenu
damag
endotheli
epitheli
cell
fulli
virul
chicken
embryo
subsequ
analyz
system
mous
model
virul
mice
mirror
result
obtain
ovo
discuss
outlook
result
demonstr
gene
essenti
caus
full
damag
epitheli
endotheli
cell
vitro
necessarili
crucial
full
virul
complex
infect
model
conclud
either
damag
potenti
critic
full
virul
complex
host
set
greater
complex
environ
anim
model
stimul
addit
fungal
regulatori
network
lead
compens
defect
thioldepend
redox
network
analys
effect
antimalari
agent
methylen
blue
introduct
develop
spread
resist
standard
antimalari
drug
chloroquin
cq
pyrimethaminesulfadoxin
psd
challeng
year
thu
standard
drug
standard
impli
afford
avail
need
continu
requir
number
drug
drug
candid
instanc
methylen
blue
mb
direct
antioxid
redoxprotein
network
plasmodium
falciparum
contain
total
redoxin
disulfid
reductas
applic
yanasquar
allow
dynam
model
enzym
inhibit
differ
drug
includ
methylen
blue
analys
affect
pathway
mode
regulatori
effect
affect
enzym
combin
effect
differ
drug
materi
method
enzym
activ
key
redox
enzym
without
influenc
methylen
blue
measur
vivo
real
time
pcr
enzym
activ
enzym
affect
cq
psd
collect
literatur
databas
plasmodb
softwar
yanasquar
use
extrem
pathway
ep
calcul
order
evalu
strainspecif
redoxnetwork
folat
synthesi
haemoglobin
degrad
well
porphyrin
carbonpool
network
contain
pathway
result
model
show
metabol
flux
gluthat
reductas
well
number
redoxspecif
enzym
chang
activ
partial
inhibit
mb
appli
subleth
concentr
monitor
chang
enzym
mrna
express
predict
valid
rtpcr
data
strongest
reduct
caus
mb
calcul
protein
protect
mode
use
thioredoxin
andor
glutaredoxin
furthermor
enzym
carbohydr
nucleotid
metabol
react
inhibit
specif
regul
pleiotrop
effect
consid
next
flux
model
differ
resist
mutat
model
resist
mutat
mdr
plasmodi
transport
cqpsd
resist
consid
mode
resist
enzym
target
drug
effect
latter
drug
complementari
flux
affect
mb
favour
synerg
instanc
cq
resist
conclus
taken
togeth
data
suggest
mb
could
becom
key
factor
drug
combin
therapi
effort
test
promis
local
erad
strategi
ctermin
hyphal
activ
motif
cham
tea
transcript
factor
essenti
activ
morpholog
develop
c
albican
w
abu
rayyan
singh
k
fischer
k
institut
mikrobiologi
und
infektionsmedizin
medic
mycolog
deutschland
candida
albican
diploid
fungal
commens
human
mammal
transit
yeast
hyphal
form
one
virul
trait
c
albican
c
albican
develop
numer
signal
pathway
activ
express
stage
specif
gene
respons
environment
cue
transcript
factor
member
teaatt
transcript
factor
famili
harbor
evolutionarili
conserv
ntermin
dnabind
domain
delet
lead
defect
hyphal
format
vitro
attenu
virul
system
model
murin
candidiasi
order
elucid
put
dna
bind
gene
activ
domain
span
c
albican
protein
integr
modifi
open
read
frame
orf
wild
type
control
c
albican
adapt
revers
tetdepend
transactiv
rtta
mutant
use
simpl
test
tetinduc
hyphal
format
readout
transform
wild
type
orf
abl
restor
hyphal
growth
abil
liquid
medium
also
show
invas
growth
solid
agar
ad
tet
medium
orf
construct
either
delet
cterminu
stop
codon
aa
delet
tea
domain
aa
show
abrog
restor
hyphal
growth
invas
growth
grow
differ
stress
condit
mutant
interestingli
phenotyp
rescu
mutant
contain
orf
addit
aa
span
region
aa
express
modifi
orf
e
coli
test
bind
recombin
promot
consensu
sequenc
tc
delet
propos
ctermin
cham
affect
dna
bind
tc
probe
conclus
show
cham
requir
dna
bind
essenti
biolog
activ
morpholog
develop
rnabind
protein
pathogen
ustilago
maydi
identif
target
mrna
use
vivo
uvcrosslink
immunoprecipit
iclip
c
coand
posttranscript
control
essenti
compon
regul
gene
express
rnabind
protein
key
mediat
determin
spatiotempor
express
protein
within
cell
accumul
evid
indic
involv
rnabind
protein
regul
express
programm
underli
pathogen
develop
phytopathogen
fungi
ustilago
maydi
current
investig
role
rnabind
protein
found
member
novel
class
fungal
multi
hnrnp
khomolog
domain
protein
homologu
human
pathogen
cryptococcu
neoforman
aspergillu
fumigatu
delet
result
disturb
cell
morpholog
sever
reduct
virul
impli
import
role
morphogenesi
recogn
distinct
hexanucleotid
motif
present
almost
annot
transcript
suggest
larg
regulatori
potenti
failur
bind
rna
element
result
aberr
phenotyp
similar
delet
phenotyp
precis
role
function
howev
still
unclear
address
question
current
appli
vivo
uvcrosslink
immunoprecipit
experi
identifi
target
mrna
icliptechniqu
enabl
identif
target
mrna
coupl
vivo
uvcrosslink
high
throughput
sequenc
furthermor
offer
advantag
resolv
crosslink
site
individu
nucleotid
resolut
enabl
detail
analysi
bind
site
present
initi
step
establish
iclip
u
maydi
use
control
rnabind
protein
mccormick
jacobsen
j
wagen
f
ebel
bakteriologi
abt
mikrobiel
jena
deutschland
aspergillu
fumigatu
mold
caus
sever
system
infect
immunocompromis
patient
high
mortal
infect
larg
due
limit
therapeut
option
sinc
fumigatu
seem
lack
sophist
virul
trait
altern
therapeut
target
identifi
abil
respond
environment
chang
vital
requir
microb
interfer
signal
pathway
help
fungu
adapt
situat
stress
therefor
promis
option
howev
approach
hamper
fact
mani
signal
pathway
molecul
conserv
fungi
men
twocompon
system
tc
compris
sensor
histidin
kinas
respons
regul
except
found
plant
microorgan
mammal
studi
analyz
put
group
iii
histidin
kinas
tcsc
fumigatu
tcsc
fumigatu
protein
compris
sever
hamp
domain
similar
protein
architectur
recent
propos
constitut
osmosens
modul
delet
tcsc
sever
impact
growth
standard
condit
growth
sporul
delta
tcsc
mutant
clearli
impair
presenc
variou
stressor
includ
high
osmolar
demonstr
tcsc
signal
requir
cope
differ
form
stress
vitro
delta
tcsc
mutant
turn
highli
resist
sever
fungicid
includ
fludioxonil
suppos
activ
hog
pathway
consist
observ
dramat
swell
fludioxoniltr
fumigatu
wild
type
hypha
mutant
defect
gene
cell
wall
integr
cwi
pathway
significantli
sensit
fludioxonil
suggest
either
crosstalk
hog
cwi
pathway
andor
requir
cell
wall
dynam
bear
fludioxonilinduc
stress
role
tcsc
infect
current
studi
e
hiller
g
brunk
jabobsen
marcethouben
gabaldon
although
candida
glabrata
becom
second
import
pathogen
candida
speci
virul
mechan
identifi
far
within
eranet
consortium
funpath
gene
potenti
virul
factor
code
predict
protein
cell
wall
known
signal
pathway
membranebound
receptor
transport
transcript
factor
identifi
compar
genom
analysi
subsequ
delet
librari
screen
biolog
assay
eg
strain
alter
cell
wall
stabil
stress
toler
adhes
behaviour
get
comprehens
idea
virul
mechan
c
glabrata
furthermor
fit
test
mice
pool
differ
mutant
perform
microarray
base
tool
read
amount
cell
differ
delet
mutant
strain
test
establish
utilis
amount
genet
barcod
specif
differ
strain
sampl
sever
strain
found
surviv
assay
plate
accord
homologu
cerevisia
gene
delet
mutant
presum
involv
cell
wall
integr
sinc
cell
wall
integr
crucial
stress
resist
virul
analysi
delet
mutant
strain
predict
part
one
signal
network
perform
base
research
done
homologu
cerevisia
presum
put
cell
wall
sensor
wherea
suppos
transcript
factor
involv
activ
cell
wall
biogenesi
gene
regard
adhes
differ
surfac
show
compar
behaviour
wild
type
wherea
mutant
strain
stronger
adher
similar
behaviour
could
observ
assay
cell
wall
stabil
composit
consider
chang
properti
comparison
mutant
strain
wild
type
compar
trancriptom
delet
strain
wild
type
presenc
absenc
congo
red
show
slight
chang
express
pattern
wherea
significantli
chang
transcript
profil
could
detect
result
obtain
suggest
differ
role
c
glabrata
cerevisia
compar
function
inspect
gene
cell
wall
integr
pathway
cerevisia
might
therefor
differ
c
glabrata
african
trypanosom
transmigr
across
vitro
blood
brain
barrier
model
direct
c
untucht
j
rasch
rohd
bergmann
steinert
tu
braunschweig
institut
mikrobiologi
braunschweig
deutschland
hzi
medizinisch
mikrobiologi
braunschweig
deutschland
introduct
african
sleep
sicknesss
vector
born
parasit
diseas
caus
human
pathogen
trypanosoma
brucei
gambiens
b
rhodesiens
diseas
threaten
million
peopl
subsaharan
nation
without
treatment
lethal
death
occur
year
parasit
transmit
blood
meal
tsets
fli
glossina
genu
multipli
within
blood
stream
depend
subspeci
trypanosom
invad
central
nervou
system
cn
within
week
sever
month
even
year
lead
fatal
outcom
diseas
project
aim
cellular
mechan
blood
brain
barrier
bbb
travers
therefor
transwel
base
vitro
bbb
model
establish
optim
use
endotheli
like
glial
cell
semisynthet
basement
membran
cell
layer
analys
electron
microscopi
em
barrier
integr
evalu
bacteri
transmigr
compar
non
invas
e
coli
strain
mening
caus
e
coli
strain
macrophag
blood
stream
cultur
differ
trypanosom
strain
name
b
brucei
b
gambiens
b
rhodesiens
use
analys
transmigr
across
vitro
bbb
model
result
em
microscopi
reveal
confluent
layer
cell
partli
overlap
neighbour
cell
insid
transwel
insert
loos
meshwork
cell
underneath
insert
membran
optim
model
permeabl
pathogen
e
coli
transmigr
wherea
apathogen
e
coli
transmigr
even
higher
inoculum
african
trypanosom
transmigr
effici
b
gambiens
strain
show
highest
transmigr
rate
analys
macrophag
transmigr
across
optim
bbb
model
indic
paracellular
extravas
macrophag
enhanc
trypanosom
transmigr
upsidedown
array
bbb
cell
repres
invers
bbb
model
reveal
brain
blood
travers
trypanosom
similar
amount
discuss
optim
bbb
reproduc
vitro
bbb
model
select
permeabl
mening
caus
e
coli
trypanosom
transmigr
across
optim
model
occur
direct
underlin
possibl
relaps
parasitemia
treatment
drug
access
cn
model
promot
analysi
cellular
molecular
mechan
underli
cn
invas
urgent
need
therapi
improv
drug
develop
candida
albican
affect
barrier
function
express
tight
adheren
junction
protein
intestin
epitheli
cell
kurzai
septom
research
centr
jena
deutschland
introduct
intestin
epitheli
cell
iec
establish
tight
monolay
form
barrier
microorgan
gut
lumen
tight
junction
transmembran
protein
notabl
claudin
regul
paracellular
permeabl
intestin
barrier
constrict
diffus
small
solut
macromolecul
barrier
function
affect
pathogen
microorgan
toxin
stimuli
polymorph
fungu
common
commens
human
gastrointestin
tract
candida
albican
capabl
establish
system
diseas
within
host
travers
barrier
investig
role
activ
barrier
disrupt
invas
iec
c
albican
method
deriv
iec
grown
permeabl
cell
cultur
insert
serv
vitro
model
intestin
mucos
epithelium
barrier
function
monolay
examin
measur
transepitheli
electr
resist
teer
cytotox
determin
ldh
releas
assay
cultur
supernat
fix
insert
candidainfect
iec
imag
confoc
microscop
result
iec
grown
membran
insert
day
establish
stabl
monolay
addit
c
albican
moi
led
increas
teer
approx
teer
peak
around
h
inocul
start
decreas
reach
background
level
ie
insert
without
iec
h
decreas
electr
resist
came
along
increas
ldh
releas
h
infect
cytotox
level
microscop
imag
reveal
profound
disrupt
monolay
examin
role
filament
activ
penetr
infect
monolay
nonfilament
c
albican
mutant
contrast
wildtyp
inocul
iec
monolay
teer
mutant
inocul
monolay
increas
reach
twofold
level
continu
end
experi
h
cytotox
latter
remain
level
noninocul
control
examin
express
level
junction
protein
defin
precis
impact
c
albican
inocul
iec
adheren
junction
ecadherin
tight
junction
jama
occludin
claudin
protein
level
decreas
markedli
infect
monolay
confoc
imag
candidainfect
cell
show
local
ecadherin
accumul
fungal
filament
penetr
cellcel
boundari
wherea
overal
ecadherin
stain
around
invas
site
lost
outlook
result
indic
activ
particip
c
albican
intestin
barrier
breakdown
howev
rel
impact
host
fungu
barrier
disturb
clarifi
ongo
work
futur
analys
intend
clarifi
local
vs
gener
effect
junction
protein
distribut
andor
degrad
c
albican
invas
vivo
imag
inflamm
invas
aspergillosi
mice
k
opfermann
p
gebhardt
hp
saluz
b
hube
jacobsen
hki
jena
mikrobiel
jena
deutschland
hki
jena
jena
deutschland
introduct
invas
aspergillosi
ia
import
diseas
immunocompromis
patient
immunosuppress
mice
gold
standard
investig
ia
vivo
mice
immunosuppress
cortison
acet
infect
accompani
strong
inflammatori
respons
immigr
immun
cell
character
increas
glucos
uptak
use
noninvas
imag
fluorin
label
glucos
fdg
f
use
tracer
positron
emiss
tomographycomput
tomographi
petct
altern
fluoresc
label
glucos
deriv
rediject
probe
calip
detect
invivoimagingsystem
ivi
sinc
non
invas
imag
tool
monitor
inflamm
potenti
reduc
number
laboratori
anim
need
investig
ia
aim
determin
whether
mention
vivo
imag
system
suitabl
quantif
host
inflammatori
respons
ia
mice
materi
method
immunosuppress
cortison
acet
mgmous
intraperitoniali
day
day
mice
infect
intranas
dose
x
conidia
bioluminesc
aspergillu
fumigatu
strain
brock
et
al
pb
mockinfect
anim
serv
control
petct
imag
perform
day
isofluran
anaesthesia
immedi
applic
mbq
fdg
later
tail
vein
ivi
measur
done
isofluran
anaesthesia
immedi
petct
hour
inject
either
control
dye
distribut
tracer
quantifi
right
left
lung
last
measur
mice
euthan
lung
remov
necropsi
measur
alon
ivi
left
right
lung
homogen
independ
myeloperoxidas
cytokin
level
quantifi
lung
homogen
molecular
marker
inflamm
result
fdg
distribut
immunocompet
mice
immunocompromis
pb
mockinfect
mice
indistinguish
contrast
fdg
accumul
lung
mice
infect
fumigatu
measur
mice
inject
control
dye
reveal
accumul
neither
infect
discuss
demonstr
inflamm
ia
monitor
noninvas
petct
ivi
use
label
glucos
tracer
method
allow
quantif
immun
cell
accumul
lung
refer
brock
et
al
appl
environm
microbiol
calip
http
malaria
parasit
hijack
human
factor
h
protect
complementmedi
lysi
mosquito
midgut
n
simon
scheuermay
l
sologub
pf
zipfel
c
skerka
g
pradel
research
center
infecti
diseas
deutschland
leibniz
institut
natur
product
research
infect
biolog
jena
deutschland
part
innat
immun
system
human
complement
first
line
defenc
microbi
infect
number
bloodborn
pathogen
evolv
strategi
complement
evas
includ
mimick
host
surfac
intraerythrocyt
blood
stage
malaria
parasit
protect
attack
human
complement
parasit
gamet
exit
envelop
erythrocyt
prior
fertil
mosquito
midgut
vulner
factor
blood
meal
includ
human
immun
cell
complement
factor
show
human
malaria
parasit
plasmodium
falciparum
bind
regulatori
protein
factor
h
fh
sexual
reproduct
mosquito
midgut
protect
extracellular
gamet
complementmedi
lysi
bloodmeal
altern
pathway
human
complement
activ
approxim
h
post
feed
fh
becom
degrad
mosquito
midgut
h
macrogamet
young
zygot
bind
fh
result
inactiv
fh
compris
complement
control
protein
modul
bind
fh
malaria
gamet
appear
primarili
mediat
modul
loss
fhmediat
protect
result
impair
gametogenesi
und
reduc
zygot
number
transmiss
block
assay
antibodi
factor
h
significantli
reduc
transmiss
mosquito
first
time
protozoan
parasit
demonstr
camouflag
use
fh
order
avoid
complementmedi
lysi
find
might
lead
novel
approach
design
transmiss
block
vaccin
littl
data
interact
human
nkc
pathogen
fungu
howev
nkc
deplet
mice
shown
suscept
system
candida
infect
basi
observ
investig
direct
indirect
effect
human
nk
cell
candida
albican
method
primari
human
pbmc
isol
buffi
coat
healthi
donor
standard
ficol
gradient
biochrom
ag
untouch
nkc
separ
mac
use
nk
cell
isol
kit
miltenyi
biotec
accord
manufactor
instruct
isol
cell
prime
cytokin
cocktail
ifnalpha
ifnbeta
viabl
heatinactiv
candida
albican
use
confront
receptor
surfac
express
quantifi
facsanalysi
reduct
fungal
viabil
determin
xtt
assay
analyz
mechan
nkc
mediat
fungal
kill
cell
treat
block
antibodi
antifasl
antitrail
strontium
chlorid
induc
granula
releas
concanamycin
perforin
inhibitor
bioplex
elisa
use
quantif
secret
marker
result
coincub
nkc
c
albican
result
downregul
tolllik
receptor
cellular
adhesin
activ
marker
itambear
receptor
nkc
parallel
mark
increas
degranul
marker
well
secret
nk
cell
specif
cytokin
detect
activ
nkc
promin
c
albican
filament
degranul
significantli
reduc
inactiv
yeast
form
wherea
heatinactiv
filament
result
level
compar
viabl
wildtyp
c
albican
cytokin
mediat
prime
primari
human
nkc
led
enrich
cytotox
granul
perforin
granzym
b
use
activ
nkc
xttbase
kill
assay
show
signific
decreas
fungal
viabil
coincub
four
hour
block
experi
suggest
cytotox
effect
perforin
depend
fasltrail
receptor
pathway
involv
parallel
direct
effect
nkc
may
interact
immun
cell
sinc
cytokin
releas
show
upregul
neutrophil
activ
cytokin
conclus
observ
suggest
nkc
may
play
import
role
first
line
defens
c
albican
infect
context
direct
indirect
antifung
effect
nkc
current
investig
characteris
innat
immun
activ
respons
candida
albican
human
whole
blood
model
infect
k
kurzai
septom
research
centr
jena
deutschland
introduct
fungal
sepsi
increas
clinic
problem
high
mortal
rate
although
incid
fungal
sepsi
increas
recent
diagnosi
still
difficult
mainli
reli
detect
pathogen
candida
spp
blood
cultur
use
human
whole
blood
model
infect
investig
innat
immun
activ
respons
candida
albican
situat
similar
vivo
analys
allow
identifi
immun
marker
might
potenti
use
clinic
diagnost
method
pathogen
ad
human
whole
blood
differ
concentr
pattern
immun
activ
monitor
time
cours
analys
initi
assay
includ
differenti
fac
stain
defin
activ
pattern
immun
cell
popul
parallel
quantifi
humor
marker
immun
activ
investig
includ
characteris
whole
blood
transcriptom
respons
c
albican
obtain
data
integr
use
bioinformat
method
gener
network
innat
immun
activ
earli
step
fungal
sepsi
result
fungal
infect
result
strong
predomin
activ
neutrophil
detect
increas
surfac
express
marker
earli
activ
hladr
degranul
neutrophil
granul
contain
import
antifung
effector
molecul
releas
granul
respons
c
albican
studi
expect
myeloperoxidas
primari
lactoferrin
secondari
granul
could
detect
plasma
nk
cell
also
show
increas
surfac
level
activ
marker
wherea
sever
receptor
fc
riii
decreas
markedli
time
fungal
infect
furthermor
c
albican
blood
infect
induc
predomin
increas
total
number
platelet
aggreg
granulocyt
well
surfac
express
multiplex
assay
reveal
secret
proinflammatori
regulatori
cytokin
ifn
tnf
well
chemokin
rant
correspond
cellular
activ
detect
fac
analys
also
measur
strong
increas
plasma
concentr
anaphylatoxin
produc
part
activ
complement
system
conclus
human
whole
blood
model
infect
enabl
analysi
innat
immun
activ
respons
c
albican
situat
similar
vivo
advantag
isol
primari
cell
physiolog
condit
possibl
commun
immun
cell
popul
furthermor
current
perform
compar
analys
gramposit
gramneg
bacteria
identifi
pathogenspecif
activ
pattern
get
global
view
innat
immun
microbi
blood
infect
protozoan
like
leishmania
undergo
apoptosi
process
phosphatidylserin
ps
extern
dna
fragment
occur
leishmani
apoptosi
endonucleas
lm
endo
g
activ
involv
dna
degrad
addit
anti
apoptot
peroxidas
lm
apx
found
inactiv
reactiv
oxygen
speci
ro
howev
protein
machineri
mediat
apoptosi
mammalian
cell
like
caspas
member
famili
complet
absent
leishmania
studi
want
identifi
mechan
protein
involv
protozoan
apoptot
program
use
axen
amastigot
cultur
promastigot
cultur
induc
apoptosi
use
staurosporin
treatment
first
perform
quant
fac
microscop
analys
subsequ
use
massspectrometri
character
abund
protein
either
regul
upon
apoptosi
induct
use
timelaps
imag
observ
induct
apoptosi
egfp
express
promastigot
result
first
round
promastigot
loss
egfp
subsequ
extern
ps
detail
investig
apoptosi
reveal
reactiv
oxygen
speci
ro
gener
parasit
stage
apoptosi
induct
depend
manner
focus
lm
endo
g
found
upregul
upon
apoptosi
induct
context
observ
downregul
anti
apoptot
lm
apx
mass
spectrometri
quantifi
total
leishmani
protein
promastigot
apoptosi
induc
upregul
protein
downregul
protein
amastigot
respect
select
protein
specif
inhibitori
compound
exist
current
investig
protein
role
leishmani
apoptosi
program
cell
death
pcd
common
featur
multicellular
organ
well
character
recent
year
increas
evid
occurr
pcd
distinct
unicellular
organ
well
howev
littl
inform
put
pcd
toxoplasma
therefor
identif
apoptosislik
marker
molecul
might
play
role
gondii
pcd
need
elucid
tunel
assay
follow
flow
cytometri
use
determin
dna
strand
break
treatment
parasit
sever
proapoptot
induc
staurosporin
miltefosin
result
show
staurosporin
miltefosin
increas
number
tunelposit
cell
variou
extent
timedepend
hour
post
treatment
treat
parasit
show
slight
reduct
cell
size
compar
untreat
parasit
reduct
cell
size
obviou
miltefosinetr
parasit
also
display
highest
percentag
tunelposit
parasit
furthermor
treatment
staurosporin
miltefosin
led
higher
percentag
annexin
vposit
parasit
expos
phosphatidylserin
cell
surfac
compar
untreat
control
protein
involv
mammalian
apoptosi
pathway
identifi
silico
analysi
gondii
genom
databas
project
focus
gondii
bax
inhibitor
silico
analysi
gondii
genom
demonstr
presenc
put
bax
inhibitor
gene
name
gondii
amino
acid
sequenc
analysi
show
ident
human
put
contain
transmembran
domain
molecular
weight
da
da
da
respect
order
unravel
possibl
function
gondii
bi
protein
regul
apoptosi
heterolog
express
tgbi
hela
cell
stabl
transfect
gene
encod
hela
cell
confirm
immunofluoresc
microscopi
well
western
blot
analysi
hoechst
stain
show
lower
level
chromatin
condens
hela
cell
hela
wild
type
cell
treatment
brefeldin
staurosporin
measur
caspas
activ
demonstr
inhibitori
effect
hela
cell
treatment
either
staurosporin
brefeldin
tunicamycin
thapsigargin
moreov
hela
cell
show
lower
induct
hypoploid
dna
subpeak
treatment
induc
find
suggest
exist
apoptoticlik
cell
death
gondii
protect
effect
tgbi
protein
regul
apoptosi
histon
deacetylas
inhibitor
rescu
macrophag
toxoplasma
gondiimedi
inhibit
ifnrespons
f
brand
c
lang
hildebrandt
cgk
univers
medic
center
institut
medic
microbiolog
deutschland
toxoplasma
gondii
eukaryot
parasit
highli
preval
warmblood
host
includ
human
worldwid
infect
individu
prematur
suppress
immun
lead
lifethreaten
toxoplasmosi
wherea
immun
compet
host
infect
mostli
asymptomat
lead
parasit
persist
host
life
cellmedi
immun
includ
product
ifni
critic
control
obligatori
intracellular
parasit
howev
use
genomewid
transcriptom
analysi
shown
gondii
lead
global
unrespons
murin
macrophag
ifnand
may
essenti
establish
longterm
infect
analysi
underli
mechan
reveal
normal
activ
nuclear
transloc
toxoplasmainfect
macrophag
though
defect
activ
promot
respons
ifn
isol
character
protein
bound
oligonucleotid
contain
consensu
sequenc
indic
defect
recruit
nonmuscl
actin
toxoplasmainfect
macrophag
ie
compon
chromatin
remodel
complex
addit
chromatin
immunoprecipit
show
gondii
inhibit
acetyl
histon
vivo
ie
major
prerequisit
chromatin
remodel
prior
transcript
histon
acetyl
transferas
hat
activ
toward
histon
gener
decreas
nuclear
extract
gondiiinfect
macrophag
furthermor
histon
deacetylas
hdac
activ
increas
infect
nonetheless
treatment
macrophag
hdac
inhibitor
sodium
butyr
prior
stimul
ifnlarg
abrog
inhibit
ifn
induc
mhc
class
ii
ciita
gene
express
exert
gondii
togeth
data
unravel
novel
insight
mechan
gondii
evad
ifnregul
immun
open
novel
strategi
therapeut
intervent
toxoplasmosi
dietsch
singh
w
abu
rayyan
k
fischer
k
institut
mikrobiologi
und
infektionsmedizin
deutschland
candida
albican
frequent
human
fungal
pathogen
infect
rang
superfici
mucos
lesion
lifethreaten
invas
mycos
high
mortal
rate
hyphal
growth
biofilm
format
transcript
regul
put
virul
trait
adapt
host
environ
key
issu
c
albican
pathogenesi
hyphal
format
prerequisit
penetr
host
tissu
caus
system
candidiasi
format
biofilm
allow
pathogen
persist
host
increas
resist
antifung
compound
transcript
factor
member
tea
transcript
factor
famili
play
import
role
morphogenet
develop
c
albican
order
defin
structur
function
relationship
protein
integr
modifi
open
read
frame
orf
wild
type
control
c
albican
adapt
revers
tetdepend
transactiv
rtta
mutant
screen
seri
c
albican
mutant
modif
abil
vitro
biofilm
format
also
examin
hyphal
format
surviv
nematod
host
use
c
elegan
infect
model
biofilm
assay
full
length
orf
abl
restor
abil
biofilm
format
abil
mutant
background
tet
induc
gene
express
biofilm
mass
similar
biofilm
form
wild
type
strain
wherea
tea
domain
mutant
mutant
lack
propos
ctermin
motif
impair
biofilm
format
similar
growth
condit
previous
c
elegan
success
use
infect
model
host
understand
virul
mechan
variou
human
pathogen
microorgan
vivo
investig
c
elegan
infect
model
reveal
c
albican
mutant
lack
ctermin
motif
show
less
virul
nematod
term
hyphal
invas
kill
nematod
mutant
librari
screen
reveal
besid
alreadi
known
essenti
region
tea
domain
import
ntermin
end
also
ctermin
motif
transcript
factor
play
import
role
morphogenet
develop
demonstr
ctermin
motif
essenti
yeasthypha
transit
infect
kill
c
elegan
nematod
biofilm
format
vr
stoldt
abtmeier
kc
huynh
scharf
institut
und
transfusionsmedizin
deutschland
introduct
candida
albican
dimorph
fungu
switch
yeast
hypha
form
abil
germin
grow
hypha
import
virul
factor
vivo
platelet
bridg
innat
adapt
immun
attack
microorgan
platelet
store
microbicid
immun
stimulatori
protein
granul
platelet
integrin
plasma
ligand
govern
bind
pathogen
activ
platelet
releas
granul
test
hypothesi
fibronectin
also
store
platelet
granular
bound
platelet
integrin
support
host
defens
c
albican
infect
materi
method
plateletrich
plasma
citrat
anticoagul
blood
sampl
wash
phosphat
buffer
salt
solut
pb
ph
contain
uml
apyras
platelet
pellet
resuspend
tyrod
buffer
ph
contain
cell
tracker
dye
cmfda
molecular
probe
isol
plasma
fibronectin
label
alexa
fluor
c
albican
cultur
night
yeast
extract
pepton
glucos
medium
wash
pb
ph
starv
h
room
temperatur
germin
induc
ad
serum
sampl
taken
germin
time
flow
cytometri
c
albican
yeast
hypha
form
optic
densiti
od
label
fnalexa
fluor
fluoresc
stain
platelet
static
condit
result
c
albican
hypha
bound
fibronectin
mean
fluoresc
intens
arbitrari
unit
au
increas
au
au
min
min
time
germin
furthermor
germin
c
albican
increas
bind
platelet
min
min
respect
moreov
pretreat
c
albican
hypha
fibronectin
enhanc
bind
platelet
conclus
hypha
c
albican
import
virul
factor
attack
platelet
fibronectin
ligand
platelet
integrin
iib
opson
hypha
form
c
albican
foster
platelet
bind
henc
platelet
fibronectin
intrins
multival
bind
site
support
platelet
mediat
host
defens
immun
respons
c
albican
k
dichtl
f
dirr
c
helmschrott
j
wagen
max
von
pettenkoferinstitut
bakteriologi
deutschland
organ
biosynthesi
fungal
cell
wall
essenti
structur
defin
organ
shape
shield
environment
stress
regul
cell
wall
integr
cwi
signal
pathway
central
map
kinas
modul
subject
divers
studi
conserv
saccharomyc
cerevisia
filament
fungi
aspergillu
spp
contrari
compon
upstream
map
kinas
modul
well
character
cerevisia
larg
unknown
aspergillu
spp
identifi
local
function
character
homologu
cerevisia
cell
surfac
sensor
fumigatu
moreov
analyz
role
three
rhogtpas
implic
cwi
signal
fungi
show
essenti
condit
downregul
delet
result
sever
impair
cwi
addit
data
indic
fundament
function
differ
sensor
level
cwi
pathway
cerevisia
fumigatu
trend
multidrug
resist
among
escherichia
coli
klebsiella
germani
kresken
hafner
antiinfect
intellig
gmbh
rheinbach
deutschland
paulehrlichgesellschaft
chemotherapi
ev
rheinbach
deutschland
institut
pharmacolog
clinic
pharmacolog
heinrichheineunivers
deutschland
introduct
escherichia
coli
eco
klebsiella
among
common
pathogen
caus
infect
inand
outpati
antimicrobi
agent
gener
cephalosporin
carbapenem
carba
fluoroquinolon
fq
essenti
drug
treat
seriou
ill
treatment
outcom
howev
increasingli
threaten
emerg
dissemin
resist
r
strain
multidrug
r
mdr
strain
particular
object
studi
document
chang
r
pattern
eco
klebsiella
pneumonia
kpn
klebsiella
oxytoca
kox
germani
method
suscept
data
clinic
isol
collect
laboratori
particip
five
surveil
studi
conduct
paulehrlichsocieti
respect
analys
mic
antimicrobi
agent
determin
broth
microdilut
procedur
accord
standard
din
iso
interpret
eucast
criteria
clsi
mic
method
use
ceftazidim
caz
clavulan
acid
cla
cefotaxim
ctx
cla
employ
screen
test
esblproduc
isol
mdr
defin
antimicrobi
r
two
follow
four
drug
class
carba
fq
aminoglycosid
result
total
isol
primarili
recov
urin
wound
respiratori
specimen
blood
test
icu
isol
nonicu
isol
singl
r
ciprofloxacin
cip
eco
kpn
kox
increas
respect
r
ctx
three
speci
rose
concurr
increas
percentag
strain
show
esbl
phenotyp
observ
r
carba
ertapenem
ert
imipenem
imp
meropenem
mem
remain
uncommonli
mdr
rate
speci
studi
year
shown
tabl
mdr
isol
recov
none
suscept
ctx
cip
gentamicin
piperacillintazobactam
contrast
carba
activ
mdr
isol
except
one
kox
mic
ert
imp
mem
mgl
conclus
singl
r
cip
ctx
repres
fq
respect
well
mdr
eco
klebsiella
increas
contrast
activ
carba
chang
last
year
introduct
follow
regulatori
approv
use
complic
skin
skin
structur
infect
complic
intraabdomin
infect
tigecyclin
tgc
introduc
germani
data
german
tigecyclin
evalu
surveil
trial
gtest
conduct
analyz
suscept
import
aerob
grampo
gramneg
pathogen
tgc
compar
method
suscept
isol
four
grampo
seven
gramneg
speci
consecut
collect
three
surveil
studi
conduct
cooper
laboratori
gtest
iiii
test
laboratori
collect
appr
pathogen
hospit
patient
mic
determin
central
laboratori
use
microdilut
method
accord
standard
iso
eucast
breakpoint
appli
antibiot
interpret
esblproduc
organ
identifi
clsi
criteria
result
total
isol
recov
wound
periton
caviti
blood
test
base
valu
tgc
demonstr
unchang
within
one
dilut
vitro
activ
speci
test
see
tabl
contrast
consider
increas
resist
r
betalactam
fluoroquinolon
fq
note
member
enterobacteriacea
famili
r
fq
escherichia
coli
enterobact
cloaca
klebsiella
pneumonia
increas
respect
increas
r
cefotaxim
e
coli
k
pneumonia
went
along
rise
esblproduc
strain
respect
r
imipenem
acinetobact
baumannii
group
isol
observ
respect
rate
vancomycinresist
strain
among
enterococcu
faecium
isol
vari
conclus
tgc
retain
good
vitro
activ
grampo
gramneg
organ
test
introduct
germani
background
pathogen
frequent
resist
variou
antibiot
class
tgc
remain
import
treatment
option
pharmacodynam
three
carbapenem
consid
current
suscept
pattern
drugresist
gramneg
bacteria
germani
kresken
b
deckerburgard
hafner
antiinfect
intellig
gmbh
rheinbach
neuss
deutschland
institut
pharmacolog
clinic
pharmacolog
heinrichheineunivers
deutschland
introduct
carbapenem
carba
wide
use
empir
therapi
seriou
infect
involv
drugresist
gramneg
pathogen
like
p
aeruginosa
baumannii
enterobacteriacea
express
esbl
phenotyp
stabli
derepress
ampc
object
studi
predict
probabl
attain
target
pharmacodynam
exposur
clinic
use
dose
regimen
doripenem
dor
imipenemcilastatin
ipm
meropenem
mem
german
collect
contemporari
drugresist
gramneg
pathogen
use
mont
carlo
simul
mc
method
isol
hospitalis
patient
collect
medic
microbiolog
laboratori
two
resist
surveil
studi
conduct
bacteri
group
investig
p
aeruginosa
baumannii
group
ceftriaxon
cro
resist
enterobacteriacea
mc
model
patient
receiv
follow
dose
regimen
dor
mg
everi
hour
infus
dor
mg
everi
hour
infus
ipm
mg
everi
hour
ipm
mg
everi
hour
mem
mg
everi
hour
mem
mg
everi
hour
pharmacodynam
target
predict
efficaci
free
drug
concentr
mic
dose
interv
simul
base
upon
normal
distribut
volum
distribut
total
bodi
clearanc
mean
pharmacokinet
paramet
distribut
taken
publish
studi
cumul
fraction
respons
cfr
calcul
consid
mic
distribut
data
three
group
organ
result
carba
regimen
achiev
cfr
rate
croresist
enterobacteriacea
vari
baumannii
group
isol
see
tabl
p
aeruginosa
highest
cfr
obtain
dor
mg
everi
hour
infus
lowest
ipm
mg
everi
hour
conclus
consid
current
suscept
pattern
drugresist
gramneg
pathogen
germani
clinic
use
dose
regimen
carba
suffici
achiev
probabl
greater
success
croresist
enterobacteriacea
contrast
dor
prolongedinfus
mem
mg
dose
regimen
achiev
least
cfr
p
aeruginosa
none
carba
regimen
achiev
cfr
baumannii
group
background
current
region
antibiot
suscept
data
hospit
patient
outpati
need
support
local
network
defenc
spread
multiresist
bacteria
materi
method
result
routin
susept
data
twelv
antibiot
agent
total
isol
staphylococcu
aureu
escherichia
coli
pseudomona
aeruginosa
enterococcu
faecali
four
thuringian
microbiolog
laboratori
analys
retrospect
year
suscept
test
perform
agar
diffus
test
breakpointtest
accord
german
standard
din
result
compar
nationwid
german
data
publish
onlin
robert
kochinstitut
antibiot
resist
surveil
websit
ar
http
arsrkid
result
resist
rate
aureu
outpati
penicillin
oxacillin
ciprofloxacin
significantli
lower
hospit
patient
p
rate
methicillin
resist
aureu
mrsa
outpati
rose
wherea
larg
bed
small
bed
hospit
mrsa
rate
remain
constant
around
resist
rate
e
coli
ampicillin
cefotaxim
gentamicin
ciprofloxacin
significantli
lower
outpati
p
resist
rate
e
coli
cefotaxim
marker
extend
spectrum
betalactamas
esbl
product
constant
hospit
quadrupl
outpati
resist
rate
p
aeruginosa
piperacillin
ciprofloxacin
ceftazidim
significantli
lower
outpati
p
wherea
gentamicin
ineffect
p
aeruginosa
inand
outpati
e
faecali
isol
remain
highli
suscept
ampicillin
conclus
decemb
thuringiagermani
mrsa
rate
outpati
hospit
remain
well
nationwid
level
determin
ar
respect
howev
alarm
increas
esbl
rate
outpati
german
ehec
outbreak
strain
harbour
extendedspectrum
lactamas
esbl
ehec
observ
germani
main
focu
northern
germani
probabl
outbreak
caus
contamin
veget
method
ehec
outbreak
isol
sent
nation
refer
laboratori
multidrugresist
gramneg
bacteria
character
suscept
test
perform
disk
diffus
etest
virul
gene
e
coli
pathovar
test
pcr
mlst
type
pcr
base
determin
phylogenet
group
perform
presenc
sever
lactamas
gene
test
pcr
genet
environ
character
transconjug
transform
resist
plasmid
attempt
restrict
follow
pulsedfield
gel
electrophoresi
subsequ
southern
blot
hybrid
done
determin
plasmid
local
resist
gene
result
ehec
outbreak
isol
isol
femal
patient
northern
germani
test
posit
aggr
neg
eae
type
reveal
mlst
type
e
coli
phylogenet
group
isol
display
esbl
phenotyp
well
could
identifi
genet
environ
show
upstream
downstream
gene
carbapenemas
gene
like
kpc
vim
ndm
found
furthermor
resist
tetracyclin
sulfamethoxazoletrimethoprim
observ
restrict
reveal
plasmid
ca
kb
transconjug
transform
plasmid
harbour
obtain
coresist
tetracyclin
sulfamethoxazoletrimethoprim
could
demonstr
conclus
within
two
day
receipt
ehec
outbreak
isol
molecular
basi
unusu
esbl
phenotyp
could
clarifi
immedi
report
german
health
author
ehec
strain
harbour
never
report
presenc
resist
gene
diarrheagen
bacteri
strain
worrisom
sinc
might
contribut
enhanc
spread
resist
determin
e
g
horizont
gene
transfer
antimicrobi
suscept
ocular
isol
germani
kresken
b
antiinfect
intellig
gmbh
rheinbach
deutschland
introduct
antimicrobi
resist
increas
past
two
decad
germani
mani
countri
data
vitro
suscept
pathogen
isol
ocular
infect
howev
scarc
two
multicentr
studi
carri
order
assess
occurr
resist
amongst
ocular
isol
antibacteri
agent
use
topic
treatment
superfici
eye
infect
method
bacteri
isol
prospect
collect
two
surveil
studi
conduct
cooper
medic
laboratori
minim
inhibitori
concentr
determin
central
laboratori
use
broth
microdilut
method
accord
german
din
standard
dineniso
interpret
criteria
appli
eucast
clinic
breakpoint
system
use
antibacteri
agent
well
eucast
epidemiolog
cutoff
valu
ecoff
avail
suscept
data
nine
antibacteri
agent
analys
levofloxacin
lvx
moxifloxacin
mxf
ofloxacin
ofx
gentamicin
gen
kanamycin
kan
azithromycin
azi
erythromycin
eri
chloramphenicol
chl
oxytetracyclin
ote
addit
suscept
staphylococci
oxacillin
oxa
determin
result
total
ocular
isol
primarili
recov
conjunctiv
swab
test
aureu
predomin
pathogen
either
studi
follow
h
influenza
pneumonia
patient
relat
data
compar
studi
two
third
isol
deriv
outpati
half
patient
aureu
isol
collect
respect
oxaresist
ie
mrsa
resist
chl
gen
kan
among
aureu
decreas
resist
eri
fluoroquinolon
fq
remain
unchang
see
tabl
signific
chang
rate
resist
observ
pneumonia
h
influenza
contrast
isol
reduc
suscept
lvx
ofx
among
enterobacteriacea
increas
respect
conclus
overal
studi
aminoglycosid
chl
display
lower
resist
rate
compar
resist
rate
fq
remain
either
unchang
slightli
increas
introduct
worldwid
increas
multidrugresist
gramneg
bacteria
becom
import
clinic
challeng
carbapenem
resist
p
aeruginosa
caus
varieti
mechan
howev
worldwid
spread
carbapenemas
especi
import
carbapenemas
p
aeruginosa
belong
ambler
class
b
metallo
lactamas
mbl
describ
novel
imptyp
mbl
found
two
isol
patient
germani
method
suscept
antibiot
determin
disk
diffus
etest
presenc
mbl
determin
edta
combineddisctest
mbl
etest
bioassay
base
cellfre
extract
modifi
hodgetest
perform
pcr
subsequ
sequenc
perform
vim
imp
ndm
gim
sim
spm
aim
dim
khm
clonal
related
isol
determin
rapdpcr
integron
structur
analys
pcr
sequenc
result
two
p
aeruginosa
isol
singl
patient
hospit
differ
geograph
region
germani
sent
nation
refer
laboratori
multidrugresist
bacteria
character
isol
resist
piperacillin
piperacillintazobactam
ceftazidim
cefepim
aztreonam
imipenem
mic
mgl
mgl
respect
meropenem
doripenem
mic
mgl
well
gentamicin
tobramycin
amikacin
ciprofloxacin
levofloxacin
isol
suscept
colistin
mic
mgl
modifi
hodgetest
posit
imipenem
meropenem
ertapenem
isol
show
synergi
edta
combin
disk
test
mbl
etest
unspecif
result
due
toxic
edta
could
exclud
posit
bioassay
base
cellfre
extract
consensu
primer
imp
bp
fragment
amplifi
sequenc
sequenc
show
similar
reveal
amino
acid
substitut
rel
isol
also
harbour
least
one
class
integron
contain
gene
aminoglycosid
adenylyltransferas
conclus
two
clinic
isol
harbour
novel
imptyp
carbapenemas
clearli
show
mbl
phenotyp
mic
differ
imipenem
like
result
addit
mechan
imipenem
resist
amino
acid
substitut
compar
identifi
imptyp
carbapenemas
show
signific
differ
known
imptyp
carbapenemas
carbapenemas
arriv
germani
report
nation
refer
laboratori
multidrugresist
gramneg
bacteria
kaas
f
szabado
ander
gatermann
abteilung
medizinisch
mikrobiologi
bochum
deutschland
introduct
multidrugresist
enterobacteriacea
pseudomona
aeruginosa
acinetobact
baumannii
utmost
therapeut
import
sinc
innov
antimicrobi
drug
gramneg
bacteria
introduc
clinic
practic
within
next
five
year
among
resist
mechan
worldwid
spread
carbapenemas
worrisom
develop
howev
correct
identif
carbapenemas
challeng
microbiolog
laboratori
method
nation
refer
laboratori
multidrugresist
gramneg
bacteria
offer
free
servic
carbapenemas
detect
bacteri
isol
elev
carbapenem
mic
isol
test
wide
array
phenotyp
molecular
method
bioassay
base
cellfre
extract
allow
detect
still
unknown
lactamas
result
total
isol
sent
nation
refer
laboratori
mainli
investig
carbapenemas
also
clarif
resist
mechan
rd
gener
cephalosporin
molecular
strain
type
sever
differ
carbapenemas
could
detect
includ
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
enterobacteriacea
carbapenemas
found
k
pneumonia
especi
frequent
carbapenemas
p
aeruginosa
baumannii
discuss
almost
carbapenemas
found
worldwid
arriv
germani
howev
molecular
epidemiolog
germani
predomin
differ
significantli
observ
made
countri
like
greec
israel
usa
unit
kingdom
ongo
surveil
resist
determin
necessari
especi
infect
control
diagnost
object
success
worldwid
dissemin
carbapenemas
produc
enterobacteriacea
special
concern
limit
therapeut
option
higher
mortal
dissemin
carbapenemas
kpc
predominantli
bound
distinct
klebsiella
pneumonia
strain
spread
enzym
mainli
due
conjug
transfer
differ
plasmid
carri
carbapenemas
gene
facilit
transmiss
among
mani
enterobacteri
speci
report
molecular
analysi
multidrugresist
enterobacteriacea
isol
oman
method
carbapenem
resist
isol
klebsiella
spp
e
coli
enterobact
cloaca
collect
three
hospit
oman
septemb
februari
relev
resist
gene
identifi
pcr
sequenc
conjug
experi
pfgetyp
perform
result
conclus
carbapenemas
identifi
five
isol
ten
isol
produc
identifi
two
isol
three
patient
recent
travel
india
pakistan
admiss
hospit
xbaimacrorestrict
analysi
reveal
seven
close
relat
isol
three
isol
indic
sever
event
clonal
transmiss
carbapenemas
produc
strain
two
hospit
furthermor
addit
esbl
well
betalactamas
detect
major
isol
gene
success
transfer
recipi
plasmid
ca
size
isol
transconjug
gene
locat
conjug
plasmid
differ
size
reduc
carbapenem
mic
valu
transconjug
indic
occurr
carbapenem
resist
mechan
like
increas
product
efflux
pump
loss
porin
outer
membran
protein
omp
clinic
isol
germani
carbapenemas
identiefi
isol
last
three
year
although
carbapenemas
produc
enterobacteriacea
still
rare
mani
european
countri
urgent
need
surveil
prevent
spread
multidrugresist
pathogen
treat
doubl
tripl
resist
helicobact
pylori
germani
background
object
enterobacteriacea
shown
play
crucial
role
transmiss
antimicrobi
resist
promin
enterobacteri
speci
human
anim
escherichia
e
coli
salmonella
enterica
dissemin
antibiot
resist
due
transfer
resist
bacteria
differ
host
organ
horizont
transfer
resist
properti
isol
differ
speci
genera
within
beyond
famili
enterobacteriacea
especi
resist
lactam
mediat
product
extendedspectrum
betalactamas
esbl
resist
fluoro
quinolon
influenc
differ
plasmidmedi
quinolon
resist
determin
concern
sinc
limit
dramat
therapeut
option
veterinari
human
medicin
therefor
reset
research
consortium
aim
assess
impact
differ
origin
transmiss
rout
pathogen
attribut
risk
human
expos
esblproduc
fluoro
quinoloneresist
enterobacteriacea
studi
method
reset
consortium
consist
network
partner
associ
partner
human
veterinari
medicin
fundament
applicationori
research
epidemiolog
reset
network
perform
differ
studi
provid
indispens
reliabl
inform
pathogen
distribut
specif
human
anim
popul
well
food
feed
environ
occurr
esbl
pmqr
plasmidmedi
quinolon
resist
gene
within
pathogen
popul
transmiss
pathway
differ
popul
anim
environ
humanor
pathogenrel
impact
use
antibiot
anim
human
respect
resist
situat
conclus
feder
ministri
health
bmg
start
dart
deutsch
antibiotikaresistenzstrategi
initi
prevent
control
spread
antimicrobi
resist
human
veterinari
medicin
reset
network
includ
differ
interact
complementari
studi
factor
associ
dissemin
emerg
resist
properti
enterobacteriacea
human
anim
environ
result
expect
reset
substanti
contribut
dart
nearli
clinic
vancomycinresist
e
faecium
strain
resist
ampicillin
mic
mgl
possess
high
level
resist
ciprofloxacin
mgl
typic
featur
hospitalassoci
clonal
type
high
level
resist
hlr
gentamicin
mic
mgl
occur
strain
increas
frequenc
hlr
streptomycin
mgl
strain
resist
antibiot
last
resort
linezolid
tigecyclin
daptomycin
quinupristindalfopristin
seldom
moder
frequenc
discussionconclus
present
frequenc
antibiot
resist
among
vancomycinresist
e
faecium
add
import
data
exist
resist
surveil
system
ar
germap
latter
collect
resist
data
enterococci
especi
focus
vre
data
show
frequent
coresist
therapeut
relev
antibiot
ampicillin
aminoglycosid
enterococci
resist
antibiot
last
resort
still
rare
compar
high
rate
vanb
vre
suggest
chang
epidemiolog
van
genotyp
recent
year
background
preval
multidrugresist
gramneg
pathogen
increas
worldwid
especi
spread
carbapenemas
produc
enterobacteriacea
worrisom
sinc
strain
usual
also
resist
antibiot
new
antibiot
activ
gramneg
bacteria
introduc
within
next
five
year
therefor
test
activ
older
rare
use
antibiot
high
clinic
impact
method
enterobacteriacea
n
elev
carbapenem
mic
sent
nation
refer
laboratori
multidrugresist
gramneg
bacteria
sever
laboratori
germani
investig
presenc
carbapenemas
modifi
hodg
test
synergi
test
use
edta
boron
acid
microbiolog
assay
use
cellfre
extract
pcr
follow
sequenc
resist
test
fosfomycin
perform
etest
disk
diffus
agar
dilut
contain
muellerhinton
agar
result
collect
multidrugresist
k
pneumonia
n
e
coli
n
e
cloaca
n
k
oxytoca
n
speci
variou
lactamas
like
n
n
n
n
n
found
regard
agar
dilut
refer
method
mgl
mgl
overal
isol
suscept
accord
eucast
mic
mgl
suscept
rate
k
pneumonia
e
coli
e
cloaca
respect
etest
gave
concord
result
show
seven
major
error
one
major
error
appli
threshold
mm
suscept
disk
diffus
fosfomycin
recommend
clsi
e
coli
eleven
major
error
major
error
found
conclus
use
eucast
criteria
agar
dilut
divers
collect
multidrugresist
enterobacteriacea
strain
show
fosfomycin
suscept
less
major
major
error
etest
accept
method
fosfomycin
suscept
test
studi
report
increas
frequenc
resist
molecular
character
resist
isol
method
isol
sent
german
refer
centr
staphylococci
test
antibiot
suscept
broth
microdilut
assign
clonal
complex
spatyp
subset
isol
antibiot
suscept
test
automat
suscept
test
vitek
etest
comparison
elucid
molecular
basi
resist
repres
isol
differ
geograph
origin
subject
solexa
whole
genom
sequenc
pool
dnasampl
addit
dna
two
clinic
isol
obtain
unsuccess
daptomycin
treatment
sequenc
solexa
whole
genom
sequenc
sequenc
data
map
appropri
aureu
refer
strain
base
whole
genom
data
mprf
locu
previous
shown
associ
daptomycin
resist
resequenc
daptomycin
resist
suscept
isol
result
among
isol
receiv
nation
refer
centr
frequenc
daptomycin
resist
increas
isol
mrsa
predominantli
belong
clonal
complex
automat
suscept
test
vitek
gener
indic
slightli
elev
mic
valu
compar
broth
microdilut
etest
sequenc
analysi
whole
genom
data
reveal
small
number
snp
put
associ
resist
howev
resequenc
correspond
loci
larger
number
resist
suscept
isol
strong
associ
resist
mutat
certain
locu
could
confirm
mprf
resequenc
mprf
reveal
point
mutat
resist
isol
mic
conclus
result
corrobor
role
mprfmutat
resist
develop
toward
daptomycin
howev
studi
must
elucid
complet
mechan
lead
reduc
suscept
spread
produc
k
pneumonia
belong
intern
clone
germani
kaas
jl
schwichtenberg
f
lang
f
szabado
n
pfennigwerth
gatermann
abteilung
medizinisch
mikrobiologi
bochum
deutschland
background
worldwid
spread
carbapenemas
produc
enterobacteriacea
worrisom
sinc
therapeut
option
strain
sever
limit
new
antibiot
licens
near
futur
data
regard
carbapenemas
germani
scarc
studi
focus
spread
carbapenemas
differ
geograph
region
germani
method
strain
elev
carbapenem
mic
sent
nation
refer
laboratori
multidrugresist
gramneg
bacteria
character
carbapenemas
detect
phenotyp
test
pcr
subsequ
sequenc
mic
carbapenem
determin
etest
genet
environ
blakpc
character
set
specif
pcr
plasmid
character
perform
nucleas
restrict
conjung
transfer
plasmid
tri
result
detect
k
pneumonia
e
coli
singl
patient
strain
ten
differ
geograph
region
germani
mic
ertapenem
fell
rang
mgl
imipenem
mgl
meropenem
mgl
modifi
hodgetest
combin
disk
test
boron
acid
posit
strain
pfge
demonstr
related
k
pneumonia
strain
mlst
type
five
exemplari
strain
reveal
pcr
detect
blatem
strain
transconjug
experi
success
one
strain
howev
presenc
blakpc
plasmid
could
demonstr
restrict
endonucleas
southern
blot
pcr
demonstr
surround
show
case
conclus
produc
k
pneumonia
belong
clone
spread
also
germani
similar
report
usa
israel
surround
isoform
low
mic
carbapenem
strain
emphas
detect
carbapenemas
challeng
resist
zink
mrsa
w
witt
c
cuni
robert
koch
institut
bereich
wernigerrod
wernigerod
deutschland
object
find
gene
code
zn
porter
czrc
contain
sccmecv
element
livestock
associ
mrsa
previou
use
zinkoxid
togeth
organ
acid
pig
feed
rais
gener
question
coselect
mrsa
use
zinkoxid
context
interest
whether
czrc
alreadi
known
resist
gene
cada
code
atpas
base
efflux
dissemin
among
differ
clonal
lineag
mrsa
preval
human
livestock
method
defin
collect
mrsa
human
hamrsa
camrsa
anim
lamrsa
attribut
differ
clonal
lineag
phenotyp
suscept
test
mean
microbroth
mic
cation
adjust
mh
broth
pcr
demonstr
zn
resist
gene
cada
czrc
result
czrc
exclus
associ
mrsa
pig
human
expos
pig
infect
infect
human
contain
defin
sccmecel
tandem
ccrc
found
hamrsa
camrsa
central
europ
clonal
lineag
cada
typic
camrsa
expect
also
detect
camrsa
camrsa
among
hamrsa
cada
found
isol
isol
among
hamrsa
two
isol
attribut
contain
cada
one
among
isol
attribut
discuss
exclud
previou
use
zinkoxid
ion
conjunct
organ
acid
feed
addit
select
czrc
possibl
coselect
mrsa
human
medicin
zinkoxid
wide
use
hospit
constitu
ointment
care
skin
wide
dissemin
mrsa
mrsa
iv
ii
remain
suscept
zn
obvious
select
favour
mrsa
respect
multiresist
methicillin
suscept
aureu
complex
past
use
zinkoxid
ointment
contain
also
boron
acid
situat
might
differ
introduct
emerg
healthcar
associ
infect
caus
multidrugresist
gramneg
bacteria
becom
increas
problem
past
year
colistin
forgotten
antibiot
attract
attent
activ
multidrugresist
gramneg
bacteria
howev
activ
proteea
serratia
spp
object
studi
evalu
suscept
clinic
isol
enterobact
cloaca
ecl
escherichia
coli
eco
klebsiella
pneumonia
kpn
klebsiella
oxytoca
kox
pseudomona
aeruginosa
pae
acinetobact
baumannii
group
aba
col
compar
method
total
isol
prospect
collect
microbiolog
laboratori
across
germani
particip
surveil
studi
conduct
paulehrlichsocieti
novemb
mic
col
ciprofloxacin
cip
ceftazidim
caz
gentamicin
gen
meropenem
mem
determin
broth
microdilut
procedur
accord
standard
din
iso
mic
interpret
eucast
criteria
avail
breakpoint
col
mgl
suscept
mgl
resist
clsi
mic
method
use
caz
clavulan
acid
cla
cefotaxim
cla
employ
screen
test
esblproduc
isol
result
isol
primarili
recov
wound
respiratori
specimen
urin
blood
icu
isol
nonicu
isol
eco
kpn
kox
isol
show
esblphenotyp
valu
mgl
display
tabl
eco
isol
suscept
col
mem
cip
gen
ecl
isol
resist
col
respect
suscept
ecl
caz
cip
gen
mem
respect
among
kpn
kox
isol
suscept
col
mem
suscept
cip
gen
respect
col
activ
drug
aba
pae
suscept
rate
either
speci
aba
suscept
compar
vari
cip
mem
suscept
rate
pae
compar
agent
follow
gen
follow
caz
mem
cip
conclus
overal
suscept
col
seem
high
among
gramneg
pathogen
germani
col
may
consid
import
treatment
option
bacteri
pathogen
neisseria
meningitidi
haemophilu
influenza
infrequ
caus
invas
diseas
manifest
sepsi
mening
respect
incid
rate
germani
per
present
antibiot
suscept
data
period
nine
three
year
meningococci
h
influenza
respect
use
gradient
test
system
etest
nondupl
meningococc
strain
test
suscept
benzylpenicillin
rifampicin
ciprofloxacin
meningococc
strain
also
assay
cefotaxim
suscept
nondupl
h
influenza
strain
assay
ampicillin
suscept
meningococci
tempor
trend
minim
inhibitori
concentr
mic
suscept
categor
accord
eucast
observ
strain
categor
suscept
intermedi
resist
penicillin
respect
rate
rifampicinresist
suscept
isol
respect
strain
suscept
ciprofloxacin
test
strain
suscept
cefotaxim
mic
penicillin
depend
serogroup
use
serogroup
b
rare
serogroup
eg
z
x
refer
categori
mean
mic
mgl
serogroup
c
show
signific
deviat
mic
mgl
respect
interestingli
serogroup
strain
intermedi
suscept
penicillin
resist
isol
serogroup
c
serogroup
resist
isol
although
resist
observ
cefotaxim
cefotaxim
mic
show
weak
yet
signific
linear
correl
penicillin
mic
accordingli
mean
cefotaxim
mic
mgl
penicillin
suscept
intermedi
resist
isol
respect
due
low
rate
nonsuscept
meaning
analys
possibl
antimicrobi
rifampicin
ciprofloxacin
meningococci
h
influenza
resist
ampicillin
accord
eucast
downard
tempor
trend
observ
resist
significantli
common
nontyp
h
influenza
lack
polysaccharid
capsul
compar
capsul
strain
rate
betalactamas
product
three
ampicillinresist
strain
total
lack
betalactamas
activ
thu
categor
betalactamasenegativeampicillinresist
blnar
antimicrobi
resist
k
pneumonia
result
german
ar
system
noll
b
schweickert
feig
g
kraus
eckmann
infektionsepidemiologi
berlin
deutschland
introduct
high
preval
resist
invas
k
pneumonia
isol
hospitalis
patient
thirdgener
cephalosporin
fluoroquinolon
fq
aminoglycosid
ag
high
level
combin
resist
class
european
countri
major
result
european
antimicrobi
resist
surveil
network
earsnet
report
germani
ar
antimicrobi
resist
surveil
system
allow
studi
resist
resist
pattern
set
urin
respiratori
sampl
inpati
well
outpati
method
analysi
base
nondupl
isol
k
pneumonia
collect
nine
laboratori
cover
hospit
practic
speci
identif
antimicrobi
suscept
test
perform
vitek
result
evalu
accord
clsi
guidelin
isol
classifi
resist
antibiot
class
show
resist
one
agent
ceftazidim
cefotaxim
ceftriaxon
fq
ciprofloxacin
levofloxacin
ag
gentamicin
tobramicin
amikacin
distinct
class
resist
combin
resist
pattern
result
sampl
compos
nondupl
k
pneumonia
isol
inpati
blood
respiratori
sampl
urin
isol
outpati
respiratori
sampl
urin
result
display
tabl
proport
resist
highest
fq
subset
rang
blood
cultur
inpati
respiratori
sampl
outpati
follow
ag
regard
resist
three
antibiot
class
simultan
reveal
tripl
resist
frequent
pattern
inpati
subset
reach
blood
cultur
respiratori
sampl
urin
outpati
sampl
singl
resist
fq
frequent
pattern
follow
tripl
resist
second
place
account
urin
sampl
respiratori
sampl
discuss
earsnetsurveil
limit
invas
isol
hospitalis
patient
captur
sector
highest
level
antimicrobi
resist
k
pneumonia
extend
approach
ar
reveal
emerg
problem
outpati
care
physician
awar
even
resist
proport
might
overestim
sampl
like
taken
pretreat
patient
german
multicentr
studi
resinet
launch
nation
refer
centr
nrc
h
pylori
aim
ongo
surveil
studi
monitor
prospect
investig
risk
factor
develop
antimicrobi
resist
h
pylori
microbiolog
centr
spread
whole
countri
collabor
gastroenterologist
particip
studi
end
decemb
h
pylori
strain
test
patient
suffer
gastriti
follow
ulcu
ventriculi
duodeni
overal
resist
rate
metronidazol
mz
clarithromycin
cla
fluoroquinolon
fq
doubl
mz
cla
tripleresist
strain
mz
cla
fq
found
respect
antimicrobi
pretreat
main
risk
factor
resist
develop
one
cours
h
pylori
erad
therapi
resist
rate
reach
mz
cla
mz
cla
one
erad
therapi
led
resist
rate
mz
cla
mz
cla
start
studi
strain
resist
mz
end
strain
resist
mz
cla
resist
rate
increas
start
follow
studi
investig
outcom
resinet
patient
patient
examin
far
major
patient
treat
erad
therapi
common
scheme
use
french
tripl
therapi
treatment
patient
report
improv
complaint
complaint
anymor
erad
control
perform
patient
use
ureabreath
test
predominantli
erad
rate
patient
patient
still
h
pylori
posit
treatment
might
explain
high
rate
clarithromycin
resist
within
popul
conclus
result
underlin
hypothesi
develop
resist
h
pylori
contrast
pathogen
depend
treatment
strategi
individu
patient
data
clearli
demonstr
cultur
suscept
test
gastric
biopsi
specimen
mandatori
alreadi
first
treatment
failur
mrsasurveil
germani
data
antibiot
resist
surveil
system
ar
mandatori
surveil
mrsa
blood
cerebrospin
fluid
inhabitantsyear
report
male
year
present
highest
incid
inhabitantsyear
stratif
feder
state
show
consider
region
differ
inhabitantsyear
posit
correl
region
mrsarat
gener
ar
spearman
correl
coeffici
conclus
mandatori
report
mrsabacteraemia
serv
indic
situat
hospit
care
ar
addit
provid
view
outpati
set
expectedli
ambulatori
care
mrsarat
consider
lower
compar
hospit
care
nevertheless
result
indic
germani
mrsa
play
relev
role
outpati
set
well
particularli
high
resist
rate
urin
sampl
suggest
investig
epidemiolog
context
infect
occur
patient
characterist
necessari
assess
possibl
consequ
antibiot
manag
compar
high
carriag
rate
extendedspectrum
betalactamas
produc
escherichia
coli
bird
prey
germani
mongolia
k
aschenbrenn
stamm
beth
stubb
lh
wieler
c
ewer
freie
berlin
institut
mikrobiologi
u
tierseuchen
berlin
deutschland
vet
med
labor
gmbh
ludwigsburg
hall
deutschland
introduct
sever
studi
give
evid
carriag
extendedspectrum
betalactamas
esbl
produc
e
coli
fece
wild
bird
even
remot
area
presenc
antibiot
select
pressur
assum
rare
present
studi
compar
wild
avian
fecal
e
coli
isol
remot
area
mongolia
intens
agricultur
use
area
germani
respect
rate
esbl
product
clonal
related
method
result
cloacal
swab
mostli
taken
juvenil
bird
screen
e
coli
result
number
isol
mean
select
growth
medium
esblproduct
confirm
german
mongolian
avian
e
coli
isol
group
determin
esbl
enzym
ctxm
famili
promin
one
domin
german
sampl
mongolian
one
genotyp
led
frequent
detect
virul
determin
associ
extraintestin
pathogen
wherea
gene
associ
intestin
pathogen
pathovar
rare
observ
phylogenet
type
via
mlst
structur
analysi
reveal
high
rate
ancestr
group
group
link
extraintestin
virul
particularli
german
esbl
strainsmost
mongolian
esbl
strain
assign
phylogenet
group
among
mongolian
sampl
identifi
sever
st
ancestr
group
hybrid
group
abd
previous
report
human
clinic
esbl
produc
isol
macrorestrict
pattern
reveal
clonal
related
wild
avian
fecal
isol
asia
anim
human
clinic
isol
europ
indic
global
interspeci
dissemin
multiresist
strain
conclus
find
underlin
urgent
need
unravel
role
wild
bird
spread
antimicrobi
resist
bacteria
due
migrat
behavior
respect
omnipres
fece
wild
urban
environ
wild
bird
might
repres
nonpoint
sourc
infect
could
consider
contribut
transmiss
esbl
produc
bacteria
frank
r
kd
thoben
biba
ikap
bremen
deutschland
qiagen
hamburg
deutschland
introduct
qrtpcr
wide
use
ten
year
enter
domain
medic
need
detect
microorgan
industri
environ
take
place
method
microbiolog
issu
reduc
time
detect
microorgan
resolv
usag
qrtpcr
method
improv
stronglyal
develop
pcr
analyz
method
need
addit
preprocess
reduc
wide
rang
nois
current
use
method
requir
use
expert
evalu
result
nois
remov
method
need
paramet
correl
detect
nois
adaptioncalibr
execut
manual
process
fact
prevent
usag
qrtpcranalysi
autom
industri
environ
focu
articl
lie
develop
autom
preprocess
method
reduc
significantli
influenc
nois
nois
gener
test
result
two
differ
type
nois
occur
wilhelm
first
type
nois
background
nois
second
type
nois
call
signal
trend
possibl
caus
occurr
yet
resolv
effect
background
nois
signal
trend
repeat
execut
sampl
analysi
may
lead
vari
result
nois
remov
nois
remov
gener
detect
mathemat
formul
background
nois
signal
trend
curv
exist
method
tri
detect
nois
tri
remov
method
use
paramet
control
strength
nois
remov
preprocess
use
curv
smooth
curv
gener
chang
curv
progress
local
extrama
remov
four
phase
exponenti
curv
pronounc
evalu
project
prodiap
project
report
fund
bundesministerium
bildung
und
forschung
support
code
use
refer
evalu
evalu
qualiti
qualit
analysi
smooth
estim
criteria
recal
precis
specif
result
recal
averag
precis
averag
specif
introduct
ulifloxacin
new
fluorochinolon
approv
treatment
lower
urinari
tract
infect
exacerb
chronic
bronchiti
prodrug
prulifloxacin
avail
oral
administr
metabol
liver
activ
form
ulifloxacin
ulifloxacin
demonstr
broad
spectrum
antimicrobi
activ
gramposit
neg
bacteria
studi
suscept
ulifloxacin
compar
fluorochinolon
isol
urinari
tract
infect
materi
method
test
period
april
clinic
isol
urinari
tract
infect
ulifloxacin
ad
routin
resist
test
use
method
disc
diffus
interpret
perform
accord
clsi
criteria
ulifloxacin
disc
contain
interpret
criteria
follow
mm
enterobacteriacea
mm
nonferment
mm
gramposit
bacteria
test
urinari
tract
infect
strain
includ
mainli
e
coli
n
enterobacteriacea
n
pseudomona
sp
n
enterococci
staphylococci
n
result
compar
ulifloxacin
vs
ciprofloxacin
norfloxacin
concord
result
could
obtain
test
strain
differ
interpret
test
substanc
found
isol
e
coli
pseudomona
sp
enterococci
case
ciprofloxacin
norfloxacin
resist
wherea
ulifloxacin
interpret
suscept
case
show
minim
interpret
variat
regard
test
isol
e
coli
n
reveal
suscept
ciprofloxacin
norfloxacin
ulifloxacin
respect
pseudomona
sp
show
suscept
ciprofloxacin
norfloxacin
respect
ulifloxacin
enterococci
follow
result
could
found
suscept
ciprofloxacin
norfloxacin
prulifloxacin
respect
discuss
ulifloxacin
new
fluorochinolon
approv
lower
urinari
tract
infect
compar
result
ciprofloxacin
norfloxacin
ulifloxacin
concord
result
strain
could
obtain
ulifloxacin
activ
ciprofloxacin
norfloxacin
gram
neg
isol
gram
posit
strain
ulifloxacin
slightli
less
activ
ciprofloxacin
norfloxacin
statement
limit
low
number
isol
minor
differ
interpret
suscept
pattern
test
ulifloxacin
andor
chinolon
resist
test
seem
noteworthi
therapi
fluorochinolon
intend
impact
thymidin
antimicrobi
activ
trimethoprimsulfamethoxazol
rifampicin
staphylococcu
aureu
object
treatment
option
aureu
gener
mrsa
particular
trimethoprimsulfamethoxazol
sxt
either
alon
combin
rifampicin
rif
sxt
inhibit
differ
enzymat
step
folic
acid
pathway
lead
cessat
bacteri
synthesi
thymidin
monophosph
via
thymidyl
synthas
howev
antimicrobi
activ
sxt
antagonis
bacteri
utilis
thymidin
present
infect
andor
inflam
tissu
airway
cystic
fibrosi
cf
patient
aim
studi
determin
thymidin
concentr
sputa
cf
patient
analys
antimicrobi
activ
sxt
idurd
rif
alon
combin
aureu
presenc
thymidin
materi
method
thymidin
concentr
cf
sputa
determin
high
perform
liquid
chromatographi
antimicrobi
activ
sxt
idurd
rif
alon
combin
aureu
analys
time
kill
assay
result
thymidin
concentr
sputa
ten
differ
cf
patient
vari
abolish
antimicrobi
activ
sxt
aureu
strain
presenc
thymidin
restor
combin
idurd
contrast
sxt
combin
rif
presenc
thymidin
show
synergist
effect
furthermor
allow
emerg
rifresist
bacteria
ad
rif
combin
sxt
idurd
improv
antimicrobi
activ
aureu
conclus
data
suggest
sxt
combin
rifampicin
may
fail
cure
clinic
aureu
infect
tissu
elev
thymidin
concentr
sxt
combin
thymidin
kinas
inhibitor
howev
may
becom
interest
antimicrobi
combin
set
futur
vitro
vivo
studi
therefor
requir
nonnucleosid
analog
bacteri
thymidin
kinas
inhibitor
identifi
multistep
virtual
screen
object
antimicrobi
activ
folic
acid
antagonist
antagon
thymidin
detect
tissu
necrot
cell
pu
sputum
cystic
fibrosi
patient
trimethoprimsulfamethoxazol
sxt
inhibit
differ
enzymat
step
folic
acid
pathway
lead
cessat
bacteri
synthesi
deoxythymidin
monophosph
dtmp
thymidyl
synthas
howev
sever
bacteri
speci
includ
aureu
possess
altern
pathway
synthesi
intracellular
dtmp
uptak
extracellular
thymidin
subsequ
intracellular
phosphoryl
dtmp
via
thymidin
kinas
studi
aim
screen
nonnucleosid
analog
inhibitor
aureu
thymidin
kinas
multistep
virtual
screen
ii
determin
vitro
activ
thymidin
kinas
inhibitor
aureu
combin
sxt
presenc
thymidin
materi
method
adapt
virtual
screen
protocol
novel
antibiot
use
combin
ligandand
structurebas
approach
appli
two
consecut
round
virtual
screen
vitro
suscept
test
perform
result
sever
nonnucleosid
hit
result
potent
compound
exhibit
substanti
antimicrobi
activ
methicillinresist
aureu
strain
atcc
nonresist
strain
atcc
combin
sxt
presenc
thymidin
conclus
studi
demonstr
multistep
virtual
screen
help
identifi
bioactiv
substanc
larg
screen
compound
pool
limit
experiment
effort
rapid
focus
promis
candid
structur
possibl
inhibitor
bacteri
thymidin
kinas
nonnucleosid
scaffold
identifi
inhibitori
compound
exhibit
moder
high
antimicrobi
activ
combin
folic
acid
antagonist
presenc
thymidin
provid
rich
opportun
optim
drug
bug
bacteri
protein
yopm
autonom
antiinflammatori
agent
reduc
inflamm
rheumatoid
arthriti
c
j
bertrand
j
scharnert
c
cromm
pap
schmidt
zmbe
infektiologi
deutschland
ukm
institut
experiment
musculoskelet
medicin
deutschland
cellperm
protein
cellpenetr
peptid
cpp
abil
cross
cellular
membran
either
alon
associ
bioactiv
cargo
identifi
yersinia
protein
yopm
novel
bacteri
cellperm
protein
describ
abil
isol
recombin
yopm
enter
host
cell
without
requir
addit
factor
furthermor
treatment
cell
recombin
yopm
lead
downregul
inflammatori
cytokin
tnf
might
contribut
system
effect
innat
immun
furthermor
suggest
potenti
therapeut
applic
yopm
eg
chronic
inflammatori
diseas
henc
interest
investig
whether
yopm
might
potenti
act
immun
modul
molecul
exhibit
benefici
effect
inflamm
product
cytokin
maintain
inflammatori
process
link
autoimmun
diseas
rheumatoid
arthriti
ra
first
analyz
penetr
recombin
yopm
cell
activ
drive
joint
bone
destruct
ra
bone
marrow
macrophag
osteoclast
synovi
fibroblast
confoc
laser
scan
microscopi
addit
studi
effect
yopm
osteoclastogenesi
use
vitro
osteoclast
format
assay
unravel
signal
pathway
involv
effect
yopm
cellular
activ
differenti
investig
activ
mapkinas
nf
b
signal
western
blot
analysi
respect
potenti
vivo
applic
yopm
inject
yopm
intraarticularli
ia
intraven
iv
wildtyp
htnftg
mice
monitor
distribut
fluoresc
reflect
imag
fri
furthermor
effect
yopm
diseas
manifest
monitor
histopatholog
establish
clinic
score
investig
reveal
insid
radriv
cell
yopm
effect
reduc
tnf
induc
product
proinflammatori
cytokin
cartilagedegrad
enzym
eg
furthermor
yopm
also
capabl
prevent
structur
damag
inhibit
rankl
induc
osteoclastogenesi
murin
bone
marrow
cell
via
nf
bpathway
ia
inject
protein
htnftg
mice
observ
drastic
reduc
onset
symptom
inflamm
skelet
joint
encourag
result
combin
possibl
focus
topic
applic
skelet
joint
underlin
strengthen
potenti
yopm
novel
pathogenderiv
immun
modulatori
agent
treatment
inflammatori
ra
comparison
genotyp
proteotyp
phenotyp
method
identif
bacteria
patel
u
herber
accugenix
market
newark
deutschland
accur
classif
unknown
bacteri
isol
essenti
first
step
understand
impact
organ
environment
monitor
program
mani
method
technolog
strategi
util
determin
ident
unknown
microorgan
howev
select
method
often
impact
perform
technolog
cost
time
amount
expertis
requir
perform
assay
major
point
consid
select
process
current
avail
method
identif
rang
genotyp
phenotyp
sequenc
univers
acknowledg
standard
routin
bacteri
identif
still
even
variabl
within
process
sequenc
method
compar
identif
base
phenotyp
characterist
method
subject
result
impact
mani
variabl
first
practic
proteotyp
identif
system
util
matrixassist
laser
desorptionion
time
flight
malditof
spectroscopi
microbi
identif
technolog
base
whole
cell
protein
profil
subject
less
express
variabl
phenotyp
system
studi
directli
compar
perform
sever
technolog
includ
metabol
profil
biomerieux
compact
malditof
bruker
autom
dna
sequenc
analysi
abi
dna
sequenc
referencequ
custom
data
analysi
process
curat
librari
accugenix
microbi
identif
method
use
analyz
unknown
environment
bacteri
isol
accuraci
well
assay
cost
time
eas
use
method
discuss
rrna
gene
sequenc
remain
standard
microbi
identif
environment
isol
proteotyp
malditof
technolog
outperform
phenotyp
method
without
compromis
assay
cost
turnaround
time
poceva
c
rueter
k
loser
schmidt
wwu
muenster
institut
infectiolog
zmbe
muenster
depart
dermatolog
muenster
deutschland
psoriasi
one
common
immunemedi
chronic
inflammatori
skin
disord
affect
approxim
popul
consid
incur
lifelong
skin
condit
affect
race
age
group
sex
pathogenesi
psoriasi
complex
clearli
understood
ongo
research
indic
immun
tcell
appear
play
domin
role
develop
diseas
cell
releas
tnfa
ifnand
proinflammatori
cytokin
lead
vasodil
leukocyt
migrat
activ
keratinocyt
activ
dendrit
cell
turn
lead
inflamm
common
disadvantag
besid
side
effect
drug
current
avail
treat
primarili
cutan
diseas
effect
given
system
larg
ineffect
appli
topic
previou
work
identifi
yopm
yersinia
enterocolitica
bacteri
cpp
capabl
penetr
eukaryot
cell
without
need
addit
factor
moreov
show
cellpenetr
yopm
effici
downregul
transcript
sever
proinflammatori
cytokin
eg
tnf
therefor
yopm
might
applic
topic
therapeut
agent
treatment
psoriasi
investig
whether
yopm
might
function
immunemodul
treatment
psoriasi
util
murin
imiquimod
imq
induc
psoriasi
model
model
daili
topic
applic
imiquimod
imq
ligand
potent
immun
activ
mous
back
skin
induc
exacerb
psoriasi
therefor
model
could
serv
analysi
pathogen
mechan
psoriasislik
dermat
appli
yopm
either
topic
intraperiton
subcutan
inject
everi
h
group
mice
period
two
week
current
result
confirm
selfdeliv
abil
yopm
across
cutan
barrier
topic
appli
yopm
alreadi
indic
remark
dampen
overt
inflammatori
reaction
repress
diseas
symptom
also
found
group
mice
subcutan
inject
yopm
wherea
signific
phenotyp
chang
observ
intraperiton
inject
mice
genom
island
legionella
pneumophila
corbi
lautner
v
herrmann
k
rydzewski
k
heuner
berlin
deutschland
exchang
genet
inform
horizont
gene
transfer
import
mechan
evolut
bacteri
genom
horizont
gene
transfer
also
observ
legionella
pneumophila
legionella
speci
genom
legionella
pneumophila
corbi
identifi
character
new
trbtra
conjug
type
iva
secret
system
local
genom
island
genom
island
integr
within
trna
pro
gene
exist
integr
chromosom
episom
circular
form
addit
essenti
trbtra
gene
requir
conjug
orit
region
sitespecif
integras
legionella
vir
region
lvr
also
identifi
delet
gene
could
demonstr
excis
form
episom
circl
integras
depend
first
experi
mutant
lack
vir
region
also
indic
growth
depend
regul
alter
integr
circular
form
whole
genom
island
transfer
legionella
strain
integr
sitespecif
genom
transconjug
use
mutant
donor
conjug
experi
obtain
reduc
conjug
frequenc
compar
parent
strain
analysi
l
pneumohila
corbi
genom
led
identif
two
addit
genom
island
flank
trna
gene
exhibit
sever
put
integras
island
exhibit
lvr
region
gene
trag
trad
pilt
hel
gene
locu
addit
contain
gene
encod
atp
synthas
variou
efflux
system
heavi
metal
toxic
substanc
similar
genom
island
also
present
genom
l
pneumophila
philadelphia
pari
len
alcoy
could
demonstr
genom
island
exist
integr
chromosom
exercis
episom
form
similar
product
lasparaginas
proteasedefici
bacillu
megaterium
character
product
optim
unravel
glycosphingolipid
receptor
enterohemorrhag
escherichia
coli
mean
solid
phase
bacteri
adhes
assay
combin
irmaldi
mass
spectrometri
glycosphingolipid
gsl
play
pivot
role
manifest
infecti
diseas
attach
site
pathogen
mani
germ
known
exploit
gsl
target
surfac
mammalian
cell
initi
protein
pathogen
carbohydr
host
interact
contribut
colon
virul
mani
pathogen
enterohemorrhag
e
coli
ehec
caus
diarrhea
bloodi
diarrhea
hemolyticurem
syndrom
human
although
substanti
amount
inform
gslreceptor
shiga
toxin
stx
major
virul
factor
ehec
avail
less
known
receptor
ehec
bacteri
cell
thinlay
chromatographi
tlc
overlay
assay
coupl
infrar
matrixassist
laser
desorptionion
orthogon
timeofflight
mass
spectrometri
irmaldiotofm
repres
power
tool
detect
structur
character
gsl
receptor
microorgan
report
employ
strategi
aim
identif
structur
character
gslreceptor
common
ehec
e
coli
consist
two
type
nonsorbitolfer
strain
serotyp
spread
worldwid
sfpfimbriat
sorbitolfer
nonmotil
strain
nm
pathogen
europ
present
studi
potenti
gsl
recognit
variou
ehec
strain
investig
employ
neutral
gsl
sialyl
gsl
gangliosid
differ
type
mammalian
cell
abl
identifi
certain
neutral
gsl
carri
oligosaccharid
configur
termin
galactos
residu
show
bind
activ
toward
ehec
type
interact
contrast
common
bind
structur
stx
specif
recogn
neutral
gsl
link
galactos
molecul
ehecbind
gsl
character
irmaldiotofm
parallel
tlc
overlay
assay
use
specif
antigsl
antibodi
gangliosid
ii
termin
sialyl
gangliosid
neolactoseri
core
neg
indic
sialyl
abrog
ehec
interact
conclus
studi
may
help
better
understand
hostpathogen
interact
particular
adhes
process
ehec
toward
target
cell
moreov
develop
strategi
prevent
treat
ehec
infect
work
support
grant
deutsch
forschungsgemeinschaft
dfg
fund
intern
graduat
school
grk
collabor
project
hk
jm
glycosphingolipid
shiga
toxin
receptor
lymphoid
myeloid
cell
line
subcellular
receptor
distribut
express
profil
glycosyltransferas
relat
biosynthesi
pathway
glycosphingolipid
gsl
amphipath
membran
constitu
compris
hydrophil
oligosaccharid
chain
hydrophob
ceramid
moieti
ceramid
lipid
anchor
gsl
embed
outer
leaflet
plasma
membran
carbohydr
chain
protrud
extracellular
environ
gsl
preferenti
organ
microdomain
known
lipid
raft
play
crucial
function
role
gslmediat
cellsurfac
interact
gsl
organ
lipid
raft
capabl
effici
interact
pathogen
virus
bacteria
pathogenreleas
virul
factor
like
bacteri
toxin
microdomain
associ
gsl
believ
linchpin
effect
bind
intern
subcellular
rout
gslbind
shiga
toxin
stx
intracellular
target
pentamer
bsubunit
stx
specif
bind
high
low
affin
neutral
gsl
globotriaosylceramid
globotetraosylceramid
respect
investig
focus
interact
analysi
stx
gsl
receptor
express
surfac
leukocyt
deriv
cell
line
structur
character
globoseri
neutral
gsl
mean
electrospray
ioniz
quadrupol
timeofflight
mass
spectrometri
esiqtofm
collisioninduc
dissoci
cid
conjunct
stx
well
antibodi
bind
assay
reveal
preval
stxreceptor
cell
line
lymphoid
b
cell
myeloid
monocyt
origin
studi
subcellular
distribut
stx
receptor
cell
type
show
predomin
associ
enrich
lipid
raft
also
provid
data
high
sensit
stx
gsl
receptor
posit
bcell
monocyt
descend
expect
gsl
profil
granulocyt
tcell
deriv
cell
line
lack
stxreceptor
found
resist
cytotox
action
stx
moreov
studi
express
glycosyltransferas
respons
biosynthesi
gsl
receptor
show
high
complianc
immunostain
gsl
isol
find
provid
basi
explor
function
role
lipid
raftassoci
stxreceptor
cell
leukocyt
origin
work
support
grant
deutsch
forschungsgemeinschaft
dfg
fund
intern
graduat
school
grk
collabor
project
jm
hk
biolog
activ
bacillu
extract
legionella
f
frese
j
tiefenau
rohd
tu
braunschweig
institut
mikrobiologi
braunschweig
deutschland
helmholtz
zentrum
infektionsforschung
braunschweig
deutschland
legionella
pneumophila
intracellular
parasit
aquat
soil
protozoa
due
manmad
water
system
like
cool
tower
air
condit
system
l
pneumophila
also
abl
accident
infect
human
caus
sever
sometim
fatal
pneumonia
term
diseas
bacterialprotozoa
interact
shelter
biofilm
lead
remark
resist
biocid
compound
chlorin
thu
repres
ecolog
nich
legionella
persist
manmad
environ
air
sampl
isol
two
differ
bacillu
speci
show
strong
growthinhibitori
activ
legionella
agar
plate
observ
inhibitori
activ
legionellaspecif
sinc
growth
brought
spectrum
gramposit
gramneg
bacteria
affect
rdna
sequenc
two
bacilli
strain
identifi
bacillu
pumilu
bacillu
licheniformi
inhibitori
compound
purifi
bacillu
cultur
solvent
extract
bind
resin
compound
reveal
resist
high
temperatur
min
remain
activ
agar
growthinhibit
assay
acid
ph
alkali
ph
treatment
respect
human
blood
agar
plate
compound
exhibit
hemolyt
activ
minim
inhibitori
concentr
mic
determin
liquid
assay
bacteriaml
crude
extract
show
specif
bactericid
activ
l
pneumophila
mic
wherea
concentr
abl
inhibit
gramneg
gramposit
bacteria
cytotox
compound
human
lung
epitheli
cell
line
analyz
mtt
assay
compar
high
bactericid
activ
crude
extract
show
low
cytotox
effect
eukaryot
cell
concentr
phenotyp
character
transmiss
electron
microcopi
tem
coincub
l
pneumophila
b
licheniformi
b
pumilu
extract
h
reveal
dosedepend
effect
l
pneumophila
membran
integr
bacteri
cell
exhibit
increas
bleb
plasmolysi
narrow
spectrum
activ
result
tem
reveal
specif
interact
bacilli
extract
highli
hydrophob
structur
uniqu
membran
legionella
promis
initi
data
suggest
character
compound
evalu
put
applic
function
analysi
translat
elong
factor
eftu
chlamydophila
pneumonia
de
benedetti
gaballah
hg
sahl
b
henrichfreis
univers
bonn
pharmaceut
microbiolog
bonn
deutschland
bacteri
translat
elong
factor
eftu
well
known
involveld
prokaryot
protein
biosynthesi
eftu
escherichia
coli
shown
polymer
vitro
recent
studi
provid
evid
protein
serv
besid
function
translat
anoth
vital
role
bacillu
subtili
affect
cell
morpholog
appar
via
interact
cytoskeleton
protein
mreb
rodshap
bacteria
actinortholog
mreb
thought
direct
incorpor
cell
wall
materi
side
wall
surprisingli
chlamydia
harbor
despit
spheric
shape
absenc
cell
wall
mreb
recent
prove
vitro
activ
protein
show
chlamydi
eftu
function
vitro
purifi
streptag
protein
polymer
concentr
ph
ion
strength
depend
fashion
light
scatter
sediment
assay
addit
copolymer
assay
reveal
interact
elong
factor
cytoskelet
protein
mreb
deeper
insight
function
eftu
role
chlamydi
cell
biolog
molecular
level
provid
valuabl
inform
design
new
antichlamydi
antibiot
ecolog
fit
investig
antibiot
resist
mutant
legionella
pneumophila
strain
mtz
olda
natur
condit
artifici
microcosm
koshkolda
c
tud
medic
microbiolog
hygien
dresden
deutschland
legionella
pneumophila
gramneg
rodshap
bacterium
ubiquit
bacterium
caus
two
form
legionellosi
legionellapneumonia
pontiac
fiver
newer
macrolid
fluoroquinolon
current
drug
choic
treatment
legionellosi
although
failur
therapi
occur
time
time
report
isol
macrolid
quinolonresist
legionella
mutant
patient
environ
date
number
macrolid
resist
mutant
l
pneumophila
strain
mtz
olda
select
vitro
use
twostep
select
investig
interact
legionella
antibiot
resist
mutant
protozoan
host
influenc
environment
flora
use
previous
establish
natur
microcosm
simul
natur
condit
microcosm
establish
base
microbi
commun
water
suppli
larg
build
divers
commun
determin
use
rrna
clone
librari
includ
multipl
heterotroph
speci
sphingomona
sp
chromobact
sp
flavimona
sp
addit
microcosm
contain
l
pneumophila
strain
mtz
olda
wild
type
amoeba
strain
hartmanella
sp
result
show
resist
mutant
surviv
within
microcosm
disappear
approx
ten
week
cultiv
furthermor
less
fit
cocultiv
experi
reduc
ecolog
fit
macrolid
resist
mutant
might
explan
lack
occurr
resist
strain
natur
condit
hundr
year
known
patient
solid
tumor
concomitantli
suffer
bacteri
infect
experi
regress
tumor
burden
still
phenomenon
bacteri
tumor
target
lysi
remain
poorli
understood
vision
behind
protumor
research
project
explor
mechan
bacteri
oncolysi
also
among
thing
find
way
augment
effect
amid
sever
theoret
interest
approach
focus
effort
immunosuppress
proinflammatori
cytokin
immunosuppress
cytokin
suppos
expand
inoculum
tumor
enabl
bacteria
penetr
host
immun
defens
shield
tumor
total
lysi
hand
proinflammatori
cytokin
attract
inflammatori
cell
boost
nk
cell
tcell
activ
eventu
lead
tumor
vaccin
go
present
first
result
recombin
fusion
protein
express
e
coli
cytokin
correspond
monomer
protein
link
glycineserinelink
order
achiev
improv
stabil
optim
yield
biolog
activ
protein
gene
use
synthes
codonoptim
dna
sequenc
commerci
provid
recombin
protein
secret
periplasmat
fraction
help
ompf
signal
sequenc
e
coli
fusion
protein
express
e
coli
origami
b
vari
condit
quantiti
express
determin
quantit
elisa
techniqu
biolog
activ
assess
cellbas
assay
measur
phosphoryl
transcript
factor
gunkel
sachs
w
pfister
e
straub
sobk
institut
medic
microbiolog
jena
deutschland
preceed
decad
mark
effici
spread
enterobacteriacea
carri
esbl
phenotyp
germani
european
countri
face
alarm
distribut
carbapenemas
harbour
isol
refer
superbug
yellow
press
isol
resist
except
monolactam
andlik
esbltyp
carri
resist
marker
basi
structur
differ
carbapenemas
divid
sever
class
superbug
enzym
like
belong
class
b
metalloenzym
requir
zinc
catalyt
centr
inhibit
lactamas
activ
cation
chelat
edta
use
screen
procedur
howev
edta
found
widespread
applic
conserv
clinic
use
hamper
toxic
side
effect
look
clinic
administr
altern
studi
cation
chelat
broadspectrum
antibiot
nitroxolin
nit
monodisk
assay
carri
carbapenemas
express
strain
appli
either
edta
nit
imipenem
disk
interact
nit
imipenem
evalu
checkerboard
assay
hydrolyt
activ
cell
lysat
whole
cell
suspens
follow
spectrophotometr
nm
presenc
absenc
nit
imipenem
pb
hour
nit
compar
effect
edta
monodisk
assay
checkerboard
assay
synerg
demonstr
nit
imipenem
strain
harbour
class
b
enzym
addit
indiffer
effect
observ
strain
express
class
lactamas
hydrolysi
imipenem
vim
imp
enzym
inhibit
nit
concentrationdepend
manner
complet
inhibit
reach
nit
wherea
effect
kpc
enzym
activ
note
class
inhibitori
effect
depend
respect
carbapenemas
type
influenc
bacteri
speci
carri
enzym
integr
bacteria
differ
lysat
cell
suspens
inhibit
complet
resolv
addit
zn
incub
mixtur
wherea
ni
minim
effect
conclus
found
nit
effect
inhibitor
class
b
carbapenemas
antibiot
clinic
use
last
year
without
seriou
side
effect
report
constitut
promis
candid
develop
new
therapeut
strategi
factor
influenc
result
microbi
surfac
water
test
south
africa
problem
statement
faecal
coliform
hydrogensulphid
test
e
coli
use
monitor
microbi
water
qualiti
rhodococcu
coprophilu
indic
faecal
contamin
anim
sourc
cattl
mutual
agreement
factor
influenc
result
studi
detail
south
africa
thu
studi
conduct
sampl
site
eastern
cape
provinc
south
africa
address
knowledg
gap
materi
method
sampl
site
locat
makana
buffalo
municip
concentr
faecal
coliform
e
coli
measur
either
use
mpn
procedur
medium
membran
filtrat
techniqu
mfc
agar
indol
test
cultiv
alway
conduct
concentr
rhodococcu
coprophilu
measur
spreadplat
use
medium
cultiv
day
hydrogensulphid
test
medium
contain
deoxychol
grab
sampl
water
column
sediment
transport
laboratori
sediment
sampl
extract
vortex
onequart
strength
ringer
solut
model
water
select
sampl
site
prepar
surviv
faecal
coliform
hydrogensulphid
test
bacteria
measur
result
concentr
faecal
coliform
e
coli
rang
x
cell
ml
suspens
accumul
sediment
led
concentr
chang
rang
posit
result
hydrogensulphid
test
observ
hour
result
suscept
influenc
sediment
resuspens
temperatur
vari
sampl
collect
transport
chang
result
hydrogensulphid
test
level
rhodococcu
coprophilu
rang
x
ml
suspens
sediment
matter
onsit
took
place
would
lead
chang
bacteri
concentr
surviv
studi
show
faecal
coliform
hydrogensulphid
produc
bacteria
surviv
day
faecal
contamin
depend
chemic
composit
water
column
conclus
resuspens
sediment
particl
compromis
result
microbi
water
qualiti
test
temperatur
fluctuat
expect
influenc
applic
hydrogensulphid
test
detect
faecal
contamin
surfac
water
adapt
multiplex
pcr
analyt
detect
microorgan
contamin
industri
product
emuls
paint
r
bj
sporkert
frank
qiagen
hamburg
gmbh
r
hamburg
deutschland
jw
ostendorf
gmbh
cokg
produkt
coesfeld
deutschland
biba
gmbh
bremen
deutschland
introduct
classic
microbiolog
coloni
count
agar
plate
diagnost
gold
standard
detect
microbi
contamin
mc
raw
materi
intermedi
good
final
product
industri
emuls
paint
product
timetoresult
take
day
correct
action
like
separ
clean
contamin
good
addit
preserv
usual
retrospect
sustain
intim
manag
emuls
paint
product
reli
fast
quantit
mc
analysi
product
effect
separ
therebi
minim
preserv
input
wast
contamin
emuls
paint
aim
studi
overal
process
optim
introduct
faster
sensit
analysi
method
trace
microbi
contamin
within
product
line
lead
german
emuls
paint
produc
propos
fast
sensit
multiplex
pcr
assay
detect
mc
develop
evalu
gold
standard
method
method
qrtpcr
well
establish
medic
routin
diagnost
human
microbi
infect
studi
focus
method
adapt
effect
dna
prepar
emuls
paint
sampl
develop
multiplex
qrt
pcr
assay
detect
relev
mc
emuls
paint
precursor
product
addit
new
pcr
expert
softwar
autom
result
analysi
qrtpcr
run
rotorgen
instrument
rg
develop
order
standard
analysi
qrt
pcr
data
result
function
multiplex
qrt
pcr
assay
central
tool
qualiti
control
trace
spike
mc
emuls
paint
sampl
demonstr
evalu
gold
standard
pcr
method
clearli
faster
equal
sensit
classic
microbiolog
plate
count
regard
readi
emuls
paint
fail
appli
raw
materi
contain
pure
acryl
compound
clearli
due
insuffici
separ
highli
pcr
inhibitori
acryl
compound
simpli
pass
dna
prepar
column
use
studi
pcr
run
analys
twice
manual
use
standard
rg
softwar
automat
use
new
pcr
expert
softwar
discrep
result
found
conclus
develop
effort
would
need
optim
sampl
prepar
special
focu
remov
inhibitori
emuls
paint
compound
method
run
must
easili
adapt
integr
sampl
analysi
robot
appli
qrtpcr
autom
analysi
interpret
result
requir
crucial
sinc
final
qrtpcr
base
qc
strategi
abl
manag
emuls
paint
product
without
interact
human
pcr
expert
model
environ
jwo
coesfeld
introduct
object
pharmaceuticalwat
system
known
harbor
biofilm
even
though
environ
oligotroph
often
contain
disinfect
control
biofilm
import
aesthet
regulatori
reason
pharmaceut
water
bacteria
affect
environ
live
also
varieti
speci
present
perform
studi
interact
present
multispeci
biofilm
basic
knowledg
sever
aspect
sociomicrobiolog
gain
aim
work
assess
role
interspeci
interact
speci
biofilm
format
characterist
materi
method
microorgan
use
throughout
studi
isol
model
laboratori
pharmaceuticalwat
distribut
system
preliminari
presumpt
bacteria
identif
done
use
select
media
chromocult
tbx
agar
pseudomona
isol
agar
methanol
minimum
medium
gram
stain
biochem
method
order
assess
biofilm
format
abil
specif
respiratori
activ
sever
bacteria
isol
pharmaceut
water
standard
microtit
plate
cristal
violet
xtt
stain
use
character
biofilm
result
rank
biofilm
format
produc
accord
method
et
al
classifi
test
bacteria
nonbiofilm
produc
weak
biofilm
produc
moder
biofilm
produc
strong
biofilm
produc
conclus
biofilm
recogn
focal
point
bacteria
microorgan
interact
recent
investig
microbi
ecolog
pharmaceut
water
system
found
pathogen
resist
chlorin
affect
commun
biodivers
interspeci
relationship
rang
interact
observ
among
microorgan
biofilm
includ
competit
mutualist
antagonist
commens
relationship
work
bacteri
isol
test
recogn
problemat
opportunist
bacteria
select
bacteri
speci
also
detect
pharmaceuticalwat
biofilm
biofilm
pharmaceuticalwat
campylobact
jejuni
secretori
protein
suitabl
antigen
serodiagnost
j
corso
r
lugert
u
ae
zautner
medizinisch
mikrobiologi
deutschland
campylobact
spp
worldwid
lead
caus
bacteri
gastroenter
main
reservoir
therefor
common
caus
infect
poultri
primari
campylobacteriosi
manifest
diarrhea
mainli
diagnos
stool
cultur
follow
infect
risk
suffer
sequela
reactiv
arthriti
neuropathia
myositi
postinfecti
complic
trace
serolog
assay
sensit
specif
test
suffer
sinc
base
crude
whole
cell
lysat
entail
cross
reactivit
relat
speci
henc
use
speci
specif
antigen
becom
favor
c
jejuni
secret
number
protein
amongst
other
requir
cell
invas
therefor
confer
pathogen
germ
protein
presum
highli
antigen
due
exposur
host
immun
system
may
use
antigen
diagnost
purpos
studi
could
demonstr
recombinant
produc
one
secret
protein
similar
sensit
specif
compar
alreadi
commerci
establish
antigen
background
horizont
gene
transfer
play
import
role
bacteri
evolut
dna
acquir
horizont
gene
transfer
incorpor
exist
regulatori
network
histonelik
nucleoid
structur
protein
hn
act
silenc
horizont
acquir
gene
avoid
potenti
damag
analyz
influenc
hn
transcript
horizont
acquir
pyp
regulatori
network
control
transcript
hrep
gene
encod
proteinas
essenti
full
virul
yersinia
enterocolitica
method
use
galactosidas
biofilm
assay
effect
dominantneg
hn
variant
hn
gene
express
hrep
regul
pypa
pypb
pypc
analyz
util
electrophoret
mobil
shift
assay
emsa
interact
hn
promot
region
hrep
pyp
gene
investig
result
hn
repress
transcript
pypa
pypb
pypc
e
coli
moreov
dominantneg
version
hn
reliev
repress
hrep
pyp
gene
enterocolitica
rova
antagonist
hn
yersinia
activ
transcript
pypc
pypa
pypb
hrep
emsa
show
hn
interact
directli
promot
region
hrep
pyp
gene
addit
analysi
biofilm
format
clearli
demonstr
overproduct
hn
strongli
increas
format
biofilm
conclus
studi
reveal
hrep
pyp
gene
part
complex
regulatori
network
repress
hn
underlin
hypothesi
gene
acquir
horizont
result
also
underscor
dominantneg
version
hn
hn
protein
import
valuabl
tool
studi
hnsdepend
phenotyp
strain
hn
delet
lethal
yersinia
spp
hostspecif
flagellin
recognit
salmonella
entericainfect
cell
maurischat
p
schwerk
lh
wieler
k
tedin
fu
berlin
institut
f
mikrobiologi
tierseuchen
fachbereich
berlin
deutschland
bacteri
flagellin
one
major
pathogenassoci
molecular
pattern
play
pivot
role
recognit
salmonella
tolllik
receptor
intracellularli
nodlik
receptor
ipaf
pathway
trigger
inflammatori
process
though
host
immun
respons
prevent
infect
salmonella
import
zoonot
pathogen
abl
infect
caus
diseas
human
anim
rang
reptil
mammal
depend
serovar
host
speci
age
immun
statu
cours
diseas
rang
asymptomat
carriag
local
acut
diarrhea
sever
system
infect
fatal
outcom
evalu
possibl
host
differ
flagellin
recognit
human
anim
cell
subsequ
induct
immunostimulatori
signal
cascad
use
activ
transcript
factor
nuclear
factor
b
nfb
nfb
report
cell
line
differ
speci
origin
express
luciferas
nfb
activ
mutant
salmonella
enterica
differ
flagellar
gene
delet
flic
fljb
flid
flhdc
express
pattern
use
infect
nfb
report
cell
line
human
porcin
avian
origin
lovo
loss
flagellarassoci
gene
affect
invas
salmonella
differ
cell
differ
host
speci
addit
loss
flagella
affect
nfb
activ
human
macrophag
epitheli
cell
porcin
chicken
cell
vari
behaviour
sens
salmonella
flagellin
differ
host
speci
might
contribut
differ
outcom
infect
host
adapt
salmonella
serovar
shiga
toxin
stx
secret
stxproduc
escherichia
coli
stec
caus
diarrhea
bloodi
diarrhea
potenti
lethal
hemolyticurem
syndrom
hu
stx
toxin
compos
singl
asubunit
ident
bsubunit
catalyt
asubunit
rrna
nglycosidas
activ
inhibit
eukaryot
protein
biosynthesi
pentamer
bsubunit
respons
bind
highand
lesseffect
cell
surfac
glycosphingolipid
gsl
receptor
globotriaosylceramid
globotetraosylceramid
respect
although
preferenti
stxmediat
damag
glomerular
microvascular
endotheli
cell
gmvec
known
major
mechan
underli
hu
caus
stec
exact
natur
stx
receptor
gsl
gmvec
includ
express
differ
lipoform
remain
defin
report
first
time
structur
stx
receptor
gmvec
employ
combin
thinlay
chromatographi
tlc
immunostain
use
antibodi
biophys
mass
spectrometrybas
analysi
full
structur
character
stx
receptor
achiev
electrospray
ioniz
esi
mass
spectrometri
combin
collisioninduc
dissoci
cid
analysi
lipoform
ceramid
moieti
mainli
compos
fatti
acid
sphingosin
determin
gmvec
lipoform
compar
previous
detect
human
brain
microvascular
endotheli
cell
hbmec
thinlay
chromatographi
tlc
immunostain
isol
gsl
demonstr
higher
content
higher
content
gmvec
hbmec
compar
cytotox
assay
reveal
high
cytotox
stx
toward
gmvec
dosedepend
manner
importantli
stx
caus
significantli
higher
toxic
effect
gmvec
hbmec
whole
span
appli
concentr
higher
sensit
gmvec
correl
enhanc
express
stxreceptor
gmvec
howev
gsl
believ
local
abundantli
lipid
raft
tightli
associ
cholesterol
raftassoci
membran
protein
sinc
lipid
raft
associ
stx
receptor
assum
function
prerequisit
stxmediat
cytotox
futur
investig
subcellular
distribut
gsl
gmvec
requir
explor
function
role
molecular
assembl
gsl
microdomain
gmvec
influenc
cag
type
iv
secret
system
helicobact
pylori
migrat
phagocyt
c
weiss
w
fischer
max
von
pettenkof
institut
helicobact
pylori
deutschland
cag
type
iv
secret
system
known
major
virul
factor
gramneg
bacteria
helicobact
pylori
togeth
caga
effector
protein
encod
cag
pathogen
island
cagpai
presenc
associ
sever
diseas
abl
transloc
caga
directli
host
cell
epitheli
cell
consequ
infect
host
cell
subject
sever
chang
actin
cytoskeleton
rearrang
loss
cell
polar
moreov
epitheli
cell
stimul
produc
secret
chemokin
h
pylori
induc
massiv
inflammatori
respons
host
effect
elimin
immun
system
therefor
like
h
pylori
abl
modul
immun
respons
advantag
studi
examin
interact
phagocyt
cag
shown
macrophag
aggreg
influenc
cag
caga
transloc
cell
well
infect
phagocyt
cell
line
freshli
isol
human
phagocyt
granulocyt
dendrit
cell
h
pylori
examin
migrat
chemotact
gradient
use
two
method
examin
cell
migrat
timelaps
microscopi
threedimension
collagen
gel
migrat
transwel
boyden
chamber
confirm
caga
transloc
cell
examin
subsequ
proteolyt
process
phosphoryl
migrat
assay
suggest
h
pylori
infect
result
chemotact
defect
phagocyt
cell
inhibit
phagocyt
migrat
infect
h
pylori
mutant
show
inhibitori
effect
human
granulocyt
migrat
like
caus
cag
conclus
result
suggest
interact
cag
phagocyt
cell
may
contribut
immun
evas
persist
h
pylori
object
clostridium
difficil
pathogen
emerg
evid
nosocomi
commun
acquir
diarrhoea
new
outbreak
strain
global
spread
characteris
toxin
b
binari
toxin
express
mutat
potenti
toxin
repressor
gene
tcdc
increas
toxin
product
vitro
recent
high
rate
detect
region
saarland
germani
singl
locu
sequenc
type
surfac
layer
protein
slpast
establish
refer
laboratori
genotyp
method
univers
saarland
hospit
tertiari
care
facil
icub
april
decemb
c
difficil
isol
n
consecut
adult
pediatr
patient
diarrhoea
propag
standard
anaerob
stool
cultur
use
ccfa
media
cloagar
genotyp
detect
slpast
previous
describ
kato
et
al
jmm
follow
sequenc
align
blast
search
grow
institut
databas
present
singl
centr
retrospect
studi
appear
differ
c
difficil
genotyp
analyz
differ
agegroup
result
sinc
juli
frequenc
significantli
decreas
end
proport
highli
preval
genotyp
eg
remain
stabl
interestingli
rate
variou
c
difficil
genotyp
differ
children
adult
high
percentag
nontoxigen
strain
pediatr
group
use
institut
databas
genet
relationship
variou
slpast
analys
show
cluster
least
three
major
genet
group
subdivid
differ
subgroup
close
associ
known
pcr
ribotyp
discuss
conclus
pandem
strain
fast
geograph
spread
could
show
rate
recent
decreas
previous
highpreval
region
hypothes
rate
epidem
strain
presum
also
strain
specif
virul
may
chang
time
eg
due
host
adapt
possibl
also
differ
region
emerg
new
epidem
c
difficil
strain
may
occur
time
therefor
detect
chang
c
difficil
epidemiolog
requir
regular
genotyp
local
global
cdi
without
restrict
strain
slpast
well
standard
method
identifi
current
epidem
c
difficil
strain
also
strain
still
unknown
epidem
relev
helicobact
pylori
caus
agent
type
b
gastriti
peptic
ulcer
gastric
adenocarcinoma
malt
lymphoma
use
cag
type
iv
secret
system
induc
strong
proinflammatori
respons
gastric
mucosa
inject
effector
protein
caga
gastric
cell
protein
transloc
result
alter
host
cell
gene
express
profil
cytoskelet
rearrang
link
cancer
develop
cag
system
distantli
relat
type
iv
secret
system
contain
sever
essenti
compon
without
function
counterpart
system
recent
shown
cag
type
iv
secret
apparatu
bind
integrin
molecul
receptor
host
cell
sever
cag
compon
involv
interact
studi
character
one
compon
integrin
bind
capac
cagi
previou
studi
identifi
cagi
gene
essenti
gene
transloc
caga
host
cell
conflict
result
requir
stimul
secret
epitheli
cell
sinc
cagi
gene
overlap
cotranscrib
cagl
gene
encod
anoth
integrininteract
protein
essenti
cag
function
discrep
might
due
transcript
effect
resist
marker
use
mutagenesi
use
markerfre
gene
delet
approach
genet
complement
show
cagi
requir
caga
transloc
induct
absenc
sever
compon
secret
apparatu
impact
cagi
cagl
protein
level
indic
partial
assembl
apparatu
requir
stabil
data
provid
evid
local
cagi
cagl
bacteri
outer
membran
furthermor
demonstr
coimmunoprecipit
cagi
cagl
interact
taken
togeth
result
consist
assumpt
cagi
cagl
form
complex
bacteri
cell
surfac
still
increas
incid
clostridium
difficileinfect
germanyne
action
b
friedrich
weitzelkag
eckmann
infektionsepidemiologi
berlin
deutschland
landesuntersuchungsanstalt
da
gesundheitsund
lua
sachsen
chemnitz
deutschland
charit
berlin
institut
hygien
und
umweltmedizin
berlin
deutschland
introduct
sinc
unit
state
canada
variou
countri
europ
report
increas
incid
individu
case
outbreak
clostridium
difficil
infect
cdi
thought
associ
emerg
virul
strain
clostridium
difficil
pcr
ribotyp
first
report
germani
sinc
sever
case
cdi
definit
notifi
accord
protect
infect
act
order
gain
comprehens
pictur
cdi
time
analysi
variou
data
sourc
present
method
describ
incid
cdi
germani
time
use
differ
data
sourc
notif
laboratoryconfirm
cdi
feder
state
saxoni
identifi
addit
mandatori
surveil
b
nation
surveil
data
sever
cdi
defin
least
one
follow
criteria
readmiss
hospit
due
relaps
intens
care
unit
due
cdi
complic
surgeri
toxic
megacolon
perfor
refractori
coliti
death
within
day
diagnosi
cdi
primari
contribut
caus
c
nosocomi
infect
surveil
system
cdi
cdadkiss
hospit
discharg
diagnosi
code
enterocol
due
clostridium
difficil
accord
intern
classif
diseas
revis
time
trend
analyz
neg
binomi
regress
use
result
cdi
incid
reach
peak
notifi
inhabit
saxoni
sever
cdi
inhabit
accord
nation
surveil
system
incid
densiti
cdi
patient
day
gener
cdadkiss
hospit
discharg
diagnosi
data
yet
avail
cdi
discharg
hospit
patient
neg
binomi
regress
model
reveal
signific
yearli
increas
cdi
incid
rate
hospit
discharg
incid
rate
ratio
irr
p
cdi
notif
saxoni
irr
nation
surveil
sever
cdi
irr
discuss
continu
increas
cdi
case
peak
show
urgent
need
action
natur
increas
yet
understood
improv
character
case
therefor
need
includ
monitor
diseas
origin
like
proport
healthcareand
communityassoci
cdi
distribut
character
strain
continu
evalu
risk
factor
help
focu
prevent
measur
introduct
clostridium
difficil
associ
diseas
last
year
increas
incid
sever
world
wide
epidem
strain
caus
sever
diseas
north
america
part
europ
observ
larg
number
germani
although
incid
cdad
greatli
increas
ribotyp
implic
sever
diseas
studi
germani
method
materi
period
larg
number
isol
collect
greater
area
subject
ribotyp
pcr
analysi
presenc
toxin
gene
tcda
tcdb
cdta
mutat
caus
truncat
tcdc
gene
well
resist
erythromycin
moxifloxacin
result
total
isol
analys
characterist
resist
erythromycin
observ
isol
resist
moxifloxacin
resist
antibiot
togeth
detect
isol
resist
either
substanc
isol
ribotyp
isol
ongo
preliminari
analysi
data
show
isol
group
approxim
distinct
ribotyp
one
ribotyp
contain
approxim
isol
next
largest
ribotyp
approxim
isol
confirm
ribotyp
await
discuss
analysi
larg
number
c
difficil
expans
urban
area
describ
germani
interest
scrutinis
data
one
may
abl
determin
increas
incid
cdad
perhap
unlik
case
north
anmerica
associ
specif
clonal
spread
therbi
also
determin
chang
perhap
due
chang
medic
practic
rather
shift
bacteri
virul
result
show
vast
major
isol
posses
toxin
b
gene
binari
toxin
gene
disproportion
number
howev
locat
isol
posit
tcda
neg
tcdb
gene
account
total
number
isol
test
previous
report
isol
resist
erythromycin
moxifloxacin
giardia
duodenali
arginin
deiminas
explor
function
hostparasit
interplay
banik
aebisch
fg
parasitologi
berlin
deutschland
protozoa
giardia
duodenali
gd
intestin
parasit
human
caus
diarrhoeal
gastrointestin
diseas
name
giardiasi
annual
around
million
peopl
becom
infect
worldwid
gd
ubiquit
distribut
also
infect
vertebr
includ
companion
anim
thu
giardiasi
major
public
veterinari
health
concern
global
remain
unclear
degre
zoonosi
determin
pathogen
human
assess
issu
gd
biobank
shall
gener
link
epidemiolog
data
function
characterist
clinic
isol
mean
identifi
virul
associ
gene
hypothes
potenti
virul
marker
enzym
releas
giardia
upon
colon
small
instestin
interact
host
epithelium
especi
gd
arginin
deiminas
adi
convert
arginin
citrullin
ammonia
shall
investig
possibl
virul
pathogen
factor
gd
arginin
play
critic
role
antimicrobi
mechan
immun
respons
sequencevari
adi
determin
clone
adi
gd
isol
collect
biobank
sequenc
variant
function
character
express
respect
recombin
adi
protein
final
correl
enzym
function
clinic
patholog
shall
investig
basi
gd
isol
relat
epidemiolog
data
present
establish
workflow
gd
clone
wb
adi
well
mutat
adi
clone
recombinantli
express
purifi
affin
chromatographi
enzym
activ
test
adapt
colorimetr
measur
arginin
citrullin
convers
verifi
activ
inact
adi
subsequ
vitro
gener
human
dendrit
cell
dc
treat
recombin
adi
mutadi
absenc
presenc
tolllik
receptor
tlr
ligand
investig
surfac
molecul
express
cytokin
releas
shall
give
first
evid
adi
role
hostparasit
interplay
make
campylobact
jejuni
thrive
contribut
amino
acid
metabol
effici
prolifer
widespread
foodborn
pathogen
campylobact
jejuni
major
caus
foodborn
diseas
industri
countri
found
recent
highli
pathogen
strain
c
jejuni
extend
capac
metabol
amino
acid
comparison
sever
c
jejuni
isol
includ
refer
strain
nctc
amino
acid
aspart
glutam
prolin
serin
growthpromot
substrat
isol
c
jejuni
possess
addit
capabl
util
asparagin
glutamin
glutathion
strikingli
addit
glutamin
glutathion
metabol
c
jejuni
contribut
enhanc
capabl
colon
intestin
mous
model
colon
wherea
asparagin
util
result
effici
persist
c
jejuni
liver
infect
mice
hofreut
et
al
continu
studi
examin
effect
amino
acid
viabil
c
jejuni
transposon
target
mutagenesi
recogn
involv
previous
uncharacter
gene
amino
acid
catabol
well
amino
acid
biosynthesi
c
jejuni
test
impact
amino
acid
metabol
surviv
wildtyp
c
jejuni
sever
mutant
defect
util
amino
acid
variou
stress
condit
contribut
amino
acid
catabol
c
jejuni
interact
cultur
intestin
epitheli
cell
investig
use
murin
infect
model
discov
distinct
correl
metabol
test
amino
acid
persist
c
jejuni
differ
tissu
result
broaden
knowledg
aminoaciddriven
growth
c
jejuni
role
colon
variou
host
gaussia
princep
luciferas
gluc
use
monitor
type
protein
secret
salmonella
enterica
serovar
typhimurium
will
rg
gerlach
robert
kochinstitut
nachwuchsgrupp
wernigerod
deutschland
introduct
gaussia
princep
luciferas
gluc
highli
activ
report
exhibit
approxim
higher
luminesc
compar
renilla
luciferas
data
applic
gluc
bacteria
limit
given
small
size
high
activ
cofactor
independ
gluc
might
especi
suit
monitor
secret
bacteri
protein
salmonella
pathogen
island
encod
siicdf
form
type
secret
system
secret
adhesin
siie
siie
mediat
intim
contact
salmonella
polar
epitheli
cell
thu
facilit
subsequ
invas
process
method
codonoptim
gluc
gene
effici
express
salmonella
enterica
sv
typhimurium
typhimurium
fusion
protein
gluc
differ
ctermin
portion
adhesin
siie
gener
transfer
typhimurium
wt
siif
luminesc
detect
bacteri
lysat
supernat
whole
cultur
result
detect
luciferas
activ
glucsii
fusion
protein
supernat
well
whole
cultur
depend
function
could
show
ctermin
moieti
siie
includ
immunoglobulin
ig
domain
essenti
suffici
mediat
type
idepend
secret
gluc
secret
effici
fusion
protein
increas
increas
length
ctermin
siie
portion
discuss
conclus
gluc
use
monitor
protein
secret
via
first
demonstr
enzymat
detect
secret
protein
without
stabl
periplasm
intermedi
gluc
might
open
venu
systemat
identif
analysi
type
isecret
protein
repres
valuabl
addit
toolbox
modern
molecular
biolog
microbiolog
helicobact
pylori
bc
genom
variabl
potenti
virul
determin
experiment
human
infect
l
kennemann
aebisch
kuhn
tf
meyer
c
josenhan
introduct
helicobact
pylori
one
bacteri
speci
highest
allel
divers
due
high
mutat
rate
frequent
recombin
mix
infect
recent
whole
genom
comparison
studi
demonstr
extens
genom
chang
four
set
sequenti
isol
obtain
chronic
infect
colombian
kennemann
et
al
pna
much
less
known
genom
adapt
may
occur
first
month
infect
new
human
host
present
complet
genom
sequenc
h
pylori
strain
bc
cagpai
defici
isol
use
sever
human
challeng
studi
us
germani
draft
sequenc
reisol
obtain
four
volunt
month
infect
result
genom
sequenc
h
pylori
challeng
strain
obtain
sequenc
subsequ
gap
closur
target
sanger
sequenc
draft
genom
sequenc
obtain
sequenc
one
addit
input
isol
four
isol
four
volunt
belong
either
control
group
ureab
vaccin
group
addit
reisol
volunt
analyz
select
loci
sanger
sequenc
conclus
contrast
sequenti
isol
colombia
evid
recombin
import
detect
reisol
infect
volunt
novel
snp
identifi
reisol
genom
permit
calcul
robust
estim
h
pylori
vivo
mutat
rate
unexpectedli
previous
unknown
variant
input
strain
detect
sever
volunt
differ
sequenc
input
clone
snp
three
cluster
nucleotid
polymorph
cnp
variant
commonli
detect
among
addit
reisol
studi
suggest
strong
vivo
select
favor
subpopul
human
host
helicobact
pylori
type
iv
secret
system
exploit
distinct
domain
human
caga
transloc
c
ertl
l
jimenezsoto
r
haa
max
von
pettenkof
institut
bakteriologi
deutschland
transloc
cytotoxinassoci
antigen
caga
via
type
iv
secret
system
host
cell
major
risk
factor
gastric
diseas
like
chronic
gastriti
gastric
cancer
immunodomin
protein
caga
encod
togeth
cagpathogen
island
cagpai
transloc
host
cell
caga
subsequ
tyrosinephosphoryl
modifi
differ
eukaryot
signal
pathway
phosphorylationdepend
independ
way
other
show
caga
transloc
depend
interact
piluslik
needl
structur
host
cell
surfac
integrin
famili
heterodimer
cell
surfac
adhes
molecul
mediat
cellcel
cellextracellular
matrix
cellpathogen
interact
three
compon
cagi
cagi
well
transloc
effector
protein
caga
bind
origin
identifi
yeast
two
hybrid
assay
attempt
local
distinct
bind
region
protein
within
receptor
want
determin
whether
bind
caga
essenti
step
caga
transloc
ntermin
integrin
bind
region
caga
narrow
stretch
amino
acid
correspond
domain
caga
bind
verifi
data
help
propos
new
model
interact
pathogen
h
pylori
eukaryot
cell
mediat
specif
interact
host
cell
result
total
aci
outbreak
pae
outbreak
esbl
outbreak
includ
shown
figur
median
durat
outbreak
day
aci
day
pae
day
esbl
respect
averag
number
affect
patient
three
group
aci
outbreak
thereof
infect
patient
thereof
die
patient
pae
esbl
figur
aci
outbreak
specif
find
includ
associ
univers
hospit
intens
care
unit
surgeri
depart
pae
outbreak
associ
significantli
less
use
isol
precaut
less
frequent
closur
ward
less
use
protect
cloth
esbl
outbreak
took
place
especi
neonatolog
depart
caus
significantli
high
number
urinari
tract
infect
addit
inform
sourc
pathogen
rout
transmiss
type
infect
age
group
patient
implement
infect
control
measur
provid
tabl
conclus
outbreak
databas
serv
valuabl
tool
character
nosocomi
outbreak
sever
signific
differ
three
group
pathogen
examin
detect
thu
find
present
studi
would
recommend
adjust
infect
control
measur
specif
type
pathogen
howev
point
view
current
mrgn
bacterium
total
disregard
respect
essen
deutschland
univers
hospit
essen
hospit
hygien
essen
deutschland
introduct
postop
wound
infect
gener
caus
consider
extra
morbid
mortal
cost
preval
total
wound
infect
cardiac
surgeri
rang
question
describ
frequenc
surgic
site
infect
ssi
follow
open
heart
surgeri
identifi
frequent
risk
factor
infect
method
prospect
surveil
perform
period
januari
april
intensiv
cardiosurgeri
unit
essen
germani
patient
evalu
daili
hospit
readmit
surgic
unit
ssi
occur
discharg
wound
infect
defin
accord
center
diseas
control
prevent
cdc
us
nation
nosocomi
infect
surveil
nni
system
criteria
descript
epidemiolog
method
use
result
total
patient
includ
mean
age
year
patient
femal
elect
procedur
repres
coronari
arteri
bypass
graft
cabg
methicillinresist
staphylococcu
aureu
mrsa
screen
perform
patient
periop
antibiot
prophylaxi
firstgener
cephalosporin
administ
case
ssi
observ
patient
superfici
infect
deep
infect
infect
occur
cabg
procedur
diagnos
day
oper
patient
bmi
asa
score
three
patient
bloodglucos
level
mgdl
postop
conclus
prevent
ssi
oper
room
primari
goal
surgic
team
attent
paid
antibiot
prophylaxi
methicillinresist
staphylococcu
aureu
mrsa
nasal
carriag
treatment
studi
bmi
high
bloodglucos
level
associ
wound
infect
overal
rate
ssi
low
surveil
need
chang
hand
hygien
complianc
profession
statu
disciplin
risk
factor
k
graf
e
ott
n
tramp
wolni
g
porep
chaberni
med
hochschul
hannov
inst
med
mikrobiologi
ukrankenhaushygien
hannov
deutschland
background
hand
hygien
effect
measur
prevent
infect
relat
healthcar
studi
aim
evalu
hand
hygien
complianc
german
univers
hospit
overal
addict
profession
statu
implement
nation
hand
hygien
campaign
aktion
sauber
largest
nationwid
survey
intens
care
unit
icu
univers
hospit
germani
method
investig
period
januari
educ
train
hand
hygien
implement
consumpt
rate
hand
rub
glove
collect
evalu
chang
healthcar
worker
behaviour
observ
compar
differ
profession
group
complianc
rate
hand
hygien
healthcar
personnel
twelv
icu
evalu
implement
campaign
implement
includ
extens
educ
train
health
care
worker
least
three
teach
unit
per
ward
five
indic
hand
hygien
classifi
accord
definit
complianc
rate
evalu
indic
health
care
worker
divid
three
group
doctor
nurs
health
care
worker
result
consumpt
rate
hand
rub
increas
hand
disinfect
per
patient
day
signific
correl
hand
rub
consumpt
hand
hygien
complianc
calcul
signific
chang
use
glove
detect
overal
opportun
hand
disinfect
monitor
signific
improv
hand
hygien
complianc
assess
p
risk
disinfect
reduc
significantli
p
ci
risk
disinfect
decreas
significantli
nurs
group
doctor
group
health
care
worker
evalu
due
small
number
signific
differ
hand
hygien
complianc
intervent
doctor
nurs
intervent
signific
differ
hand
hygien
complianc
p
ci
hand
hygien
complianc
higher
nurs
group
risk
hand
disinfect
doctor
decreas
signific
conclus
signific
chang
hand
hygien
behaviour
recogn
doctor
nurs
hand
hygien
complianc
nurs
increas
significantli
higher
henc
train
strategi
doctor
essenti
effect
rapid
analysi
nosocomi
outbreak
use
diversilab
semiautom
repetit
sequencebas
pcr
test
system
object
rapid
sensit
method
essenti
type
monitor
hospit
associ
infect
new
diversilab
system
biomerieux
exhibit
semiautom
repetitivesequencebas
polymeras
chain
reaction
reppcr
type
aim
studi
evalu
use
accuraci
diversilab
system
bacteri
strain
type
determin
genet
related
strain
associ
nosocomi
outbreak
integr
system
workflow
routin
microbiolog
laboratori
method
evalu
methicillinresist
staphylococcu
aureu
mrsa
multidrug
resist
mdr
acinetobact
baumannii
strain
produc
klebsiella
spp
strain
k
pneumonia
k
oxytoca
strain
welldefin
nosocomi
outbreak
type
use
reppcr
diversilab
system
refer
method
bacteri
strainstyp
pulsedfield
gel
electrophoresi
pfge
perform
result
concern
mrsa
isol
ident
cluster
format
diversilab
pfge
system
result
could
observ
multiresist
baumannii
strain
strain
show
ident
cluster
format
separ
cluster
similar
dendrogram
esblposit
k
pneumonia
strain
origin
two
chronolog
separ
nosocomi
outbreak
pfge
place
esblposit
k
pneumonia
strain
cluster
wherea
pfge
defin
strain
indistinguish
diversilabsystem
also
form
cluster
strain
strain
cluster
defin
ident
similar
system
identifi
k
pneumonia
strain
nonoutbreak
strain
result
k
oxytoca
outbreak
provid
similar
minor
differ
pfge
result
obtain
diversilabsystem
wherea
reppcr
diversilab
system
exhibit
slightli
discriminatori
power
pfge
conclus
diversilab
system
rapid
semiautom
repetit
sequencebas
pcr
test
system
type
analys
bacteri
strain
includ
fungi
compar
pfge
studi
confirm
good
discriminatori
power
diversilab
system
result
diversilab
system
could
obtain
short
period
essenti
advantag
rapid
analysi
hospit
associ
infect
background
sever
product
claim
sanit
surfac
quickli
easili
use
uv
radiat
product
use
household
travel
eg
toilet
facil
hotel
mattress
person
care
item
howev
often
actual
abil
kill
germ
overal
practic
daili
life
remain
unknown
method
test
disinfect
abil
sanit
wand
verilux
inc
waitsfield
usa
portabl
devic
emit
uvc
radiat
uv
light
bulb
watt
held
horizont
accord
manufactur
instruct
wand
use
close
possibl
onehalf
inch
surfac
state
oper
manual
elimin
aureu
would
expect
within
sec
procedur
aureu
atcc
e
faecium
atcc
e
coli
atcc
suspend
steril
nacl
solut
sampl
contain
cfu
spatel
standard
sheep
blood
agar
surfac
continu
uvc
radiat
appli
distanc
cm
figur
variou
time
interv
sec
reduct
bacteri
growth
determin
visual
hour
incub
purpos
number
cfu
count
defin
area
per
plate
figur
compar
number
expect
cfu
area
size
experi
perform
twice
result
correspond
kill
curv
shown
figur
suffici
reduct
log
step
achiev
aureu
e
coli
sec
alreadi
sec
need
effect
e
faecium
discuss
result
confirm
uvc
light
devic
capabl
kill
bacteria
principl
howev
use
devic
disinfect
purpos
daili
life
one
keep
mind
sec
uvc
light
exposit
time
necessari
order
properli
disinfect
rather
small
surfac
area
enterococci
thu
much
longer
time
interv
necessari
larger
surfac
toilet
seat
might
opportun
devic
could
use
tool
seem
less
help
larger
exterior
due
time
necessari
disinfect
noteworthi
new
batteri
allow
overal
devic
work
time
less
minut
kill
kinet
curv
aureu
e
faecium
e
coli
uvc
exposit
time
influenc
water
flow
rate
presenc
enter
virus
ruhr
river
l
jurzik
hamza
f
remmler
wilhelm
abt
hygien
bochum
deutschland
last
year
demonstr
presenc
enter
virus
ruhr
river
drink
water
sourc
mio
peopl
hamza
et
al
hamza
et
al
jurzik
et
al
differ
factor
control
surviv
enter
virus
aquat
environ
temperatur
sunlight
ph
organ
matter
howev
littl
known
effect
flow
rate
concentr
virus
surfac
water
therefor
present
studi
aim
investig
impact
flow
rate
presenc
enteriv
viru
ruhr
river
water
sampl
collect
nearli
weekli
five
differ
sampl
site
januari
decemb
water
sampl
concentr
use
viradel
method
highsalt
alkalin
phosphat
buffer
quantif
virus
qrealtim
pcr
carri
somat
coliphag
quantifi
use
doubl
layer
plaqu
assay
quantif
e
coli
intestin
enterococci
done
accord
standard
refer
method
din
en
iso
flow
rate
daili
measur
ruhr
river
villigst
schwert
time
period
result
show
ruhr
river
highli
contamin
human
adenoviru
gen
equl
human
polyomaviru
gen
equl
human
rotaviru
gen
equl
median
concentr
bacteri
paramet
follow
e
coli
cful
total
coliform
cful
intestin
enterococci
cful
moreov
correl
microbiolog
paramet
flow
rate
found
investig
need
character
hydrolog
factor
influenc
enter
virus
river
water
hamza
ia
l
jurzik
stang
k
sure
k
uberla
wilhelm
detect
human
virus
river
denslypopul
area
germani
use
viru
adsorpt
elut
method
optim
pcr
analys
homogen
distribut
phenotyp
characterist
clonal
unrel
pseudomona
aeruginosa
isol
technic
water
system
h
petryhansen
j
hank
j
heis
hc
flem
j
wingend
biofilm
centr
abteilung
aquatisch
mikrobiologi
essen
deutschland
p
aeruginosa
opportunist
pathogen
ubiquit
found
water
environ
persist
biofilm
cell
releas
biofilm
contamin
water
phase
pose
potenti
threat
human
health
especi
occur
manmad
water
system
genotyp
phenotyp
variabl
p
aeruginosa
technic
water
system
unknown
period
seven
year
p
aeruginosa
strain
isol
technic
water
system
drink
water
distribut
system
plumb
system
public
swim
pool
industri
water
system
use
puls
field
gel
electrophoresi
spei
restrict
genom
dna
isol
seven
p
aeruginosa
refer
strain
differ
clonal
variant
identifi
repres
strain
seven
refer
strain
follow
characterist
analyz
order
reveal
possibl
correl
water
sourc
genotyp
well
phenotyp
characterist
coloni
morpholog
pigment
product
hemolysi
cell
surfac
hydrophob
biofilm
format
resist
antibiot
occurr
virul
gene
strain
seven
refer
strain
show
typic
coloni
morpholog
p
aeruginosa
produc
least
one
pigment
pyocyanin
pyoverdin
pyorubin
pyomelanin
display
bhemolysi
hydrophil
cell
surfac
strain
sensit
ciprofloxacin
imipenem
meropenem
piperacillintazobactam
gentamycin
except
one
strain
ceftazidim
intermedi
sensit
aztreonam
determin
strain
except
one
strain
strain
resist
ampicillin
compar
refer
strain
strain
show
higher
biofilm
format
abiot
polystyren
surfac
strain
form
cluster
strong
biofilm
former
strain
virul
gene
lasb
detect
well
either
virul
gene
exo
exou
one
strain
contain
exo
exou
first
time
extens
pool
p
aeruginosa
isol
differ
type
technic
water
system
character
phenotyp
genotyp
correl
phenotyp
genotyp
trait
characterist
origin
strain
detect
phenotyp
characterist
occurr
virul
gene
seem
distribut
rel
homogen
way
among
clonal
unrel
strain
divers
manmad
water
system
seem
select
specif
genotyp
phenotyp
variant
p
aeruginosa
technic
water
system
e
ott
saathoff
legarth
k
graf
f
schwab
f
chaberni
medizinisch
hochschul
hannov
med
mikrobiologi
und
krankenhaushygien
hannov
hygien
und
umweltmedizin
berlin
deutschland
background
incid
nosocomi
infect
ni
increas
consider
last
year
knowledg
real
frequenc
nosocomi
infect
germani
rare
purpos
studi
investig
current
frequenc
nosocomi
infect
univers
hospit
pointpreval
studi
method
march
systemat
investig
conduct
adult
inpati
patient
suffer
nosocomi
infect
detect
via
intens
chart
review
interview
physician
standard
protocol
use
definit
categor
nosocomi
infect
nosocomi
infect
categor
use
cdcdefinit
inform
use
antimicrobi
agent
invas
devic
caus
organ
comorbid
invas
procedur
record
result
overal
inpati
could
includ
studi
ni
detect
patient
preval
per
patient
major
ni
identifi
surgeri
follow
intens
care
medicin
gener
medicin
surgic
site
infect
common
ni
ni
follow
gastrointestin
tract
infect
ni
respiratori
tract
infect
ni
urinari
tract
infect
ni
bloodstream
infect
ni
infect
ni
escherichia
coli
isol
frequent
follow
coagulaseneg
staphylococci
enterococcu
faecium
enterococcu
faecali
pseudomona
aeruginosa
furthermor
multivari
analysi
identifi
gastrointestin
diseas
disturb
electrolyt
fluid
balanc
histori
hospit
admiss
within
month
histori
surgeri
within
month
histori
antibiot
therapi
within
month
devic
independ
risk
factor
occurr
nosocomi
infect
conclus
studi
provid
basic
inform
current
situat
ni
hospit
data
use
provid
estim
health
burden
ni
also
help
initi
infect
prevent
control
measur
thorax
transplantationsund
hannov
deutschland
background
hand
hygien
effect
measur
prevent
infect
relat
healthcar
studi
aim
evalu
hand
hygien
behaviour
health
care
worker
german
univers
hospit
treatment
special
patient
group
addict
complianc
rate
differ
profession
group
doctor
nurs
health
care
worker
investig
transplant
patient
chosen
investig
high
risk
patient
develop
healthcar
associ
infect
due
high
number
devic
long
hospit
stay
immunosuppress
method
investig
period
januari
extens
educ
train
health
care
worker
implement
least
three
teach
unit
per
ward
consumpt
rate
hand
rub
glove
collect
evalu
chang
healthcar
worker
hand
hygien
complianc
calcul
compar
transplant
transplant
patient
therefor
five
whoindic
hand
hygien
investig
result
overal
opportun
hand
disinfect
evalu
signific
differ
hand
disinfect
behaviour
detect
occup
group
nurs
hand
hygien
complianc
significantli
higher
signific
differ
hand
hygien
complianc
transplant
transplant
patient
ci
effect
calcul
healthcar
worker
profession
group
disinfect
perform
significantli
often
intervent
p
ci
conclus
differ
hand
hygien
behaviour
health
care
worker
transplant
transplant
patient
nurs
hand
hygien
complianc
significantli
higher
risk
hand
disinfect
significantli
higher
intervent
therefor
educ
train
need
protect
special
patient
group
know
infecti
patient
resid
earli
warn
infect
inform
system
hospit
infecti
diseas
outbreak
hospit
sever
threat
patient
safeti
number
infect
person
includ
hospit
staff
climb
threshold
hospit
depart
may
close
even
whole
hospit
medic
administr
staff
member
especi
respons
hospit
hygien
manag
infect
control
need
know
infecti
patient
situat
transfer
infect
inform
system
ii
develop
hospit
oper
mtg
support
hospit
profession
monitor
infect
patient
case
outbreak
admiss
discharg
transfer
adt
oper
monitor
control
analys
retrospect
time
core
compon
monitor
dashboard
visual
bed
hospit
singl
pc
screen
infect
patient
present
one
hospit
colour
code
two
other
text
code
text
code
allow
display
multipl
infect
like
becom
prefer
standard
hospit
oper
far
noroviru
esbl
mrsa
clostriod
infect
differenti
dashboard
data
basi
ii
collect
data
data
warehous
load
central
hospit
inform
system
everi
minut
complet
copi
adt
situat
load
databas
ii
includ
note
infect
enter
perman
hospit
staff
ii
oper
sinc
januari
mtg
first
feedback
user
encourag
continu
develop
especi
linkag
type
infect
local
patient
overview
one
screen
seen
major
benefit
daili
work
monitor
dashboard
use
colour
code
visual
infect
patient
monitor
dashboard
use
text
code
visual
infect
patient
review
european
guidelin
prevent
c
difficil
infect
result
form
prohibit
object
european
commiss
fund
project
prevent
hospit
infect
intervent
train
prohibit
wwwprohibitunigech
establish
prohibit
aim
analys
exist
guidelin
practic
prevent
healthcar
associ
infect
hai
europ
identifi
factor
influenc
complianc
best
practic
test
effect
intervent
known
efficaci
wp
provid
review
current
nation
subnat
region
european
guidelin
prevent
c
difficil
infect
cdi
well
overview
surveil
system
public
report
cdi
method
hai
surveil
nation
contact
point
ncp
ecdc
hai
expert
countri
eu
member
state
wherebi
uk
count
countri
croatia
iceland
norway
switzerland
ask
provid
nationalsubn
guidelin
cdi
prevent
review
guidelin
well
comparison
exist
ecdc
guidanc
conduct
addit
questionnair
develop
gather
inform
nation
surveil
system
practic
public
report
result
eighteen
european
countri
nationalsubn
guidelin
cdi
prevent
england
northern
ireland
wale
follow
guidelin
oldest
guidelin
date
back
other
publish
within
past
year
seven
guidelin
rate
scientif
level
support
evid
strength
recommend
one
guidelin
explicitli
recommend
place
symptomat
patient
singl
room
whenev
possibl
clean
disinfect
frequent
touch
surfac
recommend
guidelin
howev
includ
specif
recommend
disinfect
prefer
chlorin
base
solut
specifi
ecdc
guidanc
variat
hand
hygien
recommend
guidelin
favour
hand
wash
soap
water
alcohol
hand
rub
mostli
mention
addit
task
erad
pathogen
thirteen
countri
provid
cdi
guidelin
also
run
nation
surveil
system
diseas
belgium
england
northern
ireland
scotland
wale
ireland
particip
compulsori
hospit
uk
ireland
public
report
cdi
rate
individu
hospit
establish
sinc
respect
conclus
although
cdi
recogn
major
challeng
infect
control
half
european
countri
present
provid
guidelin
cdi
prevent
furthermor
import
variat
scope
detail
recommend
major
guidelin
rate
scientif
level
strength
recommend
countri
mandatori
particip
nation
surveil
system
introduc
public
report
cdi
rate
hospit
blend
learn
kur
hygienebeauftragt
aktiv
zertifiziert
introduct
worldwid
trend
use
wipe
system
surfac
disinfect
health
care
set
howev
technic
challeng
taken
consider
assur
safe
use
product
recent
shown
activ
ingredi
surfac
disinfect
eg
quaternari
ammonium
compound
adsorp
fabric
wipe
impair
efficaci
disinfect
significantli
current
method
publish
test
efficaci
liquid
surfac
disinfect
therefor
aim
develop
easi
reproduc
test
method
product
type
materi
method
basi
new
test
method
dghmstandard
method
en
ortil
accord
dghm
use
test
surfac
standard
techniqu
direct
applic
soak
wipe
establish
addit
amount
disinfect
appli
surfac
investig
result
result
show
suggest
assay
suitabl
test
practic
like
efficaci
disinfect
wipe
system
addit
result
show
type
fabric
also
amount
impregn
solut
determin
suffici
efficaci
product
strong
correl
amount
impregn
solut
amount
transfer
surfac
mandatori
efficaci
product
abl
show
amount
disinfect
transfer
wipe
onto
surfac
signific
lower
amount
appli
test
carrier
current
publish
standard
discuss
reproduc
easi
standard
method
avail
use
show
microbicid
efficaci
wipe
system
author
strongli
recommend
test
microbicid
efficaci
wipe
system
practic
use
introduc
system
posit
list
vah
sfhh
wipe
correct
choic
fabric
thoroughli
impregn
disinfect
solut
abl
assur
suffici
efficaci
safe
use
disinfect
wipe
system
introduct
shiga
toxinproduc
e
coli
stec
pathogen
caus
foodborn
diarrhea
hemorrhag
coliti
hc
hemolyt
urem
syndrom
hu
may
larg
outbreak
stec
strain
husec
express
esblposit
phenotyp
occur
hot
spot
schleswigholstein
lead
great
challeng
laboratori
diagnosi
infect
control
hospit
laboratori
diagnosi
may
th
patient
stec
diarrhea
hu
admit
univers
hospit
schleswigholstein
campu
confirm
esblproduc
sorbitolefer
stec
clone
caus
agent
within
hour
chromogen
select
media
esbl
screen
immedi
introduc
diagnost
algorithm
shiga
toxinexpress
analyz
e
coli
isol
grown
media
select
esbl
stool
specimen
neg
esblproduc
e
coli
shiga
toxinexpress
analyz
enrich
broth
incub
parallel
patient
probabl
stec
infect
stool
specimen
test
laboratori
stool
specimen
stec
esbl
confirm
caus
agent
none
esbl
e
coli
cultur
neg
stool
specimen
posit
shiga
toxin
enrich
broth
patient
display
symptom
hu
stec
esbl
infect
could
confirm
noroviru
rotaviru
campylobact
jejuni
detect
five
patient
caus
pathogen
could
identifi
specimen
infect
control
measur
regular
ward
immedi
defin
quarantin
ward
manag
affect
patient
sever
ill
patient
treat
icu
barrier
precaut
peak
infect
patient
directli
examin
quarantin
ward
unburden
emerg
depart
patient
manag
barrier
precaut
singl
usag
coat
glove
direct
medic
care
procedur
establish
medic
face
mask
suggest
procedur
potenti
aerosol
product
nosocomi
transmiss
stec
esbl
observ
indic
success
infect
control
measur
conclus
introduct
select
chromogen
media
esblproduc
enterobacteriacea
prove
rapid
highli
sensit
diagnost
procedur
detect
outbreak
caus
stec
clone
time
infect
control
measur
circumv
nosocomi
transmiss
stec
rapid
screen
method
multipl
gastroenter
pathogen
also
detect
novel
ehec
patient
suspect
infect
ehec
suffer
bloodi
diarrhoea
bear
risk
develop
seriou
life
threaten
haemolyticurem
syndrom
hu
thu
need
rapid
differenti
diagnosi
avoid
misdiagnosi
potenti
guid
fals
initi
therapi
infect
control
measur
rapid
screen
diagnost
method
requir
develop
special
laboratori
howev
take
account
inflationlik
increas
number
newli
suspect
case
major
laboratori
becom
overload
risk
delay
diagnosi
increas
proport
method
thu
test
novel
xtag
gpp
assay
luminex
toronto
canada
assay
develop
simultan
detect
import
seriou
viral
bacteri
parasit
pathogen
singl
reaction
pathogen
detect
includ
shigalik
toxin
produc
ecoli
thu
assum
also
novel
variant
shigatoxin
neg
shigatoxin
posit
could
identifi
result
total
number
patient
suffer
bloodi
diarrhoea
suspect
infect
novel
ehec
variant
test
multiplex
test
reveal
patient
posit
novel
ehc
variant
two
alreadi
independ
confirm
extern
laboratori
two
patient
suffer
sever
campylobact
infect
test
neg
ehec
one
patient
test
posit
anoth
ehec
variant
produc
shigatoxin
conclus
conclud
assay
use
prescreen
patient
suffer
novel
ehec
variant
patient
monitor
close
clinician
test
result
associ
clinic
cours
hu
addit
beneficiari
effect
preselect
cohort
clinic
sampl
analys
special
laboratori
patient
neg
ehc
posit
pathogen
like
campylobact
spec
clostridium
difficil
administ
correct
antibiot
therapi
luminex
technolog
wide
avail
assay
procedur
rather
simpl
total
handson
time
less
hour
sampl
capac
sampl
per
run
assay
suitabl
high
throughput
analys
thu
cover
peak
epidemiolog
outbreak
situat
introduct
staphylococc
scald
skin
syndrom
ssss
toxinmedi
diseas
caus
exfoli
toxin
b
eta
etb
decemb
five
neonat
develop
bullou
skin
lesion
neonat
depart
within
week
index
patient
twin
one
suffer
gener
exfoli
thu
transfer
neonat
intens
care
unit
nicu
one
show
local
desquam
rump
occipit
region
remain
neonat
ward
nw
two
addit
case
occur
nicu
thereaft
local
bullou
lesion
perior
well
perior
groin
hand
respect
nw
one
case
identifi
present
desquam
around
peripher
venou
access
case
microbiolog
sampl
show
staphylococcu
aureu
isol
sensit
antimicrobi
test
method
contact
precaut
initi
children
affect
swab
nose
perineum
taken
patient
ward
three
differ
time
point
within
ten
day
order
screen
aureu
environment
sampl
perform
differ
site
item
ward
e
g
skin
care
product
aureu
isol
sent
german
refer
centr
staphylococci
character
type
subject
suscept
test
microbroth
mic
presenc
gene
exfoli
toxin
b
eta
etb
analyz
furthermor
spatyp
determin
result
skin
lesion
resolv
without
scar
newborn
desquam
skin
observ
precaut
expand
aureu
detect
environment
sampl
children
hospit
ward
within
screen
period
among
aureu
carrier
identifi
two
isol
show
phenotyp
compar
case
four
avail
isol
children
affect
one
isol
detect
screen
child
without
symptom
test
posit
eta
etaposit
strain
belong
spatyp
observ
outbreak
ssss
caus
exfoli
toxin
produc
aureu
strain
within
institut
phenotyp
antimicrobi
test
sensit
may
indic
commun
rather
nosocomi
primari
sourc
assum
introduct
strain
mayb
famili
twin
first
affect
nosocomi
transmiss
occur
howev
parent
test
initi
expand
infect
control
measur
screen
eventu
discharg
last
child
carri
strain
case
observ
background
salmonella
speci
commonli
isol
pathogen
gastroenter
hospitalis
patient
mostli
salmonella
infect
communityacquir
object
perform
prospect
inhospit
surveil
salmonella
infect
order
detect
possibl
nosocomi
case
acut
hospit
set
method
three
tertiari
care
hospit
patient
detect
salmonella
speci
investig
respect
whether
detect
occur
later
h
hospit
admiss
investig
clinic
symptom
patient
nosocomi
acquisit
interview
health
care
author
hca
inform
relev
interview
inform
result
patient
salmonella
speci
detect
hospit
b
c
march
two
nosocomi
case
enteritidi
occur
hospit
c
hospit
serv
differ
canteen
kitchen
patient
report
eaten
cheesecak
two
differ
hospitalnear
inform
hca
detect
use
raw
egg
bakeri
serv
stop
septemb
two
nosocomi
case
occur
hospit
patient
report
eaten
cheesecak
involv
hca
identifi
two
case
report
consumpt
cheesecak
visit
rel
hospit
bakeri
march
use
raw
egg
baker
one
person
test
posit
enteritidi
stool
sampl
defin
period
person
forbidden
work
food
product
case
occur
sinc
conclus
systemat
surveil
salmonellacas
identifi
rare
nosocomi
case
food
avail
food
provid
near
hospit
consid
nosocomi
salmonella
infect
occur
interact
hca
essenti
identif
control
pathogen
transmit
hospitalis
patient
acquir
outsid
hospit
cluster
adenoviru
pediatr
haematooncolog
ward
outbreak
object
human
adenoviru
hadv
caus
sever
infect
especi
haematooncolog
pediatr
patient
hospit
contactand
dropletprecaut
recommend
infect
hadv
suspect
despit
recommend
hadv
identifi
stool
nasopharyng
secret
sampl
five
children
pediatr
haematooncolog
ward
within
two
week
period
februari
nosocomi
transmiss
suspect
precaut
expand
high
complianc
precaut
ward
staff
observ
theori
outbreak
patient
patient
transmiss
question
method
retrospect
epidemiolog
investig
conduct
children
seen
children
hospit
test
posit
hadv
four
week
period
one
week
cluster
haematooncolog
ward
includ
hadv
diagnos
via
realtimepcr
molecular
type
conduct
typespecif
sequenc
result
total
eight
children
seven
month
year
age
test
posit
hadv
four
week
period
symptom
gastroenter
upper
respiratori
tract
infect
uri
five
eight
children
hospit
haematooncolog
ward
least
two
week
prior
diagnosi
two
children
seen
outpati
servic
one
child
hospit
uri
anoth
ward
develop
hadvdiarrhoea
three
day
admiss
molecular
type
seven
isol
hadv
show
four
differ
genotyp
und
two
children
haematooncolog
ward
genotyp
conclus
immedi
symptomrel
implement
specif
precaut
children
success
prevent
patienttopati
transmiss
possibl
reason
observ
cluster
may
transmiss
parent
sibl
reactiv
hadv
immunosuppress
improv
educ
inform
parent
famili
member
might
use
addit
effort
pediatr
ward
object
role
infect
andor
colon
health
care
worker
hcw
potenti
sourc
nosocomi
outbreak
yet
unclear
present
studi
summar
data
outbreak
order
elucid
area
special
interest
clarifi
potenti
reason
transmiss
method
conduct
systemat
review
medic
literatur
base
pubm
outbreak
databas
wwwoutbreakdatabasecom
hand
search
retriev
articl
extract
data
set
type
infect
number
patient
durat
epidem
infect
control
measur
result
total
outbreak
patient
got
includ
thereof
fatal
case
main
rout
transmiss
direct
indirect
contact
outbreak
durat
outbreak
rang
week
mean
week
median
week
number
affect
patient
per
outbreak
rang
mean
median
surgic
neonatolog
depart
often
involv
outbreak
primarili
caus
staff
transmiss
took
frequent
place
surgic
theater
peripher
ward
primari
type
infect
surgic
site
infect
hepat
b
correspond
caus
main
agent
staphylococcu
aureu
hepat
b
viru
streptococcu
pyogen
shown
figur
physician
thereof
surgeon
nurs
predomin
staff
spread
pathogen
patient
nine
per
cent
awar
carrier
statu
check
complianc
hand
hygien
hh
person
caus
outbreak
found
hh
consid
adequ
outbreak
poor
tabl
infect
control
measur
often
implement
order
termin
outbreak
includ
screen
personnel
patient
educ
staff
disinfect
steril
procedur
applic
antimicrobi
substanc
improv
hh
use
protect
cloth
conclus
nosocomi
outbreak
caus
staff
import
problem
field
epidemiolog
infect
control
next
step
check
characterist
hcw
may
predispos
increas
pathogen
spread
patient
staphylococcu
aureu
promin
caus
nosocomi
infect
signific
morbid
mortal
commens
nasal
carriag
around
popul
rapid
spread
multiresist
strain
necessit
novel
therapeut
strategi
challeng
task
speci
aureu
host
respons
highli
variabl
although
aureu
nasal
carrier
show
increas
risk
endogen
aureu
infect
significantli
better
outcom
propos
humor
memori
acquir
colon
shape
respons
aureu
bacteremia
prospect
studi
among
surgic
nonsurg
patient
twelv
patient
develop
aureu
bacteremia
infect
strain
isol
patient
sera
obtain
diagnosi
cours
infect
analys
detail
use
person
approach
patient
extracellular
protein
infect
aureu
strain
identifi
develop
antibodi
respons
assess
immunoblot
aureu
carrier
show
clear
evid
strain
specif
preimmunis
immunecompet
bacteremia
patient
antibodi
bind
increas
strongli
case
alreadi
diagnosi
observ
may
exploit
earlier
diagnosi
endogen
infect
pattern
antibodi
bind
similar
preinfect
pattern
exogen
infect
contrast
preinfect
pattern
radic
alter
acquisit
new
specif
characterist
individu
patient
nevertheless
common
signatur
ten
conserv
aureu
protein
recogn
least
half
bacterem
patient
identifi
patient
mount
dynam
antibodi
respons
subset
protein
humor
aureu
immunom
prove
power
tool
coordin
analysi
variabl
encount
aureu
human
host
staphylococcu
aureu
frequent
colon
also
common
pathogen
furunculosi
sever
skin
infect
mainli
caus
aureu
interestingli
clinic
isol
induc
furunculosi
frequent
harbour
pvlgene
encod
toxin
pantonvalentineleukocidin
pvl
even
low
concentr
pvl
known
induc
lysi
human
neutrophil
granulocyt
neutrophil
essenti
clearanc
aureu
besid
degranul
phagocytosi
neutrophil
abl
kill
microb
releas
dna
antimicrobi
peptid
form
neutrophil
extracellular
trap
net
test
whether
invas
aureu
strain
caus
chronic
furunculosi
differ
colon
strain
investig
abil
induc
cell
death
neutrophil
neutrophil
stimul
live
bacteria
bacteri
supernat
obtain
differ
growth
media
dna
releas
indic
cell
death
quantifi
exclus
stain
extracellular
dna
morpholog
cell
death
determin
immun
fluoresc
supernat
aureu
isol
furunculosi
patient
healthi
nasal
carrier
lyse
neutrophil
depend
presenc
pvlgene
bacteri
cultur
medium
supernat
obtain
nutrientrich
media
contain
measur
amount
pvl
caus
necrosi
neutrophil
sublyt
concentr
pvl
elicit
netosi
neutrophil
cell
death
net
format
sublyt
concentr
bacteri
supernat
induc
neutrophil
cell
death
contrast
life
span
neutrophil
extend
abil
proinflammatori
activ
conserv
exclud
indirect
effect
modul
cytokin
contamin
cell
expos
live
aureu
cell
neutrophil
die
depend
multipl
infect
observ
rapid
dna
releas
predominantli
necrosi
delay
cell
death
mainli
apoptosi
netosi
howev
differ
aureu
cell
colon
furunculosi
induc
isol
opson
aureu
cell
human
serum
follow
cocultur
neutrophil
delay
dna
releas
neutrophil
caus
higher
product
substanti
reduc
number
vital
bacteria
conclud
aureu
isol
nasal
carriag
furunculosi
infect
differ
abil
caus
pvlmediat
neutrophil
lysi
capac
induc
net
format
apoptosi
neutrophil
similar
yersinia
effector
protein
yopm
use
endocyt
pathway
reach
intracellular
destin
j
scharnert
l
greun
zeuschner
c
schmidt
zmbe
infektiologi
deutschland
cellpenetr
protein
cpp
abl
cross
cellular
membran
either
alon
associ
bioactiv
cargo
identifi
yersinia
outer
protein
yopm
novel
bacteri
cpp
antiinflammatori
properti
implic
potenti
use
yopm
immunmodulatori
agent
therapeut
applic
provid
signific
advanc
understand
intracellular
molecular
function
rout
intern
analyz
studi
hela
cell
incub
yopm
analyz
cryoimmunogold
electron
microscopi
em
quantif
fifti
cell
profil
randomli
select
antibodi
signal
evalu
number
gold
particl
link
certain
cellular
compart
furthermor
coloc
studi
specif
marker
protein
perform
use
confoc
immunofluoresc
microscopi
addit
local
yopm
confirm
cell
fraction
western
blot
cryoimmunogold
em
reveal
yopm
throughout
endosom
compart
never
secretori
membran
free
yopm
could
detect
throughout
cytoplasm
nucleu
addit
nuclear
local
confirm
cell
fraction
character
natur
yopmposit
endosom
compart
immunofluoresc
studi
perform
found
yopm
coloc
specif
endosom
marker
characterist
earli
late
endosom
well
lysosom
addit
absenc
yopm
secretori
membran
confirm
exclud
secretori
pathway
yopm
target
result
show
recombin
yopm
enter
eukaryot
cell
predominantli
endosomeassoci
manner
escap
endosom
local
cytosol
partial
nucleu
indic
intracellular
endosomalindepend
movement
yopm
witzk
fm
heinemann
pa
horn
lindemann
introduct
vaccin
streptococcu
pneumonia
recommend
german
advisori
board
vaccin
stiko
immunocomprom
patient
kidney
transplant
recipi
pneumonia
mainli
infect
upper
respiratori
tract
caus
lobar
pneumonia
mening
morbid
mortal
increas
immunocomprom
patient
aim
present
studi
defin
longterm
effici
vaccin
clinic
stabl
kidney
transplant
recipi
method
patient
femal
male
median
age
rang
year
immun
use
pneumovax
antibodi
pneumococc
capsular
polysaccharid
antigen
serotyp
determin
prior
one
month
month
vaccin
multiplex
bead
assay
luminex
result
one
month
vaccin
patient
display
signific
increas
p
total
antibodi
concentr
pneumococc
serotyp
median
mgl
rang
prior
vaccin
mgl
rang
fifteen
month
vaccin
total
antibodi
concentr
still
significantli
higher
p
prior
vaccin
median
rang
mgl
addit
kidney
transplant
recipi
show
signific
increas
number
serotyp
recogn
median
rang
rang
p
month
rang
month
antibodi
respons
vaccin
slightli
significantli
p
month
lower
publish
cohort
vaccin
healthi
control
borger
et
al
conclus
result
demonstr
kidney
transplant
recipi
produc
almost
normal
concentr
antibodi
pneumococc
polysaccharid
fifteen
month
post
vaccin
initi
antibodi
respons
month
remain
detect
cystic
fibrosi
caus
defect
express
cystic
fibrosi
transmembraneconduct
regul
cftr
gene
pulmonari
symptom
diseas
particularchron
pulmonari
inflamm
infect
pathophysiolog
mechan
bywhich
chang
induc
lung
patient
cystic
fibrosi
requiredefinit
studi
found
cftr
defici
mice
result
upregul
andactiv
activ
caus
increas
ceramid
concentr
cysticfibrosi
lung
reveal
genet
modif
normal
pulmonari
ceramideconcentr
howev
activ
increas
pulmonari
ceramid
levelsand
result
viciou
cycl
activ
ceramid
accumul
genet
studi
reveal
crucial
involv
induct
asept
inflamm
increas
inth
bronchial
cell
death
rate
increas
suscept
infect
among
cftrdeficientmic
patholog
least
partial
correct
heterozygos
incftrdefici
mice
find
identifi
import
regul
lung
functionsin
cystic
fibrosi
suggest
may
novel
target
treat
cystic
fibrosi
object
staphylococcu
aureu
play
role
commens
pathogen
human
popul
persist
colon
aureu
anterior
nare
shown
carriag
tune
adapt
immun
system
result
strainspecif
humor
respons
adapt
immun
system
mobil
differ
effector
mechan
given
antigen
eg
ig
class
switch
driven
proinflammatori
cell
wherea
product
requir
help
treg
play
role
allergi
immun
toler
respect
determin
ig
subclass
composit
human
anti
aureu
antibodi
focuss
ratio
method
colon
invas
aureu
strain
sera
carrier
aureu
bacteremia
patient
investig
use
person
approach
extracellular
protein
strain
separ
sdspage
blot
decor
serum
bind
aureusspecif
quantifi
result
carrier
bind
pattern
colon
aureu
strain
highli
individu
appli
number
protein
spot
recogn
rel
intens
versu
bind
aureu
antigen
bound
iggsubclass
wherea
other
select
bound
investig
aureu
bacteremia
patient
show
similar
result
overal
antibodi
bind
increas
infect
immun
compet
patient
new
anti
aureu
antibodi
specif
emerg
rel
increas
bind
differ
igg
subclass
protein
spot
conclus
summari
human
differ
strongli
antibodi
subclass
respons
aureu
hand
individu
aureu
antigen
elicit
heterogen
subclass
profil
individu
current
determin
antigen
signatur
antibodi
respons
aureu
yersiniainduc
apoptosi
involv
cleavag
concomit
deregul
tlr
signal
k
ruckdeschel
l
novikova
n
czymmeck
deuretzbach
eppendorf
institut
med
mikrobiologi
hamburg
deutschland
wide
varieti
pathogen
microorgan
evolv
tactic
modul
host
cell
death
surviv
pathway
colon
host
organ
establish
infect
yersinia
enterocolitica
trigger
apoptosi
macrophag
inject
yopp
effector
protein
type
iii
secret
host
cell
yopp
deactiv
sever
tlrinduc
signal
pathway
imped
develop
coordin
immun
respons
final
affect
cell
surviv
lead
macrophag
apoptosi
show
yersiniainduc
apoptosi
human
macrophag
involv
caspasedepend
cleavag
tlr
adapt
protein
manner
overexpress
cleav
cell
follow
apoptosi
induct
process
occur
advanc
stage
apoptosi
activ
accordingli
cleav
invitro
proteas
assay
process
restrict
yersinia
infect
also
observ
staurosporineinduc
apoptosi
appear
cleavag
uncoupl
activ
nfb
signal
thu
disrupt
signal
execut
apoptosi
may
render
die
cell
less
sensit
tlr
stimul
suggest
cleavag
implic
apoptot
death
signal
confer
immunogen
toler
die
cell
respons
microbi
stimul
hausner
r
dumk
e
jacob
cell
wallless
bacterium
mycoplasma
pneumonia
lead
caus
upper
lower
respiratori
infect
human
crucial
step
host
colon
adhesinmedi
bind
pathogen
cell
respiratori
epithelium
cytadher
pneumonia
exhibit
complex
membran
extens
call
attach
organel
includ
amongst
protein
major
adhesin
adherenceassoci
protein
present
studi
investig
immun
respons
guinea
pig
pneumonia
time
period
day
singl
intranas
infect
elisa
western
blot
fac
analysi
shown
earli
strong
serum
immun
respons
major
adhesin
timedepend
reduct
adhes
mycoplasma
hela
cell
pretreat
bacteria
differ
antisera
previous
publish
work
creat
chimer
protein
deriv
function
adhes
region
protein
polyclon
antiserum
abl
decreas
pneumonia
adher
three
differ
human
cell
line
around
use
chimer
protein
antigen
immun
strategi
elicit
antibodi
respons
respiratori
tract
guinea
pig
reduc
adhes
pneumonia
purpos
combin
adher
inhibitori
properti
mucoadhes
characterist
polysaccharid
chitosan
adjuv
guinea
pig
immun
intranas
optim
mixtur
chitosan
laboratori
experi
confirm
stabil
proteinchitosan
mixtur
timedepend
releas
antigen
immun
respons
immun
anim
group
compar
obtain
subcutan
sc
immun
preliminari
test
shown
immun
chitosan
abl
induc
higher
mucos
iga
titr
sc
immun
alon
result
promis
achiev
increas
level
pneumoniaespecif
secretori
iga
comparison
convent
system
immun
use
advantag
chitosan
nasal
vaccin
host
organ
character
antigen
fibrinogen
bind
protein
fbl
staphylococcu
lugdunensi
involv
invas
epitheli
endotheli
cell
bacteri
invas
nonphagocyt
host
cell
import
pathogen
factor
escap
host
defens
system
sever
staphylococci
staphylococcu
aureu
staphylococcu
saprophyticu
staphylococcu
epidermidi
intern
eukaryot
cell
mechan
discuss
import
part
infect
process
fibronectin
bind
protein
discuss
import
prerequisit
intern
describ
aureu
epidermidi
fibronectin
independ
mechan
via
also
recent
describ
two
fibrinogen
bind
adhesin
previous
describ
lugdunensi
fibrinogen
bind
protein
support
adhes
bacteria
eukaryot
cell
consid
prerequisit
intern
process
aureu
date
fibronectin
bind
protein
lugdunensi
describ
sought
investig
whether
lugdunensi
intern
epitheli
endotheli
cell
line
cell
eahi
use
previous
describ
facsbas
invas
assay
could
show
clinic
isol
lugdunensi
intern
human
urinari
bladder
carcinoma
cell
line
endotheli
cell
line
eahi
interestingli
strain
invad
human
urinari
bladder
carcinoma
cell
line
bound
fibronectin
contrast
strain
bind
solidphas
fibronectin
intern
fibrinogen
bind
protein
fbl
involv
intern
process
sinc
isogen
fbl
knockout
mutant
also
invad
eukaryot
cell
unalt
bound
fibronectin
discoveri
intern
attribut
lugdunensi
linkag
fibronectin
bind
suggest
intern
import
pathogen
also
occur
via
fibronectin
mediat
surfac
contact
j
elia
tremmel
u
vogel
institut
hygien
und
mikrobiologi
deutschland
laboratori
staff
work
neisseria
meningitidi
offer
immun
avail
vaccin
serogroup
c
part
biolog
safeti
manag
perform
crosssect
studi
individu
year
vaccin
quadrival
polysaccharid
vaccin
aim
studi
estim
durat
protect
polysaccharid
vaccin
assess
whether
revaccin
newli
avail
quadrival
conjug
vaccin
necessari
timepoint
immun
retrospect
obtain
immun
card
particip
serumbactericid
activ
test
wide
accept
surrog
paramet
assess
vaccin
effect
meningococci
test
sera
use
tilt
method
maslanka
et
al
refer
strain
cdc
strain
serogroup
c
respect
minim
durat
protect
estim
intersect
lower
predict
band
linear
model
describ
tempor
declin
titr
logarithm
base
horizont
line
repres
protect
titr
minim
durat
protect
month
serogroup
c
respect
mean
protect
durat
howev
exceed
month
serogroup
individu
titr
vaccin
quadrival
conjug
vaccin
protect
titr
restor
week
data
shown
conclus
analys
might
point
less
effect
immun
serogroup
polysaccharideonli
vaccin
corrobor
find
addit
measur
concentr
anticapsular
igg
present
sera
vaccine
underway
haemophilu
influenza
use
pe
surfac
protein
acquir
human
plasminogen
evad
innat
immun
haemophilu
influenza
import
respiratori
pathogen
respons
varieti
infect
human
nontyp
h
influenza
nthi
strain
bind
human
plasminogen
identifi
adhes
protein
protein
e
pe
nthi
new
major
plasminogen
bind
protein
plasminogen
kda
human
plasma
protein
express
liver
cell
key
enzym
fibrinolysi
plasminogen
compos
five
homolog
tripl
loop
kringl
domain
ctermin
serin
proteas
domain
plasminogen
bound
dose
depend
intact
bacteria
also
recombin
pe
nthi
plasminogen
also
bound
ten
differ
test
clinic
h
influenza
isol
plasminogenp
interact
mediat
lysin
residu
affect
ionic
strength
plasminogen
bind
pe
knock
strain
nthi
pe
reduc
compar
wildtyp
nthi
addit
plasminogen
bound
pe
ectop
express
surfac
e
coli
zymogen
plasminogen
convert
specif
activ
serin
proteas
plasmin
activ
plasmin
control
complement
attack
degrad
also
degrad
extracellular
matrix
compon
fibrinogen
plasminogen
bound
intact
nthi
pe
convert
human
upa
activ
plasmin
cleav
synthet
substrat
also
natur
substrat
fibrinogen
plasminogenbind
region
local
within
pe
protein
use
synthet
linear
peptid
major
plasminogenbind
region
local
linear
peptid
repres
aa
nterminu
ie
aa
pe
bind
plasminogen
well
vitronectin
two
human
plasma
protein
compet
pe
bind
thu
pe
h
influenza
major
plasminogenbind
protein
pe
bound
human
plasminogen
convert
plasmin
aid
immun
evas
contribut
bacteri
virul
hepatocytespecif
knockout
augment
defens
malaria
liver
stage
infect
x
wang
j
introduct
malaria
infect
plasmodium
sporozoit
migrat
sever
host
cell
final
infect
hepatocyt
develop
erythrocyteinfect
merozoit
cytosol
factor
releas
travers
hepatocyt
activ
nfb
pathway
adjac
hepatocyt
turn
lead
reduct
parasit
load
induc
express
tnf
ino
ubiquitinedit
enzym
block
proxim
nfb
signal
pathway
variou
stimul
knockout
mice
succumb
prematur
uncontrol
hyperinflamm
order
explor
function
plasmodium
liver
stage
develop
hepatocytespecif
mice
gener
investig
malaria
infect
materi
method
hepatocytespecif
knockout
mice
gener
util
creloxp
system
control
albumin
promot
effici
specif
delet
hepatocyt
ko
mice
express
affect
control
mice
appli
blood
stage
parasitemia
quantit
rtpcr
liver
parasit
load
two
complementari
primari
endpoint
malaria
sporozoit
challeng
infect
infiltr
leukocyt
isol
liver
subpopul
investig
fac
express
cytokin
chemokin
infect
liver
also
assess
qrtpcr
result
fortytwo
hour
post
infect
ko
mice
lower
liver
parasit
load
compar
mice
first
day
infect
parasitemia
ko
mice
also
significantli
lower
compar
control
mice
differ
gradual
disappear
diseas
progress
fac
analysi
show
infiltr
cell
b
cell
macrophag
inflammatori
monocyt
ko
mice
besid
higher
level
tnf
also
detect
liver
ko
mice
indic
stronger
inflammatori
respons
interestingli
mrna
level
ino
respons
produc
antimalari
also
significantli
higher
infect
ko
mice
studi
demonstr
delet
hepatocyt
benefici
parasit
clearanc
malaria
liver
stage
infect
presum
induc
stronger
local
inflammatori
respons
augment
antiliv
stage
defens
mechan
may
improv
experiment
malaria
vaccin
strategi
introduct
tuberculosi
tb
still
major
threat
global
health
accord
nearli
peopl
die
wherea
nearli
peopl
infect
tb
worldwid
sinc
drugresist
strain
mycobacterium
tuberculosi
mtb
continu
rise
new
way
treat
diseas
establish
therefor
basic
understand
infect
mechan
tb
need
shown
mycobacteria
infect
host
variou
mechan
eg
phagosom
matur
inhibit
via
et
al
inhibit
inflamm
infect
gueninmac
group
found
lipid
phenol
glycolipid
pgl
outer
cell
wall
mycobacterium
marinum
mmar
model
organ
research
mtb
might
interfer
innat
immun
system
robinson
et
al
current
focus
establish
link
pgl
pathway
innat
immun
system
materialmethod
pgl
isol
cultur
mmar
subsequ
purifi
human
monocyt
deriv
macrophag
hmdm
isol
buffi
coat
cultur
day
rpmi
fc
pgl
coat
onto
paramagnet
bead
heatkil
bacillu
calmetteguerin
hkbcg
chase
hmdm
hour
case
magnet
bead
hmdm
costimul
lp
rna
extract
cytokin
tnfalpha
analys
qrtpcr
hmdm
transfect
luciferas
base
report
system
promotor
differ
signal
pathway
innat
immun
system
infect
pglcoat
hkbcg
luciferas
activ
analys
result
upon
infect
hmdm
pglcoat
hkbcg
amount
rna
greatli
reduc
prolong
incub
cytokin
like
tnfa
show
effect
even
stimul
hmdm
lp
pgl
time
cytokin
rna
level
significantli
reduc
promotor
activ
nfkb
stimul
hmdm
pglcoat
hkbcg
greatli
reduc
comparison
activ
stimul
uncoat
hkbcg
discuss
find
suggest
pgl
inde
abl
interfer
signal
pathway
innat
immun
system
could
show
pgl
supress
product
tnfa
rna
hmdm
stimul
hkbcg
lp
reduc
promotor
activ
nfkb
indic
pgl
interfer
pathway
innat
immun
system
still
remain
elus
exactli
pgl
interfer
pathway
result
show
import
pgl
mycobateria
abl
undermin
respons
immun
system
work
could
therefor
help
complet
pictur
infect
mechan
mycobacteria
intracellular
protozoan
parasit
toxoplasma
gondii
invad
brain
caus
persist
infect
toxoplasm
enceph
te
ifnproduc
cell
activ
microglia
macrophag
astrocyt
appear
major
effector
mechan
host
immun
infiltr
brain
depend
express
differ
adhes
molecul
integr
blood
brain
barrier
adhes
degranulationpromot
adapt
protein
adap
express
cell
myeloid
cell
platelet
adapt
protein
involv
cell
receptor
tcr
depend
insideout
signal
therebi
regul
activ
adhes
cell
littl
known
role
adap
brain
cell
sinc
could
demonstr
adapdefici
adap
mice
show
amelior
diseas
progress
experiment
autoimmun
encephalomyel
eae
model
function
adap
brain
cell
hypothes
studi
perform
low
dose
infect
adap
mice
wildtyp
mice
gondii
monitor
surviv
furthermor
examin
cyst
load
inflammatori
infiltr
use
immunohistochemistri
well
distribut
microglia
cell
macrophag
lymphocyt
brain
fac
analysi
strikingli
adap
mice
show
significantli
reduc
surviv
line
increas
cyst
load
day
infect
compar
wildtyp
mice
although
number
ifnproduc
lymphocyt
increas
brain
adap
mice
adap
mice
die
day
post
infect
wildtyp
mice
surviv
contrast
number
activ
microglia
cell
astrocyt
reduc
brain
adap
mice
data
indic
import
role
adap
activ
microglia
cell
toxoplasmosi
wherea
integrinmedi
migrat
cell
bloodbrainbarri
seem
independ
adap
adap
contribut
surviv
te
therefor
play
major
role
maintain
immun
homeostasi
brain
staphylococc
protein
efb
bind
plasminogen
enhanc
plasminmedi
degrad
tk
enghardt
barthel
reuter
pf
zipfel
c
skerka
staphylococcu
aureu
human
pathogen
live
human
commens
also
caus
superfici
lifethreaten
infect
upon
infect
aureu
induc
host
innat
immun
reaction
activ
complement
system
recruit
phagocyt
cell
secret
antimicrobi
peptid
howev
aureu
master
immun
evas
interfer
particularli
action
complement
system
complement
activ
normal
lead
opson
lysi
pathogen
microorgan
well
inflammatori
reaction
aureu
develop
multipl
strategi
target
inhibit
central
molecul
complement
system
aureu
secret
efb
extracellular
fibrinogen
bind
protein
directli
bind
precursor
opsonin
block
convertas
activ
upon
bind
efb
induc
conform
chang
lead
enhanc
suscept
degrad
proteas
trypsin
sinc
aureu
also
recruit
human
serum
protein
plasminogen
subsequ
activ
plasminogen
staphylokinas
sak
plasmin
ask
whether
efb
modul
plasminmedi
cleavag
show
efb
recruit
plasminogen
efb
bound
plasminogen
access
human
plasminogen
activ
upa
well
bacteri
sak
gener
proteolyt
activ
plasmin
interact
efb
plasmin
lead
enhanc
degrad
plasmin
thu
efb
target
two
way
directli
bind
induc
conform
chang
indirectli
facilit
proteolyt
activ
plasmin
type
type
iii
interferon
ifn
bind
differ
cell
surfac
receptor
induc
ident
signal
transduct
pathway
lead
express
antivir
host
effector
molecul
although
ifnl
shown
predominantli
act
mucos
organ
lung
gastrointestin
tract
studi
use
ifnl
receptordefici
mice
fail
defin
nonredund
function
show
protect
role
ifnsignal
rotaviru
infect
use
suckl
wildtyp
type
ifn
receptordefici
ifnl
receptordefici
doubleknockout
mice
enhanc
viru
replic
tissu
damag
found
absenc
ifnl
signal
wherea
signific
contribut
ifnab
signal
antivir
host
defenc
detect
quantit
rtpcr
simultan
immunostain
virusinfect
cell
antivir
protein
highlight
distinct
respons
intestin
epitheli
cell
ifnl
critic
role
restrict
epitheli
viral
replic
vivo
thu
antivir
host
protect
intestin
epithelium
respons
rotaviru
infect
reli
intact
ifnl
signal
recognit
pathogen
microb
intestin
epitheli
cell
result
transcript
activ
secret
solubl
mediat
attract
profession
immun
cell
site
infect
defenc
mechan
work
effici
despit
often
low
number
pathogen
limit
amount
mediat
secret
per
epitheli
cell
recent
identifi
horizont
intercellular
commun
critic
compon
effici
epitheli
innat
host
defenc
chemokin
product
l
monocytogen
infect
primarili
observ
neighbor
noninfect
cell
despit
invasiondepend
natur
listeriainduc
epitheli
activ
celltocel
commun
independ
gap
junction
format
cytokin
secret
ion
flux
nitric
oxid
synthesi
requir
nadph
oxidas
nox
oxygen
radic
format
conclus
result
provid
novel
concept
coordin
epitheli
host
respons
upon
microbi
challeng
maintain
mucos
homeostasi
provid
effici
protect
infect
enteropathogen
microorgan
human
cell
stimul
ifnresult
strong
activ
tryptophan
degrad
enzym
indoleamin
ido
import
antimicrobialand
immunoregulatori
effector
mechan
ido
convert
essenti
amino
acid
tryptophan
formylkynurenin
channel
kynurenin
pathway
ido
mediat
antimicrobi
effect
mainli
starvat
tryptophan
howev
tryptophan
metabolit
produc
kynurenin
pathway
abl
inhibit
growth
immun
cell
studi
analys
effect
kynurenin
kyn
acid
quinolin
acid
qa
prolifer
tcell
staphylococcu
aureu
toxoplasma
gondii
tumor
cell
found
kyn
influenc
growth
aureu
metabolit
abl
inhibit
prolif
respons
tcell
addit
experi
show
influenc
metabolit
growth
gondii
glioblastoma
cell
detail
analys
indic
antiparasit
effect
due
toxic
effect
tryptophan
metabolit
host
cell
astonish
result
furthermor
investig
use
differ
type
tumor
cell
found
strongest
toxic
effect
mediat
follow
kyn
qa
influenc
growth
tumor
cell
test
addit
detect
synergist
effect
kyn
tumor
cell
viabil
quantit
analysi
toxic
indic
tumor
cell
eg
cell
lung
cancer
cell
resist
tcell
vivo
mani
human
tumor
cell
express
ido
activ
therefor
abl
produc
kynurenin
metabolit
might
inhibit
activ
tumor
specif
tcell
enhanc
resist
tumor
cell
toxic
effect
tryptophan
metabolit
might
repres
immun
escap
mechan
background
fibroblast
regul
epitheli
cell
differenti
respons
wound
heal
control
inflamm
process
seem
play
import
role
cancerogenesi
bacteria
product
play
well
involv
preventionpromot
chronic
inflammatori
diseas
wound
heal
cancer
linkag
might
hyaluronan
ha
metabol
bacteria
produc
hyaluronidas
bacteri
product
interact
tolllikereceptor
tlr
also
seem
link
ha
metabol
investig
far
microorganismsmicrobi
product
influenc
metabol
ha
human
dermal
fibroblast
tlr
activ
stimul
human
dermal
fibroblast
staphylococc
toxin
enterotoxin
b
seb
lipopolysaccharid
lp
peptidoglycan
pgn
well
solubl
product
clinic
staphylococcu
aureu
epidermidi
lactobacillu
crispatu
isol
releas
chemokin
analyz
elisa
well
quantit
realtim
pcr
rtpcr
activ
tlr
tlr
hyaluronan
acid
synthas
hyaluronidas
hyal
analyz
rtpcr
result
fibroblast
respond
lp
solubl
product
epidermidi
l
crispatu
releas
high
amount
increas
mrna
level
pronounc
chang
tlr
express
seen
tlr
tlr
tlr
epidermidi
staphylococc
superantigen
seb
pgn
lp
pgn
activ
releas
predominantli
activ
addit
stimuli
use
signal
well
unstimul
fibroblast
highest
mrna
express
seen
hyal
moder
express
seen
hyal
signal
obtain
hyal
howev
microorgan
microbi
product
studi
modul
ha
metabol
breakdown
hyaluronan
staphylococc
hyaluronidas
chang
mrna
express
hyal
well
conclus
data
clearli
show
fibroblast
interact
microorganismsmicrobi
product
differ
degre
eg
tlr
howev
possibl
role
ha
metabol
hostmicroorgan
interact
need
studi
j
kehrmann
r
tatura
effector
cell
accus
influenc
origin
cours
sever
chronic
infect
autoimmun
diseas
certain
tumour
also
evid
septic
patient
percentag
treg
cell
refer
cell
increas
sepsi
patient
show
sepsisinduc
immunoparalysi
poor
outcom
besid
exact
quantif
treg
cell
great
interest
elucid
role
cell
develop
progress
mani
diseas
even
concept
cell
therapi
appoint
diseas
reestablish
balanc
treg
cell
effector
cell
studi
quantifi
treg
cell
analysi
surfac
marker
transcript
factor
use
flow
cytometri
date
constitut
express
specif
uniqu
marker
human
treg
cell
avail
exact
quantif
protein
rna
level
imprecis
recent
found
epigenet
differ
dna
methyl
treg
cell
effector
cell
exist
differ
use
quantif
treg
cell
treg
specif
demethyl
region
tsdr
demonstr
applic
genom
region
treg
quantif
present
data
quantif
treg
cell
newli
develop
methyl
sensit
realtim
pcr
assay
use
compar
data
analysi
treg
cell
flow
cytometri
data
quantif
treg
cell
blood
septic
patient
compar
quantifi
treg
cell
blood
healthi
peopl
w
abdel
halim
microbiolog
deutschland
salmonella
enterica
serovar
typhimurium
facult
intracellular
pathogen
enter
host
cell
replic
within
special
membran
compart
salmonella
also
interest
vehicl
display
recombin
antigen
profession
antigen
present
cell
apc
heterolog
antigen
express
salmonella
fusion
recombin
nativ
protein
approach
use
mainli
direct
express
desir
antigen
particular
locat
bacteri
cell
increas
immunogen
foreign
antigen
fuse
protein
could
exert
carrier
effect
type
iii
secret
system
mediat
transloc
salmonella
use
effici
deliveri
heterolog
antigen
cytosol
apc
lead
stimul
tcell
work
investig
use
subset
effector
protein
ssej
sifa
ssel
stec
effector
protein
associ
endosom
membran
transloc
invitro
invivo
experi
vaccin
show
effector
ssej
suitabl
fusion
partner
previou
work
shown
sifb
promot
effici
invivo
induc
promot
show
ssej
antigen
fusion
protein
control
sifb
promot
effici
comparison
effector
fusion
control
invivo
induc
promot
comparison
variou
attenu
carrier
strain
observ
htrapurd
doubl
mutant
strain
use
effici
attenu
carrier
vaccin
observ
effici
stimul
invitro
tcell
prolifer
delta
sifa
mutant
strain
carrier
product
cytokin
respons
microbi
danger
signal
regul
level
mapk
activ
dual
specif
phosphatas
dusp
control
mapk
activ
dephosphoryl
threonin
tyrosin
residu
differenti
express
induc
dusp
gene
express
suggest
phosphatas
specifi
outcom
mapk
activ
term
cytokin
product
investig
role
also
known
immun
system
express
macrophag
dendrit
cell
induc
tlr
stimuli
vitro
vivo
express
constitut
organ
b
lymphocyt
contrast
lp
challeng
upregul
mrna
spleen
gene
trap
es
cell
clone
bear
insert
locu
abrog
express
full
length
mrna
use
gener
mice
lack
mate
heterozyg
mice
fail
yield
homozyg
mice
wean
howev
embryon
develop
homozyg
mice
grossli
normal
indic
mice
die
perinat
fetal
liver
cell
use
gener
macrophag
vitro
reconstitut
lethal
irradi
mice
vivo
analysi
macrophag
respond
normal
tlr
stimul
cytokin
analys
show
significantli
higher
product
vivo
fetal
liver
cell
reconstitut
b
cell
compart
similar
wt
follow
inject
lp
mice
significantli
overproduc
consist
phenotyp
macrophag
vitro
taken
togeth
product
cytokin
respons
tlr
stimul
vitro
vivo
select
control
ongo
work
address
function
consequ
model
inflamm
infect
cellular
respons
human
monocyt
deriv
macrophag
infect
genet
distinct
tuberculosi
complex
strain
aim
studi
mycobacterium
tuberculosi
complex
mtbc
initi
regard
highli
homogen
popul
howev
recent
data
suggest
caus
agent
tuberculosi
genet
function
divers
appreci
previous
impact
natur
variat
virul
pathogen
clinic
manifest
remain
larg
unknown
method
studi
analyz
host
respons
human
primari
monocyt
deriv
macrophag
upon
infect
genet
distinct
mtbc
strain
studi
includ
strain
caus
larger
outbreak
hamburg
germani
well
attenu
strain
belong
haarlem
genotyp
supernat
collect
monitor
releas
proand
antiinflammatori
mediat
result
conclus
strain
induc
compar
releas
tumor
necrosi
factor
tnf
alpha
interleukin
il
rant
signific
differ
cluster
isol
attenu
strain
observ
data
demonstr
differ
strain
success
monitor
longitudin
epidemiolog
studi
reflect
level
mediat
releas
infect
human
monocytederiv
macrophag
howev
addit
data
also
demonstr
particular
mtbc
genotyp
translat
distinct
biolog
respons
profil
get
contact
human
immun
cell
supp
part
bmbf
grant
project
wp
pathogen
variabl
clinic
tb
isol
implic
modul
immun
system
infect
diseas
progress
sn
nr
j
strebovski
p
walker
dalpk
heidelberg
dept
infektiologi
heidelberg
deutschland
activ
innat
immun
cell
infect
tightli
control
avoid
overshoot
reactiv
suppressor
cytokin
signal
soc
protein
well
known
feedback
inhibitor
janu
kinas
jak
signal
transduc
activ
transcript
stat
signal
pathway
unexpectedli
observ
member
soc
famili
local
predominantli
nucleu
nuclear
local
due
far
unknown
bipartit
nuclear
local
signal
nl
use
photoactiv
construct
confirm
rapid
transloc
cytoplasm
nucleu
within
nucleu
highli
mobil
demonstr
frap
experi
character
novel
function
within
cell
nucleu
gener
nlsmutant
whose
express
restrict
cytoplasm
therebi
identifi
gene
differ
regul
depend
nuclear
avail
abl
identifi
nfkb
compon
novel
interact
partner
bound
within
nuclear
compart
increas
ubiquitin
degrad
domain
contribut
bind
wherea
ubiquitin
mediat
soc
box
limit
avail
result
reduc
express
subset
nfkb
depend
gene
mass
spectrometri
identifi
interact
partner
result
show
regul
durat
nfkb
signal
mean
ubiquitin
ligas
activ
therebi
exert
far
unrecogn
function
within
cell
nucleu
nuclear
function
import
limit
proinflammatori
stimul
innat
immun
cell
microbi
product
mycobacteri
cord
factor
tdm
major
virul
factor
tuberculosi
recogn
innat
immun
cell
depend
manner
recent
identifi
ctype
lectin
receptor
clr
mincl
receptor
tdm
synthet
analogu
tdb
two
glycolipid
potent
adjuv
elicit
mix
respons
wherea
tolllik
receptor
ligand
cpg
dna
induc
exclus
respons
clr
tlr
ligand
trigger
distinct
profil
cytokin
effector
antigen
present
cell
uniqu
transcript
respons
gener
role
play
induct
incomplet
understood
tlr
clr
signal
activ
mapkinas
pathway
transcript
factor
tf
nfkappab
contrast
latent
tf
nfat
activ
upon
clr
upon
tlr
stimul
howev
littl
known
tf
profil
induc
downstream
constitut
express
tf
assess
express
kinet
induc
tf
macrophag
tdb
cpg
stimul
understand
similar
differ
express
profil
elicit
two
type
prr
tdb
rapidli
directli
induc
earli
growth
respons
gene
express
depend
mincl
cebpbeta
upregul
protein
level
stimul
tdb
cpg
chip
experi
observ
recruit
ino
promot
furthermor
defici
macrophag
result
strong
reduct
releas
tdb
cpg
stimul
taken
togeth
data
shed
new
light
regulatori
network
control
transcript
activ
induc
clr
mincl
respons
microbi
mincl
ligand
type
interferon
induc
protein
contribut
type
interferon
mediat
proinflammatori
immun
respons
siegfri
berchtold
b
mannck
ott
b
autenrieth
e
bohn
institut
medizinisch
mikrobiologi
und
krankenhaushygien
deutschland
izkfserviceeinrichtung
transgen
tier
deutschland
also
call
type
interferon
induc
protein
belong
famili
tetratricopeptid
repeat
protein
upregul
variou
viru
infect
well
known
upregul
lead
better
surviv
tumor
patient
resect
tumor
report
bind
translat
initi
factor
therefor
inhibit
translat
protein
specif
may
recogn
may
prevent
translat
cap
viral
mrna
lack
methyl
stimul
interferon
receptor
ifnar
bone
marrow
deriv
macrophag
bmdm
demonstr
ligand
well
ifninduc
protein
express
type
interferon
receptor
depend
indic
directli
induc
type
interferon
studi
want
elucid
role
effector
type
interferon
induc
biolog
process
purpos
knockout
mice
gener
order
investig
potenti
role
inflammatori
respons
bmdm
stimul
lp
bmdm
show
significantli
reduc
tnf
secret
indic
contribut
type
interferon
mediat
amplif
lp
induc
proinflammatori
respons
line
find
could
demonstr
mice
less
suscept
lp
mediat
endotoxin
shock
compar
litterm
wildtyp
control
taken
togeth
data
demonstr
contribut
effector
type
interferon
mediat
amplif
inflammatori
respons
vertebr
coagul
system
play
major
role
hemostasi
wound
heal
coagul
factor
xiii
fxiii
plasma
transglutaminas
final
crosslink
form
fibrin
network
gener
stabil
plasma
clot
seal
injur
site
evid
accumul
impli
coagul
also
contribut
earli
innat
immun
respons
pathogen
activ
intrins
pathway
coagul
also
known
contact
system
seem
play
import
role
process
previou
work
shown
activ
surfac
mani
pathogen
bacteri
speci
turn
lead
gener
antimicrobi
peptid
bacteri
kill
present
data
demonstr
contact
system
activ
especi
human
fxiii
benefici
effect
infect
streptococcu
pyogen
find
system
activ
surfac
bacteria
exposur
human
plasma
follow
activ
thrombin
fxiii
consequ
interact
bacteria
immobil
kill
within
clot
vivo
experi
use
streptococc
skin
infect
model
reveal
fxiii
mice
develop
sever
sign
patholog
inflamm
focu
infect
compar
wildtyp
anim
analyz
skin
biopsi
infect
wildtyp
mice
bacteria
found
cluster
within
fibrin
network
local
site
infect
howev
infect
fxiii
anim
bacteria
widespread
scatter
larg
affect
area
treatment
wildtyp
mice
human
fxiiiconcentr
three
hour
bacteri
inocul
dampen
system
dissemin
pyogen
earli
phase
infect
proof
vitro
vivo
result
also
appli
clinic
situat
analyz
tissu
biopsi
patient
suffer
streptococc
necrot
fasciiti
seen
murin
biopsi
detect
fxiiimedi
bacteri
crosslink
fibrin
network
biopsi
support
concept
coagul
fxiii
contribut
earli
innat
immun
respons
pathogen
role
lysosom
phospholipas
immun
respons
intracellular
bacteria
b
schneider
k
hagen
j
shayman
u
schaibl
phospholipas
form
ubiquit
class
enzym
catalys
cleavag
membran
phospholipid
smaller
bioactiv
molecul
recent
lysosom
phospholipas
identifi
shown
highli
enrich
alveolar
macrophag
play
import
role
surfact
degrad
knockout
ko
mice
develop
phospholipidosi
phenotyp
demonstr
mark
accumul
phospholipid
alveolar
periton
macrophag
spleen
given
high
express
macrophag
import
membran
homeostasi
phospholipid
turnov
hypothes
contribut
host
respons
intracellular
bacteria
order
studi
role
macrophag
respons
intracellular
bacteria
perform
function
vitro
analys
periton
macrophag
wild
type
wt
ko
mice
addit
studi
role
antibacteri
host
respons
lung
tuberculosi
vivo
defici
macrophag
show
defect
kill
intracellular
bacteria
nonpathogen
e
coli
pathogen
mycobacterium
tuberculosi
found
impair
digest
intracellular
bacteria
vitro
even
nonpathogen
e
coli
readili
clear
persist
long
wt
macrophag
degrad
furthermor
absenc
function
strongli
affect
abil
macrophag
stimul
cell
vitro
line
adapt
immun
impair
defici
mice
upon
infect
lung
pathogen
tuberculosi
vivo
absenc
number
activ
tuberculosi
specif
cell
well
cytokin
level
significantli
reduc
upon
tuberculosi
infect
defici
mice
present
mild
patholog
lung
spleen
due
reduc
cellular
infiltr
organ
bacteri
load
significantli
increas
taken
togeth
data
indic
involv
clearanc
bacteria
macrophag
process
bacteri
antigen
subsequ
gener
cell
respons
though
il
helper
th
cell
potent
induc
tissu
inflamm
associ
sever
chronic
autoimmun
inflammatori
diseas
main
function
cell
appear
clearanc
pathogen
appropri
affect
cell
evalu
role
protect
role
mycobacterium
tuberculosi
mtb
infect
analyz
outcom
experiment
tuberculosi
tb
mice
receptor
interestingli
mtbinfect
mice
effici
gener
interferongamma
ifngamma
produc
cell
ifngammadepend
effector
respons
low
dose
cfu
infect
howev
mice
abl
control
mycobacteri
replic
chronic
phase
experiment
tb
low
dose
infect
die
earlier
day
post
infect
dpi
correspond
wildtyp
mice
high
dose
infect
cfu
mice
rapidli
die
alreadi
earli
stage
mtbinfect
dpi
breakdown
control
mycobacteri
replic
low
high
dose
infect
associ
modul
gene
express
proinflammatori
cytokin
chemokin
receptor
especi
highli
increas
gene
express
mice
lead
hypothesi
hypercompens
defici
induc
neutrophilia
suscept
mtb
infect
fact
contrast
mice
mice
defici
receptor
f
resist
high
dose
infect
mtb
far
find
lead
conclus
account
suscept
mtbinfect
mice
henc
appear
play
direct
role
protect
mtb
infect
support
inflamm
research
excel
cluster
staphylococcu
aureu
frequent
caus
sever
skin
soft
tissu
infect
human
treatment
complic
emerg
multiresist
hypervirul
strain
abil
control
infect
larg
depend
rapid
recruit
polymorphonuclear
neutrophil
granulocyt
pmn
gain
insight
pmn
migrat
hostpathogen
interact
vivo
investig
mous
model
aureu
flank
skin
infect
use
intravit
twophoton
microscopi
purpos
gener
aureu
report
strain
express
codonadapt
fluoresc
protein
pmn
migrat
respons
infect
vivo
visual
use
lysmegfp
transgen
mice
inject
bacteria
observ
rapid
appear
pmn
extravascular
space
dermi
direct
movement
toward
focu
infect
result
accumul
larg
number
cell
led
delin
abscess
within
one
day
surprisingli
direct
encount
bacteri
cell
pmn
alway
lead
uptak
pathogen
deplet
pmn
block
gprotein
coupl
receptor
gpcr
lead
uncontrol
prolifer
bacteria
moreov
track
transfer
label
bonemarrow
deriv
neutrophil
show
pmn
recruit
site
infect
depend
gpcr
cell
wherea
requir
host
cell
pmn
final
use
report
staphylococc
agr
quorumsens
system
abl
follow
bacteri
gene
regul
vivo
singl
cell
level
observ
agr
activ
could
local
small
area
margin
infect
focu
result
establish
twophoton
microscopi
power
tool
investig
dynam
immun
respons
bacteri
cell
locat
gene
express
vivo
singl
cell
level
aureu
infect
absenc
cyld
essenti
surviv
murin
listeriosi
introduct
infecti
diseas
activ
well
inhibitori
transcript
factor
requir
enabl
pathogen
control
prevent
overshoot
patholog
immun
reaction
cyld
deubiquityl
enzym
play
pivot
inhibitori
role
immun
respons
cyld
downregul
nfkb
activ
proteolysi
ubiquitin
signal
transduc
molecul
like
tnfr
addit
nfb
cyld
also
known
inhibit
mapk
tissu
protect
factor
plasminogen
activ
inhibitor
gain
insight
function
cyld
listeriosi
infect
cyld
wildtyp
wt
mice
lethal
dose
listeria
monocytogen
bacteri
burden
mice
group
determin
day
pi
day
pi
tissu
liver
spleen
obtain
rtpcr
wb
analysi
character
role
cyld
function
assay
like
inhibit
fibrin
product
warfarin
vivo
neutalis
perform
final
cyld
knock
wt
mice
sirna
show
import
listeriosi
result
discuss
wherea
wt
mice
succumb
infect
day
pi
cyld
mice
surviv
infect
indic
cyld
inhibit
protect
host
respons
macroscop
examin
reveal
wt
mice
suffer
multiorgan
bleed
succumb
liver
failur
shown
increas
ast
alt
level
compar
cyld
mice
contrast
bacteri
burden
partial
increas
wt
mice
addit
wb
analysi
show
increas
activ
nfb
mapk
well
increas
product
protect
ifn
cyld
mice
importantli
cyld
mice
increas
fibrin
deposit
liver
upon
inhibit
fibrin
product
warfarin
cyld
mice
succumb
listeriosi
indic
clyd
inhibit
fibrin
product
via
inhibit
illustr
import
fibrin
limit
spread
listeriosi
good
agreement
stimul
cyld
hepatocyt
result
stronger
activ
transcript
factor
fibrinogen
product
compar
wt
hepatocyt
clyd
hepatocyt
upon
stimul
neutral
abolish
protect
effect
cylddefici
result
multiorgan
bleed
cyld
mice
conclus
absenc
cyld
essenti
surviv
murin
listeriosi
observ
neutralis
cyld
wt
mice
sirna
partial
protect
wt
mice
lethal
listerios
identifi
cyld
potenti
therapeut
target
listerioisi
complement
system
direct
immun
effector
function
modul
intens
innat
specif
immun
respons
activ
extracellular
pathogen
damag
cell
almost
noth
known
role
complement
system
infect
intracellular
bacteriathi
project
demonstr
import
role
c
psittaci
lung
infect
use
sever
complement
factor
receptor
knockout
defici
mice
mice
intranas
infect
nonavian
c
psittaci
strain
dc
sacrif
day
detail
analysi
weight
clinic
score
determin
daili
complement
activ
occur
symptom
pneumonia
becam
appar
surprisingli
follow
phase
partial
protect
complement
factor
mice
die
day
post
infect
compar
wildtyp
control
mice
lack
complement
effector
function
time
suscept
intracellular
bacteria
phase
partial
protect
mice
day
granulocyt
migrat
inflam
lung
proinflammatori
cytokin
elev
seem
even
stronger
bacteri
load
lung
knockout
mice
significantli
decreas
lost
less
weight
clinic
score
better
experi
addit
knockmic
perform
identifi
respons
complement
effector
function
downstream
summari
data
indic
function
harm
earli
c
psittaci
infect
increas
chlamydia
uptak
mediat
might
reason
howev
later
infect
specif
immun
becom
essenti
defenc
complement
activ
seem
necessari
finetun
otherwis
deleteri
immun
respons
data
show
first
time
strong
influenc
complement
activ
outcom
infect
intracellular
bacteria
lipoamid
dehydrogenas
lpd
pseudomona
aeruginosa
bind
vitronectin
human
termin
complement
pathway
regul
complement
evas
gramneg
bacterium
pseudomona
aeruginosa
opportunist
human
pathogen
major
caus
hospitalacquir
infect
particularli
immunocompromis
individu
order
cross
first
line
host
innat
immun
defenc
p
aeruginosa
develop
multipl
strategi
escap
host
complement
attack
complement
resist
crucial
bacteri
virul
sever
pathogen
acquir
host
complement
inhibitor
vitronectin
factor
h
modul
attack
present
studi
show
p
aeruginosa
bind
human
vitronectin
plasma
protein
regul
termin
complement
pathway
bound
surfac
p
aeruginosa
vitronectin
block
insert
assembl
termin
complement
complex
therebi
increas
bacteri
surviv
human
serum
upon
incub
vitronectindeplet
complement
activ
human
serum
surviv
p
aeruginosa
decreas
compar
bacteri
surviv
normal
human
serum
thu
confirm
protect
role
vitronectin
bacteri
surfac
identifi
lipoamid
dehydrogenas
lpd
first
vitronectin
bind
protein
p
aeruginosa
although
lpd
initi
identifi
cytoplasm
protein
flow
cytometri
electron
microscopi
experi
reveal
lpd
local
bacteri
surfac
addit
lpd
found
outer
membran
fraction
twenti
differ
p
aeruginosa
strain
analyz
western
blot
use
specif
lpd
antiserum
lpd
bound
vitronectin
dosedepend
manner
heparin
inhibit
lpdvitronectin
bind
suggest
lpd
bind
one
heparin
bind
domain
vitronectin
use
recombin
fragment
major
lpd
interact
site
within
human
vitronectin
locat
amino
acid
residu
posit
within
ctermin
heparin
bind
domain
vitronectin
taken
togeth
surfac
expos
lpd
p
aeruginosa
bind
human
vitronectin
termin
complement
pathway
regul
therebi
protect
bacteria
complementmedi
attack
yersinia
enterocolitica
caus
enter
foodborn
diseas
mous
model
infect
yersinia
caus
system
diseas
replic
small
intestin
invad
payer
patch
pp
distal
ileum
dissemin
liver
spleen
enterocolitica
carri
plasmid
encod
type
iii
secret
system
yersinia
outer
protein
yop
paralys
phagocyt
innat
immun
enabl
yersinia
surviv
replic
extracellularli
yersinia
expect
releas
typic
pathogenassoci
molecular
pattern
pamp
lipopolysaccharid
lp
peptidoglycan
fragment
pg
lipoprotein
lp
yersinia
v
antigen
lcrv
recogn
respect
host
receptor
prr
divers
tlr
receptor
prr
signal
lead
releas
proinflammatori
cytokin
tnf
first
step
host
defens
activ
follow
antiinflammatori
respons
secret
suggest
infect
process
separ
two
differ
mode
pathogen
host
cell
commun
shortdist
effect
silenc
contact
cell
longdist
effect
releas
pamp
recruit
activ
phagocyt
aim
unravel
pampreceptor
involv
control
yersiniainfect
use
differ
komic
defin
defect
innat
immun
tlrsund
nod
signal
pathway
defect
product
suscept
test
toward
enterocolitica
result
enabl
us
defin
differ
group
suscept
highsuscept
yeh
suscept
ye
highresist
mice
strain
yehr
histolog
analysi
spleen
cryosect
reveal
yersinia
microcoloni
grow
within
margin
zone
white
pulp
tcell
area
tightli
surround
infiltr
neutrophil
lead
abscess
format
histolog
analysi
spleen
cryosect
reveal
homogen
bacteri
spread
whole
red
pulp
damag
splenic
architectur
obtain
evid
yersinia
suscept
mice
close
associ
dynam
neutrophil
recruit
site
infect
due
host
cell
chemokin
product
recruit
high
amount
neutrophil
periton
space
first
infect
due
high
chemokin
product
gcsf
kc
lead
initi
inhibit
yersinia
replic
character
delay
neutrophil
infiltr
lead
uncontrol
yersinia
replic
find
elicit
decis
role
prrsignal
yersiniainfect
model
peptid
deriv
virul
factor
ecoli
inhibit
tlr
signal
new
promis
candid
treatment
autoimmun
diseas
sepsi
f
roemmler
c
cirl
miethk
technic
univers
munich
institut
medic
microbiolog
immunolog
hygien
deutschland
toll
like
receptor
signal
known
part
first
line
defens
innat
immun
system
last
decad
import
autoimmun
diseas
system
lupu
erythematosu
sle
psoriasi
rheumathoid
arthriti
reveal
sle
inappropri
excess
activ
self
rna
dna
sequenc
involv
observ
activ
pdc
ifnalpha
pathway
autoreact
bcell
mediat
autoantibodi
product
furthermor
stimul
play
key
role
hyper
inflammatori
situat
system
inflamm
sepsi
date
rather
unspecif
immun
modul
avail
treatment
corticosteroid
cytostat
reagent
eg
cyclophosphamid
limit
effici
caus
immens
side
effect
therefor
need
new
therapeut
strategi
specif
inhibit
certain
tlr
tcpc
tir
domain
contain
protein
c
identifi
virul
factor
uropathogen
ecoli
cft
inhibit
tlr
respons
make
suitabl
therapeut
approach
develop
peptid
deriv
expos
loop
region
tirdomain
tcpc
mainli
bbloop
ddloop
peptid
bbloop
tcp
known
inhibit
tlrsignal
ddloop
highli
conserv
domain
among
bacteri
pathogen
harbor
tcp
upon
stimul
peptid
inhibit
cytokin
product
includ
tnfalpha
kc
bone
marrow
derivedmacrophag
bmdm
dendrit
cell
bmdc
vitro
without
show
toxic
moreov
peptid
show
promis
effect
murin
lp
shockmodel
lead
significantli
reduc
tnfalpha
serum
level
conclus
tcpcderiv
peptid
abl
inhibit
tlr
signal
without
show
side
effect
promis
candid
new
therapeut
autoimmun
diseas
sepsi
object
invari
human
natur
killer
cell
inktcel
innat
immun
effector
cell
character
express
tand
nk
cell
marker
therefor
connect
link
innat
adapt
immun
cell
defin
tcell
receptor
consist
specif
invari
chain
chain
deriv
limit
repertoir
strongli
react
upon
stimul
lipid
antigen
present
context
mhclike
molecul
dendrit
cell
dc
thu
expand
vitro
stimul
prototyp
agonist
galactosylceramid
galcer
protect
role
inkt
cell
autoimmun
diseas
cancer
immun
well
action
differ
pathogen
well
document
howev
littl
known
direct
interact
fungi
especi
aspergillu
fumigatu
fumigatu
omnipres
mold
preval
caus
highli
devast
opportunist
infect
affect
mainli
immunocompromis
patient
method
order
expand
human
inkt
cell
inkt
pbmc
treat
galcer
day
expans
puriti
fraction
purifi
fraction
posit
select
microbead
perform
puriti
increas
inkt
cell
cocultur
differ
morpholog
fumigatu
rest
conidia
germl
gene
induct
evalu
microarray
analysi
affymetrix
protein
releas
use
multiplex
elisa
assay
biorad
bioplex
addit
induct
ifn
major
cytokin
analyz
flow
cytometri
final
xtt
assay
use
examin
toxic
effect
inkt
cell
fumigatu
result
stimul
inkt
cell
differ
fumigatu
morpholog
observ
timeand
morphotypedepend
induct
inf
germl
shown
immunogen
conidia
furthermor
challeng
inkt
cell
fumigatu
germl
found
inkt
cell
caus
signific
fungal
damag
could
also
observ
defin
pattern
gene
induct
especi
regard
cytokin
chemokin
gene
express
profil
multiplex
elisa
assay
gene
express
pattern
could
confirm
conclus
found
specif
interact
inkt
cell
fumigatu
reveal
lead
defin
cytokin
induct
fungicid
effect
inf
cytokin
known
protect
role
ia
produc
inkt
cell
confront
fumigatu
cours
plasmodium
yoeliiinfect
affect
regulatori
tcell
regulatori
tcell
treg
play
critic
role
control
varieti
differ
immun
respons
howev
studi
impact
treg
cours
plasmodiuminfect
shown
conflict
result
demonstr
plasmodium
yoelii
p
yoelii
infect
balbc
mice
lead
expans
highli
suppress
treg
diphtheria
toxinmedi
deplet
p
yoeliiinfect
dereg
mice
result
signific
increas
activ
tcell
accompani
signific
decreas
parasitaemia
gene
express
analysi
tcell
p
yoeliiinfect
mice
reveal
molecul
describ
context
treg
upregul
treg
also
tcell
eg
due
fact
p
yoeliiinfect
induc
strong
upregul
antiinflammatori
treg
cell
analyz
impact
tcell
deriv
detail
use
flfl
x
mice
interestingli
p
yoeliiinfect
mice
lead
reduc
suppress
capabl
treg
signific
enhanc
inflammatori
tcell
respons
compar
wt
mice
wherea
parasit
burden
marginallyl
affect
protozoan
parasit
trypanosoma
cruzi
caus
agent
human
chaga
diseas
obligatori
intracellular
parasit
replic
cytoplasm
parasit
cell
although
cruzi
abl
infect
almost
nucleat
cell
bodi
macrophag
repres
import
site
cruzi
replic
acut
phase
infect
howev
helper
th
immun
respons
develop
interferon
ifn
gammaactiv
macrophag
primari
immun
cell
control
cruzi
replic
product
reactiv
nitric
intermedi
rni
studi
analyz
role
interleukin
il
protect
cruzi
infect
mous
model
chaga
diseas
compar
wildtyp
mice
mice
develop
higher
parasitemia
increas
mortal
howev
suscept
due
impair
immun
respons
product
reduc
mice
infect
mice
cruzi
studi
relev
cytokin
protect
immun
respons
like
mice
mice
exhibit
higher
parasitemia
elev
mortal
alter
liver
patholog
moreov
immun
respons
affect
absenc
endogen
vitro
studi
reveal
directli
stimul
trypanocid
activ
macrophag
lead
erad
intern
parasit
contrast
unstimul
macrophag
trypanosom
quickli
escap
parasitophor
vacuol
cytoplasm
macrophag
led
prolong
resid
parasit
endosomallysosom
compart
vulner
lytic
activ
macrophag
taken
togeth
result
suggest
necessari
host
protect
cruzi
infect
stimul
antimicrobi
mechan
macrophag
background
health
benefici
effect
resveratrol
curcumin
compound
found
red
wine
grape
curri
spice
respect
well
cholesterollow
drug
simvastatin
demonstr
variou
experiment
model
inflamm
investig
potenti
antiinflammatori
immunomodulatori
mechan
mention
compound
murin
model
hyperacut
ileiti
follow
peror
infect
toxoplasma
gondii
methodologyprincip
find
show
peror
administr
resveratrol
curcumin
simvastatin
mice
protect
ileiti
develop
surviv
acut
phase
inflamm
wherea
placebo
treat
control
die
particular
resveratrol
treatment
result
longerterm
surviv
resveratrol
curcumin
simvastatin
treat
anim
display
significantli
increas
number
regulatori
cell
augment
intestin
epitheli
cell
prolifer
regener
ileum
mucosa
compar
placebo
control
anim
contrast
mucos
lymphocyt
neutrophil
granulocyt
number
treat
mice
reduc
addit
level
antiinflammatori
cytokin
ileum
mesenter
lymph
node
spleen
increas
wherea
proinflammatori
cytokin
express
ifng
tnfa
found
significantli
lower
ileum
treat
anim
compar
placebo
control
furthermor
treat
anim
display
fewer
proinflammatori
enterobacteria
enterococci
also
higher
antiinflammatori
lactobacilli
bifidobacteria
load
importantli
treatment
three
compound
preserv
intestin
barrier
function
indic
reduc
bacteri
transloc
rate
spleen
liver
kidney
blood
conclusionsignific
oral
treatment
resveratrol
curcumin
simvastatin
amelior
acut
small
intestin
inflamm
downregul
immun
respons
prevent
bacteri
transloc
maintain
gut
barrier
function
find
provid
novel
potenti
prophylaxi
treatment
option
patient
inflammatori
bowel
diseas
helminth
modul
immun
system
host
induc
regulatori
antiinflammatori
milieu
enabl
parasit
surviv
within
host
also
benefit
host
thu
helminth
infect
prevent
amelior
autoimmun
diseas
like
type
diabet
rheumatoid
arthriti
multipl
sclerosi
inflammatori
bowel
diseas
ibd
regard
ibd
concept
led
fda
approv
treat
patient
egg
porcin
whipworm
trichuri
sui
sepsi
one
major
caus
mortal
partli
due
exagger
proinflammatori
immun
respons
test
whether
natur
infect
rodent
filari
nematod
litomosoid
sigmodonti
amelior
system
inflammatori
immun
respons
induc
via
ip
inject
subleth
dose
e
coli
lp
mice
dpi
vital
e
coli
bacteria
dpi
balbc
mice
l
sigmodonti
infect
mice
reduc
hypothermia
hour
post
lp
inject
compar
uninfect
mice
correl
significantli
increas
amount
periton
bioactiv
tgf
infect
mice
compar
uninfect
control
wherea
level
proinflammatori
cytokin
ifn
decreas
rather
trend
increas
l
sigmodonti
infect
mice
similarli
increas
express
periton
macrophag
neutrophil
suggest
stronger
activ
cell
type
l
sigmodonti
infect
mice
hour
lp
challeng
use
lethal
dose
lp
surviv
rate
l
sigmodonti
infect
mice
improv
l
sigmodonti
infect
anim
stronger
initi
proinflammatori
immun
respons
evalu
whether
challeng
vital
e
coli
may
effici
control
infect
mice
inde
l
sigmodonti
infect
balbc
mice
regain
initi
bodi
temperatur
post
e
coli
challeng
wherea
uninfect
control
progress
drop
bodi
temperatur
significantli
increas
bacteremia
post
e
coli
challeng
result
suggest
l
sigmodonti
induc
modul
immun
respons
may
increas
surviv
rate
bacteri
challeng
induc
strong
proinflammatori
immun
respons
control
bacteremia
follow
potent
antiinflammatori
mechan
reduc
patholog
due
exagger
inflamm
introduct
effect
therapi
vital
reduc
mortal
pneumocysti
jirovecii
pneumonia
pcp
inabl
grow
fungu
vitro
current
reliabl
method
assess
p
jirovecii
antimicrobi
sensit
identifi
treatment
failur
physician
reli
sole
clinic
present
radiolog
result
unspecif
paramet
ldh
level
dglucan
bg
cell
wall
compon
p
jirovecii
variou
fungi
previou
studi
shown
bg
excel
biomark
pcp
sensit
specif
howev
moment
noth
known
use
monitor
patient
clinic
cours
identifi
treatment
failur
method
conduct
retrospect
case
control
studi
investig
whether
consecut
serum
bgmeasur
use
assess
treatment
respons
pcp
patient
present
univers
medic
centr
freiburg
januari
juli
confirm
pcp
sera
followup
enrol
serum
bg
level
measur
use
fungitel
assay
studi
patient
group
accord
pattern
bg
kinet
independ
clinic
cours
bg
kinet
clinic
cours
compar
patient
result
patient
hivpati
nonhiv
patient
fulfil
inclus
criteria
enrol
studi
median
seven
followup
sera
iqr
per
patient
test
median
serum
bg
level
pgml
iqr
therefor
highli
elev
cutoff
pgml
followup
patient
constantli
decreas
bg
level
patient
increas
bg
level
patient
complex
bg
kinet
one
episod
decreas
increas
bg
concentr
comparison
bg
kinet
clinic
cours
gave
overal
correl
patient
separ
analysi
differ
subgroup
show
decreas
bglevel
associ
favour
outcom
case
fig
contrast
increas
bglevel
reflect
death
treatment
failur
remain
respond
well
pcptherapi
one
patient
complex
bgkinet
clinic
radiolog
microbiolog
proven
treatment
failur
bg
level
increas
fold
time
fig
conclus
decreas
bglevel
show
good
correl
favour
treatment
respons
may
assist
decid
whether
continu
firstlin
therapi
case
miss
clinic
improv
special
circumst
consecut
bgmeasur
might
suitabl
identifi
treatment
failur
howev
overal
correl
increas
bglevel
advers
outcom
poor
use
followup
sever
pcp
limit
introduct
infect
caus
methicillinresist
staphylococcu
aureu
mrsa
rang
skin
soft
tissu
infect
sepsi
toxic
shock
becom
worldwid
challeng
hospit
prospect
multicentr
preval
screen
patient
admit
hospit
perform
region
saarland
germani
mrsaarnet
method
present
evalu
mrsaisol
collect
studi
period
univers
hospit
saarland
select
detail
phenotyp
genotyp
character
control
group
match
methicillinsensit
isol
mssa
colon
patient
riskfactor
treat
univers
hospit
saarland
select
accord
patient
characterist
time
period
sinc
hospit
gender
age
isol
collect
nasopharyng
swab
infect
site
spa
type
assign
use
ridom
staphtyp
spa
server
matrixassist
laser
desorpt
ionizationtimeofflight
mass
spectrometri
malditof
ms
base
spectra
use
detect
discrimin
protein
profil
differ
mrsa
mssa
strain
antimicrobi
resist
gene
pathogen
associ
gene
virul
factor
examin
use
microarray
base
system
cover
aureu
gene
sequenc
allel
spa
type
mrsa
collect
analyz
identifi
spa
type
predomin
spa
type
found
isol
follow
found
isol
isol
posit
structur
gene
blaz
transcript
regul
blai
blar
resist
gene
erma
confer
resist
macrolid
lincosamid
streptogramin
antibiot
found
isol
nearli
strain
possess
capsul
type
genotyp
one
strain
exhibit
capsul
type
predomin
accessori
gene
regul
agr
type
identifi
collect
type
found
mrsa
isol
mrsa
isol
posit
agr
type
isol
neg
pantonvalentin
leukocidin
pvl
ant
tst
encod
toxic
shock
syndrom
toxin
harbor
gene
staphylococc
superantigenlik
protein
c
enterotoxin
gene
cluster
egc
compris
gene
seg
sei
sem
sen
seo
seu
well
gene
code
enterotoxin
n
u
found
isol
result
genotyp
phenotyp
character
mrsa
collect
analyz
compar
match
control
patient
riskfactor
colon
methicillinsuscept
aureu
strain
backround
rapid
detect
caus
microorgan
patient
bloodstream
infect
crucial
earli
initi
adapt
adequ
antimicrobi
therapi
object
goal
prospect
studi
evalu
commerci
pcrbase
kit
septifast
sf
detect
clinic
import
pathogen
septic
patient
liver
transplant
ltx
major
abdomin
surgeri
nonltx
method
overal
blood
sampl
patient
ltx
nonltx
suspect
sepsi
obtain
parallel
blood
cultur
sf
period
three
year
tertiari
care
centr
result
total
sf
bc
yield
concurr
result
neg
sampl
posit
blood
sampl
sf
positivebc
neg
sampl
bc
positivesf
neg
twelv
case
detect
pathogen
consid
contamin
use
bc
gold
standard
sensit
specif
posit
neg
predict
valu
sf
ltx
nonltx
respect
conclus
ltx
nonltx
patient
sf
yield
higher
posit
rate
bc
sf
perform
higher
sensit
posit
predict
valu
ltx
patient
lower
specif
neg
predict
valu
compar
nonltx
patient
object
grow
evid
microgap
dental
implant
abut
lead
bacteri
contamin
interior
implant
might
provid
reservoir
pathogen
caus
periimplant
aim
studi
investig
intraimpl
bacteri
spectrum
two
stage
implant
compar
result
two
differ
sampl
collect
method
method
ten
healthi
patient
without
clinic
symptom
periimplant
twostag
implant
side
wear
ballattach
remov
prosthodont
took
part
investig
abut
remov
month
median
month
connect
sampl
obtain
collect
intraimpl
fluid
plancton
bacteria
ii
brush
caviti
biofilm
growth
bacteri
colon
evalu
aerob
anaerob
incub
agar
broth
media
isol
bacteri
coloni
identifi
mean
malditof
identif
classic
biochem
differenti
test
rdna
sequenc
result
specimen
total
implant
investig
result
median
differ
bacteri
speci
per
implant
repres
total
differ
taxa
streptococcu
anginosu
actinomyc
naeslundii
veillonella
parvula
found
frequent
periimplant
marker
bacteria
prevotella
intermedia
fusobacteria
sporad
detect
aggregatibact
actinomycetemcomitan
comparison
specimen
collect
rins
brush
show
low
consist
result
median
taxa
per
implant
found
detect
brush
collect
median
speci
howev
combin
method
allow
complet
analysi
intraimpl
microbiom
conclus
result
suggest
ubiquit
heavi
contamin
intern
space
dental
implant
reveal
broad
spectrum
bacteri
speci
analysi
intraimpl
microflora
combin
examin
intraimpl
fluid
caviti
surfac
sampl
recommend
order
cover
biofilmgrown
well
plankton
microorgan
genom
staphylococcu
aureu
adapt
cystic
fibrosi
lung
n
hirschhausen
c
neumann
goesmann
g
peter
b
kahl
medizinisch
mikrobiologi
deutschland
bielefeld
cebitec
bielefeld
deutschland
airway
cystic
fibrosi
cf
patient
frequent
colon
infect
staphylococcu
aureu
often
accompani
sever
cours
diseas
mani
patient
persist
colon
one
predomin
aureu
clone
although
detail
knowledg
genom
alter
aureu
longtim
persist
cf
lung
assumedli
select
phenotyp
tightli
adapt
specif
environment
nich
uniqu
cfderiv
aureu
collect
allow
us
track
genom
adapt
due
persist
cf
lung
clonal
earli
late
isol
three
cf
patient
isol
year
apart
sequenc
genom
analyz
illumina
solexa
screen
snp
insert
delet
identifi
sever
mutat
late
aureu
isol
compar
respect
earli
isol
sanger
sequenc
could
confirm
mutat
number
gene
associ
virul
antibiot
resist
protein
spa
autoinduc
sensor
kinas
agrc
allel
variant
bone
sialoproteinbind
protein
bbpsdre
dna
topoisomeras
type
ii
iv
gyra
parcgrla
mutat
associ
amino
acid
chang
current
analyz
potenti
outcom
alter
gyra
correspond
acquir
resist
toward
fluoroquinolon
wherea
alter
agrc
assumedli
associ
differ
characterist
affect
aureu
virul
furthermor
includ
sequenc
intermedi
aureu
isol
determin
time
mutat
occur
preliminari
data
suggest
adapt
persist
cf
isol
includ
chang
dna
level
regul
protein
express
howev
detect
mutat
occur
patient
indic
host
environ
promot
individu
adapt
process
result
alter
virul
may
favor
precis
camouflag
respons
hostil
environ
specif
clinic
situat
result
may
help
understand
complex
pathogenesi
chronic
infect
background
hostpathogen
interact
staphylococcu
pettenkoferi
coagulaseneg
staphylococcu
cn
recent
describ
rare
isol
new
speci
whether
new
speci
harm
pathogen
harmless
bystand
could
answer
yet
nevertheless
case
report
suggest
invas
role
pettenkoferi
staphylococcu
lugdunensi
pettenkoferi
describ
potenti
relat
speci
shown
biochem
method
determin
whether
new
speci
could
put
pathogen
similar
lugdunensi
strain
character
presenc
fibrinogen
fibronectin
bind
adhesin
addit
intern
bacteria
eukaryot
cell
invesitg
use
previous
publish
facsbas
internalizatio
assay
occurr
put
lugdunensi
adhesin
hemolysin
gene
evalut
use
primer
pair
design
lugdunensi
estim
lugdunensi
strain
bound
fibrinogen
none
pettenkoferi
isol
bound
fibrinogen
fibronectin
addit
estim
lugdunensi
isol
intern
bladder
carcinoma
cell
line
cell
contrast
one
isol
pettenkoferi
intern
lack
fibrinogen
fibronectin
bind
adhesin
lack
intern
abil
indic
pettenkoferi
like
harmless
colon
human
skin
flora
harm
infect
pathogen
introduct
chlamydia
pneumonia
cpn
oblig
intracellular
bacterium
caus
mildtomoder
pharyng
bronchiti
addit
cpn
infect
suppos
play
role
chronic
diseas
like
asthma
copd
atherosclerosi
system
dissemin
cpn
lung
peripher
organ
arter
vessel
shown
mediat
blood
mononuclear
cell
pbmc
use
whole
genom
sequenc
recent
found
genet
differ
isol
cultiv
differ
tissu
shown
previous
intracellular
morpholog
growth
characterist
chlamydia
signficantli
differ
human
monocyt
epitheli
cell
howev
phenotyp
differ
isol
differ
anatom
origin
investig
far
therefor
compar
growth
characterist
progeni
cpn
isol
three
differ
infect
site
materi
method
cpn
strain
isol
respiratori
tract
coronari
arteri
pbmc
respect
use
studi
infect
dose
cell
differ
isol
adjust
determin
amount
genom
encod
ribosom
rna
rate
infect
number
intracellular
inclus
product
infecti
progeni
development
pace
isol
investig
fluoresc
microscopi
transmiss
electron
microscopi
recoveri
assay
result
coronari
arteri
strain
show
highest
infect
multipl
inclus
rate
among
three
differ
isolatesth
isol
deriv
pbmc
show
dramat
less
product
infecti
progeni
slower
development
speed
compar
respiratori
strain
conclusiondiscuss
clinic
isol
cpn
bood
circul
pbmc
coronari
arteri
differenti
lung
isol
nonsynonym
snp
orf
relat
chlamydi
metabol
bacteri
transit
inclus
membran
format
lp
synthesi
regul
sigma
factor
studi
show
whether
genet
differ
respons
observ
phenotyp
differ
isol
regard
intracellular
growth
progeni
detect
carbapenemas
rare
report
germani
order
assess
presenc
carbapenemas
hamburg
number
carbapenem
resist
gramneg
bacteri
isol
collect
period
eight
month
analys
detect
divers
enterobacteri
speci
pseudomona
aeruginosa
isol
suggest
widespread
preval
carbapenemas
germani
current
believ
proteom
analysi
earli
late
staphylococcu
aureu
isol
cystic
fibrosi
patient
block
n
hirschhausen
engelmann
g
peter
b
kahl
medizinisch
mikrobiologi
deutschland
greifswald
institut
mikrobiologi
greifswald
deutschland
due
mutat
gene
encod
cystic
fibrosi
transmembran
conduct
regul
lung
cystic
fibrosi
cf
patient
exhibit
dehydr
airway
mucu
lead
decreas
mucociliari
clearanc
chronic
infect
one
earliest
pathogen
isol
lung
cf
patient
staphylococcu
aureu
often
lung
cf
patient
infect
predomin
aureu
clone
mani
year
longterm
colon
pathogen
need
adapt
environ
lung
project
aim
reveal
mechan
underli
adapt
aureu
persist
colon
infect
hostil
nich
cf
patient
use
proteom
analysi
addit
virul
potenti
assess
vitro
well
vivo
assay
uniqu
longitudin
collect
aureu
strain
isol
airway
cf
patient
earli
late
aureu
isol
three
patient
chosen
comparison
proteom
earli
late
isol
perform
use
follow
malditof
mass
spectrometri
aureu
strain
cultur
artifici
sputum
medium
order
mimic
vivo
situat
virul
potenti
strain
investig
vitro
mean
invas
assay
use
epitheli
cell
line
furthermor
virul
potenti
studi
vivo
caenorhabd
elegan
kill
assay
preliminari
result
invas
assay
reveal
differ
alter
invas
properti
compar
earli
late
isol
late
isol
two
patient
increas
invas
properti
compar
earli
isol
could
observ
wherea
properti
late
isol
one
patient
decreas
first
result
use
isol
one
patient
c
elegan
kill
assay
reveal
signific
differ
virul
earli
late
isol
investig
proteom
chang
longterm
colon
still
progress
project
studi
adapt
mechan
aureu
persist
colon
within
airway
cf
patient
function
level
gain
insight
interact
pathogen
host
sinc
adapt
bacteria
occur
genom
well
regulatori
level
import
investig
alter
late
isol
compar
earli
isol
proteom
approach
allow
analysi
differ
protein
express
well
posttransl
modif
describ
therapi
outcom
odri
difficulttotreat
organ
enterococcu
faecali
patient
method
five
patient
chronic
hip
implant
infect
caus
e
faecali
treat
twostag
replac
use
antimicrobi
cement
long
term
treatment
antimicrobi
agent
five
isol
sensit
ampicillin
four
five
isol
highlevel
resist
gentamicin
patient
reciev
system
therapi
ampicillin
amoxycillin
six
week
plu
vancomycin
contain
cement
second
devic
implant
took
place
mean
time
month
outcom
month
sign
infect
five
patient
two
patient
need
revis
surgeri
surgic
site
infect
prior
second
devic
implant
conclus
chronic
infect
e
faecali
difficult
treat
patient
reciev
gentamicin
contain
cement
first
implant
mani
e
faecali
isol
show
highlevel
gentamicin
resist
combin
vancomycin
containig
cement
system
ampicillin
therapi
might
use
option
patient
introduct
infect
host
mycobacterium
tuberculosi
mtb
face
oxid
nitros
stress
thu
pathogen
need
effect
antioxid
system
maintain
infect
due
lack
glutathion
system
mtb
thioredoxin
reductas
trxr
system
essenti
mechan
reduc
reactiv
oxid
nitrosativ
speci
assur
bacteri
surviv
similar
mycobacteri
eukaryot
trxr
system
low
therefor
may
use
novel
drug
target
fight
tuberculosi
method
identifi
new
substanc
inhibit
interact
thioredoxin
trx
trxr
silico
high
throughput
screen
conduct
four
alter
low
mass
scaffold
chosen
test
vitro
examin
inhibitori
effect
mtb
trxr
optim
compound
whole
cell
test
perform
mtb
liquid
cultur
use
mgit
system
becton
dickinson
result
interfer
low
mass
compound
mycobacteri
trxr
test
vitro
percent
chosen
low
mass
compound
show
activ
low
concentr
optim
compound
show
bacteriostat
effect
mtb
cultur
even
within
low
rang
conclus
effect
interact
trx
trxr
small
molecul
inhibitor
micromolar
level
lead
bacteriostat
effect
mtb
cultur
expec
although
sever
import
upec
virul
factor
role
pathogenesi
describ
mani
upec
isol
unambigu
distinguish
commens
e
coli
base
presenc
upec
virulenceassoci
gene
contrast
intestin
pathogen
e
coli
ipec
caus
diarrhoea
character
typic
set
virul
factor
usual
absent
upec
major
virulenceassoci
gene
expec
ipec
locat
mobil
accessori
genet
element
eg
plasmid
bacteriophag
pathogen
island
thu
horizont
transfer
analyz
e
coli
isol
hospit
patient
urinari
tract
infect
isol
screen
multiplex
pcr
import
virul
determin
upec
ipec
interestingli
isol
carri
one
known
ipec
virul
gene
sometim
combin
classic
upec
virul
gene
addit
molecular
epidemiolog
phenotyp
analys
perform
assess
related
similar
isol
notabl
among
atyp
urin
e
coli
isol
strain
carri
marker
gene
enteroaggreg
e
coli
eaec
addit
isol
type
atyp
enteropathogen
e
coli
aepec
shiga
toxinproduc
e
coli
stec
result
indic
nosocomi
uti
due
e
coli
may
caus
divers
group
e
coli
variant
repres
ipec
carri
virul
properti
diarrheagen
e
coli
combin
typic
expec
ipec
virul
determin
also
support
find
e
coli
exhibit
mark
genom
plastic
gene
transfer
may
promot
evolutionari
transit
ipec
expec
vice
versa
rel
high
preval
eaec
marker
gene
among
urin
isol
also
demonstr
heterogen
pathotyp
rais
possibl
eaec
strain
may
potenti
uropathogen
aibinu
odugbemi
w
koenig
b
ghebremedhin
uni
lago
med
microbiol
parasitol
lago
nigeria
uniklinik
magdeburg
immb
magdeburg
deutschland
background
investig
associ
preval
extendedspectrum
betalactamas
genet
lineag
escherichia
coli
two
tertiari
hospit
lago
nigeria
within
period
month
method
identif
suscept
test
ecoli
isol
vitek
etest
extendedspectrum
betalactamas
quinolon
resist
gene
aac
lbcr
plasmidmedi
quinolon
resist
pmqr
gene
character
use
pcr
sequenc
clonal
determin
eric
pcr
multilocu
sequenc
type
mlst
result
isol
found
esblproduc
esbl
isol
resist
ceftazidim
cefotaxim
mic
resist
ciprofloxacin
mic
aminoglycosid
coexist
also
esbl
isol
howev
sensit
carbapenem
esbl
gene
detect
isol
produc
carri
insert
sequenc
isecpi
recent
demonstr
mobil
gene
transfer
dna
replicon
involv
spread
esbl
ericpcr
identifi
type
among
esblproduc
divers
mlst
type
also
observ
clonal
group
predomin
st
close
follow
clonal
complex
sequenc
type
establish
strain
includ
complex
st
complex
st
plasmidmedi
quinolon
resist
gene
detect
among
esbl
isol
esbl
isol
harbour
aac
lbcr
gene
conclus
first
report
e
coli
clonal
complex
westafrica
nigeria
found
predomin
among
hospit
isol
e
coli
high
divers
st
remark
among
posit
isol
studi
highlight
need
adopt
appropri
control
measur
overcom
esbl
dissemin
nigeria
bacteriocin
product
staphylococc
nasal
isol
janek
peschel
b
krismer
uniklinik
medizinisch
mikrobiologi
deutschland
staphylococcu
aureu
major
pathogen
hospitaland
communityacquir
infect
colonis
anterior
nare
popul
major
risk
factor
aureu
infect
recent
composit
nasal
microbiota
inverstig
interestingli
bacteri
divers
human
nose
reach
aerob
strictli
anaerob
bacteria
frequent
occur
speci
corynebacterium
accolen
c
macginleyi
staphylococcu
epidermidi
propionibacterium
acn
order
investig
bacteriocin
product
might
play
role
nasal
colonis
analys
bacteriocin
product
nasal
staphylococcu
strain
test
strain
micrococcu
luteu
aureu
cast
agar
plate
nasal
isol
stamp
plate
variou
isol
show
growth
inhibit
zone
test
strain
indic
baceriocin
product
transposon
plasmid
could
transform
variou
strain
mutagenesi
perform
identifi
correspond
bacteriocinbiosynthet
gene
analysi
stapylococc
nasal
isol
reveal
variou
strain
produc
bacteriocin
luteu
aureu
bacteriocin
product
nasal
isol
turn
induc
certain
stress
condit
one
bacteriocin
produc
epidermidi
strain
could
character
nukacinlik
lantibiot
activ
micrococco
luteu
extend
knowledg
variou
interact
staphylococc
nasal
speci
could
import
find
new
effect
anti
aureu
strategi
humanis
murin
antiisaa
antibodi
potenti
target
antibodybas
therapi
multiresist
staphylococcu
aureu
strain
b
oesterreich
institut
molekular
infektionsbiologi
deutschland
background
gramposit
bacterium
staphylococcu
aureu
major
caus
nosocomi
infect
particular
diseas
caus
methicillinresist
aureu
mrsa
associ
higher
morbid
mortal
medic
cost
due
show
resist
sever
class
establish
antibiot
abil
develop
resist
mechan
new
antibiot
rapidli
therefor
urgent
need
novel
treatment
option
immunotherapi
potenti
close
gap
treatment
infect
caus
multiresist
aureu
immunodomin
staphylococc
antigen
isaa
identifi
put
target
immunotherapi
due
express
clinic
strain
vivo
surfac
exposur
preclin
experi
reveal
protect
properti
monoclon
mous
antiisaa
antibodi
differ
experiment
model
aureu
infect
addit
vitro
phagocytosi
assay
show
enhanc
opsonophagocyt
kill
aureu
presenc
therefor
mous
monoclon
antibodi
select
human
prerequisit
clinic
studi
human
hybridoma
clone
basi
identif
antibodi
bind
domain
isaa
code
sequenc
use
construct
recombin
scfv
scfvfc
fragment
toward
isaa
fig
humanis
murin
antigen
bind
domain
murin
humans
scfv
fragment
express
ecoli
murin
humanis
scfvfc
fragment
express
eucaryot
cell
scfvand
scfvfc
fragment
character
function
specif
western
blot
analysi
elisastudi
immunofluoresc
analysi
fac
experi
result
reveal
construct
fragment
show
high
specif
toward
isaa
properti
antigen
bind
fragment
detect
isaa
cell
surfac
differ
aureu
strain
conclus
isaa
antigen
structur
express
vivo
differ
aureu
strain
murin
antiisaa
antibodi
protect
anim
model
murin
humanis
scfvand
scfvfc
fragment
show
high
specif
toward
isaa
improv
treatment
infecti
diseas
identif
optim
combin
antibiot
promis
approach
major
requir
investig
rapid
test
moder
number
differ
compound
combin
limit
number
infecti
agent
develop
devic
combinatori
gener
compound
mixtur
diffus
concentr
sever
order
magnitud
diffus
take
place
cell
compat
polym
matric
agaros
gelatin
agar
mixtur
test
compound
gener
superposit
concentr
gradient
two
pipet
step
requir
gener
seri
assay
depend
spatial
resolut
diffus
gradient
convert
biolog
assay
diffus
devic
compat
microtit
plate
enabl
effici
test
combin
differ
compound
devic
applic
diffus
compound
small
molecul
peptid
lipopeptid
antibodi
present
investig
antibiot
combin
differ
staphylococc
strain
defin
antibiot
combin
addit
synergist
effect
miniatur
parallel
especi
reduct
number
step
requir
prepar
sampl
enabl
rapid
effici
screen
drug
combin
differ
microbi
strain
invas
fungal
infect
main
caus
morbid
mortal
transplant
recipi
immunocompromis
patient
clinic
thu
grow
health
problem
regard
constantli
grow
number
resist
strain
discoveri
new
class
antimycot
drug
highli
necessari
high
throughput
activityselect
screen
seri
benzimidazol
deriv
strong
antimycot
activ
candida
albican
identifi
collect
analogu
sarstudi
prepar
order
evalu
improv
antimicrobi
properti
examin
activ
five
benzimidazol
set
twentyon
fungal
strain
includ
differ
type
strain
signific
clinic
isol
candida
spp
confirm
antimycot
activ
activ
compound
studi
show
potenc
equal
fluconazol
consequ
novel
nontox
benzimidazol
repres
promis
candid
futur
develop
antimycot
drug
discoveri
current
studi
caenorhabd
elegan
carri
bavarian
health
food
safeti
author
bayerisch
landesamt
gesundheit
und
lebensmittelsicherheit
lgl
provid
sever
microbiolog
servic
local
health
author
bavaria
accord
german
protect
act
infektionsschutzgesetz
ifsg
public
health
system
respons
ensur
adequ
care
tb
case
follow
perform
contact
investig
activ
identifi
infect
person
context
lgl
maintain
tblaboratori
facil
diagnosi
tuberculosi
infect
interferongammareleaseassay
igra
shown
improv
diagnosi
better
specif
sensibl
tst
especi
latent
tuberculosi
infect
ltbi
test
increasingli
request
sampl
health
care
worker
clinician
igra
eg
gold
intub
test
measur
person
immun
reactiv
specif
mycobacteri
antigen
specimen
mix
either
peptid
simul
antigen
tuberculosi
tuberculosi
specif
antigen
und
lack
bcg
strain
almost
nontubercul
mycobacteria
ntm
except
kansasii
szulgai
marinum
person
infect
tuberculosi
white
blood
cell
recogn
peptid
releas
interferongamma
test
result
base
amount
interferongamma
relea
present
lgl
suppli
gold
intub
test
qft
mainli
due
oper
advantag
regard
highthroughput
blood
sampl
poster
give
overview
laboratori
perform
qft
lgl
salmonella
enterica
one
common
caus
human
gastroenter
worldwid
also
respons
nosocomi
outbreak
particularli
develop
countri
tunisia
mani
nosocomi
outbreak
occur
pediatr
servic
involv
variou
differ
serotyp
especi
serotyp
livingston
belgium
report
sporad
human
case
enterica
serotyp
livingston
infect
low
studi
enterica
serotyp
livingston
analyz
isol
human
strain
tunisia
belgium
tow
strain
came
food
product
pork
beef
meat
tunisian
strain
isol
hospit
differ
period
strain
character
antibiogramm
multilocu
sequenc
type
mlst
virulotyp
last
techniqu
carri
simpl
pcr
chromosom
gene
agfa
irob
phopq
sli
plasmid
gene
spva
spvb
spvc
tunisian
strain
resist
amoxicillin
amoxicillinclavulan
acid
ticarcillin
gentamicin
kanamycin
show
particular
lactam
resist
phenotyp
belgium
strain
suscept
major
antibiot
mlst
analys
tunisian
strain
belong
sequenc
type
belgium
isol
strain
profil
strain
profil
one
strain
unknown
sequenc
type
analys
virul
gene
content
show
strain
isol
differ
year
differ
origin
human
food
product
differ
countri
virul
profil
carri
chromosom
virul
gene
plasmid
virul
gene
lack
combin
differ
type
method
show
major
belgium
strain
tunisian
strain
isol
differ
time
period
close
relat
belong
sequenc
type
virul
profil
drk
kliniken
berlin
westend
institut
mikrobiologi
und
krankenhaushygien
berlin
deutschland
object
esbl
produc
ecoli
strain
becom
seriou
problem
strain
often
leav
therapeut
option
especi
intens
care
unit
therapeut
option
seem
limit
furthermor
former
eucast
expert
rule
chang
definit
sensibl
beta
lactam
chang
intermedi
intermedi
resist
whenev
esbl
record
respect
strain
chang
read
cephalosporin
breakpoint
enterobacteriacea
detect
clinic
import
resist
mechan
includ
esbl
strain
produc
betalactamas
suscept
intermedi
gener
cephalosporin
breakpoint
report
found
ie
presenc
absenc
esbl
influenc
categor
suscept
analys
isol
order
see
chang
eucast
expert
rule
open
new
therapeut
option
method
laboratori
particip
network
use
autom
bd
phoenixsystem
measur
mic
bd
epicent
datamanagementsystem
use
evalu
lab
data
transfer
data
joint
analysi
studi
analys
mic
esbl
produc
e
coli
isol
esbl
product
check
associ
bdexpert
system
phoenix
show
excel
perform
esbl
detect
maurin
leversteinvan
hall
et
al
j
clin
microbiol
octob
copi
strain
exclud
qualiti
control
assay
routin
perform
result
use
mic
strain
produc
esbl
produc
strain
ceftazidim
caz
cefotaxim
ctx
cefepim
fmc
aztreonam
atm
calcul
sensit
use
new
eucast
breakpoint
dendrogram
creation
microflex
mass
spectromet
bruker
daltonik
bremen
germani
maldi
biotyp
softwar
vre
isol
underw
extract
procedur
describ
elsewher
spectra
record
posit
linear
mode
laser
frequenc
hz
ion
sourc
voltag
kv
ion
sourc
voltag
kv
len
voltag
kv
mass
rang
da
spectrum
shot
differ
posit
target
spot
collect
per
isol
spectra
clean
calibr
peak
ribosom
protein
e
faecium
kda
subsequ
minimum
span
tree
msp
creat
creation
dendrogram
base
crosswis
msp
match
topolog
dendrogram
figur
gener
spectra
vre
isol
agreement
infer
pfge
analysi
figur
three
differ
strain
could
clearli
identifi
index
case
held
respons
transmiss
other
beforehand
epidemiolog
analysi
reveal
actual
two
transmiss
first
patient
second
patient
patient
b
probabl
alreadi
preval
case
dendrogram
strain
b
separ
other
closer
relat
strain
c
discussio
malditof
ms
provid
result
concord
pfge
gold
standard
fraction
time
cost
result
show
great
promis
malditof
mass
spectrometri
epidemiolog
tool
realtim
manag
vre
outbreak
cologn
preval
spa
type
singl
patient
conclus
sab
common
infect
german
hospit
associ
high
mortal
cologn
preval
spa
type
current
also
one
preval
spatyp
germani
control
infecti
agent
usual
determin
factor
favour
outcom
infecti
diseas
final
stadium
rather
control
overreact
immun
system
complement
import
part
humor
innat
immun
system
inherit
mutat
system
particularli
regulatori
protein
lead
overreact
state
eventu
haemolyt
uraem
syndrom
hu
type
hu
term
atyp
unrel
infect
enterohaemorrhag
e
coli
ehec
eculizumab
recent
success
use
block
complement
treatment
paroxysm
nocturn
haemoglobinuria
pnh
red
blood
cell
lyse
complement
due
inherit
lack
inhibitor
cell
surfac
eculizumab
work
pnh
atyp
hu
also
show
uncontrol
complement
activ
humanis
antibodi
also
success
use
us
boy
suffer
inherit
mutat
lead
clinic
condit
zimmerhackl
et
al
n
engl
j
med
last
least
provid
rational
treatment
typic
hu
complement
inhibitori
antibodi
although
well
establish
releas
ehec
shiga
toxin
direct
deleteri
effect
kidney
cell
also
activ
complement
bind
factor
h
main
regul
lead
stronger
activ
weaker
control
complement
orth
et
al
j
immunol
sever
lab
corrobor
role
complement
typic
hu
thurman
et
al
clin
j
soc
nephrol
stahl
et
al
blood
open
field
use
eculizumab
typic
hu
recent
success
perform
lapeyraqu
cowork
three
patient
lapeyraqu
et
al
n
engl
j
med
press
evalu
outcom
mani
dozen
patient
treat
outbreak
eventu
demonstr
clinic
impact
complement
typic
hu
result
blood
sampl
posit
use
multiplexpcr
use
convent
cultur
sampl
multiplexpcr
detect
one
microorgan
among
microorgan
identifi
multiplexpcr
could
confirm
blood
cultur
addit
could
confirm
microbiolog
test
result
signific
patient
specimen
posit
blood
sampl
independ
detect
method
character
signific
elev
level
procalcitonin
infect
aureu
result
clinic
condit
rang
system
inflammatori
respons
syndrom
septic
shock
multipl
organ
dysfunct
one
common
spectrum
evolv
eventu
overwhelm
host
immun
respons
often
manifest
clinic
pulmonari
edema
ceramid
biolog
activ
sphingolipid
creat
hydrolysi
sphingomyelin
induc
enzym
acid
sphingomyelinas
membran
constitu
signal
molecul
ceramid
function
integr
compon
multipl
signal
pathway
present
studi
sought
demonstr
induc
ceramid
import
mediat
overwhelm
immun
respons
lead
septic
shock
aureu
bacteremia
wt
mice
acid
sphingomyelinas
knockout
asm
litterm
inocul
intraven
clinic
isol
aureu
dose
organ
induc
state
septic
shock
death
within
hour
mice
use
immunohistochem
techniqu
quantif
posit
stain
cell
lung
reveal
decreas
neutrophil
traffick
hour
asm
mice
compar
wt
control
measur
evan
blue
dye
extravas
lung
display
twofold
reduct
pulmonari
edema
asm
anim
sequest
neutrophil
lung
pulmonari
edema
diminish
asm
mice
anim
fail
clear
infect
indic
progress
increas
aureu
cfu
isol
saponin
treat
splenic
homogen
wild
type
mice
comparison
began
clear
infect
hour
postinocul
data
indic
membran
ceramid
import
mediat
immun
system
activ
pulmonari
dysfunct
aureu
induc
septic
shock
pulmonari
manifest
septic
shock
reduc
asm
mice
demonstr
impair
bacteri
clearanc
ultim
succumb
infect
outcom
implic
acid
sphingomyelinas
depend
ceramid
product
import
compon
innat
immun
respons
wolbachia
endbacteria
filari
nematod
sensit
acyldepsipeptid
introduct
resist
carbapenem
gramneg
bacteria
increas
worldwid
pseudomona
aeruginosa
resist
mediat
product
metallo
lactamas
mbl
mbl
abl
hydrolys
penicillin
cephalosporin
even
carbapenem
aztreonam
germani
member
verona
integronencod
vim
famili
mbl
report
frequent
report
detect
mbl
imp
activ
imipenem
two
clinic
isol
p
aeruginosa
univers
hospit
northern
germani
best
knowledg
first
report
organ
clinic
specimen
germani
case
report
two
p
aeruginosa
strain
isol
clinic
sampl
februari
march
respect
one
isol
detect
urin
old
male
patient
neurogen
disturb
bladder
rectum
patient
admit
hospit
surgic
treatment
sacral
decubit
ulcer
second
p
aeruginosa
isol
found
inguin
wound
swab
old
male
patient
admit
hospit
type
b
dissect
aorta
patient
receiv
multipl
antibiot
detect
impproduc
p
aeruginosa
patient
develop
clostridium
difficileassoci
diarrhea
stay
hospit
bacteri
isol
cultiv
identifi
standard
microbiolog
procedur
suscept
test
done
autom
system
product
mbl
confirm
etest
pcr
whole
cell
lysat
amplifi
pcrproduct
sequenc
analyz
use
blast
algorithm
mic
p
aeruginosa
isol
isol
gml
piperacillintazobactam
ceftazidim
imipenem
meropenem
product
mbl
confirm
etest
phenotyp
sequenc
bp
fragment
isol
bp
fragment
isol
respect
reveal
mbl
isol
discuss
although
detect
isol
countri
like
itali
argentina
austria
best
knowledg
first
report
detect
clinic
isol
germani
far
report
underscor
sustain
spread
multidrugresist
bacteria
produc
broadspectrum
betalactamas
stress
need
effect
infect
control
measur
develop
new
antibiot
drug
urinari
antibiot
nitroxolin
block
septic
stone
format
multipl
mechan
better
nontox
altern
acetohydroxam
acid
treatment
urinari
tract
infect
p
mirabili
p
vulgari
p
rettgeri
often
complic
refactori
therapi
ureas
activ
organ
uniqu
mediat
urin
ph
rise
higher
therebi
lead
format
precipit
contain
viabl
bacteria
biofilm
format
cathet
epitheli
surfac
enhanc
retent
septic
crystal
treatment
infect
nickel
chelat
ureas
inhibitor
acetohydroxam
acid
aha
clinic
use
usa
howev
due
sever
side
effect
aha
approv
europ
purpos
studi
test
urinari
antisept
cation
chelat
nitroxolin
nit
possibl
nontox
altern
uti
isol
p
mirabili
p
vulgari
p
rettgeri
collect
routin
diagnost
procedur
mic
determin
accord
clsi
recommend
artifici
urin
tsb
mic
valu
nit
found
lie
slightli
lower
urin
contrast
inhibitori
effect
note
aha
concentr
mm
effect
enzymat
ureas
activ
examin
suspend
bacteria
artifici
urin
without
nit
aha
take
sampl
regular
interv
one
hour
incub
period
mm
urin
concentr
found
oral
treatment
nit
nearli
complet
block
ph
rise
caus
ammonia
format
measur
gla
electrod
indophenol
method
respect
effect
concentr
depend
partial
resolv
addit
ni
fe
similarli
precipit
format
complet
block
mm
nit
determin
ar
stain
subsequ
spectrophotometr
quantif
comparison
aha
slightli
weaker
assay
precipit
format
preform
p
mirabili
biofilm
examin
complet
blockag
obtain
alreadi
nit
lowest
concentr
studi
contrast
result
observ
aha
correl
well
result
obtain
ureas
activ
assay
howev
biofilm
preform
presenc
urea
subsequ
nit
effect
precipit
format
lower
thu
indic
addit
effect
nit
ureas
induct
final
observ
reduct
biofilm
presenc
nit
determin
crystal
violet
stain
subsequ
spectrophotometr
quantif
taken
togeth
nit
thu
found
good
better
aha
inhibit
ureas
activ
moreov
found
exhibit
potent
antimicrobi
effect
clinic
isol
examin
reduc
precipit
format
p
mirabili
biofilm
presum
combin
biofilm
degrad
inhibit
ureas
induct
blockag
ureas
activ
background
studi
aim
assess
risk
cronobact
sakazakii
contamin
spray
dri
process
within
infant
milk
formula
product
three
main
aspect
examin
bacteria
specif
dvalu
thermic
sterilis
properti
biofilm
format
certain
filter
materi
effici
clean
agent
clean
place
system
dvalu
analyz
caso
bouillon
reconstitut
infant
formula
inocul
c
sakazakii
dsm
concentr
cfuml
inocul
sampl
taken
everi
two
minut
bacteria
count
determin
cast
plate
method
caso
agarfor
optic
detect
biofilm
format
cellulos
polypropylen
filter
inocul
c
sakazakii
expos
dri
condit
filter
materi
fix
glutaraldehyd
dri
ethanol
critic
point
dryer
pictur
made
scan
electron
micrograph
leo
stereoscan
agar
diffus
test
qualit
suspens
test
made
test
effect
acid
base
c
sakazakii
sodium
hydroxid
nitric
acid
use
differ
concentr
bacteria
count
determin
cast
plate
method
caso
agar
inactiv
c
sakazakii
caso
bouillon
infant
formula
influenc
factor
heat
conduct
media
cultur
condit
state
cell
growth
c
sakazakii
abl
form
biofilm
cellulos
polypropylen
fibr
dri
condit
cellulos
fibr
bacteria
rodshap
polypropylen
coccoid
form
occur
c
sakazakii
approvingli
sensit
nitric
acid
sodium
hydroxid
treatment
lead
aggreg
format
bacteria
total
deplet
incub
time
conclus
c
sakazakii
adher
organ
synthet
filter
materi
spray
dri
process
milk
base
product
risk
contamin
therefor
pasteuris
process
valid
kind
heat
exchang
clean
regim
nitric
acid
sodium
hydroxid
reduc
specif
contamin
risk
cronobact
bacteria
formerli
classifi
enterobact
sakazakii
implic
sever
incid
caus
mening
enterocol
high
mortal
rate
prematur
infant
result
feed
contamin
powder
infant
formula
pif
pif
therefor
strictli
recommend
sakazakiifre
defin
absenc
coloni
form
unit
sampl
pif
cooper
food
process
engin
section
institut
milchwerk
mittelelb
gmbh
industri
produc
pif
develop
modifi
product
process
assur
inactiv
cronobact
pasteur
raw
materi
detect
viabl
cell
accomplish
quantit
realtim
pcr
well
select
growth
chromogen
media
follow
enrich
cultur
go
present
first
result
heat
inactiv
kinet
cronobact
speci
raw
materi
pif
base
upon
data
modifi
pasteur
process
develop
clean
room
essenti
asept
pharmaceut
food
product
monitor
microbi
distribut
identifi
predomin
isol
part
good
manufactur
practic
aim
research
screen
predomin
bacteria
strain
distribut
clean
room
analyz
microbiolog
molecular
character
materi
method
bacteria
strain
isol
routin
asept
monitor
cours
clean
room
pharmaceut
factori
use
air
sampler
air
settl
plate
method
repres
bacteria
strain
select
base
coloni
morpholog
diverg
coloni
gram
stain
well
oxid
catalas
test
perform
method
test
follow
john
et
al
process
base
distribut
frequenc
isol
predomin
strain
name
select
morpholog
physiolog
biochem
characterist
test
accord
john
et
al
strain
gramposit
human
pathogen
speci
listeria
monocytogen
caus
sever
foodborn
outbreak
diseas
includ
fatal
speci
character
ubiquit
occurr
well
wide
rang
growth
temperatur
phvalu
risk
food
especi
raw
milk
raw
milk
product
meat
fish
especi
readi
eatfood
smoke
grave
salmon
identifi
risk
product
listeria
may
spread
fishprocess
equip
machineri
may
persist
today
insuffici
data
exist
whether
appli
machin
put
reservoir
sourc
l
monocytogen
project
investig
surviv
three
l
monocytogen
strain
differ
chemic
composit
appli
fish
industri
first
step
presenc
l
monocytogen
nativ
assess
upon
neg
result
second
step
studi
lubric
contamin
three
l
monocytogen
strain
surviv
lubric
monitor
period
day
furthermor
influenc
water
content
lubric
surviv
listeria
evalu
none
nativ
lubric
contain
listeria
upon
contamin
lubric
three
l
monocytogen
strain
viabl
count
decreas
significantli
least
within
seven
day
reduct
rate
found
depend
chemic
composit
lubric
well
investig
strain
interestingli
isol
smoke
salmon
toler
environ
better
refer
type
strain
water
content
lubric
influenc
surviv
base
result
studi
conclud
investig
strain
surviv
cronobact
sakazakii
emerg
foodborn
pathogen
involv
lifethreaten
infect
mening
enterocol
septicemia
neonat
infant
outbreak
rare
sever
case
contamin
powder
infant
formula
identifi
sourc
c
sakazakii
infect
detect
c
sakazakii
current
isot
standard
method
requir
five
six
day
confirm
speci
identif
therefor
rapid
specif
sensit
method
detect
identif
c
sakazakii
powder
infant
formula
necessari
studi
describ
develop
realtim
pcr
rtpcr
base
assay
detect
c
sakazakii
powder
milk
product
infant
formula
propos
method
combin
unspecif
enrich
sampl
prepar
rtpcr
bacteri
strain
grown
brain
heart
infus
broth
agit
genom
dna
extract
overnight
cultur
use
illustra
tm
bacteria
genom
prep
mini
spin
kit
gehealthcar
two
primer
taqman
probe
design
beacon
design
softwar
target
outer
membran
protein
gene
ompa
assay
valid
c
sakazakii
strain
strain
close
relat
speci
genera
taqman
rtpcr
assay
success
develop
detect
limit
dnaml
reaction
effici
test
c
sakazakii
strain
identifi
min
reproduc
amplif
curv
non
c
sakazakii
strain
detect
develop
taqman
rtpcr
assay
reliabl
detect
identifi
c
sakazakii
fast
analysi
time
complet
assay
includ
enrich
sampl
prepar
approxim
h
describ
method
solid
basi
fast
reliabl
detect
c
sakazakii
powder
milk
product
differenti
proteom
express
enterohemorrhag
e
enterohemorrhag
escherichia
coli
ehec
enter
pathogen
caus
sever
ill
human
ehec
foodborn
infect
may
lead
nonbloodi
diarrhea
bloodi
diarrhea
hemolyt
urem
syndrom
hu
surviv
ehec
food
chain
human
intestin
depend
environment
condit
avail
nutrient
andor
exposur
stress
agent
bile
salt
andor
pancreat
enzym
exposur
differ
environ
may
caus
shift
metabol
pathway
ehec
may
also
lead
shift
express
virul
determin
order
test
behaviour
ehec
strain
grown
gut
human
host
use
simul
ileal
environ
medium
siem
simul
colon
environ
medium
scem
compar
tryptic
soy
broth
tsb
use
standard
rich
medium
twodimension
gel
electrophoresi
differenti
cytosol
protein
least
higher
express
siem
scem
compar
tsb
growth
aerob
anaerob
condit
protein
detect
evalu
softwar
identifi
malditofanalysi
tsb
found
high
amount
flagellin
protein
flic
suggest
downregul
siem
scem
contrast
sever
protein
involv
biofilm
synthesi
upregul
latter
media
also
found
modul
locu
enterocyt
effac
associ
protein
espp
espb
well
overexpress
phageassoci
protein
cooper
group
wolfgang
eisenreich
tu
munich
test
incorpor
rate
glucos
respect
synthesis
amino
acid
therefor
cultur
siem
scem
tsb
media
result
analys
gave
us
hint
environment
condit
affect
metabol
virul
properti
ehec
strain
antifung
activ
lactic
acid
bacteria
lactobacillu
plantarum
penicillium
sp
stapl
food
rice
wheat
corn
peanut
greenbean
often
store
warehous
stockpil
suppli
often
damag
larg
number
fungi
one
fungi
caus
damag
penicillium
sp
sever
speci
penicillium
grow
food
given
potassium
sorbat
use
synthet
preserv
antifung
often
induc
resist
food
industri
use
lactic
acid
bacteria
wide
biocontrol
agent
improv
food
safeti
minimum
food
process
import
explor
lactic
acid
bacteria
biopreserv
antifung
aim
research
know
antifung
activ
lactic
acid
bacteria
lactobacillu
plantarum
penicillium
sp
coloni
lactobacillu
plantarum
isol
cultur
gyp
liquid
medium
incub
two
day
cultur
centrifug
supernat
done
ammonium
sulfat
precipit
centrifug
precipit
obtain
resuspend
buffer
l
sampl
ad
paper
disk
put
mr
agar
contain
penicillium
sp
antifung
activ
lactobacillu
plantarum
stain
penicillium
sp
rang
mm
sampl
neutral
still
produc
clear
zone
suggest
antifung
activ
acid
condit
lactobacillu
plantarum
produc
plantaricin
antifung
activ
penilcillium
sp
lactobacillu
plantarum
antifung
penicillium
sp
antibacteri
effect
probiot
isol
yoghurt
contain
probiot
common
bacteri
pathogen
technolog
databas
design
rapid
identif
microorgan
design
clinic
isol
mind
adapt
use
microorgan
monitor
program
pharmaceut
nutraceut
steril
manufactur
environ
technolog
underperform
due
divers
organ
found
environ
whole
cell
proteotyp
analysi
matrixassist
laser
desorptionion
time
flight
malditof
spectroscopi
emerg
rapid
inexpens
method
identifi
bacteria
studi
test
accuraci
robust
reproduc
technolog
appli
extens
panel
known
cultur
collect
strain
frequent
seen
speci
found
pharmaceut
nutraceut
steril
manufactur
environment
monitor
program
malditof
manufactur
recommend
method
sampl
process
data
analysi
directli
compar
method
optim
laboratori
environment
monitor
advantag
limit
use
malditof
technolog
applic
discuss
studi
show
fewer
frequent
seen
environment
isol
could
accur
identifi
maldi
system
bruker
dalton
fail
identifi
larg
due
limit
clinic
focus
databas
accugenix
method
optim
addit
made
librari
number
sampl
identifi
increas
custom
databas
method
modif
requir
optim
technolog
environment
monitor
applic
low
cost
rapid
turnaround
time
malditof
analysi
remain
strong
advantag
technolog
gramneg
bacterium
pseudomona
aeruginosa
pa
frequent
opportunist
human
pathogen
lead
caus
morbid
mortal
among
patient
suffer
cystic
fibrosi
cf
longterm
persist
dehydr
highli
viscou
sputum
cf
airway
pa
adapt
phenotyp
remark
respons
prevail
requir
cf
lung
environ
includ
loss
acut
virul
determin
contrast
pa
gain
obvious
metabol
adapt
previou
studi
group
shown
end
stage
cf
isol
icd
idh
gene
significantli
upregul
comparison
earlystag
cf
isol
interestingli
pa
possess
two
isoenzym
isocitr
dehydrogenas
name
dimer
icd
monomer
idh
catalyz
oxid
decarboxyl
isocitr
ketoglutar
nad
p
h
besid
pa
bacteria
two
isoenzym
isocitr
dehydrogenas
suggest
role
adapt
environment
chang
addit
isocitr
dehydrogenas
metabol
key
enzym
control
metabol
flux
tricarbox
acid
tca
cycl
glyoxyl
shunt
use
icd
idh
singl
transposon
mutant
construct
doubl
mutant
tri
figur
metabol
role
enzym
bluenativepag
abl
display
activ
enzym
furthermor
doubl
mutant
show
signific
growth
defect
modifi
growth
behavior
minim
media
supplement
differ
tca
intermediatescsourc
construct
malat
dehydrogenas
mutant
also
involv
tcacycl
moreov
mani
line
evid
nad
p
depend
isocitr
dehydrogenas
malat
dehydrogenas
involv
defens
oxid
stress
therefor
investig
metabol
enzym
view
oxid
stress
well
campylobact
jejuni
import
foodborn
bacteri
pathogen
industri
countri
develop
world
one
major
caus
bacteri
diarrhoea
identifi
new
gene
import
invas
host
cell
pathogen
screen
transposon
gener
mutant
librari
base
clinic
c
jejuni
isol
therebi
identifi
clone
transposon
insert
gene
gene
encod
togeth
adjac
gene
suppos
act
chemoreceptor
could
show
gene
translat
one
protein
diminish
motil
pathogen
alter
chemotact
behaviour
c
jejuni
toward
formic
acid
relat
util
formic
acid
format
dehydrogenas
second
gene
repres
one
subunit
sulphit
cytochrom
c
oxidoreductas
character
show
genotyp
possess
clearli
reduc
motil
diminish
adher
host
cell
furthermor
transcript
gene
respons
synthesi
legionamin
acid
legam
downregul
mutant
possess
reduc
capac
autoagglutin
contrast
neither
prolifer
mutant
intracellular
atp
quantiti
alter
compar
parent
strain
transposon
mobil
genet
element
capabl
random
insert
host
genom
fundament
featur
employ
sinc
decad
inactiv
gene
leav
detect
signatur
locu
integr
differ
modif
tradit
transposon
mutagenesi
facilit
develop
new
techniqu
signatur
target
mutagenesi
transposon
mediat
differenti
hybrid
genet
footprint
gene
express
analysi
crucial
step
method
local
transposon
insert
site
process
usual
timeconsum
experiment
procedur
requir
intens
optim
infireinsert
finder
via
restrict
digest
novel
softwar
tool
allow
comput
identif
transposon
insert
site
known
bacteri
genom
sequenc
transposon
mutagenesi
experi
strategi
procedur
outlin
fig
base
restrict
digest
genom
dna
combin
southern
blot
hybrid
first
step
genom
dna
cleav
differ
restrict
endonucleas
restrict
enzym
produc
uniqu
pattern
dna
fragment
defin
size
second
step
size
fragment
insert
transposon
determin
southern
blot
hybrid
transposonspecif
probe
size
fragment
origin
genom
equal
obtain
fragment
size
minu
length
transposon
final
use
deriv
fragment
size
pattern
probabl
genom
posit
transposon
calcul
infir
softwar
afterward
confirm
accur
determin
insert
site
perform
pcr
method
potenti
applic
viru
sequenc
organ
known
genom
sequenc
outlin
method
provid
solid
basi
establish
new
highthroughput
technolog
softwar
implement
stand
alon
rpackag
addit
web
interfac
program
avail
http
wwwinfiretubsd
altern
sigma
factor
b
modul
virul
gene
express
murin
staphylococcu
aureu
infect
model
influenc
kidney
gene
express
pattern
host
rtqpcr
mix
eukaryot
prokaryot
rna
infect
tissu
result
detect
sigbdepend
higher
express
level
clfa
wild
type
strain
aureu
wherea
agreement
vitro
data
express
hla
aur
higher
kidney
tissu
anim
infect
sigb
mutant
strain
although
virul
sigb
defici
strain
often
report
similar
wild
type
strain
pathomechan
differ
infect
set
might
vari
therefor
rational
studi
investig
whether
delet
sigb
would
lead
differ
reaction
infect
host
gene
express
profil
indic
highli
reproduc
host
kidney
respons
infect
aureu
comparison
infect
noninfect
sampl
h
post
infect
reveal
strong
inflammatori
reaction
includ
e
g
tlr
signal
complement
system
antigen
present
ifn
signal
also
counterregulatori
signal
howev
result
studi
provid
hint
differ
pathomechan
aureu
strain
outer
membran
vesicl
releas
outer
membran
pathogen
neisseria
previou
work
suggest
role
omv
invas
meningococc
diseas
imd
recent
studi
omv
view
long
distanc
deliveri
tool
bacteri
pathogen
factor
meningococc
omv
purifi
plasma
imd
patient
ask
whether
impact
polymorphonuclear
neutrophil
pmn
first
line
defenc
imd
flow
cytometri
fluoresc
microscopi
detect
fusion
neisseria
meningitidi
nm
omv
pmn
whole
blood
assay
isol
cell
fraction
differenti
prepar
lymphycyt
result
fusion
omv
phagocytosi
ro
releas
pmn
impair
live
imag
reveal
pmn
motil
also
affect
omv
result
suggest
reduc
pmn
mediat
kill
nm
presenc
meningococc
omv
possibl
causal
effector
protein
identifi
ribosyl
transferas
prove
present
omv
whose
knockout
reduc
mention
omv
effect
neutrophil
taken
togeth
data
provid
evid
nm
abl
modul
cellular
immun
respons
mechan
releas
omv
fuse
host
immun
cell
might
aid
rapid
spread
bacteria
blood
vessel
invad
thu
support
rapid
develop
septic
shock
mani
patient
suffer
invas
meningococc
diseas
cell
invas
n
meningitidi
requir
common
interact
focal
adhes
kinas
csrc
cortactin
entri
neisseria
meningitidi
meningococcu
human
brain
microvascular
endotheli
cell
hbmec
mediat
fibronectin
vitronectin
bound
surfac
protein
opc
form
bridg
respect
integrin
interact
lead
cytoskelet
rearrang
uptak
meningococci
report
bind
pathogen
n
meningitidi
trigger
recruit
focal
contact
associ
protein
vinculin
paxillin
zyxin
site
bacteri
attach
determin
focal
adhes
kinas
fak
directli
associ
integrin
involv
integrinmedi
intern
n
meningitidi
hbmec
overexpress
dominantneg
version
fak
frnk
block
integrinmedi
intern
n
meningitidi
importantli
fakdefici
fibroblast
resist
n
meningitidi
invas
show
reduc
phosphoryl
cytoskeleton
protein
decreas
develop
stress
fiber
furthermor
n
meningitidi
induc
tyrosin
phosphoryl
sever
host
protein
includ
csrc
fak
complex
substrat
cortactin
inhibit
cortactin
express
sirna
silenc
mutat
critic
amino
acid
residu
within
cortactin
significantli
reduc
meningococc
invas
brain
endotheli
cell
indic
critic
role
cortactin
meningococc
uptak
moreov
demonstr
phosphoryl
statu
cortactin
enhanc
infect
involv
fak
src
kinas
activ
togeth
result
indic
n
meningitidi
exploit
integrin
signal
pathway
entri
fak
import
signal
molecul
mediat
transfer
signal
activ
integrin
cytoskeleton
cooper
interplay
fak
csrc
cortactin
enabl
endocytosi
n
meningitidi
eukaryot
cell
despit
antibiot
therapi
infect
neisseria
meningitidi
still
demonstr
high
rate
morbid
mortal
even
develop
countri
fulmin
septicem
cours
name
waterhousefriderichsen
syndrom
massiv
hemorrhag
adren
gland
widespread
petechi
bleed
suggest
pathophysiolog
inhibit
platelet
function
data
show
n
meningitidi
produc
import
physiolog
platelet
inhibitor
cardiovascular
signal
molecul
nitric
oxid
also
known
endotheliumderiv
relax
factor
edrf
n
meningitidisderiv
inhibit
adp
induc
platelet
aggreg
activ
solubl
guanylyl
cyclas
sgc
follow
increas
platelet
cyclic
nucleotid
level
subsequ
activ
platelet
cgmpand
campdepend
protein
kinas
pkg
pka
furthermor
direct
measur
horseradish
peroxidas
hrp
passag
vascular
endotheli
cell
monolay
reveal
n
meningitidi
significantli
increas
endotheli
monolay
permeabl
immunfluoresc
analysi
demonstr
depend
disturb
structur
endotheli
adheren
junction
coincub
n
meningitidi
contrast
platelet
inhibit
effect
hbmec
mediat
cyclic
nucleotid
studi
provid
evid
play
essenti
role
pathophysiolog
septicem
meningococc
infect
legionella
pneumophila
gramneg
intracellular
pathogen
caus
sever
form
pneumonia
bacterium
natur
inhabit
freshwat
parasit
protozoan
host
aerosol
format
manmad
water
system
l
pneumophila
enter
colon
destroy
human
lung
infect
pathogen
employ
sophist
machineri
deliv
protein
host
cell
tissu
besid
secret
individu
protein
l
pneumophila
shed
vesicl
deriv
outer
membran
outer
membran
vesicl
omv
spheric
bilay
structur
consist
characterist
outer
membran
constitu
includ
outer
membran
protein
phospholipid
lipopolysaccharid
lp
shevchuk
et
al
well
periplasm
compon
group
describ
comprehens
proteom
refer
map
omv
l
pneumophila
galka
et
al
function
classif
proteom
show
omv
contain
mani
virul
factor
zymographi
enzym
assay
demonstr
omv
display
proteolyt
lipolyt
activ
may
contribut
destruct
alveolar
line
infect
confoc
laser
scan
microscopi
reveal
spatial
associ
l
pneumophila
omv
host
cell
surfac
remain
unclear
indic
adhes
bind
fusion
event
omv
host
membran
role
l
pneumophila
omv
interbacteri
commun
also
unknown
address
question
omv
materi
incorpor
target
cell
membran
human
macrophag
differ
bacteria
coincub
omv
pb
sampl
taken
analys
variou
time
point
presenc
l
pneumophila
major
outer
membran
protein
momp
could
detect
target
cell
western
blot
find
hint
toward
weak
interact
cell
surfac
rapid
ingest
degrad
omv
materi
ongo
studi
address
effect
l
pneumophila
omv
human
macrophag
regard
metabol
activ
cytoskeleton
rearrang
interbacteri
effect
l
pneumophila
omv
dissect
immunofluoresc
microscopi
fac
analysi
b
aureu
studi
extens
littl
known
latter
two
sigma
subunit
belong
group
ecftyp
sigma
factor
recent
shown
modul
stress
respons
virul
pathogen
h
hand
share
homolog
h
bacillu
subtili
comx
streptococcu
pneumonia
involv
regul
genet
compet
stress
respons
aureu
altern
sigma
factor
seem
control
small
regulon
includ
operon
prophageencod
integras
gene
int
howev
noth
known
date
whether
condit
h
activ
pathogen
address
question
analyz
express
sigh
hdepend
gene
differ
approach
first
construct
gfplux
base
report
system
control
promot
vector
harbor
sigh
control
cadmiuminduc
promot
cotransform
plasmid
aureu
strain
allow
confirm
h
depend
promot
monitor
luciferas
activ
aureu
newman
strain
harbor
growth
tsb
howev
fail
identifi
signific
level
luciferas
activ
gfp
format
nearli
growth
stage
analyz
confirm
previou
find
indic
h
essenti
activ
growth
vitro
condit
earli
lag
phase
immedi
inocul
fresh
medium
cell
overnight
cultur
detect
short
clear
increas
luciferas
activ
realtim
pcr
experi
allow
confirm
find
show
clear
increas
sigh
transcript
earli
lag
phase
strain
newman
effect
visibl
newman
sigh
mutant
interestingli
neither
overexpress
sigh
strain
newman
allow
enhanc
transcript
int
gene
inocul
newman
sighderiv
fresh
medium
reveal
clear
differ
int
transcript
wildtyp
mutant
strongli
suggest
int
gene
direct
target
h
highli
pathogen
staphylococcu
aureu
opportunist
pathogen
staphylococcu
epidermidi
secret
phenolsolubl
modulin
psm
peptid
virul
epidermidi
depend
mostli
psm
peptid
induc
chemotaxi
neutrophil
cytokin
induct
peripher
blood
mononuclear
cell
pbmc
regul
psm
secret
product
occur
agr
regul
chemotaxi
cytokin
induct
crucial
infect
molecular
basi
recognit
leucocyt
remain
unknown
demonstr
human
formyl
peptid
receptor
sens
epidermidi
psm
nanomolar
concentr
specif
block
regul
psm
gene
agr
mutant
led
sever
diminish
capac
neutrophil
detect
epidermidi
psm
moreov
staphylococci
develop
quorum
sens
system
agr
control
detect
via
human
thu
innat
immun
system
use
global
mechan
detect
bacteri
pathogen
target
may
help
manag
sever
infect
induc
differ
pathogen
endotheli
cytokineexpress
respons
streptococcu
gallolyticu
subsp
gallolyticu
weinstock
j
dreier
c
knabb
vollmer
bad
oeynhausen
deutschland
introduct
infect
endocard
ie
infect
endocardium
broad
spectrum
caus
microorgan
streptococcu
gallolyticu
subsp
gallolyticu
sgg
identifi
streptococcalcaus
ie
case
studi
influenc
differ
sgg
strain
endotheli
cell
damag
analyz
basi
express
profil
macrophag
inflammatori
tumor
necrosi
factor
tnf
materi
method
endotheli
cell
line
inocul
isol
sgg
cfuml
cell
lyse
h
h
incub
follow
rnaisol
cdnasynthesi
gene
express
inflammatori
cytokin
quantifi
use
realtim
pcr
tnfgene
express
cell
incap
measur
quantit
realtim
pcr
furthermor
differ
sggisol
cfuml
compar
concern
potenti
stimul
tnf
synthesi
whole
blood
h
incub
tnfmeasur
conduct
use
immulit
immunoassay
system
result
overal
differ
sgg
isol
show
signific
differ
stimulationintens
eg
rel
gene
express
h
isol
vs
isol
rel
gene
express
signific
increas
even
h
inocul
sgg
endotheli
cell
rel
gene
express
h
incub
gene
express
level
still
increas
rel
gene
express
contrast
gene
express
signific
increas
h
markedli
h
incub
gene
express
stimul
margin
h
inocul
endotheli
cell
sgg
h
inocul
two
isol
caus
increas
gene
express
sgg
caus
increas
gene
express
endotheli
cell
incub
period
comparison
potenti
differ
strain
stimul
tnf
synthesi
whole
blood
reveal
signific
differ
eg
isol
c
tnf
pgml
vs
isol
c
tnf
pgml
conclus
sgg
isol
reveal
differ
potenti
stimul
tnfgene
express
endotheli
cell
whole
blood
diverg
could
affect
dimens
progress
endotheli
cell
damag
ie
character
inflammatori
process
focu
orchestr
inflammatori
paramet
interact
sgg
endotheli
cell
monocyt
introduct
streptococcu
pneumonia
colon
nasopharyng
caviti
human
caus
agent
otiti
media
mening
pneumonia
septicaemia
pneumococci
bind
human
plasminogen
bacteri
cell
surfac
via
surfac
expos
glycolyt
enzym
bergmann
et
al
phosphoglycer
kinas
pgk
present
bacteri
cytoplasm
convert
within
glycolyt
pathway
therebi
gener
atp
plasminogen
fibrinolyt
proenzym
serin
proteas
plasmin
key
enzym
fibrinolyt
pathway
miyashita
et
al
first
four
kringl
domain
plasminogen
act
inhibitori
molecul
angiogenesi
term
angiostatin
pgk
gene
clone
use
system
qiagen
express
recombin
histag
protein
purifi
affinitychromatographi
plasminogen
bind
analys
use
western
blot
overlay
dot
spot
analys
spot
membran
repres
amino
acid
sequenc
pgk
overlap
peptid
amino
acid
immobil
membran
local
pgk
pneumococc
surfac
perform
immun
electron
microscopi
bind
kinet
paramet
plasminogenpgk
interact
determin
surfac
plasmon
reson
result
plasminogen
bind
analys
pgk
streptococcu
pneumonia
identifi
plasminogenbind
protein
electron
microscop
studi
use
pgkspecif
antibodi
visual
local
pneumococc
surfac
encapsul
non
capsul
strain
protein
overlay
analys
demonstr
pgk
bind
angiostatin
dissoci
constant
pgkplasminogen
interact
reveal
kd
within
nanomolar
rang
peptid
spot
array
indic
presenc
two
plasminogenangiostatin
bind
site
locat
within
ntermin
pgk
fragment
detect
lysin
arginin
crucial
plasminogen
interact
protein
structur
pneumococc
pgk
determin
crystal
structur
analysi
perform
csic
madrid
confirm
local
amino
acid
pgk
molecul
surfac
discuss
pneumococc
glycolyt
enzym
provid
group
multifunct
protein
display
bacteri
surfac
bind
plasminogen
interestingli
amino
acid
sequenc
crucial
plasminogen
bind
seem
vari
respect
local
within
glycolyt
protein
respect
charg
properti
requir
specif
interact
sinc
pgk
bind
preferenti
ntermin
kringl
domain
plasminogen
interact
pneumococc
pgk
angiostatin
display
new
mode
interact
refer
bergmann
et
al
mol
microbiol
miyashita
c
e
wenzel
heiden
haemostasi
streptococcu
pneumonia
pneumococci
colon
human
mucos
respiratori
epithelium
abl
caus
sever
local
infect
otiti
media
lifethreaten
diseas
includ
communityacquir
pneumonia
mening
pneumococci
evolv
sophist
strategi
encount
host
produc
wide
varieti
virul
factor
contribut
pathogen
pneumococc
surfac
protein
c
pspc
major
virul
factor
adhesin
interact
complement
regul
factor
h
polymer
immunoglobulin
receptor
pigr
respiratori
mucos
epitheli
cell
human
specif
pspcpigr
interact
mediat
pneumococc
adher
invas
host
cell
howev
mechan
pneumococc
endocytosi
via
pspchpigr
interact
known
demonstr
pspcmediat
endocytosi
requir
clathrin
coat
vesicl
format
regul
dynamin
visual
subsequ
endosom
traffick
pneumococci
upon
ingest
host
cell
pretreat
epitheli
cell
dynasor
potent
inhibitor
dynamin
reduc
pneumococc
uptak
compar
untreat
cell
similar
knockdown
dynamin
shrna
also
impair
pneumococc
intern
suggest
pneumococc
uptak
requir
function
dynamin
pneumococc
intern
also
reduc
significantli
inhibit
clathrin
chlorpromazin
clathrin
shrna
indic
import
role
clathrin
machineri
pneumococc
intern
pigr
express
host
epitheli
cell
furthermor
confoc
laser
scan
microscopi
perform
elucid
endocyt
pathway
pneumococci
thirti
minut
post
infect
pneumococci
coloc
clathrin
hour
post
infect
pneumococc
traffick
visual
variou
endosom
compart
includ
earli
recycl
late
endosom
use
gfplabel
rab
protein
conclus
result
suggest
pneumococci
intern
via
clathrinmedi
endocyt
pathway
sort
differ
endosom
compart
epitheli
host
cell
howev
intracellular
fate
reach
phagolysosom
still
matter
debat
sustain
phosphoryl
antagon
cell
autonom
defens
aureu
toxin
g
von
hoven
n
kloft
c
neukirch
w
bobkiewicz
wei
k
boller
husmann
previous
shown
cell
mount
autonom
defens
pore
form
toxin
allow
surviv
membran
perfor
aureu
toxin
demonstr
clearanc
pore
complex
plasma
membran
hacat
cell
one
requir
cellular
surviv
toxin
caus
state
energi
crisi
starvat
translat
arrest
inhibit
prevent
replenish
cellular
atp
propos
autophagi
serv
maintain
metabol
homeostasi
target
cell
keep
concept
autophagosom
format
toxintr
cell
depend
phosphoryl
like
starv
cell
cell
fail
recov
attack
toxin
investig
cell
interestingli
phosphoryl
trigger
toxin
similar
kinet
hacat
cell
respons
markedli
sustain
cell
moreov
transmiss
electron
microscopi
analysi
toxintr
cell
reveal
stronger
vesicul
cell
dephosphoryl
toxintr
hacat
cell
pharmacolog
inhibit
cell
fail
recov
toxin
attack
sinc
effect
due
block
translat
sustain
phosphoryl
seem
promot
kill
toxintr
cell
unusu
mechan
endotheli
progenitor
cell
epc
heterogen
mixtur
adult
stem
cell
play
essenti
role
revascular
vascular
damag
shown
promis
result
regen
therapi
ischem
injuri
work
investig
unconvent
method
improv
angiogen
potenti
epc
bacteri
infect
bartonella
spp
facult
intracellular
pathogen
known
bacteria
induc
angiogenesi
human
describ
cours
bacteri
infect
epc
vasculotrop
bacterium
b
hensela
data
demonstr
epc
highli
suscept
b
hensela
infect
disturb
differenti
toward
endotheli
cell
upon
infect
epc
show
strong
activ
hypoxia
induc
key
transcript
factor
angiogenesi
follow
signatur
proangiogen
cell
respons
includ
product
cytokin
vascular
endotheli
growth
factor
vegf
adrenomedullin
adm
furthermor
b
hensela
prevent
apoptosi
epc
induc
cell
migrat
along
stromal
cellderiv
factor
sdf
gradient
essenti
function
compon
angiogen
respons
final
cultur
plate
coat
basement
membran
simul
extracellular
matrix
matrigel
tm
infect
epc
prolifer
assembl
complex
lumen
contain
vessellik
structur
vitro
experi
examin
structur
reveal
strong
regul
endotheli
marker
gene
vascular
endotheli
growth
factor
endotheli
nitric
oxid
eno
vascular
endotheli
cadherin
vecadherin
indic
vessellik
structur
inde
made
endotheli
cell
cumul
data
demonstr
infect
b
hensela
improv
angiogen
capac
epc
even
induc
vessellik
growth
vitro
former
studi
use
cultur
cell
show
interact
yersinia
via
adhes
factor
yada
invasin
host
cell
site
prerequisit
yop
transloc
studi
want
show
yada
invasin
contribut
yop
transloc
vitro
purpos
lactamas
report
system
use
detect
quantifi
yop
inject
infect
cell
present
evid
yada
invasin
show
strike
differ
contribut
yop
transloc
ii
invasin
mediat
yop
transloc
intact
cytoplasm
domain
connect
actin
cytoskeleton
seem
import
term
integr
whole
receptor
abil
perform
high
affin
ligand
bind
iii
contrast
yada
requir
cytoplasm
domain
might
requir
addit
factor
besid
integrin
effect
yop
inject
iiii
depend
cell
type
yada
mediat
yop
inject
even
occur
complet
independ
express
streptococcu
pneumonia
pneumococci
gramposit
bacteria
highli
adapt
human
respiratori
tract
pneumonia
microaerophil
pathogen
strictli
ferment
requir
rapid
effici
respons
mechan
oxid
stress
abil
grow
surviv
host
reactiv
oxid
condit
like
facult
anaerob
protect
cellular
macromolecul
reactiv
oxygen
speci
ro
produc
endogen
metabol
dioxygen
aerob
growth
exogen
polymorphonuclear
leukocyt
pmn
macrophag
host
immun
respons
essenti
pneumococc
surviv
besid
protect
mechan
thioredoxin
famili
protein
play
import
role
oxid
stress
toler
group
small
ubiquit
protein
number
differ
import
cellular
function
live
organ
thioredoxin
possess
highli
conserv
secondari
structur
cxxc
activ
site
motif
common
architectur
thioredoxin
motif
two
put
surfaceexpos
lipoprotein
gene
predict
pneumococc
genom
belong
famili
thioredoxinlik
protein
protein
respons
keep
cellular
reduc
environ
accept
electron
nadph
transfer
acceptor
investig
role
pneumococc
growth
oxid
stress
phagocytosi
intracellular
surviv
gene
mutat
allel
replac
pneumococci
differ
genet
background
conclus
data
show
individu
impact
thioredoxinlik
protein
addit
effect
resist
pneumococci
oxid
stress
essenti
invas
pneumococc
diseas
cell
surfac
protein
streptococcu
pneumonia
pneumococci
play
key
role
infect
process
therefor
consid
import
virul
factor
pathogen
surfac
protein
pspa
pspc
known
mediat
bacteri
adhes
host
cell
contribut
colon
invas
involv
immun
evas
differ
cluster
protein
decor
cell
surfac
pneumococci
lpxtg
cell
wallanchor
protein
cholinebind
protein
pspc
pspa
lipoprotein
surfaceexpos
lipoprotein
gramposit
bacteria
fulfil
import
function
cell
signal
protein
export
substrat
transport
protein
fold
due
pleiotrop
effect
upon
inactiv
lipoprotein
compon
abc
transport
initi
identifi
adhesin
psaa
virul
factor
direct
contribut
virul
yet
shown
lipoprotein
slra
belong
famili
peptidylprolyl
cistran
isomeras
ppma
role
lipoprotein
pneumococc
colon
virul
transmiss
systemat
investig
although
function
genom
analysi
point
toward
implic
virul
bioinformat
analysi
pneumococc
genom
reveal
presenc
approxim
gene
encod
lipoprotein
hypothet
lipoprotein
lipoprotein
unknown
function
select
explor
role
pneumococc
fit
virul
strikingli
candid
identifi
surfac
proteom
analysi
pneumococc
mutant
select
ten
lipoprotein
encod
gene
gener
insert
delet
mutagenesi
pneumococci
differ
genet
background
initi
comprehens
analysi
includ
growth
behavior
stabil
mutant
unalt
even
chemicallydefin
medium
assess
effect
individu
lipoprotein
phagocytosi
intracellular
surviv
phagocytosi
assay
conduct
use
murin
phagocyt
role
lipoprotein
pneumococc
adher
invas
lung
alveolar
epitheli
cell
elucid
antibiot
protect
assay
immunofluoresc
microscop
studi
result
reveal
variou
impact
intracellular
surviv
adher
detail
function
analysi
perform
use
vivo
infect
model
bind
experi
recombin
protein
gram
posit
bacterium
staphylococcu
aureu
human
pathogen
caus
sever
diseas
includ
nosocomi
infect
sepsi
endocard
one
import
factor
colonis
resist
antimicrobi
peptid
antibiot
cell
wall
anchor
glycopolym
known
wall
teichoic
acid
wta
aureu
strain
produc
ribitolphosph
rbop
wta
polym
decor
nacetylglucusamin
dalanin
dala
aureu
strain
l
produc
extraordinari
kind
wta
consist
repetit
unit
polyglycerolphosph
grop
substitut
dala
nacetylgalatosamin
galnac
renam
wta
ltype
wta
far
staphylococc
phage
classifi
major
sergroup
b
f
also
differ
morpholog
eg
tail
length
flexibl
contract
head
shape
size
interestingli
electron
micrograph
imag
reveal
serogroup
l
phage
phage
infect
strain
l
doublegang
serogroup
b
phage
although
serogroup
b
phage
almost
morpholog
abl
infect
strain
l
intent
analys
ltype
wta
serv
adsorpt
receptor
phage
therefor
creat
first
time
ltype
wta
defici
mutant
strain
background
via
delet
tago
gene
respons
initi
step
wta
biosynthesi
confirm
complet
loss
wta
aureu
strain
l
tago
phosphat
assay
moreov
aureu
strain
l
tago
resist
serogroup
l
serogroup
phage
shown
phage
suscept
eop
assay
show
phage
resist
due
loss
wta
phage
suscept
could
restor
complement
use
vector
express
tago
gene
furthermor
phage
adsorpt
assay
perform
analys
observ
phage
resist
due
loss
receptor
due
unknown
post
adsorpt
process
data
clearli
demonstr
ltype
wta
serv
adsorpt
receptor
serogroup
l
phage
besid
phage
adsorpt
studi
analys
mutant
detail
growth
kinet
demonstr
loss
ltype
wta
dispens
growth
vitro
contrast
ltype
wta
essenti
growth
high
temperatur
furthermor
mutant
produc
lower
amount
biofilm
possibl
role
ltype
wta
biofilm
format
exclud
far
taken
togeth
compar
known
function
rbopglcnac
wta
type
data
suggest
similar
role
uniqu
ltype
wta
small
membraneact
peptid
psm
requir
phagosom
escap
staphylococcu
aureu
nonprofession
phagocyt
grosz
ss
chatterje
c
goerk
c
background
staphylococcu
aureu
one
common
bacteri
pathogen
men
aureu
abl
invad
human
host
cell
nonprofession
phagocyt
eg
epitheli
endotheli
cell
other
report
phagosom
escap
aureu
howev
controversi
regard
mechan
phagosom
escap
partial
understood
method
phagosom
integr
human
host
cell
hela
monitor
ph
determin
fitclabel
bacteria
intraphagosom
ph
determin
use
fac
analysi
h
h
infect
marker
acidif
quench
fitc
fluoresc
low
ph
use
et
al
addit
microscop
report
recruit
techniqu
employ
demonstr
phagosom
escap
gies
et
al
isogen
mutant
defici
specif
toxin
compar
wild
type
strain
result
cell
line
loss
intraphagosom
ph
h
infect
demonstr
escap
aureu
strain
strong
toxin
produc
well
toxinneg
strain
lac
three
strain
psm
defici
mutant
unabl
reduc
acidif
signal
complement
partial
restor
wild
type
phenotyp
contrast
mutant
test
psm
toxin
pvl
behav
ident
parent
wild
type
strain
lac
atoxindefici
mutant
strain
differ
wild
type
determin
phmonitor
yfpfc
coloc
time
cours
analysi
use
rifampicin
inhibit
demonstr
suscept
window
roughli
hr
strain
lac
furthermor
identifi
two
addit
strain
moder
phagosom
escap
phenotyp
discuss
data
suggest
psm
psm
toxin
pvl
requir
phagosom
escap
staphylococc
strain
lac
hela
cell
surprisingli
toxin
appear
requir
model
abl
identifi
sever
escapeposit
strain
differ
distantli
genet
background
use
common
mechan
growth
inhibit
assay
deposit
activ
complement
compon
analyz
immunofluoresc
microscopi
result
bind
complement
regul
immobil
could
detect
western
blot
elisa
use
specif
antibodi
unexpectedli
cfh
present
eluat
fraction
assess
sdspage
western
blot
howev
bind
serumpurifi
cfh
recombin
demonstr
elisa
far
western
blot
serum
adsorpt
assay
reveal
produc
borreli
cell
capabl
bind
extent
cfh
function
analysi
also
shown
upon
incub
activ
human
serum
express
spirochet
kill
complement
larg
amount
complement
compon
membran
attack
complex
deposit
surfac
discuss
taken
togeth
identifi
complement
protein
novel
ligand
infectionassoci
protein
b
burgdorferi
seemingli
bind
differ
cfhr
suffici
protect
cell
complementmedi
kill
thu
data
strongli
suggest
play
subordin
support
role
complement
resist
b
burgdorferi
introduct
inform
genom
dysgalactia
subsp
equisimili
sdse
highli
desir
sinc
pathogen
caus
spectrum
infect
similar
caus
pyogen
two
genom
sdse
serolog
group
g
recent
publish
report
complet
genom
sequenc
sdse
strain
possess
group
cell
wall
carbohydr
lancefield
antigen
compar
streptococc
genom
materi
method
sdse
strain
origin
blood
cultur
adult
without
stss
pyrosequenc
shotgun
kb
pairedend
librari
combin
coverag
method
appli
gap
closur
achiev
sanger
sequenc
pcr
product
assembl
finish
obtain
appli
differ
bioinformat
tool
annot
perform
combin
result
gendb
rast
basi
server
manual
curat
result
genom
consist
one
circular
chromosom
bp
predict
protein
code
sequenc
cdss
identifi
rrna
rrna
loci
trna
found
gc
content
three
phagerel
chromosom
island
prci
complet
prophag
identifi
contain
known
phageencod
virul
factor
pyogen
two
cluster
regularli
interspac
short
palindrom
repeat
crispr
identifi
spacer
homolog
pyogen
phage
may
explain
lack
complet
phage
genom
low
degre
rearrang
sdse
genom
contrast
pyogen
numer
ortholog
nonphageassoci
virul
factor
gene
pyogen
includ
determin
mprotein
emm
pili
streptokinas
hemolysin
slo
sl
nadas
extracellular
matrixprotein
bind
surfac
protein
etc
detect
found
superantigen
gene
uniqu
featur
found
genom
includ
salivaricin
gene
cluster
put
gene
group
cell
wall
polysaccharid
synthesi
identifi
compar
analys
reveal
high
degre
homolog
colinear
publish
dysgalactia
genom
closer
relationship
pyogen
base
avail
genom
betahemolyt
streptococci
includ
group
c
g
streptococci
anim
origin
conclusiondiscuss
sdse
possess
lancefield
group
antigen
highli
homolog
dysgalactia
close
relat
pyogen
streptococc
speci
includ
group
c
g
streptococci
anim
origin
surfac
protein
gramposit
bacteria
contribut
interact
human
kohler
n
gisch
u
hammerschmidt
adher
bacteria
host
cell
multifactori
process
proce
bacteri
infect
versatil
interplay
pathogen
bacteria
host
depend
numer
interact
bacteri
surfac
structur
host
matrix
protein
matricellular
glycoprotein
mainli
secret
thrombocyt
also
mani
human
cell
type
multifunct
multidomain
kda
homotrim
wide
rang
predict
function
adher
migrat
cell
morpholog
prolifer
apoptosi
well
interact
extracellular
proteas
furthermor
part
extracellular
matrix
show
bind
differ
matrix
protein
includ
fibronectin
fibrinogen
heparin
furthermor
surfac
receptor
integrin
recent
studi
reveal
new
role
interplay
differ
gramposit
pathogen
host
cell
shown
act
molecular
bridg
host
cell
gramposit
bacteria
facilit
adher
invas
differ
human
epitheli
endotheli
cell
nevertheless
receptor
bacteri
side
well
host
side
still
unknown
work
isol
human
buffi
coat
purifi
via
fast
protein
liquid
chromatographi
bioactiv
purifi
verifi
bind
assay
human
epitheli
cell
differ
gramposit
pathogen
bacteria
use
flow
cytometri
surfac
plasmon
reson
spr
studi
immobil
biosensor
ligand
overlay
assay
reveal
potenti
protein
bind
partner
bacteri
side
staphylococcu
aureu
streptococcu
pneumonia
identifi
protein
interest
surfac
protein
fraction
aureu
perform
peptid
analyz
mass
spectrometri
result
indic
bind
candid
whose
specif
bind
investig
interact
differ
gramposit
bacteria
via
surfac
expos
protein
like
import
colon
bacteri
dissemin
could
benefici
develop
sever
infect
like
infect
endocard
pneumonia
discoveri
antibiot
one
import
mileston
medicin
fight
infecti
diseas
today
rapid
evolut
emerg
multidrugresist
bacteria
necessit
search
new
antibiot
substanc
sourc
lantibiot
lanthionin
contain
antibiot
ribosom
produc
bacteri
peptid
antibiot
show
interest
antibacteri
activ
even
nanomolar
rang
multiresist
human
pathogen
characterist
thioether
amino
acid
lanthionin
methyllanthionin
introduc
extens
enzymemedi
posttransl
modif
rare
amino
acid
form
intramolecular
ring
essenti
threedimension
structur
lantibiot
enhanc
stabil
proteas
oxid
convey
antimicrobi
activ
featur
make
lantibiot
interest
candid
lead
structur
novel
antimicrobi
applic
medic
food
industri
ross
vandera
blast
search
employ
characterist
lantibiot
modif
enzym
lanm
b
c
ncbi
databas
show
orf
code
protein
involv
lantibiot
product
widespread
bacteria
differ
phyla
base
genom
data
identifi
put
lantibiot
gene
cluster
also
bacteri
phyla
product
lantibiot
never
describ
like
cyanobacteri
nostoc
punctiform
strain
focu
project
homolog
andor
heterolog
express
far
uncharacter
lantibiot
context
abl
identifi
character
novel
twopeptid
lantibiot
lichenicidin
produc
bacillu
licheniformi
addit
reveal
presenc
partial
lantibiot
gene
cluster
code
protein
involv
produc
selfprotect
wellknown
lantibiot
mersacidin
bacillu
amyloliquefacien
transfer
biosynthet
part
mersacidin
gene
cluster
b
amyloliquefacien
result
success
express
fulli
modifi
activ
mersacidin
strain
put
lantibiot
produc
includ
anaerococcu
thermophilum
strain
identifi
project
still
focu
ongo
work
ross
ac
vedera
jc
j
antibiot
tokyo
jan
c
seifert
l
mildenberg
berscheid
p
sass
g
bierbaum
gramposit
bacteria
character
massiv
cell
wall
form
multipl
layer
peptidoglycan
structur
integr
cell
wall
directli
affect
viabil
bacterium
biosynthesi
peptidoglycan
tightli
control
also
emphas
import
cell
wall
target
antibiot
clinic
treatment
bacteri
infect
despit
much
less
known
detail
bacteria
control
interplay
degrad
new
synthesi
peptidoglycan
coordin
cell
divis
cell
growth
twocompon
regulatori
system
tcss
compos
sensor
histidinekinas
cognat
respons
regul
protein
play
predomin
role
way
bacteria
respond
adapt
environment
stress
condit
aureu
essenti
yycfg
walrkvicrk
tc
play
major
role
homeostasi
cell
wall
control
express
autolysin
context
antiinfect
treatment
vrasr
tc
involv
resist
vancomycin
lactam
antibiot
moreov
confer
mechan
sens
inhibit
damag
bacteri
cell
wall
gener
research
tc
system
restrict
use
truncat
protein
miss
part
entir
kinas
want
show
vitro
phosphoryl
activ
fulllength
vra
yycg
kinas
mutat
version
yycg
phosphotransf
cognat
respons
regul
protein
vrar
yycf
c
weber
k
krauel
greinach
hammerschmidt
gramposit
gramneg
bacteria
apart
lifethreaten
infecti
pathogen
also
suppos
etiolog
agent
develop
heparininduc
thrombocytopenia
hit
hit
iggantibodymedi
advers
drug
reaction
complex
positivelycharg
chemokin
platelet
factor
frequent
use
anion
anticoagul
clinic
medicin
heparin
interestingli
even
patient
gener
iggantibodi
specif
complex
soon
day
exposur
heparin
presum
patient
encount
complex
similar
bound
anion
bacteri
surfac
infect
like
candid
neg
charg
molecul
bacteri
surfac
lipopolysaccharid
lp
teichoic
acid
ta
well
protein
studi
abl
pinpoint
bacteri
bind
partner
show
interact
lp
gramneg
model
organ
escherichia
coli
salmonella
typhimurium
teichoic
acid
gramposit
staphylococcu
aureu
shown
elisa
competit
inhibit
bind
experi
experi
surprisingli
e
coli
typhimurium
mutant
success
shorten
lpsbackbon
display
increas
bind
capac
highest
bind
detect
e
coli
waac
e
coli
waaa
mutant
lack
oantigen
core
lp
howev
e
coli
mutant
waaa
addit
defici
acid
kdo
suggest
lipid
structur
contribut
similarli
aureu
mutant
sever
truncat
wall
teichoic
acid
tago
show
increas
recruit
compar
wildtyp
strain
addit
pretreat
bacteria
pronas
e
trypsin
impair
bind
aureu
e
coli
indic
protein
anoth
major
bind
partner
gramposit
bacteria
antibodi
gener
upon
bind
bacteria
enhanc
phagocytosi
bacteria
thu
act
bacteriaopson
protein
abl
induc
humor
immun
respons
specif
wide
varieti
bacteri
speci
might
therefor
ancient
host
defens
mechan
interfac
innat
adapt
immun
key
transcript
factor
involv
adapt
process
mammal
hypoxia
play
crucial
role
eg
cancer
angiogenesi
recent
evid
suggest
lead
role
inflammatori
infecti
diseas
demonstr
previous
human
pathogen
aureu
lead
activ
vitro
ex
vivo
vivo
activ
detriment
aureu
periton
model
analyz
role
aureu
infect
detail
investig
depend
host
cell
respons
upon
aureu
infect
purpos
control
cell
infect
aureu
gene
express
analyz
four
hour
later
use
affymetrix
wt
gene
array
data
reveal
express
total
gene
influenc
turn
regul
via
gene
includ
gene
involv
cell
metabol
gene
known
affect
tumour
growth
one
upregul
gene
lysyl
oxidas
lox
copperdepend
amin
oxidas
catalyz
cross
link
collagen
elastin
molecul
extracellular
matrix
might
involv
develop
fibrosi
aureu
infect
experi
reveal
lox
upregul
vitro
vivo
use
infect
model
abscessharbour
kidney
intraven
infect
nmrimic
tissu
sampl
patient
suffer
microbiolog
proven
aureu
infect
role
lox
abscess
format
moreov
chronic
infect
known
result
fibrou
scar
tissu
need
elucid
character
antiapoptot
activ
coxiella
burnetii
effector
ankg
r
eckart
l
klingenbeck
wittmann
erlangen
mikrobiologisch
institut
erlangen
deutschland
coxiella
burnetii
gramneg
oblig
intracellular
pathogen
caus
qfever
worldwid
zoonot
diseas
qfever
mild
flulik
ill
associ
chronic
even
fatal
outcom
c
burnetii
typic
transmit
human
inhal
infecti
materi
intracellular
pathogen
c
burnetii
manipul
host
cell
pathway
import
ensur
product
infect
may
play
role
establish
chronic
diseas
c
burnetii
employ
type
iv
secret
system
sever
substrat
identifi
one
substrat
protein
ankg
inhibit
pathogeninduc
apoptosi
probabl
bind
host
cell
protein
mitochondri
matrix
protein
seem
proapoptot
protein
howev
mechan
unknown
studi
differ
truncat
deriv
show
amino
termin
region
suffici
interact
inhibit
host
cell
apoptosi
wherea
interact
inhibit
host
cell
apoptosi
ectop
express
ankg
show
vesicular
pattern
mitochondri
associ
protein
seem
involv
bridg
signal
pathway
extend
mitochondria
cell
nucleu
aim
investig
interact
ankg
determin
antiapoptot
activ
ankg
therefor
test
whether
interact
ankg
direct
indirect
use
gsta
well
hispulldown
experi
demonstr
direct
bind
mitochondri
protein
hypothes
antiapoptot
activ
ankg
mediat
ankg
inhibit
intrins
extrins
apoptosi
pathway
hypothesi
confirm
use
ectop
express
experi
furthermor
use
local
studi
show
ankg
shuttl
cytosol
nucleu
apoptosi
induct
interestingli
ectop
express
show
nterminu
nuclear
cytosol
case
local
chang
apoptosi
induct
data
suggest
nuclear
localis
well
bind
necessari
antiapoptot
activ
coxiella
burnetii
effector
protein
ankg
staphylococcu
saprophyticu
import
caus
urinari
tract
infect
young
women
amino
acid
dserin
occur
rel
high
concentr
human
urin
bacteriostat
toxic
effect
mani
nonuropathogen
bacteria
saprophyticu
harbor
cytoplasmat
enzym
dserin
deaminas
dsda
found
mani
uropathogen
shown
dsda
enabl
saprophyticu
cleav
dserin
pyruv
ammonia
probabl
factor
enabl
colon
urinari
tract
contrast
e
coli
dsdaoperon
saprophyticu
encod
specif
dserinetransport
three
gene
genom
saprophyticu
encod
put
dserinetransport
show
ident
similar
cyca
unspecif
dserin
transport
uropathogen
ecoli
creat
knockout
mutant
gene
order
character
dserinetransport
saprophyticu
defin
medium
dserin
elong
lagphas
saprophyticu
transport
mutant
measur
dserin
transport
uptak
essay
analyz
remain
concentr
dserin
supernat
bacteri
suspens
nmrspectroscopi
keep
observ
growth
defin
medium
dserin
uptak
lower
nmr
assay
reduct
dserin
uptak
therefor
posit
effect
growth
defin
medium
condit
take
account
result
appear
major
player
dserin
uptak
saprophyticu
knowledg
dserin
transport
metabol
presum
offer
us
insight
physiolog
virul
saprophyticu
larg
group
bacteri
surfac
protein
repres
famili
autotransport
protein
repres
belong
type
v
secret
system
found
almost
gramneg
bacteria
autotransport
protein
frequent
repres
import
virul
factor
eg
trimer
autotransport
adhesin
yada
enteropathogen
yersinia
enterocolitica
typic
autotransport
consist
three
function
domain
ntermin
signal
sequenc
ctermin
transloc
domain
passeng
domain
synthesi
cytosol
secmedi
transport
across
inner
membran
periplasm
transloc
domain
form
betabarrel
pore
outer
membran
presum
help
bam
complex
pore
passeng
domain
transloc
surfac
cell
second
unrel
famili
outer
membran
protein
expos
passeng
domain
bacteri
outer
surfac
intimin
invasin
nonfimbri
adhesin
pathogen
bacteria
specif
interact
host
cell
surfac
receptor
mediat
bacteri
attach
invas
integr
bacteri
outer
membran
aminotermin
region
carboxytermin
region
polypeptid
expos
bacteri
outer
membran
wherea
surfaceloc
part
protein
function
well
describ
topolog
insert
ntermin
membran
domain
transloc
process
describ
investig
topolog
mechan
transloc
detail
closer
look
amino
acid
sequenc
invasin
intimin
use
signalp
psiblast
hhalign
herefrom
got
predict
signal
peptid
twelv
differ
strand
might
build
barrel
within
outer
membran
predict
develop
topolog
model
membran
anchor
invasin
intimin
introduct
hatag
defin
orient
transloc
domain
within
outer
membran
extens
immunofluoresc
studi
abl
confirm
model
moreov
came
believ
intimin
int
invasin
inv
two
major
pathogen
factor
ecoli
yersinia
monomer
autotransport
remark
differ
domain
order
revers
streptococcu
anginosu
commens
oral
caviti
gastrointestin
femal
urogenit
tract
clinic
signific
abscess
format
recent
suggest
play
pathogen
role
patient
cystic
fibrosi
interest
featur
bacteria
inconsist
phenotyp
regard
lancefield
antigen
well
haemolyt
activ
consider
percentag
anginosu
strain
display
promin
phenotyp
correspond
gene
identifi
yet
differ
streptococc
speci
modifi
short
peptid
sl
relat
class
bacteriocin
encod
sag
gene
cluster
includ
gene
correspond
posttransl
modif
transport
machineri
random
chromosom
integr
transposit
vector
gener
plasmidbas
mutant
librari
haemolyt
streptococcu
anginosu
strain
atcc
librari
screen
mutant
show
loss
phenotyp
blood
agar
plate
nonhaemolyt
mutant
select
investig
sequenc
insert
site
mutant
identifi
thu
far
differ
mutat
site
gene
cluster
kb
harbour
open
read
frame
orf
signific
similar
sag
sl
associ
gene
gene
cluster
streptococcu
pyogen
encod
haemolysin
streptolysin
sl
orf
correspond
sag
gene
saga
sagi
could
identifi
similar
deduc
amino
acid
put
anginosu
sag
gene
cluster
sagprotein
pyogen
rang
sagf
sagd
investig
anginosu
haemolysin
function
haemolysin
assay
cultur
supernat
whole
bacteria
carri
haemolyt
activ
observ
whole
cell
supernat
indic
like
sl
pyogen
anginosu
haemolysin
abl
lyse
erythrocyt
cellassoci
form
summari
abl
success
establish
mutant
librari
anginosu
identifi
slslike
gene
cluster
genet
basi
anginosu
product
magnet
isol
method
analyz
differenti
chlamydia
pneumonia
interact
protein
profil
persist
infect
introduct
chlamydia
pneumonia
cpn
oblig
intracellular
bacteri
pathogen
caus
acut
infect
respiratori
tract
cpn
also
caus
prolong
chronic
infect
may
due
persist
infect
respiratori
nonrespiratori
tissu
implic
develop
number
chronic
diseas
asthma
copd
atherosclerosi
persist
chlamydia
exhibit
characterist
protein
express
profil
refractori
kill
antibiot
howev
hostpathogen
interact
protein
persist
infect
investig
far
recent
develop
novel
magnet
isol
techniqu
chlamydia
use
chlamydi
lipid
biotinyl
magnet
nanobead
label
key
characterist
techniqu
gentl
mechan
sonic
plasma
membran
follow
magnet
separ
label
target
subsequ
allow
biochem
detect
compartmentcontain
protein
studi
appli
method
investig
persist
cpn
interact
protein
materi
method
fac
confoc
microscopi
electron
microscopi
use
check
label
efficaci
biotinyl
lipid
magnet
nanobead
fraction
contain
magnet
label
cpn
isol
use
magnet
chamber
interferon
ifn
use
induc
persist
infect
cpn
persist
cpn
interact
protein
profil
investig
sdspage
result
fraction
contain
magnet
label
cpn
effici
separ
nonlabel
cytoplasm
fraction
use
magnet
chamber
earli
infect
h
pi
cpn
protein
like
heat
shock
protein
hsp
inclus
membran
protein
inc
macrophag
infect
potenti
mip
also
earli
endosom
marker
protein
significantli
detect
magnet
chlamydi
fraction
compar
mock
sampl
gapdh
serv
control
strongli
enrich
nonmagnet
cytoplasm
fraction
express
inca
mip
reduc
magnet
chlamydi
fraction
ifntreat
cell
comparison
nontreat
cell
h
pi
contrast
protein
band
enhanc
detect
magnet
chlamydi
fraction
ifntreat
cell
sdspage
need
character
conclusiondiscuss
result
indic
suitabl
novel
magnet
isol
method
identifi
pathogenhost
interact
protein
target
untarget
approach
escherichia
coli
strain
preval
sourc
urinari
tract
infect
uti
one
common
bacteri
infect
human
major
caus
morbid
uropathogen
e
coli
upec
caus
uti
divid
pathogen
strain
caus
symptomat
uti
nonpathogen
strain
caus
asyptomat
bacteriuria
abu
without
provok
host
respons
reason
abuassoci
e
coli
strain
evok
symptom
host
complet
understood
yet
mani
abu
e
coli
isol
seem
lack
virul
associ
phenotyp
although
carri
mani
typic
upec
virul
gene
shown
isol
express
less
virul
factor
evolut
toward
commens
virul
attenu
genom
reduct
alter
essenti
virul
gene
includ
singl
base
mutat
delet
dna
rearrang
might
gener
mechan
longterm
colon
mucos
pathogen
evolv
toward
commens
consist
low
immun
respons
host
studi
import
twocompon
system
tc
barauvri
urovirul
e
coli
analys
barauvri
tc
involv
bacteri
adapt
surviv
urinari
tract
play
signific
role
control
common
regulatori
network
affect
multitud
cellular
function
eg
regul
carbon
metabol
biofilm
format
motil
adhes
thu
contribut
urovirul
previou
studi
genom
sequenc
analysi
reveal
frequent
occurr
singl
nucleotid
polymorph
uvri
gene
upon
prolong
colon
urinari
tract
may
indic
uvri
mutat
hot
spot
ii
posit
select
bacteri
adapt
longterm
growth
urinari
tract
correl
uvri
nucleotid
sequenc
variabl
prolong
colon
urinari
tract
uvri
gene
sequenc
e
coli
strain
repres
abu
acut
uti
isol
well
control
group
commens
variant
sequenc
data
obtain
compar
dna
sequenc
housekeep
gene
strain
result
discuss
light
genom
plastic
bacteri
adapt
strategi
chang
environment
condit
despit
key
staphylococcu
epidermidi
pathogen
implantassoci
infect
larg
proport
invas
staphylococcu
epidermidi
isol
form
biofilm
vitro
condit
test
hypothesi
appar
paradox
relat
exist
superimpos
regulatori
system
suppress
multicellular
biofilm
life
style
inde
transposon
mutagenesi
clinic
signific
biofilm
neg
epidermidi
sara
chief
regul
staphylococc
virul
identifi
neg
regul
epidermidi
biofilm
format
genet
analysi
found
inactiv
sara
induc
express
giant
mda
extracellular
matrix
bind
protein
embp
promot
intercellular
adhes
biofilm
accumul
furthermor
relat
signific
autolyt
behaviour
sara
mutant
extens
releas
edna
biofilm
matrix
increas
autolysi
edna
releas
biofilm
format
directli
link
boost
process
major
autolysin
atl
metallo
proteas
sepa
overexpress
sara
mutant
henc
result
provid
first
evid
key
regul
sara
promot
polysaccharid
intercellular
adhesin
depend
biofilm
format
one
hand
neg
control
epidermidi
biofilm
format
suppress
embp
product
autolysisrel
edna
releas
henc
report
first
time
identifi
regul
enabl
epidermidi
switch
polysaccharidedepend
independ
biofilm
format
furthermor
novel
function
sara
link
sepa
mediat
escap
defensin
dermicidin
biofilm
relat
protect
phagocytosi
decreas
proinflammatori
macrophag
respons
appar
sara
play
central
role
regul
ensur
epidermidi
adapt
hostil
environ
streptococcu
pneumonia
evolv
versatil
strategi
adher
directli
human
host
cell
indirectli
interact
compon
extracellular
matrix
ecm
prerequisit
pneumococci
colon
upper
respiratori
airway
pneumococc
attach
host
compon
mediat
bacteri
surfac
molecul
includ
cell
wall
compon
cholinebind
protein
lpxtg
protein
lipoprotein
nonclass
adhesin
surfaceassoci
glycolyt
enzym
major
adhesin
pneumococci
pspc
pneumococc
surfac
protein
c
bind
ectodomain
human
polymer
ig
receptor
hpigr
addit
pspc
recruit
complement
factor
h
consequ
pspc
directli
involv
pneumococc
adhes
human
host
cell
via
bind
sc
hpigr
indirectli
via
factor
hmediat
adhes
mechan
recent
shown
multimer
hostcellbound
vitronectin
vn
adhes
glycoprotein
present
plasma
ecm
exploit
pneumococci
molecular
bridg
facilit
adher
invas
host
cell
induc
protein
host
signal
transduct
cascad
although
interact
pneumococci
vitronectin
cellular
consequ
demonstr
pneumococc
adhesin
vitronectin
remain
unknown
provid
first
evid
multifunct
pspc
protein
capabl
interact
human
vitronectin
surfac
plasmon
reson
studi
conduct
vitronectin
immobil
biosensor
chip
differ
pspc
deriv
analyt
sensorgram
demonstr
bind
ntermin
pspc
deriv
vitronectin
addit
pspc
pspclike
hic
express
surfac
nonpathogen
lactococcu
lacti
similar
pneumococci
heterolog
l
lacti
control
strain
interact
immobil
vitronectin
remark
pspcdefici
pneumococci
show
lower
capabl
bind
vitronectin
analyz
flow
cytometri
current
proteom
approach
employ
confirm
interact
pspc
vitronectin
order
local
bind
site
pspc
vitronectin
molecul
differ
vn
deriv
clone
express
vector
express
purifi
recombin
vn
fragment
appli
biochem
immunolog
assay
conclus
pspc
possess
vitronectinbind
activ
howev
role
pneumococc
pathogenesi
via
vitronectin
assess
detail
k
blank
rg
gerlach
robert
kochinstitut
wernigerod
deutschland
salmonella
enterica
serovar
typhimurium
typhimurium
facult
intracellular
pathogen
abl
caus
acut
gastroenter
diarrhea
human
typhoid
feverlik
diseas
mice
mani
gene
encod
virul
factor
typhimurium
cluster
togeth
salmonella
pathogen
island
spi
salmonella
pathogen
island
encod
type
secret
system
siicdf
secret
siie
giant
nonfimbri
adhesin
shown
mediat
intim
contact
salmonella
apic
membran
polar
epitheli
cell
siia
siib
two
addit
inner
membraneassoci
protein
might
regul
siie
function
howev
express
control
regul
encod
outsid
locu
besid
central
regul
hila
transcript
activ
sira
act
global
regul
salmonella
enteropathogenesi
control
express
well
sira
part
twocompon
regulatori
system
barasira
sens
environment
signal
activ
gene
among
other
import
motil
invas
delet
entir
locu
well
delet
sira
shown
result
dramat
reduct
adhes
polar
epitheli
cell
gain
insight
function
want
investig
proteinprotein
interact
encod
protein
use
gener
protein
complex
purif
strategi
method
includ
addit
histidinebiotinhistidin
hbh
tag
bait
protein
eg
siib
sira
via
recombin
dna
techniqu
ii
vivo
biotinyl
iii
vivo
crosslink
paraformaldehyd
pfa
bacteri
deriv
vivo
biotinyl
signal
peptid
induc
effici
biotin
attach
hbhtag
function
eukaryot
like
saccharomyc
cerevisia
well
bacteria
membraneperm
crosslink
reagent
pfa
use
stabil
transient
weak
protein
interact
crosslink
complex
enrich
tandem
affin
purif
tap
fulli
denatur
condit
follow
identif
protein
bound
bait
protein
liquidchromatographi
conjunct
tandem
massspectrometri
lcm
verifi
effici
purif
approach
use
membraneassoci
protein
siib
cytosol
protein
sira
bait
protein
respect
could
immunodetect
distinct
set
protein
complex
ctermin
hbhtag
siib
sira
use
antibodi
peptid
impli
low
crossreact
nontag
protein
ms
analys
includ
two
neg
control
elimin
possibl
identifi
background
nonspecif
bound
protein
interact
partner
result
provid
new
insight
function
success
adhes
subsequ
colon
host
cell
novotni
l
marlinghau
kort
neumann
gatermann
f
szabado
staphylococcu
lugdunensi
coagulaseneg
staphylococcu
cn
caus
sever
infect
like
skin
soft
tissu
infect
sepsi
potenti
fatal
endocard
similar
diseas
caus
aureu
contrast
aureu
virul
associ
protein
describ
fibrinogen
bind
protein
von
willebrand
bind
adhesin
synergist
hemolysin
discuss
put
pathogen
factor
lugdunensi
studi
design
primer
detect
two
annot
put
fibrinogen
bind
adhesin
three
annot
hemolysin
collect
differ
staphylococcu
lugdunensi
strain
detect
occurr
gene
preval
fibrinogen
bind
protein
hemolysin
gene
compar
phenotyp
correl
strain
test
bind
fibrinogen
also
columbia
blood
agar
plate
hemolysi
except
slush
gene
cluster
alleg
hemolysin
adhesin
high
preval
sluhemolysiniii
preval
sluhemolysin
slush
gene
cluster
found
indic
slush
gene
cluster
absent
gene
cluster
differ
strain
h
incub
lugdunensi
strain
show
hemolysi
even
strong
hemolysi
alreadi
shown
previous
report
hemolysi
h
typic
lugdunensi
high
occurr
hemolysin
gene
also
indic
hemolysi
attribut
less
like
determin
singl
hemolysin
gene
rather
suppos
combin
effect
sever
hemolysin
gene
differ
express
sinha
et
al
polar
cell
integrin
primarili
locat
basolater
side
minor
fraction
local
apic
membran
hypothes
initi
bind
fnbp
apic
locat
receptor
increas
permeabl
endotheli
barrier
thu
facilit
access
basolater
pool
integrin
method
human
endotheli
cell
eahi
infect
differ
wild
type
specif
mutant
complement
staphylococc
strain
transwel
filter
permeabl
measur
transendotheli
flux
fitcdextran
differ
time
point
inhibit
experi
perform
src
famili
proteintyrosin
kinas
inhibitor
genistein
egfr
inhibitor
serv
control
specif
effect
mediat
cytotox
quantifi
sever
viabil
test
chang
imped
reflect
chang
cell
morpholog
endotheli
layer
determin
realtim
imped
analysi
result
infect
wild
type
aureu
carnosu
heterolog
express
fnbp
clump
factor
clf
induc
increas
permeabl
compar
noninfect
cell
contrast
nonpathogen
carnosu
wild
type
opposit
effect
fnbp
doubl
knock
mutant
wild
type
aureu
fail
increas
permeabl
genistein
reduc
loss
integr
roughli
wherea
protect
effect
fnbp
express
per
se
lead
substanti
cell
death
determin
cell
mass
crystal
violet
stain
mitochondri
respiratori
activ
convers
hypodiploid
dna
modifi
cell
cycl
analysi
realtim
imped
analysi
yield
similar
result
permeabl
data
demonstr
imped
declin
upon
infect
fnbpexpress
strain
discuss
data
show
fnbp
requir
increas
permeabl
endotheli
cell
layer
src
famili
kinas
crucial
compon
integrin
signal
pathway
partial
protect
genistein
suggest
src
famili
kinas
mediat
increas
permeabl
endotheli
cell
supposedli
affect
tight
junction
protein
effect
might
mediat
phosphoryl
either
tight
junction
regulatori
protein
studi
includ
scan
electron
microscopi
determin
chang
cell
morpholog
immunodetect
local
tight
junction
protein
sirna
transfect
knock
src
famili
kinas
streptococcu
pneumonia
cell
surfac
protein
play
central
role
infect
process
consid
import
virul
factor
pathogen
thought
implic
colon
bacteri
adhes
invas
host
cell
immun
evas
mechan
well
differ
cluster
protein
lpxtg
cell
wallanchor
protein
cholinebind
protein
lipoprotein
decor
pneumococc
cell
surfac
among
lipoprotein
repres
largest
group
anchor
membran
via
lipid
moieti
coval
attach
diacylglyceryl
transferas
lgt
signal
peptid
cut
lipoproteinspecif
signal
peptidas
lsp
global
analysi
pneumococc
surfaceassoci
extracellular
protein
perform
use
combin
biotinyl
gelcmsm
studi
fate
lipoprotein
pneumococci
surfaceand
exoproteom
nonencapsul
cp
compar
protein
profil
isogen
lgt
lsp
lgt
lsp
mutant
defici
lipoprotein
matur
base
genom
data
lipoprotein
lpxtganchor
protein
cholinebind
protein
predict
strain
respect
identifi
abund
lipoprotein
found
surfaceassoci
significantli
decreas
lgt
mutant
accordingli
abund
exoproteom
consider
increas
contrast
amount
surfaceexpos
lipoprotein
lsp
mutant
unaffect
major
identifi
lipoprotein
lipoprotein
less
abund
howev
correspond
exoproteom
lsp
mutant
show
signific
chang
doubl
knockout
lgt
lsp
show
major
lipoprotein
similar
amount
surfac
minor
less
abund
remark
amount
lipoprotein
exoproteom
significantli
increas
cp
lgt
lsp
streptococcu
agalactia
colon
urogenit
tract
healthi
women
deliveri
transmit
mother
newborn
caus
sepsi
pneumonia
mening
adhes
extracellular
matrix
protein
import
pathogen
mechan
gram
posit
bacteria
laminin
receptor
brain
endotheli
cell
recent
shown
crucial
initi
contact
mening
pathogen
blood
brain
barrier
agalactia
surfac
protein
lmb
mediat
attach
human
placent
laminin
locat
pathogen
islet
absent
mani
bovin
agalactia
isol
crystal
structur
lmb
recent
solv
show
belong
cluster
famili
abc
atp
bind
cassett
transport
system
structur
organ
lmb
close
resembl
abc
type
solut
bind
protein
sbp
two
structur
relat
globular
domain
interact
form
metal
bind
caviti
interfac
bound
zinc
lmb
tetrahedr
coordin
residu
domain
highli
disord
loop
span
residu
observ
shown
play
role
metal
uptak
releas
protein
homolog
structur
analyz
role
individu
amino
acid
residu
bind
properti
lmb
immobil
laminin
target
mutat
zn
bind
motif
introduc
lmb
vector
construct
allow
express
lmb
histidin
fusion
protein
bind
recombin
lmb
laminin
investig
elisa
plate
coat
human
placent
laminin
analysi
mutat
wild
type
version
lmb
show
delet
metal
bind
loop
mutat
led
sever
reduct
bind
laminin
ubiquit
serotyp
group
b
streptococcu
gb
detail
knowledg
amino
acid
residu
critic
laminin
bind
may
allow
futur
develop
target
antimicrobi
strategi
interf
adhes
properti
agalactia
introduct
immun
effector
molecul
interferon
ifn
arrest
intracellular
growth
chlamydia
pneumonia
cpn
induc
persist
infect
impli
induct
jakstat
signal
pathway
tryptophan
catabolis
enzym
indoleamin
ido
persist
infect
suggest
promot
diseas
progress
chronic
obstruct
pulmonari
diseas
copd
epitheli
mesenchym
cell
transit
emt
known
key
factor
diseas
character
region
declin
avail
oxygen
content
foster
underli
inflammatori
process
chlamydia
well
adapt
low
oxygen
environ
therefor
analyz
effect
acut
persist
cpn
infect
emt
differ
environment
oxygen
concentr
method
cell
seed
plate
treat
ifnto
induc
chlamydi
persist
incub
normox
hypox
condit
cell
infect
cpn
recoveri
assay
perform
pi
calcul
use
immunofluoresc
microscopi
ido
express
analyz
western
blot
smooth
muscl
actin
sma
express
level
analyz
immunofluoresc
microscopi
statist
analysi
perform
one
tail
unpair
student
ttest
result
ifntreat
effect
limit
growth
cpn
low
oxygen
concentr
compar
normox
condit
accompani
diminish
phosphoryl
subsequ
reduc
express
ido
hypox
condit
interestingli
cpn
could
rescu
ifninduc
persist
hypox
condit
express
epitheli
marker
protein
ecadherin
significantli
downregul
acut
persist
infect
cell
p
wherea
mesenchym
marker
protein
sma
upregul
normox
hypox
condit
effect
pronounc
cell
cultur
hypox
condit
conclus
ifnmedi
immun
control
cpn
depend
environment
oxygen
avail
thu
cpn
escap
host
immun
control
hypox
atmospher
acut
persist
cpn
induc
emt
lung
cell
even
pronounc
oxygen
scarc
carbon
catabolit
repress
ccr
bacteria
widespread
global
regulatori
phenomenon
allow
modul
express
gene
operon
involv
carbon
util
metabol
presenc
prefer
carbon
sourc
lowgc
gramposit
bacteria
ccr
mediat
mainli
catabolit
control
protein
ccpa
member
galrlaci
repressor
famili
staphylococcu
aureu
ccpa
shown
modul
express
metabol
gene
virul
determin
respons
glucos
second
regul
link
carbon
metabol
virul
factor
product
organ
codi
sensor
carbon
nitrogen
avail
respond
intracellular
concentr
branchedchain
amino
acid
bcaa
gtp
recent
report
aureu
produc
third
regulatori
molecul
member
lysr
famili
transcript
regul
homolog
ccpc
b
subtili
affect
express
tca
cycl
gene
show
regulatori
molecul
also
link
carbon
metabol
virul
aureu
alter
express
import
virul
factor
affect
pathogen
organ
found
inactiv
significantli
decreas
transcript
cap
operon
reduc
capsul
format
mutant
howev
transcript
hla
encod
ahemolysin
rnaiii
effector
molecul
agr
locu
significantli
increas
mutat
suggest
act
repressor
hla
rnaiii
activ
cap
transcript
murin
footpad
infect
model
delet
mutant
caus
increas
footpad
swell
compar
wildtyp
complement
deriv
indic
higher
infect
mutant
system
anim
model
belong
group
close
relat
protein
oper
molecular
chaperon
chaperon
regard
import
element
bacteria
respond
variou
stress
condit
refold
degrad
misfold
protein
major
human
pathogen
staphylococcu
aureu
express
number
name
clpb
clpc
clpl
clpx
clpi
aureu
clpb
clpc
regul
repressor
ctsr
clpc
probabl
support
activ
conform
repressor
condit
stress
clpc
shift
ctsr
damag
protein
consequ
ctsr
loos
activ
conform
result
transcript
induct
ctsr
repress
gene
clpb
clpc
ctsr
clpb
lesser
extent
clpc
shown
promot
intracellular
multipl
aureu
epitheli
cell
addit
clpc
found
stimul
express
citb
encod
tricarboxyl
acid
tca
cycl
enzym
aconitas
support
metabol
acet
therebi
affect
poststationaryphas
recoveri
inactiv
clpc
hand
led
enhanc
stationaryphas
surviv
base
find
wonder
impact
clpb
clpc
intracellular
persist
aureu
within
human
cell
vitro
viabil
studi
confirm
previou
find
show
aureu
clpc
clpbc
mutant
cultur
possess
increas
stationari
phase
surviv
compar
wildtyp
clpb
mutant
cultur
line
detect
enhanc
surviv
clpc
clpbc
doubl
mutant
keratinocyt
hour
internalis
case
clpb
mutant
show
persist
rate
compar
wildtyp
term
invas
howev
clpb
clpbc
mutant
possess
significantli
decreas
intern
capac
probabl
due
lower
product
fibronectin
bind
protein
b
find
suggest
clpb
contribut
invas
pathogen
influenc
persist
capac
organ
function
clpc
seem
decreas
intracellular
surviv
capac
aureu
affect
invas
organ
irrespect
impact
clpb
express
aggregatibact
actinomycetemcomitan
gramneg
commens
bacterium
oral
caviti
associ
pathogenesi
aggress
periodont
howev
genet
mechan
underli
host
suscept
periodont
infect
periodont
progress
still
illdefin
studi
aim
identifi
genet
host
factor
confer
resist
actinomycetemcomitansinduc
periodont
murin
model
nadph
oxidasedefici
mice
ko
induc
nitric
oxid
synthasedefici
mice
ino
ko
wildtyp
mice
oral
inocul
actinomycetemcomitan
analys
bacteri
colon
differ
mous
strain
variou
time
point
infect
actinomycetemcomitan
cultur
oral
swab
perform
furthermor
linear
measur
threedimension
microcomput
tomographi
use
quantifi
degre
alveolar
bone
destruct
well
alveolar
bone
miner
densiti
persist
actinomycetemcomitan
murin
oral
caviti
vari
among
three
mice
strain
show
highest
rate
infect
ko
mice
accord
actinomycetemcomitan
persist
ko
mice
develop
sever
periodont
compar
ino
ko
wildtyp
mice
uninfect
control
character
signific
higher
alveolar
bone
loss
inflammatori
reaction
addit
significantli
lower
alveolar
bone
miner
densiti
observ
three
group
mice
infect
actinomycetemcomitan
compar
uninfect
control
result
indic
nadph
oxidas
import
resist
murin
oral
caviti
actinomycetemcomitan
colon
clearli
associ
alveolar
bone
destruct
influx
inflammatori
cell
nadph
oxidasedefici
mice
model
give
insight
molecular
genet
mechan
actinomycetemcomitan
induc
periodont
develop
n
ackermann
untiet
g
and
j
heesemann
max
von
pettenkof
institut
bakteriologi
deutschland
yersinia
enterocolitica
pseudotuberculosi
enteropathogen
bacteria
caus
diseas
rang
selflimit
diarrhoea
sepsi
mous
model
yersinia
pass
gut
via
cell
invad
patch
subsequ
septic
dissemin
trimer
autotransport
yersinia
adhesin
yada
essenti
mous
virul
mv
factor
enterocolitica
pseudotuberculosi
form
lollipoplik
structur
head
connector
stalk
membran
anchor
yada
differ
yersinia
speci
show
differ
head
stalk
region
compar
role
differ
regard
autoagglutin
extracellular
matrix
cell
adher
serum
resist
mv
differ
yada
variant
introduc
enterocolitica
strain
result
show
even
though
vitro
differ
collagen
fibronectin
autoagglutin
exist
variant
differ
capabl
induc
mous
virul
data
show
test
enterocolitica
pseudotuberculosi
yada
variant
capabl
mediat
compar
mv
enterocolitica
mycobacterium
tuberculosi
eat
get
l
denkel
hampel
r
c
bolten
c
wittmann
fc
bang
medizinisch
hochschul
hannov
institut
medizinisch
mikrobiologi
und
krankenhaushygien
hannov
deutschland
technisch
braunschweig
institut
bioverfahrenstechnik
braunschweig
deutschland
introduct
new
technolog
fluxom
analysi
metabolom
transcriptom
allow
insight
metabol
bacteria
techniqu
often
requir
medium
defin
singl
carbon
sourc
media
howev
use
cultur
mycobacterium
tuberculosi
quit
complex
contain
sever
carbon
nitrogen
sourc
show
tuberculosi
grow
minim
medium
glucos
carbon
sourc
also
metabol
supplement
ingredi
like
fatti
acid
contamin
albumin
surprisingli
also
deterg
tween
method
studi
tuberculosi
cultiv
defin
minim
medium
c
label
glucos
sole
carbon
sourc
supplement
albumin
deterg
tween
tyloxapol
respect
method
use
involv
isotop
tracer
studi
gcm
ga
chromatographi
mass
spectrometri
measur
label
pattern
metabolit
result
use
minim
medium
fulli
clabel
glucos
expect
measur
non
label
amino
acid
gcm
howev
turn
metabolit
label
thu
lead
us
two
suggest
either
tuberculosi
use
anoth
carbon
sourc
besid
label
glucos
wash
step
insuffici
improv
wash
step
chang
fraction
non
label
amino
acid
howev
substitut
albumin
contamin
fatti
acid
highli
purifi
albumin
contamin
fatti
acid
could
decreas
fraction
non
label
amino
acid
less
replac
tween
tyloxapol
could
diminish
non
label
amino
acid
improv
protocol
prepar
tuberculosi
cell
extract
use
cellulos
nitrat
filter
instead
harvest
cell
centrifug
could
diminish
part
non
label
amino
acid
almost
conclus
summari
studi
show
tuberculosi
use
minim
medium
supplement
tween
fatti
acid
adher
albumin
metabol
thu
new
challeng
approach
like
fluxom
analysi
requir
defin
medium
care
select
ingredi
well
establish
protocol
harvest
cell
will
rg
gerlach
junior
research
group
wernigerod
deutschland
introduct
proteinprotein
interact
import
regulatori
layer
kingdom
life
involv
vast
set
cellular
process
includ
virulenceassoci
pathway
identif
character
interact
one
challeng
task
postgenom
era
crucial
understand
molecular
base
virul
sever
method
success
employ
past
decad
identifi
proteinprotein
interact
bacteria
method
often
includ
tediou
timeconsum
manipul
dna
gateway
system
fast
conveni
tool
effici
transfer
dnafrag
plasmid
use
set
proprietari
recombin
sequenc
deriv
bacteriophag
lambda
sitespecif
recombin
system
use
combin
differ
attsit
multisit
gateway
allow
site
direct
clone
four
fragment
one
construct
method
develop
new
set
gateway
vector
facilit
investig
proteinprotein
interact
bacteria
set
includ
custom
made
entri
vector
clone
gene
interest
front
optim
rb
modular
destin
vector
test
approach
design
destin
vector
includ
two
recombin
loci
frame
fragment
split
gaussia
luciferas
gluc
control
tetracyclineinduc
promot
result
salmonella
pathogen
island
encod
type
three
secret
system
ttss
togeth
effector
cognat
secret
chaperon
chaperon
invb
bind
effector
sipa
via
ntermin
chaperon
bind
domain
cbd
compris
first
amino
acid
proof
principl
want
character
interact
effector
sipa
chaperon
invb
use
split
gluc
approach
singl
gateway
recombin
reaction
result
simultan
integr
gene
custom
destin
vector
final
express
vector
cand
ntermin
portion
gluc
fuse
ctermini
invb
sipa
respect
transfer
construct
salmonella
enterica
sv
typhimurium
typhimurium
luminesc
measur
reveal
signific
higher
signal
full
length
sipa
compar
truncat
version
lack
cbd
discuss
conclus
system
provid
valuabl
tool
investig
proteinprotein
interact
bacteria
approach
simplifi
clone
step
modular
natur
enabl
fast
adapt
kind
fusion
protein
streptococcu
agalactia
group
b
streptococci
gb
import
caus
human
invas
infect
newborn
pregnant
women
immunocompromis
adult
patient
agalactia
surfac
associ
toxin
regard
major
virul
factor
regul
cov
twocompon
regulatori
system
control
numer
virul
factor
gb
mutat
cov
gene
associ
increas
hemolyt
activ
impair
intracellular
surviv
gb
granulocyt
determin
role
intracellular
surviv
rule
effect
virul
factor
control
cov
investig
hemolyt
nonhemolyt
gb
mutant
intracellular
surviv
primari
human
granulocyt
monocyt
cell
examin
role
interact
monocyt
granulocyt
cell
use
serotyp
ia
agalactia
wild
type
strain
isogen
nonhemolyt
delet
mutant
strain
strain
fluoresc
label
egfp
express
plasmid
follow
infect
eukaryot
cell
gb
multipl
infect
moi
rang
intracellular
bacteria
evalu
fac
analysi
cultur
intracellular
bacteria
interestingli
nonhemolyt
mutant
abl
surviv
intracellular
environ
significantli
higher
number
hemolyt
strain
find
observ
primari
granulocyt
well
cell
exclud
possibl
observ
differ
surviv
due
host
cell
death
induc
hemolyt
nonhemolyt
strain
lactat
dehydrogenas
ldh
assay
carri
confirm
better
surviv
capac
nonhemolyt
strain
gb
previous
describ
potent
induc
macrophag
assess
induct
follow
infect
gb
elisa
determin
perform
consider
releas
could
observ
howev
could
find
signific
differ
abil
hemolyt
nonhemolyt
strain
induc
chemokin
determin
bacteri
mediat
releas
set
cell
wall
prepar
strain
incub
cell
prepar
found
exert
potent
proinflammatori
stimulu
cell
conclus
result
indic
agalactia
strong
influenc
intracellular
surviv
gb
tightli
control
regul
express
requir
success
establish
gb
differ
host
nich
conclus
abil
express
znud
upon
zinc
starvat
well
conserv
among
meningococci
argu
essenti
role
meningococc
znud
intrigu
inactiv
znud
mutat
event
seem
restrict
two
clonal
lineag
cc
mutat
insert
slip
strand
mispair
ex
vivo
event
induc
cultur
must
therefor
consid
work
firstli
describ
act
nutrit
substrat
replac
tryptophan
vitro
cultur
initi
experi
show
allow
growth
tryptophanauxotroph
bacteria
parasit
staphylococcu
aureu
toxoplasma
gondii
complet
absenc
tryptophan
line
describ
contrast
counteract
idodepend
inhibit
human
tcell
prolifer
detail
analysi
show
contrast
incorpor
human
tcell
protein
tryptophan
lack
cultur
medium
summari
data
indic
inhibit
idomedi
antiprolif
activ
via
two
independ
effect
one
hand
act
competit
enzym
inhibitor
therefor
reduc
tryptophan
degrad
ido
hand
replac
tryptophan
protein
biosynthesi
therefor
allow
bacteri
parasit
cellular
growth
mass
spectroscopi
analysi
necessari
analys
whether
incorpor
protein
either
directli
demethyl
process
hypothet
type
vi
secret
protein
involv
virul
burkholderia
pseudomallei
background
communityassoci
methicillinresist
staphylococcu
aureu
camrsa
strain
especi
pantonvalentineleukocidin
pvl
produc
strain
associ
sever
necrot
infect
necrot
pneumonia
high
mortal
rate
epidemiolog
studi
reveal
necrot
pneumonia
often
preced
influenzalik
symptom
influenza
infect
nevertheless
combin
action
influenza
viru
poreform
aureu
toxin
pvl
hardli
investig
method
studi
examin
effect
pvl
differ
cell
type
granulocyt
epitheli
cell
line
without
anteced
infect
cell
influenza
viru
puerto
proinflammatori
activ
cell
measur
chemokin
express
via
rtpcr
express
cell
death
induct
determin
flow
cytometri
integr
cell
monolay
evalu
light
microscopi
result
found
pvl
induc
cell
activ
rapid
cell
death
granulocyt
affect
cell
viabil
nonprofession
phagocyt
epitheli
cell
influenza
viru
infect
alon
enhanc
granulocyt
cell
death
induct
previou
infect
significantli
enhanc
proinflammatori
cytotox
effect
pvl
human
granulocyt
contrast
cell
viabil
epitheli
cell
affect
singl
combin
stimul
pvl
andor
influenza
viru
highli
activ
impact
chemokin
express
rant
cell
howev
treat
epitheli
cell
monolay
supernat
human
granulocyt
lyse
pvl
found
dosedepend
destruct
epitheli
cell
monolay
mainli
caus
detach
epitheli
cell
fetal
bovin
serum
human
serum
proteas
inhibitor
cocktail
interf
destruct
impact
granulocyt
supernat
preserv
integr
monolay
conclus
find
show
pvl
lyse
effect
granulocyt
influenza
viru
activ
impact
epitheli
cell
could
result
massiv
recruit
granulocyt
subsequ
lyse
pvl
pvl
influenza
viru
togeth
show
even
enhanc
impact
neutrophil
substanc
releas
lyse
neutrophil
eg
granul
protein
defensin
abl
turn
destruct
epitheli
cell
monolay
result
cell
cultur
model
suggest
pvl
influenza
viru
act
togeth
possibl
agent
caus
necrot
pneumonia
j
popp
dandekar
w
eisenreich
mikrobiologi
deutschland
bioinformatik
deutschland
technisch
biochemi
deutschland
intracellular
lifestyl
salmonella
enterica
reli
adapt
nutrit
condit
within
salmonellacontain
vacuol
scv
host
cell
base
previou
result
metabol
requir
salmonella
scv
shall
character
includ
predict
intracellular
phenotyp
mutant
strain
base
metabol
model
experiment
test
ii
isotopologu
profil
use
compound
intracellular
salmonella
iii
complement
metabol
defect
attenu
mutant
strain
collabor
work
dandekar
hensel
group
lead
comprehens
understand
metabol
requir
intracellular
lifestyl
salmonella
analys
intracellular
phenotyp
base
improv
metabol
predict
vice
versa
base
analys
mutant
phenotyp
isotopologu
analys
iter
refin
metabol
flux
achiev
vision
comprehens
understand
adapt
salmonella
lifestyl
membranebound
compart
mammalian
cell
toward
integr
model
profit
comparison
salmonella
lifestyl
pathogen
metabol
requir
infect
cytoplasm
lifestyl
found
listeria
within
membran
compart
legionella
kort
l
marlinghau
neumann
f
szabado
n
pfennigwerth
gatermann
bochum
abteilung
medizinisch
mikrobiologi
bochum
deutschland
saprophyticu
speci
staphylococci
typic
uropathogen
genom
one
sequenc
staphylococci
possess
dserin
deaminas
enzym
convert
dserin
pyruv
ammonia
interestingli
also
present
uropathogen
bacteria
like
e
coli
upec
amino
acid
dserin
present
rel
high
concentr
human
urin
toxic
bacteriostat
sever
nonuropathogen
bacteria
therefor
uncommon
abil
degrad
dserin
may
play
import
role
virul
uropathogen
addit
presenc
dserin
may
use
cue
uropathogen
presenc
urinari
tract
analyz
metabol
understand
signific
dserin
catabol
saprophyticu
virul
conduct
end
saprophyticu
grown
either
glucos
dserin
sole
carbon
energi
sourc
chemic
defin
medium
develop
previous
protein
extract
saprophyticu
adapt
glucos
dserin
appli
protein
pattern
analyz
protein
reproduc
upregul
excis
follow
identif
via
malditof
protein
upregul
dserin
condit
affect
carbohydr
metabol
amino
acid
metabol
energi
metabol
also
found
accessori
protein
ureas
virul
factor
upregul
result
lead
us
hypothesi
dserin
inde
use
cue
presenc
within
urinari
tract
regul
pathway
import
viabil
environ
staphylococcu
saprophyticu
gramposit
coagulaseneg
pathogen
staphylococcu
caus
urinari
tract
infect
young
women
hydrophob
abl
bind
fibronectin
laminin
collagen
hemagglutin
sheep
erythrocyt
surfac
protein
characteris
earli
past
serineaspart
repeat
protein
sdri
contain
longest
sd
repeat
region
describ
far
aa
lpxtgmotif
cell
wall
anchor
member
mscramm
protein
famili
show
typic
abb
domain
structur
within
domain
specif
amino
acid
sequenc
tytftnyvd
found
motif
variant
also
found
mani
fibronectin
collagen
bind
protein
staphylococci
even
anoth
surfac
protein
saprophyticu
uafa
previou
experi
indic
sdri
mutant
show
decreas
fibronectin
bind
vivo
follow
hint
isol
sdri
domain
test
fibronectin
bind
vitro
use
fibronectin
coat
microtit
plate
test
show
fibronectin
bind
mediat
domain
localis
area
bind
within
domain
divid
three
part
clone
vector
overexpress
purif
use
ntermin
histag
bind
assay
carri
whole
domain
posit
control
coat
microtit
plate
bound
protein
detect
elisa
expect
result
show
high
bind
activ
slightli
reduc
bind
compar
alon
show
bind
subject
xray
structur
analysi
data
analysi
still
ongo
suprisingli
uafa
knock
mutant
also
associ
decreas
fibronectin
bind
protein
also
separ
domain
use
bind
test
mention
expect
gain
new
insight
domain
conform
sdri
role
uafa
implic
uroadher
staphylococcu
saprophyticu
staphylococcu
aureu
caus
wide
spectrum
sever
communityacquir
nosocomi
infect
recent
acknowledg
intracellular
pathogen
intern
persist
nonprofession
phagocyt
cell
vitro
intern
process
aureu
adapt
new
intracellular
environ
surviv
even
persist
within
host
recent
abl
analyz
adapt
process
intern
aureu
use
infect
assay
combin
pulsechas
label
approach
silac
high
capac
cell
sort
gelfre
proteom
aim
studi
compar
investig
adapt
respons
aureu
wild
type
isogen
agr
mutant
cell
upon
cointern
human
bronchial
epitheli
cell
accessori
gene
regul
agr
one
major
global
regul
aureu
virul
posit
influenc
synthesi
ofhemolysin
proteas
contrast
adhes
neg
influenc
agr
strike
evid
regulatori
system
play
import
role
establish
infect
instanc
express
agr
initi
increas
acut
phase
infect
nonprofession
phagocyt
cell
furthermor
agr
mutant
attenu
varieti
anim
model
also
shown
escap
endosom
requir
agrdepend
factor
strike
advantag
coinfect
assay
would
strain
intern
simultan
adapt
host
exactli
condit
allow
us
studi
competit
intracellular
behavior
two
strain
proteom
level
timeresolv
fashion
c
trachomati
frequent
transmit
sexual
diseas
women
may
result
sever
clinic
sequela
like
pelvic
inflammatori
diseas
pid
tubal
occlus
infertil
suggest
acut
infect
effici
clear
immun
system
intracellular
persist
chlamydia
eventu
occur
lead
chronic
inflammatori
process
within
infect
tissu
could
recent
show
ifninduc
persist
c
trachomati
human
fallopian
tube
cell
overcom
decreas
environment
oxygen
concentr
hypox
condit
chlamydia
start
replic
redifferenti
infecti
elementari
bodi
aim
studi
character
hypoxia
induc
reactiv
intracellular
chlamydi
growth
respect
proinflammatori
immun
respons
mapkinas
signal
materi
method
persist
induc
treat
c
trachomati
serovar
infect
cell
ifnfor
normox
condit
persist
c
trachomati
subsequ
incub
normox
hypox
condit
phosphoryl
mapkinas
detect
western
blot
analysi
express
level
tnfmrna
measur
realtim
pcr
result
reactiv
persist
c
trachomati
induc
ifnwa
observ
hypox
normox
condit
preliminari
experi
suggest
mapkinas
activ
normox
hypox
condit
contrast
mrna
express
level
proinflammatori
chemotact
cytokin
tnfwere
enhanc
hypox
normox
condit
discuss
data
indic
first
time
persist
chlamydia
recov
hypox
environ
found
physiolog
condit
femal
urogenit
tract
intracellular
reactiv
formerli
persist
chlamydia
might
perpetu
inflammatori
process
result
chronic
sequelea
diseas
tissu
hopf
b
henrich
med
mikrobiologi
und
krankenhaushygien
mycoplasmen
arbeitsgrupp
deutschland
introduct
adher
host
tissu
one
first
step
bacteri
colon
progress
infect
extracellular
matrix
ecm
compon
becam
access
host
surfac
receptor
bacteri
adhes
bridg
invas
cytoadhes
mycoplasma
homini
facultativepathogen
human
urogenit
tract
depend
ectoatpas
activ
uniqu
mediat
oppa
substratebind
domain
oligopeptid
permeas
character
bind
oppa
host
cell
structur
oppa
mutant
gener
mutat
walker
b
motif
atpas
domain
region
conserv
oppa
protein
speci
attach
histidinetag
mutant
extracellular
matrix
ecm
compon
analyz
micropl
format
compar
adher
hela
cell
presenc
increas
amount
ecm
compon
competitor
result
wild
type
oppa
shown
bind
sulfat
compon
like
heparin
fucoidan
dextran
sulfat
well
plasminogen
plasmin
laminin
bind
observ
mucin
addit
plasminogen
adhes
oppa
hela
cell
reduc
presenc
fucoidan
dextran
sulfat
adhes
nearli
abolish
interestingli
mutat
walker
motif
well
delet
entir
atpas
domain
lead
twofold
enhanc
bind
sulfat
ecm
structur
like
heparin
dextran
sulfat
delet
ntermin
region
conserv
bacteri
oppa
protein
result
reduc
bind
oppa
mutant
dextran
sulfat
heparin
demonstr
region
involv
bind
sulfat
compon
abund
human
endometrium
find
ectoatpas
activ
oppa
essenti
cytoadhes
homini
wherea
region
involv
ecmbind
suggest
two
function
region
play
differ
role
pathophysiolog
process
hostpathogen
interact
r
prager
fruth
flieger
w
rabsch
fg
bakteriel
infektionen
wernigerod
deutschland
monophas
variant
salmonella
typhimurium
express
second
phase
flagellar
antigen
becom
one
predomin
agent
caus
foodborn
infect
human
germani
monophas
variant
repres
human
typhimurium
isol
sent
nation
refer
centr
involv
outbreak
spite
variat
phage
type
pfge
resist
pattern
within
emerg
monophas
strain
one
type
characteris
phage
type
pfge
pattern
tetradrugresist
toward
antibiot
includ
ampicillin
streptomycin
sulfamerazin
tetracyclin
clearli
domin
germani
meanwhil
kind
strain
increas
concern
variou
european
countri
genomebas
analys
display
kb
fragment
adjac
thrw
trna
locu
domin
strain
type
sequenc
detect
insert
reveal
open
read
frame
significantli
lower
gc
content
compar
close
relat
typhimurium
genom
vs
indic
acquisit
via
horizont
gene
transfer
transcript
shown
orf
nucleotid
level
homolog
sequenc
open
read
frame
found
e
coli
shigella
genom
protein
blast
analys
reveal
sever
phagerel
gene
indic
insert
might
phageorigin
orf
predict
code
effector
experi
suggest
product
secret
probabl
via
infect
experi
show
reduc
replic
capac
islanddelet
mutant
mous
macrophag
cell
line
raw
shown
island
abl
form
circular
intermedi
therefor
seem
mobilis
certain
condit
aim
studi
uncov
function
differ
gene
product
role
whole
island
term
bacteri
fit
pathogen
yersinia
two
pyruv
kinas
pk
isoenzym
pyka
pykf
exist
glycolyt
enzym
catalys
irrevers
convers
phosphoenolpyruv
pep
pyruv
coupl
synthesi
atp
requir
monoval
k
dival
mg
bacteri
pk
alloster
regul
via
fbp
atpamp
andor
monophosphoryl
sugar
recombinantli
produc
yenterocolitica
pyka
pykf
milligram
amount
characteris
structur
enzymat
properti
pyka
pykf
overproduc
e
coli
without
affin
tag
combin
anion
exchang
chromatographi
size
exclus
chromatographi
yield
highli
homogen
protein
compar
enzymat
activ
alloster
regul
studi
conform
state
isoenzym
absenc
presenc
alloster
effector
fbp
appli
small
angl
xray
scatter
sax
nativ
polyacrylamid
gel
electrophoresi
techniqu
next
spatial
tempor
distribut
two
isoenzym
variou
condit
shall
studi
expect
highpathogenicityassoci
determin
enterocolitica
subsp
enterocolitica
eg
highpathogen
island
hpi
type
type
secret
system
absent
genom
analys
howev
latter
acquir
put
virul
fit
associ
factor
may
substitut
classic
yersini
virul
trait
gene
cluster
encod
larg
kda
rtxalik
toxin
altern
chromosom
ysp
insecticid
toxin
pertactin
fimbria
put
hemolysin
invasin
sever
toxinantitoxin
system
larg
kbp
flagellar
cluster
similar
gene
cluster
evid
acqusit
filament
prophag
highli
homolog
e
coli
ypf
prophag
pesti
present
genom
howev
suffer
success
delet
strain
prophag
design
integr
trnaleu
genom
absent
demonstr
precis
excis
restor
attach
site
trnaasn
gene
occupi
hpi
unidentifi
kbp
genom
island
island
function
integras
leav
trnaasn
integr
site
conclus
enterocolitica
subsp
palearctica
open
genom
carri
trace
ancient
fresh
acquisit
acquir
put
virul
fitnessassoci
determin
may
play
import
role
host
pathoadapt
support
dissemin
group
pathogen
staphylococcu
aureu
adher
host
structur
critic
first
step
aureu
pathogenesi
mediat
multipl
adhesin
overlap
function
role
adhesin
particularli
mscram
microbi
surfac
compon
recogn
adhes
matrix
molecul
alreadi
well
establish
wherea
function
secret
rebind
seram
secret
expand
repertoir
adhes
molecul
emp
extracellular
matrix
bind
protein
less
clear
studi
focuss
bind
mechan
emp
elucid
rebind
bacteri
cell
wall
explor
bind
site
host
structur
emp
gene
devid
differ
subdomain
clone
overexpress
investig
emp
rebind
bacteri
surfac
adhes
assay
perform
ad
bacteri
suspens
aureu
strain
newman
cowan
microtit
plate
coat
emp
subdomain
cterminu
emp
protein
appear
respons
bind
aureu
regard
interact
emp
differ
extracellular
matrix
protein
vitronectin
fibronectin
fibrinogen
collagen
well
extracellular
suprastructur
human
skin
cartilag
found
emp
ntermin
part
import
mediat
aureu
adher
host
structur
could
also
confirm
emp
bind
assay
differ
eukaryot
cell
type
endotheli
epitheli
cell
altern
method
peptid
librari
compris
amino
acid
amino
acid
overlap
span
full
length
emp
use
identifi
cluster
amino
acid
show
bind
activ
ligand
howev
emp
bind
could
broken
short
amino
acid
sequenc
fact
bind
mediat
whole
fragment
structur
analysi
cd
hnmr
emp
reveal
protein
mainli
form
random
coil
line
calcul
valu
use
selfoptim
predict
method
sopma
hypothes
contact
bind
partner
essenti
protein
structur
taken
togeth
result
indic
ntermin
part
emp
mediat
bind
host
structur
wherea
ctermin
part
emp
respons
rebind
bacteri
cell
wall
kositska
g
valenza
abelehorn
h
hebestreit
k
ohlsen
institut
molekular
infektionsbiologi
deutschland
institut
hygien
und
mikrobiologi
deutschland
kinderklinik
deutschland
introduct
cystic
fibrosi
cf
one
common
lethal
autosom
recess
disord
white
individu
diseas
caus
mutat
gene
protein
cystic
fibrosi
transmembran
conduct
regul
cftr
common
death
cf
respiratori
failur
secondari
pulmonari
infect
pseudomona
aeruginosa
staphylococcu
aureu
often
coisol
cf
respiratori
cultur
patient
method
cf
patient
survey
colon
aureu
p
aeruginosa
last
year
sputum
cultur
collect
wherea
routin
clinic
visit
admiss
hospit
puls
field
gel
electrophoresi
pfge
multilocu
sequenc
type
mlst
use
determin
clonal
relationship
strain
microarray
experi
allow
comparison
express
profil
aureu
isol
result
discuss
studi
characteris
phenotyp
genotyp
featur
aureu
isol
term
antibiot
resist
biofilm
format
mutat
frequenc
pfge
reveal
patient
infect
variou
aureu
strain
includ
mrsa
strain
whole
period
ongo
studi
aim
identifi
gene
express
profil
aureu
strain
persist
period
sever
year
presenc
p
aeruginosa
isol
chikkab
hensel
universitaet
osnabrueck
mikrobiologi
osnabrueck
deutschland
salmonella
intracellular
pathogen
live
replic
membran
bound
compart
call
salmonella
contain
vacuol
scv
entri
pathogen
host
cell
facilit
salmonella
pathogen
island
encod
type
three
secret
system
success
intracellular
lifestyl
requir
hallmark
intracellular
salmonella
format
extend
tubular
network
scv
call
salmonellainduc
filament
sif
recent
studi
group
identifi
sif
highli
dynam
structur
extend
retract
branch
although
sif
identifi
long
back
role
intracellular
life
salmonella
molecular
mechan
underli
dynam
yet
known
howev
work
other
group
identifi
sif
lie
next
microtubul
track
often
associ
link
motor
protein
observ
hypothes
sif
move
along
microtubul
track
requir
activ
motor
protein
kinesin
dynein
identif
role
motor
protein
context
requir
inhibit
activ
either
sirnamedi
silenc
express
domin
neg
allel
howev
approach
render
cell
compromis
even
bacteri
infect
henc
present
investig
initi
attempt
made
microinject
specif
antibodi
motor
protein
specif
time
infect
character
role
motor
protein
intracellular
life
salmonella
dynam
sif
streptococcu
gallolyticu
subsp
gallolyticu
emerg
pathogen
infect
endocard
hins
vollmer
c
knabb
j
dreier
bad
oeynhausen
deutschland
background
infecti
endocard
ie
diseas
rise
incid
high
degre
mortal
morbid
rdna
pcr
analysi
explant
human
heart
valv
reveal
signific
relev
streptococcu
gallolyticu
subsp
gallolyticu
sgg
former
bovi
biotyp
caus
agent
furthermor
knowledg
virul
factor
contribut
pathogenesi
sgg
ie
still
limit
materi
method
elucid
potenti
virul
gene
bacterium
perform
ultrahighthroughput
dna
sequenc
use
sequenc
platform
select
strain
isol
herzund
diabeteszentrum
nordrheinwestfalen
endocarditisderiv
blood
cultur
woman
aortic
heart
valv
endocard
gendb
edgar
softwar
use
genom
analysi
comparison
detect
microbi
surfac
compon
recogn
matrix
molecul
mscramm
isol
differ
origin
clinic
isol
ie
patient
anim
isol
refer
strain
perform
pcr
analysi
nick
translat
dig
label
plasmid
dna
southern
blot
use
plasmid
screen
result
genom
sgg
strain
contain
bp
circular
dna
molecul
gccontent
bp
plasmid
design
bioinformat
analysi
predict
orf
presenc
trna
rrna
addit
orf
detect
plasmid
includ
tetracyclin
resist
gene
tell
tetm
screen
sgg
isol
reveal
one
plasmid
homolog
furthermor
adhes
protein
contain
cell
wallsort
motif
lpxtg
shown
play
function
role
pathogenesi
identifi
screen
sgg
strain
protein
reveal
heterogen
distribut
correl
bind
characterist
ecmmolecul
whole
genom
comparison
recent
sequenc
sgg
strain
reveal
signific
differ
includ
habit
hostpathogen
interact
characterist
order
detect
larger
amount
put
virul
affect
gene
differ
strain
design
dna
microarray
experi
conclus
analysi
whole
genom
sequenc
sgg
advanc
understand
genet
factor
concern
pathogenesi
adhes
ecm
pathogen
furthermor
show
first
time
occurr
resist
plasmid
characterist
vector
later
genet
transfer
align
microarray
data
alreadi
evalu
phenotyp
data
includ
ecmbind
adhes
invas
host
cell
biofilm
format
capabl
strain
substanti
underli
genom
base
pathomechan
e
becker
jh
hegemann
institut
funktionel
genomforschung
der
mikroorganismen
deutschland
chlamydia
oblig
intracellular
bacteria
respons
wide
rang
diseas
signific
import
clinic
public
health
c
trachomati
lead
caus
sexual
transmit
diseas
blind
trachoma
c
pneumonia
import
respiratori
pathogen
recogn
common
caus
commun
acquir
pneumonia
bioinformat
studi
led
identif
larg
famili
put
autotransport
polymorph
membran
protein
pmp
member
c
trachomati
c
pneumonia
divid
subtyp
previou
studi
character
cell
surfac
local
protein
bacteri
adhesin
mediat
attach
c
pneumonia
human
cell
furthermor
domain
mutat
analysi
identifi
two
pmpcharacterist
repetit
motif
gga
l
v
fxxn
essenti
adhes
process
character
subtyp
pmp
protein
famili
adhes
infect
process
select
repres
candid
pmp
subtyp
c
pneumonia
orthologu
c
trachomati
use
yeast
display
system
well
latex
bead
coat
recombin
protein
test
pmp
found
act
adhesin
pmp
adhesin
import
c
pneumonia
infect
process
preincub
human
cell
differ
recombin
protein
reduc
subsequ
infect
interestingli
use
far
western
experi
identifi
interact
pmp
test
possibl
suggest
homoandor
heteromer
pmp
adhes
complex
might
form
chlamydi
cell
surfac
moreov
examin
express
posttransl
process
protein
infect
cycl
c
pneumonia
process
uniform
pmpspecif
set
cleav
form
detect
agreement
previou
find
pmp
autotransport
protein
cell
fraction
experi
reveal
cleav
pmpfragment
partial
releas
chlamydi
surfac
may
exist
inclus
lumen
possibl
host
cytosol
perhap
serv
addit
function
effector
protein
interestingli
use
immunofluoresc
microscopi
detect
individu
pmp
protein
express
fraction
inclus
analyz
possibl
indic
form
antigen
variat
similar
recent
describ
pmp
protein
c
trachomati
work
support
dfg
project
manchot
graduat
school
molecul
infect
human
pathogen
chlamydia
pneumonia
nucleat
stabil
factin
via
secret
protein
support
host
cell
entri
r
zrieq
jh
hegemann
institut
funktionel
genomforschung
der
mikroorganismen
deutschland
chlamydia
gramneg
oblig
intracellular
bacteri
pathogen
human
anim
among
chlamydia
speci
c
pneumonia
common
respiratori
pathogen
like
pathogen
bacteria
believ
chlamydia
deliv
effector
protein
recruit
factin
site
entri
trigger
entri
host
cell
among
chlamydi
effector
protein
identifi
thu
far
c
trachomati
tarp
transloc
host
cell
coloc
factin
underneath
attach
bacteria
nucleat
actin
polymer
clifton
et
al
pna
jewett
et
al
pna
studi
character
c
pneumonia
homolog
protein
present
infecti
form
bacteria
minut
infect
secret
could
found
associ
host
factin
analyz
role
modul
actin
cytoskeleton
use
yeast
saccaromyc
cerevisia
model
system
yeast
cell
exhibit
strongli
reduc
growth
phenotyp
analysi
reveal
transform
yeast
actin
cytoskeleton
actin
clump
per
cell
fusion
protein
exclus
coloc
factin
clump
similar
observ
obtain
transfect
cell
actin
phenotyp
reminisc
actin
clump
form
yeast
human
cell
treat
jasplakinolid
drug
induc
actin
polymer
inhibit
actin
depolymer
inde
could
show
yeast
stabil
factin
actin
destabil
drug
latrunculin
impli
inhibit
actin
depolymer
furthermor
found
evid
vivo
compet
andor
displac
actin
depolymer
factor
cofilin
bind
factin
yeast
result
extend
vitro
experi
use
mammalian
factin
cofilin
protein
could
show
presenc
abrog
cofilin
bind
factin
line
data
actin
clump
transfect
cell
resist
actin
depolymer
drug
cytochalasin
suggest
inde
abl
inhibit
actin
depolymer
human
cell
addit
show
also
recombin
alon
induc
actin
nucleat
vitro
independ
cellular
protein
final
delet
analysi
identifi
central
domain
within
crucial
interact
factin
conserv
hydrophob
amino
acid
within
domain
identifi
essenti
interact
knowledg
first
bacteri
protein
exert
dual
function
inhibit
actin
depolymer
nucleat
factin
overal
goal
maxim
factin
accumul
site
bacteri
entri
work
support
project
sedlag
ulm
institut
mikrobiologi
und
biotechnologi
ulm
deutschland
listeria
monocytogen
caus
agent
listeriosi
common
highli
infecti
diseas
clinic
manifest
gastroenter
diarrhoea
mening
immun
compromis
elderli
pregnant
peopl
frequent
result
fatal
outcom
first
step
infect
intracellular
pathogen
listeria
monocytogen
locat
phagosom
matur
fulli
acidifi
phagolysosom
l
monocytogen
abl
activ
lyse
membran
compart
escap
cytosol
replic
l
monocytogen
equip
peptid
sens
system
homolog
staphylococcu
aureu
agr
system
shown
involv
regul
biofilm
format
vitro
vivo
virul
global
gene
express
aureu
express
agr
system
consist
four
gene
encod
exportand
process
protein
agrb
put
autoinduc
peptid
agrd
respons
regul
agra
receptor
kinas
agrc
express
control
pii
promot
preliminari
experi
piiluxfus
show
lack
measur
luciferas
activ
delet
mutant
l
monocytogen
egd
lack
agrd
gene
encod
put
auto
induc
peptid
test
listeri
agra
act
transcript
factor
like
homolog
saureu
bind
pii
promot
fusion
express
ecoli
isol
purifi
recombin
protein
test
bind
capac
electrophoret
mobil
shift
assay
emsa
abl
shift
full
length
pii
promot
sequenc
strongli
suggest
agr
system
l
monocytogen
subject
autoregulatori
circuit
consensu
agrabind
motif
establish
silico
analysi
promot
sequenc
avail
peptid
sens
system
varieti
gramposit
bacteria
use
consensu
motif
number
put
bind
site
identifi
listeri
pii
promot
sequenc
put
bind
site
analys
emsa
use
differ
fragment
pii
promot
mutat
alter
bind
motif
interestingli
put
agrabind
motif
identifi
promot
prfa
major
virul
regul
l
monocytogen
could
explain
strong
regul
gene
agrddelet
mutant
observ
previous
inde
abl
shift
pcramplifi
prfa
promot
confirm
involv
agr
peptid
sens
virul
regul
l
monocytogen
first
indic
direct
regul
virul
gene
l
monocytogen
agr
system
novel
class
antibacteri
acyldepsipeptid
adep
exert
promin
antibacteri
activ
gramposit
bacteria
includ
multiresist
staphylococcu
aureu
vitro
vivo
adep
act
via
yet
unpreced
mechan
dysregul
caseinolyt
proteas
clpp
usual
activ
clpp
tightli
control
atpdepend
clpatpas
accessori
protein
adep
overcom
tight
control
mechan
switch
clpp
regul
uncontrol
proteas
predominantli
target
unfold
flexibl
protein
well
nascent
polypeptid
ribosom
absenc
clpatpas
although
activ
adep
explain
molecular
level
target
clpp
specif
event
final
lead
bacteri
cell
death
still
remain
unknown
studi
investig
effect
adep
treatment
differ
gramposit
speci
use
highresolut
microscopi
presenc
low
inhibitori
adep
concentr
coccoid
cell
aureu
streptococcu
pneumonia
swell
volum
wild
type
cell
rodshap
cell
b
subtili
grew
long
filament
reach
length
untreat
cell
clearli
indic
stall
bacteri
cell
divis
gain
insight
underli
molecular
mechan
follow
event
led
inhibit
cell
divis
cell
divis
gramposit
bacteria
concert
divisom
highli
dynam
character
timedepend
twostep
assembl
specif
cell
divis
protein
like
ftsz
ftsa
zapa
ezra
well
ftsw
diviva
etc
observ
adep
treatment
led
inhibit
septum
format
aureu
b
subtili
chromosom
segreg
rather
unaffect
local
studi
gfplabel
cell
divis
protein
reveal
adepclpp
complex
interfer
key
compon
earli
cell
divis
therefor
perturb
normal
divisom
format
analyz
cell
extract
adeptr
aureu
b
subtili
cell
immunoblot
reveal
adepclpp
proteolyt
complex
degrad
essenti
compon
cell
divis
machineri
henc
destin
bacteria
death
adep
demonstr
besid
interest
antibacteri
potenc
excel
tool
examin
central
mechan
bacteri
physiolog
like
cell
divis
regul
proteolysi
berscheid
p
sass
jansen
oedenkoven
c
szekat
strittmatt
g
gottschalk
g
bierbaum
infect
caus
methicillinresist
staphylococcu
aureu
mrsa
commonli
treat
glycopeptid
vancomycin
howev
mrsa
strain
reduc
suscept
vancomycin
emerg
last
decad
due
increas
antibiot
treatment
failur
obviou
need
understand
bacteria
develop
resist
approach
studi
impact
elev
mutat
frequenc
vancomycin
resist
develop
previous
isol
highli
vancomycin
resist
aureu
strain
mic
serial
passag
strain
mut
mic
mut
gene
delet
mutant
laboratori
strain
presenc
increas
concentr
vancomycin
current
studi
antimicrobi
suscept
test
strain
addit
reveal
cross
resist
lipopeptid
antibiot
daptomycin
recent
introduc
treatment
complic
skin
skin
structur
infect
csssi
caus
mrsa
gain
insight
resist
phenotyp
aureu
full
genom
sequenc
strain
parent
strain
aureu
mut
determin
use
sequenc
technolog
strain
total
mutat
gene
relat
cell
wall
metabol
transport
gene
regul
includ
twocompon
regulatori
system
vrasr
walkr
detect
sinc
latter
regulatori
protein
significantli
affect
biosynthesi
turnov
rate
bacteri
cell
wall
perform
morpholog
studi
use
transmiss
electron
microscopi
strain
character
abnorm
cell
envelop
morpholog
includ
increas
cell
wall
thick
may
result
deregul
vrar
walkr
system
cell
wall
thicken
previous
link
vancomycin
resist
even
correl
daptomycin
cross
resist
howev
find
alon
explain
highlevel
resist
phenotyp
strain
character
strain
necessari
provid
import
inform
accumul
mutat
result
autonom
develop
vancomycin
daptomycin
highlevel
resist
aureu
schielk
g
freiburg
institut
medizinisch
mikrobiologi
und
hygien
freiburg
deutschland
chlamydia
trachomati
special
surviv
growth
within
human
epitheli
host
cell
vivo
bacteria
like
face
advers
replic
condit
particular
immun
respons
activ
cytokin
secret
condit
mimick
number
way
instanc
addit
lactam
antibiot
cultur
vitro
condit
chlamydia
enter
socal
persist
state
persist
phenotyp
character
enlarg
aberr
reticul
bodi
rb
replic
form
chlamydia
neither
abl
divid
redifferenti
infecti
elementari
bodi
eb
reactiv
upon
withdraw
persistenceinduc
reagent
persist
infect
thought
relev
outcom
chlamydi
diseas
especi
chronic
infect
investig
develop
chlamydi
inclus
persist
state
infect
human
cervic
epitheli
cell
hela
mous
oviduct
epitheli
cell
mous
embryon
fibroblast
mef
c
trachomati
presenc
penicillin
g
result
develop
aberr
nonprolifer
rb
although
rb
per
inclus
vacuol
grew
substanti
size
propos
growth
inclus
product
infect
requir
secret
chlamydi
proteas
cpaf
persist
infect
express
activ
cpaf
also
detect
time
cours
hour
matur
c
trachomati
depend
host
cell
lipid
acquir
upon
cpafdepend
fragment
golgi
apparatu
penicillininduc
persist
golgi
fragment
likewis
occur
result
format
golgi
ministack
around
inclus
result
suggest
even
upon
entri
persist
state
treatment
penicillin
g
c
trachomati
maintain
machineri
lipid
acquisit
inclus
growth
like
maintain
product
secret
cpaf
understand
chlamydi
activ
may
help
understand
persist
infect
vivo
introduct
staphylococcu
aureu
small
coloni
variant
scv
frequent
isol
cystic
fibrosi
patient
defect
airway
clearanc
prolong
antibiot
treatment
predispos
scv
format
object
assess
relev
intrastrain
divers
hostpathogen
interact
present
studi
analyz
consecut
aureu
scv
isol
patient
method
result
pulsedfield
gel
electrophoresi
maldi
biotyp
demonstr
strain
related
scv
isol
nevertheless
scv
isol
could
distinguish
spatyp
eg
one
isol
display
truncat
spatyp
interestingli
western
blot
analysi
protein
express
reveal
truncat
spa
gene
associ
protein
decreas
size
two
scv
isol
could
distinguish
increas
protein
express
function
comparison
scv
isol
compar
activ
biofilm
format
result
obtain
indic
increas
spa
express
correl
increas
activ
biofilm
form
capac
enhanc
role
protein
subsequ
confirm
comparison
spadefici
aureu
mutant
dspa
isogen
wild
type
strain
wt
biofilm
assay
conclus
conclud
quantit
differ
protein
express
reflect
intrastrain
variabl
translat
function
differ
modul
hostpathogen
interact
howev
specul
concomit
chang
observ
microbi
environ
eg
infect
colon
microbi
speci
pulmonari
clinic
statu
patient
antibiot
regim
may
respons
function
genet
chang
scv
phenotyp
surfaceassoci
motil
long
describ
acinetobact
lack
flagella
mechan
motil
never
elucid
acinetobact
baumannii
often
multidrugresist
nosocomi
pathogen
may
profit
motil
infect
persist
hospit
environ
identifi
determin
acinetobact
motil
librari
transposon
mutant
strain
atcc
gener
screen
mutant
motil
defect
could
identifi
two
akinet
mutant
carri
transposon
insert
dat
ddc
gene
respect
neighbour
gene
encod
decarboxylas
respect
contribut
synthesi
dap
polyamin
ubiquit
produc
acinetobact
motil
defect
mutant
could
cure
supplement
semisolid
media
dap
make
use
natur
compet
clinic
acinetobact
isol
verifi
transform
mutant
dna
ddc
dat
requir
motil
differ
isol
collect
surfaceassoci
motil
acinetobact
baumannii
requir
dap
current
work
aim
elucid
dap
contribut
motil
weiss
j
soltwisch
j
brockmey
institut
lebensmittelchemi
forschung
deutschland
institut
medizinisch
physik
und
biophysik
deutschland
enterohemorrhag
escherichia
coli
ehec
natur
occur
intestin
tract
cattl
rumin
human
mainli
infect
via
contamin
anim
food
addit
infect
via
veget
possibl
shown
current
outbreak
germani
clinic
outcom
ehec
infect
rang
intestin
dysfunct
lifethreaten
hemolyticurem
syndrom
date
systemat
therapi
hamper
fact
detail
mechan
pathogen
still
fulli
understood
ehec
express
number
factor
might
contribut
virul
one
plasmidencod
extracellular
serin
proteas
espp
shown
espp
might
interact
hemostasi
immun
respons
systemat
screen
relev
substrat
still
lack
therefor
screen
novel
substrat
espp
use
human
plasma
platelet
plasma
first
deplet
albumin
igg
incub
purifi
recombin
espp
inact
mutant
fragment
plasma
protein
assess
sdspage
gel
electrophoresi
compar
nonincub
protein
analysi
espp
substrat
platelet
perform
platelet
lysat
obtain
whole
cell
extract
collagenactiv
platelet
analyz
secret
protein
follow
incub
espp
protein
pattern
investig
aforement
electrophoresi
techniqu
indentifi
novel
substrat
protein
spot
shift
gel
electrophoret
mobil
compar
neg
control
digest
ingel
subject
mass
spectrometr
analysi
use
malditofm
well
altogeth
shown
espp
cleav
sever
physiolog
relev
protein
plasma
well
platelet
includ
proteas
inhibitor
surfac
adhes
molecul
studi
elucid
contribut
newli
identifi
substrat
role
espp
possibl
virul
factor
ehec
hlya
e
coli
secret
unfold
state
requir
ctermin
locat
amino
acid
lytic
function
thoma
jumpertz
p
bakk
smit
l
schmitt
heinrich
hein
univers
institut
biochemi
duesseldorf
deutschland
escherichia
coli
haemolysin
hlya
rtx
toxin
secret
probabl
unfold
intermedi
type
abc
transporterdepend
pathway
util
ctermin
secret
signal
howev
mechan
transloc
posttransloc
fold
understood
identifi
mutat
extrem
c
terminu
domin
competit
experi
block
secret
wildtyp
toxin
coexpress
cell
suggest
unlik
recess
mutat
affect
recognit
transloc
machineri
mutat
interfer
later
step
secret
inde
mutat
reduc
haemolyt
activ
toxin
activ
betalactamas
latter
fuse
ctermin
kda
fragment
hlya
carri
mutat
second
mutant
lack
six
ctermin
residu
hlya
also
show
reduc
haemolyt
activ
neither
mutant
protein
regain
normal
haemolyt
activ
vitro
unfoldingrefold
experi
tryptophan
fluoresc
spectroscopi
indic
differ
structur
secret
form
wildtyp
hlya
hlya
mutant
result
suggest
mutat
affect
correct
fold
hlya
betalactamas
fusion
thu
propos
dual
function
hlya
c
terminu
involv
import
role
posttransloc
fold
well
target
hlya
secret
hli
transloc
complex
export
varieti
passeng
protein
fuse
ntermin
secret
sequenc
howev
fusion
secret
effici
demonstr
maltos
bind
protein
male
lack
natur
export
signal
fuse
hlya
secret
signal
poorli
secret
hli
system
anticip
fold
kinet
might
limit
introduc
fold
mutat
male
inde
fusion
protein
secret
much
higher
level
level
enhanc
introduct
second
male
fold
mutat
fold
analysi
reveal
mutat
reduc
refold
rate
substrat
wherea
unfold
rate
unaffect
thu
hlya
secret
unfold
state
fold
lytic
conform
upon
bind
calcium
ion
medium
h
funken
knapp
brocker
wilhelm
f
rosenau
ke
jaeger
univers
duesseldorf
imet
deutschland
forschungszentrum
deutschland
univers
ulm
biotechnolog
ulm
deutschland
one
essenti
element
live
organ
iron
iron
act
cofactor
rang
redox
enzym
involv
mani
central
cellular
process
like
electron
transport
dna
synthesi
also
essenti
amino
acid
pyrimidin
biosynthesi
one
characterist
featur
fluoresc
pseudomonad
abil
produc
yellowgreen
fluoresc
pigment
pyoverdin
major
siderophor
best
studi
pyoverdin
opportunist
human
pathogen
pseudomona
aeruginosa
requir
growth
play
major
role
virul
among
factor
pyoverdin
biosynthesi
p
aeruginosa
regul
iron
starvat
sigma
factor
pvd
appli
proteom
approach
use
dige
system
transcript
analysi
qpcr
studi
role
p
aeruginosa
lipas
lipa
pyoverdin
product
clearli
demonstr
lipas
regulatori
effect
pvd
transcript
lipa
neg
mutant
p
aeruginosa
lipa
show
signific
lower
pyoverdin
concentr
cultur
supernat
compar
wild
type
addit
secretom
p
aeruginosa
lipa
reveal
differ
pvd
regul
protein
includ
proteas
prpl
apra
protein
present
lipa
defici
strain
lipas
express
complement
tran
result
obtain
qpcr
reveal
significantli
decreas
level
pvd
mrna
p
aeruginosa
lipa
consequ
transcript
sever
pvd
regul
gene
also
downregul
result
indic
lipa
play
import
role
regul
iron
starvat
sigma
factor
pvd
p
aeruginosa
therebi
influenc
synthesi
pyoverdin
virul
factor
pelzer
serci
f
rosenau
ke
jaeger
wilhelm
heinrichheineunivers
duesseldorf
institut
molecular
enzym
technolog
juelich
deutschland
ulm
univers
institut
pharmaceut
biotechnolog
ulm
deutschland
pseudomona
aeruginosa
ubiquit
distribut
live
wet
humid
surround
rang
soil
human
bodi
produc
huge
varieti
extracellular
protein
import
part
arsen
bacteri
virul
factor
proteas
proteas
enzym
hydrolyz
peptid
bond
therefor
degrad
protein
peptid
protein
one
basic
build
block
natur
proteas
influenc
broad
rang
biolog
function
includ
infect
process
opportunist
human
pathogen
p
aeruginosa
arsen
effici
proteas
help
establish
maintain
infect
therebi
control
modifi
environ
accord
need
bacterium
within
host
tissu
proteas
like
elastas
proteas
iv
well
character
other
exist
noth
known
hoge
et
al
focus
serin
proteas
belong
peptidas
famili
subtilas
subtilas
encod
preproenzym
carri
signal
peptid
drive
transloc
cytoplasm
membran
propeptid
act
fold
mediat
requir
give
proteas
final
nativ
conform
homolog
identifi
open
read
frame
sprp
spr
genom
sequenc
p
aeruginosa
gene
sprp
encod
far
hypothet
protein
put
member
subtilisinlik
serin
proteas
famili
gene
product
sprp
contain
predict
signal
sequenc
peptidas
domain
sequenc
analysi
reveal
presenc
addit
element
domain
organ
proteas
sprp
carri
addit
signal
peptid
domain
domain
unknown
function
duf
element
proteas
activ
sprp
demonstr
character
differ
virul
associ
phenotyp
abl
illustr
emin
role
sprp
virul
p
aeruginosa
delet
sprp
result
loss
motil
increas
biofilm
format
accumul
cell
aggreg
growth
second
subtilas
spr
belong
autotransport
protein
famili
type
v
secret
case
spr
ntermin
passeng
domain
contain
proteas
function
similar
sprp
delet
strain
p
aeruginosa
dspr
show
loss
motil
increas
biofilm
format
addit
secretom
show
sprsneg
strain
produc
less
virul
associ
extracellular
proteas
compar
wild
type
initi
result
suggest
regulatori
relationship
two
proteas
final
result
indic
two
novel
proteas
sprp
spr
play
role
p
aeruginosa
virul
ironregul
gene
irga
homologu
adhesin
iha
encod
island
oi
genom
prototyp
enterohemorrhag
e
coli
ehec
strain
role
molecul
virul
ehec
incomplet
understood
uropathogen
e
coli
iha
function
siderophor
receptor
identifi
sever
ehec
strain
underw
spontan
intern
complet
delet
andor
lead
iha
loss
ihaneg
deriv
display
ironlimit
condit
promot
iha
transcript
significantli
lower
adher
human
intestin
epitheli
cell
ihaposit
parent
strain
moreov
iha
loss
reduc
abil
strain
grow
liquid
well
solid
media
iron
limit
isogen
iha
delet
mutant
parent
strain
display
adher
capac
growth
abil
compar
spontan
ihaneg
deriv
wherea
iha
complement
iha
delet
mutant
ihaneg
spontan
deriv
restor
adher
growth
speed
level
parent
strain
data
suggest
iha
play
dual
role
virul
andor
fit
ehec
adhesin
siderophor
receptor
epidermidi
accumul
associ
protein
aap
proteolyt
process
consequ
biofilm
format
kotasinska
busch
michel
n
schommer
c
burdelski
g
kroll
h
h
rohd
eppendorf
klinisch
chemi
hamburg
deutschland
implant
associ
staphylococcu
epidermidi
infect
essenti
depend
biofilm
format
epidermidi
biofilm
format
depend
polysaccharid
pia
accumul
associ
protein
aap
kda
aap
essenti
consist
ntermin
domain
aa
repetit
ctermin
domain
b
importantli
aap
mediat
biofilm
format
proteolyt
process
domain
remov
turn
repetit
b
domain
induc
cell
cluster
format
therefor
proteolyt
process
fundament
import
aap
function
howev
underli
mechan
proteas
involv
character
use
specif
epidermidi
mutant
recombin
aap
subdomain
ntermin
sequenc
character
dynam
aap
process
aap
cleav
least
three
posit
two
cleavag
site
identifi
within
domain
posit
aa
third
cleavag
site
locat
junction
domain
b
posit
aa
use
supernant
proteas
overexpress
epidermidi
mutant
mutant
process
aap
assign
metalloproteas
sepa
experi
use
proteas
inhibitor
suggest
aap
cleavag
could
also
occur
addit
proteas
result
indic
epidermidi
use
specif
proteas
control
coordin
process
function
activ
aap
given
import
aapmedi
epidermidi
biofilm
format
pathogenesi
foreignmateri
associ
infect
result
could
open
new
way
futur
develop
therapeut
approach
eg
interfer
proteas
depend
dynam
proaggreg
epidermidi
cell
surfac
properti
tryptophan
essenti
amino
acid
human
be
well
microorgan
therefor
reduct
local
tryptophan
concentr
tissu
influenc
growth
microorgan
invad
bodi
human
cell
ifninduc
enzym
indoleamin
ido
degrad
tryptophan
therefor
abl
mediat
antimicrobi
effect
could
shown
vitro
system
ido
activ
inhibit
growth
bacteria
parasit
virus
addit
observ
ido
immunoregulatori
function
control
activ
surviv
tcell
ido
dioxygenas
catalys
oxid
cleavag
tryptophan
howev
remain
unclear
oxygen
condit
ido
promot
antimicrobi
immunoregulatori
effect
therefor
enzymat
activ
ido
differ
tissu
variabl
oxygen
suppli
need
clarifi
recent
studi
could
show
activ
ido
inhibit
hypox
condit
vitro
comparison
normox
condit
ido
produc
reduc
amount
kynurenin
downstream
product
tryptophan
line
observ
antibacteri
effect
abrog
hypoxia
could
find
idomedi
inhibit
staphylococcu
aureu
well
group
b
streptococcu
growth
abrog
ifnstimul
human
glioblastoma
cell
helacel
respect
hypoxia
impair
ido
enzym
activ
also
result
reduc
ifnmedi
signal
via
jakstat
pathway
ifninduc
ido
enzym
activ
jakstat
signal
inhibit
oxygen
concentr
find
indic
influenc
oxygen
concentr
ido
function
could
import
defens
sever
pathogen
affect
organ
differ
oxygen
suppli
phospholipas
pla
repres
group
bacteri
virul
factor
abil
interact
host
membran
lipid
signal
pla
proven
virul
factor
total
number
known
pla
still
limit
detail
hostpathogen
interact
mechan
involv
pla
remain
elucid
opportunist
human
pathogen
pseudomona
aeruginosa
produc
varieti
virul
factor
howev
pla
describ
far
comprehens
silico
analys
p
aeruginosa
genom
reveal
number
gene
encod
put
lipolyt
enzym
describ
identif
character
plbf
novel
phospholipas
b
produc
p
aeruginosa
plbf
display
sequenc
homolog
prokaryot
eukaryot
pla
lipas
esteras
involv
lipid
metabol
lipid
signal
succeed
purifi
enzym
demonstr
esteras
phospholipas
b
activ
subcellular
localis
experi
reveal
associ
membran
fraction
p
aeruginosa
detail
localis
studi
suggest
plbf
like
anchor
bacteri
inner
membran
integr
membran
protein
experiment
data
agreement
silico
analys
predict
presenc
hydrophob
transmembran
helic
ntermin
sequenc
plbf
addit
recognis
within
plbf
amino
acid
sequenc
signatur
motif
present
integr
membran
protein
motif
requir
helixhelix
interact
inner
membran
protein
suggest
plbf
may
exist
dimer
assumpt
experiment
confirm
cross
link
experi
contribut
plbf
p
aeruginosa
virul
investig
melanogast
virul
modelbi
use
plbf
neg
p
aeruginosa
mutant
compar
wild
type
strain
p
aeruginosa
signific
attenu
plbf
neg
mutant
strain
kill
fli
observ
confirm
plbf
may
repres
novel
virul
factor
produc
p
aeruginosa
investig
cellular
function
plbf
particularli
relat
plbf
dimeris
virul
p
aeruginosa
might
elucid
novel
mechan
plabas
pathogen
mechan
bacteria
noncod
small
rna
ncrna
recognis
import
player
regulatori
network
control
gene
express
bacteria
recent
research
led
profound
insight
way
action
thu
transencod
ncrna
often
act
direct
base
pair
interact
targetmrna
cisencod
ncrna
directli
regul
transcript
within
encod
mani
cisencod
ncrna
locat
untransl
region
utr
gene
operon
control
downstream
gene
transcript
act
riboswitch
bind
variou
metabolit
describ
detect
characteris
novel
cisencod
ncrna
utr
preced
methionin
biosynthesi
gene
aureu
epidermidi
staphylococci
bioinformat
analys
staphylococc
met
leader
rna
reveal
homolog
predict
structur
element
associ
bacillu
tbox
system
repres
terminatorantitermin
transcript
control
element
gramposit
bacteria
undergo
conform
chang
upon
specif
bind
charg
uncharg
trna
staphylococc
met
leader
rna
conserv
sequenc
stretch
identifi
tbox
motif
transcript
termin
well
unexpectedli
codi
bind
site
vitro
bind
assay
met
leader
rna
trna
met
demonstr
specif
bind
interact
two
rna
speci
mutat
studi
tbox
motif
reveal
import
singl
nucleotid
trna
bind
transcript
level
met
leader
rna
downstream
methionin
biosynthesi
gene
shown
vari
differ
staphylococc
strain
gener
induc
methionin
starvat
pleiotrop
repressor
codi
seem
regul
overal
transcript
tbox
system
interfer
tight
methioninedepend
regul
biosynthesi
gene
met
leader
rna
variou
aureu
rnase
mutant
investig
influenc
met
leader
rna
metoperon
transcript
stabil
experi
demonstr
involv
rnase
rnase
rnase
iii
met
leader
rna
mrna
process
degrad
combin
data
demonstr
staphylococci
de
novo
methionin
biosynthesi
obvious
control
tbox
regulatori
element
unusu
contrast
gramposit
bacteria
regul
pathway
mostli
sbox
system
repres
sadenosyl
methionin
sam
bind
riboswitch
mehlitz
g
krohn
rudel
mikrobiologi
deutschland
elektronenmikrokopi
deutschland
simkania
negevensi
chlamydialik
emerg
pathogen
implic
pulmonari
diseas
howev
knowledg
regard
intracellular
accommod
remain
spars
demonstr
expans
negevensi
vacuol
within
epitheli
cell
accompani
massiv
spatial
reorgan
host
mitochondria
endoplasm
reticulum
er
spatial
reorgan
mitochondriaand
erspecif
golgi
apparatu
appear
intact
posit
nucleu
negevensi
vacuol
ultrastructur
analysi
reconstruct
reveal
negevensi
form
one
larg
vacuol
locat
within
er
lumen
locat
vacuol
within
er
led
format
far
describ
pathogencontain
tripl
membran
structur
express
nonfimbri
larg
adhesin
bapa
salmonella
enterica
sv
typhimurium
b
hensel
mikrobiologi
deutschland
two
adhesin
recent
describ
locu
salmonella
pathogen
island
secret
type
secret
system
encod
loci
siie
necessari
adhes
polar
epitheli
cell
wherea
bapa
associ
biofilm
format
overexpress
bapa
put
promot
substitut
promot
red
recombin
background
strain
mutant
luciferas
report
strain
bap
operon
well
csgdba
mutant
strain
also
creat
red
recombin
strain
use
deriv
nctc
wt
strain
western
blot
wb
immunostain
perform
use
bapa
kindli
provid
dr
lasa
spain
psii
promot
exchang
clone
bapa
bapd
wt
strain
incub
either
rigor
shake
static
condit
h
c
bacteri
cell
supernat
aliquot
taken
h
sever
time
interv
wb
analysi
express
kinet
perform
use
luciferas
report
gen
static
cultur
bapa
overexpress
strain
incub
c
develop
biofilm
h
result
wb
analys
reveal
band
theoret
molecular
weight
bapa
bacteri
pellet
first
h
bacteri
pellet
supernat
h
final
supernat
h
express
kinet
contrari
observ
phenotyp
obtain
wb
wt
strain
sinc
express
bapa
bapd
static
condit
around
fold
higher
c
c
h
wt
background
one
could
conclud
bapa
transcript
underground
degrad
signal
observ
use
wb
final
imag
clsm
bacteri
biofilm
reveal
sever
cluster
pattern
comparison
wt
strain
bapa
strain
form
larg
cluster
bapa
overexpress
strain
found
small
group
bacteria
contain
cell
hand
singl
isol
bacteri
cell
observ
use
csgd
strain
altogeth
result
show
bapa
may
play
role
surfac
bacteria
secret
pattern
depend
time
medium
condit
could
suggest
protect
function
bacteri
cell
analysi
regul
express
possibl
role
invasionadhes
current
progress
understand
role
bapa
host
cell
helicobact
pylori
htra
new
secret
virul
factor
cleav
ecadherin
disrupt
intercellular
adhes
b
hoy
c
weydig
g
carra
n
tegtmey
geppert
pr
n
sewald
backert
g
schneider
helicobact
pylori
hp
gramneg
bacterium
colon
gastric
epithelium
approxim
world
popul
lead
develop
inflammatori
diseas
even
gastric
cancer
promot
full
virul
hp
disrupt
gastric
epitheli
barrier
enter
intercellular
space
howev
underli
mechan
hpinduc
epitheli
barrier
subvers
current
well
understood
report
entir
new
function
serin
proteas
chaperon
htra
new
secret
virul
factor
hp
cleav
ectodomain
ecadherin
import
molecul
cellcel
adhes
tumor
suppressor
upon
infect
detect
extracellular
ecadherin
domain
solubl
fragment
supernat
hpcolon
gastric
epitheli
cell
correspondingli
amount
full
length
ecadherin
cellular
lysat
drastic
reduc
use
pharmacolog
inhibitor
rnai
exclud
involv
host
cell
proteas
ecadherin
degrad
howev
identifi
htra
secret
bacteri
factor
exhibit
proteolyt
activ
vitro
studi
use
recombin
ecadherin
reveal
activ
htra
specif
cleav
ntermin
ectodomain
ecadherin
wherea
inact
pointmut
htra
variant
importantli
use
comput
assist
homolog
model
e
coli
htra
homologu
degp
design
synthes
smallmolecul
hphtra
inhibitor
hhi
hhi
effici
block
htra
activ
ecadherin
cleavag
experi
hpcolon
epitheli
cell
therebi
significantli
reduc
intercellular
invas
hp
epitheli
monolay
without
affect
bacteri
viabil
taken
togeth
data
impli
htra
mediat
ecadherin
shed
hp
infect
disrupt
epitheli
barrier
function
thu
allow
bacteria
access
intercellular
space
assum
block
htra
activ
might
help
combat
hp
persist
earli
phase
bacteri
infect
introduct
oxid
stress
convert
methionin
mixtur
methioninessulfoxid
metsso
methioninersulfoxid
metrso
methionin
sulfoxid
reductas
protect
bacteria
repair
oxid
methionin
msra
msrb
reduc
metso
former
specif
sform
latter
specif
rform
studi
character
msra
msrb
third
methionin
sulfoxid
reductas
frmsr
typhimurium
frmsr
previous
shown
specif
free
metrso
e
coli
method
method
use
studi
gener
delet
mutant
typhimurium
onestep
inactiv
via
homolog
recombin
transduct
bacteriophag
suscept
assay
infect
experi
macrophag
cell
line
competit
infect
balbcj
mice
typhimurium
growth
experi
salmonella
methionin
methionin
sulfoxid
overexpress
purif
typhimurium
histag
msra
msrb
nadph
link
methionin
reductas
activ
assay
result
show
delet
msra
typhimurium
increas
suscept
exogen
reduc
bacteri
replic
insid
activ
macrophag
mice
contrast
msrb
mutant
show
wild
type
phenotyp
construct
frmsr
msrb
mutant
strain
methionin
auxotroph
background
typhimurium
frmsr
mutant
msrb
mutant
fail
util
free
oxid
methionin
recombin
msra
activ
free
peptidyl
metsso
wherea
recombin
msrb
weakli
activ
specif
peptidyl
metrso
examin
role
frmsr
oxid
stress
respons
compar
frmsr
singl
mutant
frmsrmsrb
doubl
mutant
found
frmsr
affect
surviv
typhimurium
follow
exposur
growth
macrophag
mice
conclus
thu
summari
show
mutant
typhimurium
lack
compon
methionin
sulfoxid
reductas
pathway
attenu
vitro
expos
insid
activ
macrophag
mice
previous
msra
msrb
consid
principl
enzym
msrsystem
play
role
oxid
stress
respons
show
addit
frmsr
contribut
significantli
antagon
damag
caus
oxid
stress
typhimurium
upon
salmonella
enterica
serovar
typhimurium
infect
gut
earli
line
defens
gastrointestin
epithelium
sens
pathogen
intrus
along
epitheli
barrier
one
first
event
toward
diseas
recent
show
high
intracellular
amount
secondari
messeng
cdigmp
typhimurium
abolish
stimul
proinflammatori
immun
respons
inhibit
invas
gastrointestin
epitheli
cell
line
suggest
regul
transit
biofilm
format
virul
cdigmp
intestin
show
highli
complex
cdigmp
signal
network
consist
distinct
group
cdigmp
synthes
degrad
protein
modul
virul
phenotyp
product
invas
vivo
colon
streptomycintr
mous
model
impli
spatial
time
modul
virul
properti
typhimurium
cdigmp
signal
inhibit
invas
phenotyp
cdigmp
associ
inhibit
secret
type
three
secret
system
effector
protein
sipa
inhibit
invas
phenotyp
cdigmp
partial
requir
major
biofilm
activ
csgd
andor
bcsa
synthas
extracellular
matrix
compon
cellulos
find
show
cdigmp
signal
least
equal
import
regul
salmonellahost
interact
regul
biofilm
format
ambient
temperatur
brunk
jacobsen
candida
albican
success
commens
pathogen
human
infect
broad
rang
bodi
site
infect
process
c
albican
potenti
adapt
differ
host
nich
surviv
attack
phagocyt
macrophag
previou
evid
suggest
microevolut
play
central
role
process
exampl
forch
et
al
found
c
albican
rapidli
react
environ
undergo
chromosomelevel
genet
variat
suffici
gener
new
variant
c
albican
studi
use
vitro
experiment
microevolut
approach
identifi
factor
activ
necessari
surviv
within
escap
macrophag
use
system
also
investig
whether
c
albican
utilis
altern
signal
transduct
pathway
select
pressur
first
analys
rang
mutant
defect
hyphalform
capac
escap
macrophag
normal
four
hour
postinfect
wild
type
cell
escap
macrophag
although
none
test
mutant
achiev
high
escap
rate
mani
capabl
lower
level
escap
doubl
mutant
hand
entir
unabl
escap
therefor
chose
strain
investig
monitor
adapt
macrophag
seri
cocultur
passag
passag
mutant
began
exhibit
dramat
phenotyp
chang
form
filament
filament
enabl
evolv
mutant
escap
macrophag
surprisingli
strain
also
abl
form
filament
condit
contrast
origin
mutant
regain
abil
invad
epitheli
cell
furthermor
significantli
higher
virul
altern
model
infect
phenotyp
stabl
absenc
select
pressur
indic
microevolutionari
event
bypass
relianc
filament
qrtpcr
pfge
highthroughput
sequenc
indic
major
chromosom
rearrang
investig
genet
caus
adapt
yield
insight
genom
genet
plastic
import
fungal
pathogen
adapt
specif
host
nich
koenig
c
hammerschmidt
barthel
introduct
borrelia
burgdorferi
etiolog
agent
lyme
diseas
exploit
array
strategi
order
overcom
host
immun
respons
establish
infect
strategi
involv
interact
spirochet
divers
host
protein
includ
plasminogen
extracellular
matrix
protein
complement
regul
number
genet
unrel
outer
surfac
protein
ie
ospa
ospc
cspa
erpa
erpc
erpp
previous
identifi
ligand
hostderiv
plasminogen
report
identif
novel
borrelia
plasminogen
bind
protein
bopa
materi
method
bind
plasminogen
bopa
first
assess
use
elisa
verifi
whether
bound
plasminogenplasmin
proteolyt
activ
perform
substrat
degrad
assay
util
chromogen
substrat
dvalylleucyllysinepnitroanilidedihydrocholrid
well
natur
substrat
fibrinogen
character
bopaplasminogen
interact
region
creat
number
truncat
version
bopa
investig
bind
variou
plasminogen
construct
final
bopa
gene
express
assess
use
rtpcr
analysi
result
compar
borreli
protein
bopa
display
strongest
bind
capac
plasminogen
bound
plasminogen
convert
proteolyt
activ
plasmin
presenc
urokinas
type
plasminogen
activ
subsequ
cleav
chromogen
substrat
dvalylleucyllysinepnitroanilidedihydrochlorid
well
natur
substrat
fibrinogen
employ
divers
truncat
borreli
protein
plasminogen
interact
site
map
within
cterminu
bopa
lysin
residu
locat
within
particular
helic
ctermin
domain
appear
crucial
bind
plasminogen
lysin
analog
tranexam
acid
significantli
inhibit
interact
util
sever
plasminogen
construct
contain
singl
multipl
kringl
domain
determin
kringl
domain
like
repres
major
bopa
interact
site
final
rtpcr
analysi
reveal
vitro
cultiv
spirochet
express
bopa
encod
gene
discuss
present
data
identif
character
novel
plasminogen
bind
protein
bopa
b
burgdorferi
bopa
bind
host
plasminogen
upon
activ
surfacebound
plasmin
proteolyt
cleav
host
fibrinogen
bind
plasminogenplasmin
might
endow
b
burgdorferi
capabl
resist
opson
degrad
compon
extracellular
matrix
furthermor
interact
plasminogen
activ
system
repres
import
virul
factor
enabl
spirochaet
success
establish
infect
dissemin
effici
human
host
vitro
infect
studi
usual
base
cell
cultur
monolay
two
dimension
system
infect
respect
pathogen
microorgan
limit
model
restrict
dimension
contrast
three
dimension
host
tissu
environ
use
collagen
gel
setup
shown
yersinia
enterocolitica
prototyp
extracellularli
replic
pathogen
exhibit
unusu
growth
behaviour
system
resembl
vivo
microcoloni
format
infect
tissu
freund
et
al
present
first
result
growth
behaviour
staphylococcu
aureu
interact
neutrophil
model
use
confoc
microscopi
aureu
known
multipli
extracellularli
tissu
termin
abscess
format
due
neutrophil
infiltr
first
approach
compar
growth
behavior
strain
newman
deriv
mutant
saer
ica
surprisingli
found
strain
newman
mutant
form
bacteri
cluster
similar
observ
cell
cultur
medium
without
collagen
second
approach
supplement
defin
plasma
protein
creat
tissuelik
condit
strikingli
strain
newman
ica
mutant
form
microcoloni
uniform
size
surround
concentr
structur
differ
optic
densiti
contrast
saer
mutant
form
microcoloni
devoid
structur
final
studi
interact
murin
neutrophil
aureu
grown
alon
neutrophil
migrat
toward
aureu
microcoloni
phagocytos
microb
contrast
concentr
structur
form
supplement
plasma
protein
abl
prevent
neutrophil
infiltr
phagocytosi
aureu
microcoloni
includ
mutant
studi
abl
identifi
sever
aureu
pathogen
factor
involv
aureu
protect
neutrophil
attack
pathogen
vacuol
proteom
legionella
pneumophilainfect
phagocyt
c
hoffmann
finsel
becher
hecker
h
hilbi
deutschland
legionella
pneumophila
opportunist
human
pathogen
caus
agent
sever
pneumonia
diseas
upon
intern
gramneg
bacterium
phagocyt
cell
uniqu
legionellacontain
vacuol
lcv
form
prerequisit
intracellular
growth
fusion
lysosom
avoid
lcv
acquir
endosom
marker
associ
mitochondria
earli
secretori
vesicl
endoplasm
reticulum
intern
lcv
format
intracellular
growth
l
pneumophila
depend
bacteri
icmdot
type
iv
secret
system
transloc
differ
effector
protein
host
cell
identif
biochem
cellular
function
icmdot
substrat
challeng
delet
singl
multipl
effector
mani
case
show
intracellular
growth
phenotyp
establish
simpl
fast
method
isol
purifi
intact
lcv
social
soil
amoeba
dictyostelium
discoideum
straightforward
twostep
protocol
includ
enrich
lcv
immunomagnet
separ
use
antibodi
effector
select
bind
exclus
lcv
follow
densiti
centrifug
histodenz
gradient
cushion
proteom
isol
intact
lcv
analys
lcmsm
reveal
host
cell
protein
recent
success
adapt
protocol
isol
intact
lcv
macrophag
allow
compar
proteom
studi
differ
host
cell
first
result
indic
high
overlap
identifi
host
protein
yet
also
reveal
number
small
gtpase
host
protein
previous
identifi
lcv
marker
current
confirm
relev
lcv
format
novel
host
cell
protein
lcv
fluoresc
microscopi
pulldown
assay
function
test
opportunist
pathogen
legionella
pneumophila
legionella
longbeacha
employ
conserv
mechan
replic
amoeba
macrophag
within
uniqu
compart
call
legionellacontain
vacuol
lcv
format
lcv
requir
bacteri
icmdot
type
iv
secret
system
l
pneumophila
transloc
effector
protein
target
host
cell
l
pneumophila
sidm
sidc
effector
protein
anchor
phosphoinositid
pi
lipid
pi
p
cytosol
face
lcv
interfer
host
cell
vesicl
traffick
signal
transduct
pulldown
experi
pi
lipid
coupl
agaros
bead
reveal
l
longbeacha
sidc
also
specif
bind
pi
p
l
pneumophila
modifi
pi
pattern
lcv
icmdot
depend
manner
yet
mechan
remain
elus
recent
discov
bacteri
pi
phosphatas
transloc
host
via
icmdot
preferenti
hydrolys
polyphosphoryl
pi
yield
pi
p
pi
phosphatas
term
lppa
might
shape
lcv
pi
pattern
promot
bind
l
pneumophila
effector
protein
genet
tractabl
social
amoeba
dictyostelium
discoideum
use
number
studi
analyz
lcv
format
l
pneumophila
pi
dictyostelium
homologu
local
lcv
restrict
intracellular
bacteri
growth
implic
retrograd
traffick
similarli
intracellular
replic
l
longbeacha
found
enhanc
discoideum
lack
current
effort
aim
detail
character
lcv
format
intracellular
replic
l
longbeacha
use
discoideum
epiderm
growth
factor
receptor
cellular
target
c
pneumonia
adhes
k
jh
hegemann
funktionel
genomforschung
deutschland
chlamydia
signific
human
pathogen
c
pneumonia
import
respiratori
pathogen
associ
communityacquir
case
pneumonia
worldwid
seropreval
group
concentr
first
initi
step
infect
adhes
subsequ
intern
chlamydia
human
cell
recent
character
first
chlamydi
adhesin
human
receptor
pair
could
demonstr
glycosaminoglycan
gag
host
cell
surfac
involv
attach
subsequ
infect
c
pneumonia
bacteri
surfaceassoci
omcb
protein
gagbind
adhesin
moelleken
hegemann
use
yeast
surfac
display
system
combin
function
adhes
test
procedur
subsequ
identifi
second
c
pneumonia
adhesin
adhes
studi
use
purifi
recombin
protein
abl
show
could
bind
human
cell
gener
delet
variant
singl
amino
acid
mutat
within
protein
map
adhes
properti
short
repetit
amino
acid
motiv
gga
v
fxxn
inhibit
interact
host
cell
antibodi
solubl
recombin
protein
let
reduc
infect
well
reduc
bind
bacteria
human
cell
biochem
approach
tri
identifi
human
cellular
interact
partner
chlamydi
protein
gener
recombin
protein
fragment
analog
natur
process
fragment
found
eb
use
protein
isol
interact
partner
human
cell
surfac
mass
spectrometri
identifi
epiderm
growth
factor
receptor
potenti
target
deplet
egf
receptor
sirna
knock
show
decreas
infect
c
pneumonia
comparison
nontransfect
cell
cell
transfect
non
target
sirna
importantli
knockdown
egfr
result
diminish
bind
fluoresc
label
bacteria
indic
egfr
inde
serv
receptor
c
pneumonia
vice
versa
could
enhanc
infect
approxim
factor
two
overexpress
egfr
cell
defici
receptor
tyrosin
kinas
delet
ligandbind
domain
within
receptor
significantli
reduc
infect
due
reduc
intern
bacteria
find
impli
c
pneumonia
use
egfr
receptor
infect
bacteri
surfac
interact
partner
work
support
dfg
project
reactiv
oxygen
speci
ro
convent
consid
part
immun
respons
kill
pathogen
oblig
intracellular
bacteria
chlamydia
trachomati
c
trachomati
howev
evolv
mechan
use
ro
advantag
c
trachomatisinduc
increas
ro
level
activ
inflammasom
protein
depend
mechan
proteolyt
activ
requir
chlamydi
inclus
format
epitheli
cell
despit
posit
effect
ro
chlamydi
develop
incomplet
understood
differ
cellular
condit
lead
alter
ro
product
affect
chlamydi
growth
therefor
aim
deciph
molecular
mechan
underli
benefici
effect
ro
chlamydi
inclus
format
inflammasom
activ
host
cell
mitochondri
cytoplasm
ro
format
modifi
differ
approach
hypoxia
inhibit
mitochondri
complex
iii
antimycin
increas
concentr
mitochondri
ro
support
decreas
c
trachomati
develop
respect
induct
cytoplasm
ro
addit
small
amount
exogen
tertbutyl
hydrogen
peroxid
cobaltchlorid
increas
c
trachomati
develop
role
cytoplasm
nadph
essenti
regener
host
cell
oxid
defens
system
studi
cell
perman
overexpress
nadkinas
enzym
consequ
host
cell
signal
chang
follow
detect
hypoxia
induc
factor
stabil
phosphoryl
acetylcoenzym
acarboxylas
acc
enzym
might
mediat
host
cell
metabol
chang
support
chlamydi
growth
fluoresc
lifetim
imag
metabol
coenzym
nad
p
h
twophoton
microscopi
use
precis
character
effect
differ
sourc
ro
metabol
activ
c
trachomati
chang
chlamydi
metabol
detect
measur
rel
amount
proteinbound
nad
p
h
fluoresc
lifetim
insid
inclus
also
observ
traffick
golgi
lysosom
close
proxim
nucleu
c
trachomatisinfect
cell
live
cell
imag
organel
traffick
might
escort
perinuclear
cluster
inflammasom
requir
rosinduc
activ
studi
role
ro
chlamydi
develop
contribut
understand
fundament
hostpathogen
interact
chlamydi
growth
progeni
format
show
differ
regul
depend
concentr
origin
ro
gener
host
cell
consequ
stabil
metabol
chang
b
prusti
l
rudel
univers
depart
microbiolog
deutschland
introduct
human
herp
viru
chlamydia
c
trachomati
c
pneumonia
detect
togeth
differ
human
disord
includ
chronic
fatigu
syndrom
cf
autoimmun
disord
like
multipl
sclerosi
ms
possibl
interact
two
type
pathogen
influenc
fate
insid
host
cell
still
unknown
materi
method
use
vitro
epitheli
cell
cultur
model
studi
cross
talk
c
trachomati
coinfect
result
vitro
growth
condit
acut
infect
reduc
chlamydi
infect
contrari
bacteri
replic
infect
strongli
regul
latent
contain
cell
interestingli
c
trachomati
favor
enhanc
entri
surviv
coinfect
model
pathogen
affect
entri
surviv
well
infect
influenc
replic
transcript
pattern
conclus
find
strongli
argu
increas
biolog
signific
coinfect
pathogen
transposon
mutant
mycoplasma
agalactia
exploit
modifi
qtd
pcr
methodolog
novel
strategi
sequenc
tn
insert
site
optim
select
quantit
screen
hegd
zimmermann
r
rosengarten
r
chopradewasthali
ibmh
vet
med
uni
vienna
depart
pathobiolog
vienna
oesterreich
mycoplasma
poorli
understood
pathogen
difficult
erad
despit
consider
advanc
area
mycoplasma
molecular
genet
past
decad
progress
toward
understand
pathogen
mechan
hinder
pauciti
avail
genet
tool
mycoplasma
agalactia
import
rumin
pathogen
pathogen
mechan
larg
unknown
mainli
previou
incap
genet
manipul
year
initi
studi
direct
construct
transposon
tn
mutant
librari
insert
almost
import
categori
includ
hypothet
lipoprotein
transport
metabol
relat
gene
function
analysi
gene
tn
mutant
subject
sever
vitro
screen
protocol
especi
could
direct
role
pathogen
biofilm
format
growth
adher
antibiot
sensit
order
shortlist
experiment
sheep
infect
studi
result
identif
mani
import
mutant
known
hypothet
gene
display
signific
phenotyp
pdhb
uhpt
growth
mani
lipoprotein
gene
adhes
assay
although
report
mycoplasma
direct
genom
sequenc
method
sequenc
tn
insert
site
alway
success
rather
costli
labori
exploit
develop
uniqu
pcr
strategi
integr
part
qtd
method
sequenc
mutant
involv
select
specif
amplif
tninsert
site
use
pair
primer
mutant
ligationmedi
pcr
offer
easi
fast
altern
sequenc
strategi
sinc
qtd
novel
effici
highthroughput
method
capabl
also
identifi
quantit
phenotyp
mix
popul
screen
adapt
optim
variou
paramet
success
reproduc
specif
amplif
individu
well
pool
select
tnmutant
studi
highlight
biolog
signific
specif
mutat
gene
also
pave
way
success
applic
novel
qtd
method
mycoplasma
facilit
better
understand
biolog
pathogen
background
inflammatori
activ
endothelium
lead
releas
von
willebrand
factor
vwf
expos
blood
flow
vwf
get
activ
conform
chang
globular
protein
stretch
mulitmer
ultra
larg
vwf
ulvwf
fiber
ulvwf
fiber
bind
platelet
site
vascular
injuri
even
high
shear
rate
condit
moreov
ulvwf
consid
potenti
bind
partner
pathogen
bacteria
worth
emphas
ulvwf
fiber
form
intact
endotheli
cell
layer
independ
vascular
damag
previou
studi
indic
staphylococcu
aureu
bind
vwf
via
staphylococc
protein
spa
howev
influenc
ulvwf
fiber
known
far
therefor
present
studi
focus
impact
ulvwf
adhes
aureu
intact
endotheli
layer
method
simul
blood
flow
condit
differ
shear
rate
use
variou
microfluid
devic
human
umbil
vein
endotheli
cell
huvec
perfus
fluorescencelabel
aureu
cowan
enabl
quantif
bacteri
adhes
fluoresc
microscopi
investig
role
spa
compar
adhes
aureu
wild
type
spadefici
isogen
mutant
non
pathogen
carnosu
prove
whether
bind
aureu
endothelium
specif
mediat
ulvwf
use
experi
specif
vwf
degrad
proteas
disintegrin
metalloproteinas
thrombospondin
motif
result
overal
capac
ulvwf
bind
aureu
dramat
higher
comparison
globular
vwf
spa
support
bind
aureu
mainli
globular
form
vwf
agreement
previou
studi
contrast
bind
aureu
ulvwf
fiber
larg
independ
spa
adhes
carnosu
ulvwf
compar
aureu
indic
adhes
mechan
independ
aureusspecif
surfac
structur
addit
fix
live
staphylococci
adher
similar
extent
ulvwf
experi
use
instantan
cleavag
ulvwf
document
therebi
inhibit
bacteri
adhes
discuss
within
context
clinic
studi
signific
contribut
vwf
vascular
diseas
progress
shown
previous
show
first
time
aureu
abl
bind
intact
endotheli
cell
layer
physiolog
blood
flow
condit
bind
mainli
due
ulvwf
fiber
independ
spa
depend
data
suggest
adhes
mechan
independ
secret
factor
surfac
associ
adhesin
howev
act
molecular
mechan
trigger
strong
bind
aureu
ulvwf
current
unknown
requir
research
streptococcu
pneumonia
induc
releas
von
willebrand
factor
primari
human
endotheli
cell
introduct
streptococcu
pneumonia
colon
human
nasopharyng
caviti
invas
pneumococc
infect
caus
mening
pneumonia
septic
dissemin
within
vascular
system
cartwright
poreform
cytotoxin
pneumolysin
describ
major
virul
factor
pneumococci
mitchel
mitchel
pulmonari
microvascular
endotheli
cell
hpmec
form
inner
line
blood
microvessel
produc
special
storag
granul
name
weibelpalad
bodi
wpb
wpb
contain
procoagul
factor
like
von
willebrand
factor
vwf
proinflammatori
interleukin
releas
respons
inflammatori
stressrel
stimuli
weibel
palad
rondaij
et
al
materi
method
confluent
grown
primari
hpmec
cultur
glass
cover
slip
two
chamber
transwel
system
infect
serotyp
serotyp
pneumococci
pneumolysindefici
mutant
bacteri
adher
wpb
exocytosi
visual
immun
fluoresc
microscopi
cell
confluenc
control
measur
biolog
imped
use
cellzscop
nanoanalyt
quantif
vwf
within
cell
cultur
supernat
perform
elisa
result
microscop
quantif
demonstr
pneumococc
adher
confluent
hpmec
correl
decreas
amount
intracellular
wpb
follow
time
cours
infect
pneumococci
increas
amount
vwf
determin
cell
cultur
supernat
releas
vwf
slightli
lower
infect
pneumolysindefici
pneumococc
mutant
compar
wildtyp
bacteria
sublyt
amount
recombin
pneumolysin
significantli
stimul
wpb
exocytosi
similar
level
physiolog
agonist
like
histamin
thrombin
moreov
vwf
releas
determin
cell
cultur
supernat
infect
hpmec
apic
basolater
cell
surfac
equal
amount
discuss
report
describ
first
time
induct
wpb
exocytosi
pneumococc
adher
cytotoxin
pneumolysin
use
primari
lung
endotheli
cell
stimul
vwf
releas
apic
basolater
infect
impli
stimul
wpb
exocytosi
direct
insid
vasculatur
also
follow
invas
pneumococc
transmigr
pulmonari
tissu
bloodstream
data
describ
new
endothelialspecif
respons
sever
pneumococc
infect
provid
new
insight
pathophysiolog
consequ
h
christner
h
rohd
medizinisch
mikrobiologi
virologi
und
hygien
hamburg
deutschland
staphylococcu
epidermidi
lead
caus
foreign
bodi
associ
infect
pathogen
speci
mainli
relat
biofilm
form
capabl
biofilm
format
crucial
depend
bacteri
interact
surfac
organ
host
extracellular
matrix
compon
analyz
role
giant
mda
extracellular
matrix
bind
protein
embp
epidermidi
adher
surfac
bound
fibronectin
analysi
fibronectin
interact
recombin
embp
subdomain
either
compris
found
variou
architectur
fivar
domain
alon
combin
grelat
albumin
bind
ga
domain
elsabas
assay
surfac
plasmon
reson
produc
evid
fivar
domain
suffici
embpfn
interact
addit
far
western
blot
experi
map
embp
fibronectin
interact
fniii
domain
make
use
embp
express
epidermidi
strain
isogen
embpneg
mutant
function
relev
embpfn
interact
epidermidi
surfac
colon
test
semiquantit
adher
assay
show
embpexpress
suffici
necessari
epidermidi
bind
surfac
immobil
fn
import
embp
bacteri
adher
fibronectin
valid
test
surrog
host
carnosu
carri
plasmid
allow
express
fusion
protein
compris
fivar
domain
ntermin
ysirkcontain
export
signal
put
ctermin
cell
wall
bind
region
wherea
wild
type
carnosu
exhibit
almost
fnadher
capac
tran
express
construct
lead
signific
increas
bacteri
bind
result
establish
role
embp
bona
fide
bacteri
fibronectin
adhesin
test
epidermidi
adher
fibronectin
also
involv
interact
fniii
domain
adher
epidermidi
immobil
fn
test
presenc
heparin
dose
depend
inhibit
epidermidi
adher
record
therefor
heparin
specif
bind
fniii
particular
domain
obvious
crucial
embp
mediat
epidermidi
adher
fibronectin
find
establish
role
embp
import
epidermidi
adhesin
mediat
adher
immobil
fibronectin
therebi
contribut
first
phase
biofilm
format
underli
molecular
basi
embp
fibronectin
interact
involv
novel
far
undescrib
mechan
r
ziobro
b
henri
e
gulbin
pseudomona
aeruginosa
lead
respiratori
pathogen
eventu
caus
death
patient
cystic
fibrosi
cf
ceramid
bioactiv
sphingolipid
involv
cell
signal
shown
assembl
along
cell
membran
airway
epithelium
patient
cf
rel
abund
ceramid
enrich
domain
term
platform
larger
size
accumul
domain
directli
correl
patient
matur
vulner
infect
increas
assemblag
ceramid
molecular
outlier
patient
cf
act
potenti
stage
aberr
signal
studi
show
although
commonli
found
along
basal
later
membran
beta
integrin
maintain
perman
posit
ceramid
enrich
domain
lumin
side
airway
epitheli
cell
cf
mice
visual
ceramid
beta
integrin
p
aeruginosa
via
immunohistochemistri
indic
coloc
point
infect
trachea
bronchi
epitheli
tissu
beta
integrin
known
rgd
bind
domain
facilit
bind
variou
microb
p
aeruginosa
adher
via
rgd
sequenc
test
vitro
treat
chang
cell
vivo
inhal
grgdn
peptid
prior
infect
treatment
diminish
virul
bacteria
measur
bacteri
adher
mucocilliari
clearanc
data
indic
ceramid
enrich
domain
beta
integrin
molecul
host
play
import
role
virul
p
aeruginosa
within
airway
patient
cystic
fibrosi
addit
observ
competit
inhibit
rgd
sequenc
receptor
decreas
pathogen
bacteria
vivo
two
find
suggest
rgd
bind
domain
beta
integrin
may
act
adher
mechan
p
aeruginosa
increas
cluster
receptor
patient
cf
may
play
import
role
infecti
manifest
diseas
preliminari
data
indic
inhal
rgd
peptid
may
novel
treatment
option
patient
figur
confoc
microscopi
immunofluoresc
stain
beta
integrin
bronchial
epithelium
shift
observ
basal
later
apic
side
tissu
cftrmice
paraffin
embed
tissu
b
c
situ
stain
paraffin
embed
tissu
e
type
three
secret
system
ttss
yersinia
enterocolitica
ye
crucial
evad
host
immun
respons
adhes
bacteria
via
yada
invasin
inv
integrin
ttss
inject
yersinia
outer
protein
yop
host
cell
dissect
role
yada
invasin
integrin
yop
inject
lactamas
report
system
use
measur
yop
inject
leukocyt
flow
cytometri
vitro
infect
splenic
leukocyt
low
infect
dose
ye
yada
inv
strain
reveal
yop
inject
dc
macrophag
pmn
occur
extent
much
lower
extent
b
cell
yadaand
invdepend
manner
yop
inject
infect
yada
mutant
occur
similar
frequenc
test
cell
popul
infect
inv
strain
pmn
target
yop
inject
highest
cell
lowest
frequenc
detect
yop
inject
perform
mous
infect
model
result
similar
bacteri
load
spleen
wildtyp
mutant
yersinia
compar
infect
yada
mutant
yop
inject
could
detect
inv
mutant
show
nearli
similar
yop
inject
wildtyp
strain
indic
yada
inv
crucial
yop
inject
leukocyt
mous
infect
investig
role
integrin
yop
inject
pmn
macrophag
b
cell
investig
use
deplet
splenocyt
deriv
condit
knockout
mice
integrin
deplet
impact
yop
inject
inv
mutant
reduc
significantli
yop
inject
yada
mutant
infect
b
cell
pmn
macrophag
data
provid
evid
system
mous
infect
yada
inv
essenti
yop
inject
inv
mediat
yop
inject
leukocyt
contrast
yada
mediat
yop
inject
occur
integrin
independ
manner
trimer
autotransport
adhesindepend
adher
bartonella
hensela
bartonella
quintana
yersinia
enterocolitica
matrixcompon
endotheli
cell
static
dynam
flow
condit
trimer
autotransport
adhesin
taa
import
virul
factor
gramneg
bacteria
respons
adher
extracellular
matrix
ecm
host
cell
analyz
three
differ
taa
bartonella
adhesin
bada
bartonella
hensela
variabl
express
outer
membran
protein
vomp
bartonella
quintana
yersinia
adhesin
yada
yersinia
enterocolitica
mediat
bacteri
adher
ecm
endotheli
cell
use
static
cell
cultur
vial
dynam
capillari
flow
chamber
experiment
set
adher
wildtyp
bacteria
respect
taaneg
strain
analyz
static
condit
ecm
adher
b
hensela
b
quintana
enterocolitica
strongli
depend
express
particular
taa
yada
enterocolitica
mediat
bacteri
bind
plasma
cellular
fibronectin
neither
static
dynam
condit
taadepend
host
cell
adher
appear
signific
dynam
condit
although
total
number
bound
bacteria
diminish
compar
static
condit
dynam
model
expand
methodolog
perform
bacteri
adher
experi
realist
bloodstream
like
condit
allow
dissect
biolog
role
taa
ecm
host
cell
adher
static
dynam
condit
ca
danzer
hensel
mikrobiologi
deutschland
fau
erlangen
mikrobiologisch
institut
erlangen
deutschland
order
adher
invad
polar
epitheli
cell
intestin
salmonella
inject
virul
protein
type
secret
host
cell
reorgan
actin
cytoskeleton
allow
bacteri
intern
recent
microvilli
effac
polar
epitheli
cell
caus
salmonella
describ
consequ
cooper
adhesin
siie
investig
disrupt
brush
border
polar
epitheli
cell
wildtyp
wt
sipa
sopa
sopb
sope
strain
strain
lack
five
mention
effector
protein
complement
deriv
use
invas
experi
mdck
pf
cell
line
later
also
use
evalu
disrupt
transepitheli
electr
resist
teer
salmonella
infect
result
compar
wtstrain
show
wherea
singl
sopemut
strain
two
third
less
invas
one
third
invas
recov
singl
introduct
sope
hand
sope
abrog
teer
similarli
wt
strain
microvilli
effac
small
ruffl
observ
actinstain
mdck
cell
infect
sopesingl
mutant
strain
microvilli
infect
cell
seem
fuse
salmonella
invas
point
result
demonstr
cell
infect
wt
strain
present
reticular
actin
around
entri
point
apic
side
host
cell
addit
sipa
strain
intim
anchor
microvilli
sopa
sopb
enhanc
adher
compar
background
mutant
strain
induc
small
accumul
actin
final
sope
effac
microvilli
also
induc
reticular
actin
observ
wt
strain
hand
chainlik
structur
former
tightjunct
observ
stain
cell
infect
sope
follow
invas
process
time
laps
imag
use
egfplifeact
mdck
cell
reveal
bacteria
intim
adher
microvillu
first
min
thereaft
microvilli
effac
simultan
occur
membran
ruffl
min
final
min
ruffl
fuse
promot
bacteri
cluster
delay
invas
sopestrain
observ
min
time
salmonella
migrat
microvilli
basement
induc
moder
membran
ruffl
without
microvilli
effac
altogeth
result
show
microvilli
effac
reticular
actin
disrupt
tight
junction
depend
presenc
sope
delet
effector
protein
also
caus
chang
ruffl
morpholog
spatial
distribut
bacteria
apic
side
host
cell
work
progress
understand
molecular
basi
microvilli
destruct
caus
salmonella
fuld
rohd
hitzmann
kt
preissner
dp
nitscheschmitz
nerlich
gs
chhatwal
bergmann
helmholtz
zentrum
infektionsforschung
medizinisch
mikrobiologi
braunschweig
biochemi
giessen
deutschland
stiftung
hochschul
hannov
mikrobiologi
hannov
deutschland
technisch
braunschweig
mikrobiologi
braunschweig
deutschland
introduct
streptococcu
cani
abl
caus
sever
invas
diseas
mainli
cat
dog
increas
incid
streptococc
infect
human
also
attribut
cani
thu
prompt
investig
mechan
underli
pathogenesi
method
result
bind
plasmin
ogen
common
virul
trait
establish
invas
bacteri
infect
plasmaabsorpt
analysi
demonstr
strong
interact
cani
human
plasminogen
furthermor
compar
radioact
bind
assay
use
human
canin
plasminogen
differ
qualiti
interact
could
observ
prerequisit
establish
infect
across
host
speci
bind
plasminogen
depend
presenc
cani
mlike
protein
scm
genet
organ
mgascm
locu
surfac
plasmon
reson
techniqu
reveal
dissoci
constant
nanomolar
rang
indic
specif
biolog
import
interact
plasminogenbind
site
locat
ntermin
part
scm
rang
aminoacid
matur
protein
furthermor
western
blot
analysi
use
truncat
fragment
plasminogen
reveal
interact
ctermin
part
compris
kringl
domain
catalyt
domain
also
known
miniplasminogen
mplg
best
knowledg
scm
repres
first
bacteri
receptor
directli
interact
mplg
even
though
cani
possess
streptokinas
activ
use
eukaryot
plasminogen
activ
urokinas
enabl
bacterium
immobil
plasmin
activ
surfac
led
degrad
purifi
fibrinogen
synthet
aggreg
fibrin
clot
furthermor
electron
microscop
illustr
time
laps
imag
demonstr
plasminmedi
transmigr
fibrin
thrombi
cani
therefor
may
repres
mechan
bacteri
dissemin
within
host
discuss
although
cani
zoonot
pathogen
littl
known
virul
factor
mechan
inde
describ
streptococc
pathogen
cani
util
similar
strategi
tissu
destruct
bacteri
dissemin
host
howev
bind
scm
mplg
present
mechanist
differ
bacterialplasminogen
interact
role
interact
etiopathogenesi
infect
requir
investig
burkholderia
pseudomallei
etiolog
agent
melioidosi
burkholderia
thailandensi
close
relat
organ
mainli
found
soil
southeast
asia
northern
australia
genom
b
pseudomallei
encod
six
type
vi
secret
system
contain
complet
repertoir
core
compon
ortholog
five
system
present
b
thailandensi
type
vi
secret
system
widespread
multicompon
apparatu
involv
bacteri
eukaryot
cell
interact
burkholderia
present
genom
evolutionarili
distinct
lead
us
hypothes
secret
system
perform
discret
function
test
inactiv
individu
investig
role
virul
bacteri
fit
found
one
mutant
lost
virul
aerosol
deliv
murin
model
melioidosi
like
due
specif
role
play
subvers
resist
depend
immun
respons
sinc
highli
virul
mice
next
screen
b
thailandensi
mutant
divers
array
gram
posit
neg
bacteri
speci
growth
competit
assay
prolifer
surviv
b
thailandensi
presenc
sever
competitor
speci
requir
cell
contact
depend
manner
intriguingli
two
speci
pseudomona
fluorescen
pseudomona
putida
also
soil
inhabit
tropic
addit
essenti
persist
b
thailandensi
mix
biofilm
assay
p
putida
data
substrat
scarc
burkholderia
effector
identifi
date
shed
light
mechan
action
aim
identifi
protein
secret
system
util
quantit
orbitrap
mass
spectrometri
compar
secretom
b
thailandensi
wild
type
two
protein
identifi
substrat
extracellular
structur
compon
apparatu
high
structur
similar
phage
tail
tube
tail
spike
protein
respect
interestingli
contain
put
c
termin
effector
domain
display
signific
sequenc
similar
protein
known
function
show
c
termin
domain
requir
b
thailandensi
induc
format
multinucl
giant
cell
phagocyt
nonphagocyt
cell
togeth
data
suggest
import
role
burkholderia
determin
outcom
infect
directli
target
eukaryot
host
cell
allow
bacteria
persist
environ
amino
acid
metabol
streptococcu
pneumonia
analyz
cisotopologu
profil
streptococcu
pneumonia
pneumococci
produc
larg
fraction
abc
transport
system
involv
uptak
metabol
sugar
solubl
compound
amino
acid
studi
carbon
metabol
assess
c
isotopologu
perturb
growth
pneumococci
chemic
defin
media
cdm
presenc
glucos
glucos
sole
carbon
sourc
gcm
analysi
show
pattern
label
nonlabel
amino
acid
lack
isotopologu
label
indic
glu
pro
gli
branch
amino
acid
bcca
ile
leu
val
also
requir
supplement
cdm
asp
synthes
via
gener
pathway
includ
pyruv
acetylcoa
instead
oxaloacet
synthes
phosphoenolpyruv
pep
pep
carboxylas
oxaloacet
convert
asp
later
reaction
essenti
glutam
convert
reaction
catalyz
aspart
transaminas
furthermor
shikim
pathway
could
determin
gcm
analysi
complet
label
aromat
amino
acid
de
novo
synthes
two
molecul
pep
via
intermedi
chorism
strikingli
unlabel
gli
glucos
supplement
cdm
indic
inabl
pneumococci
synthes
ser
complet
label
subsequ
step
gli
contrast
pneumococci
synthes
ser
glycin
hydroxymethyl
part
one
carbon
pool
pathway
verifi
use
glycin
supplement
cdm
result
label
serin
final
gener
carbon
amino
acid
metabol
also
investig
pneumococc
mutant
defici
pava
codi
howev
isotopologu
profil
mutant
similar
wildtyp
conclus
data
show
first
time
varieti
amino
acid
synthesi
pathway
pneumococci
essenti
role
pneumococc
amino
acid
transport
system
bacteri
fit
und
host
milieu
adapt
human
innat
immun
system
counteract
bacteri
invad
multipl
antimicrobi
mechan
includ
polymorphonuclear
leukocyt
pmn
repres
effici
phagocyt
human
formyl
peptid
receptor
belong
famili
seventransmembran
gprotein
coupl
receptor
recent
could
show
crucial
recruit
activ
pmn
staphylococc
infect
sens
concentr
major
staphylococc
cytolysin
phenolsolubl
modulin
psm
peptid
moreov
adjust
pmn
respons
respect
psm
releas
pathogen
staphylococc
speci
enterococci
repres
anoth
group
import
nosocomi
pathogen
studi
show
staphylococci
also
certain
enterococci
capabl
produc
ligand
therebi
underscor
import
role
receptor
antibacteri
host
defens
pmn
chemotaxi
intracellular
calcium
influx
induc
dosedepend
manner
supernat
enterococcu
faecali
enterococcu
faecium
effect
could
inhibit
enterococcu
faecali
enterococcu
faecium
vancomycinresist
isol
elicit
consider
stronger
pmn
respons
vancomycinsuscept
isol
calcium
flux
receptortransfect
cell
show
e
faecium
elicit
respons
wherea
e
faecali
howev
speci
activ
paralog
sens
bacteri
formyl
peptid
enterococc
genom
encod
peptid
appar
similar
psm
peptid
peptid
psmlike
properti
could
identifi
enterococc
cultur
supernat
suffici
quantitit
detect
character
unknown
ligand
produc
e
faecium
supernat
treat
proteas
complet
abolish
abil
stimul
transfect
cell
therebi
indic
unknown
ligand
e
faecium
repres
peptid
conclus
abl
demonstr
certain
enterococci
produc
peptidederiv
microbi
associ
molecular
pattern
sens
human
pmn
structurefunct
relationship
zwitterion
cell
wall
polym
depend
immun
modulatori
mechan
c
weidenmai
wanner
rautenberg
baur
l
kull
imit
deutschland
recent
advanc
field
glycobiolog
led
discoveri
novel
mechan
bacteri
cell
wall
glycopolym
directli
modul
host
immun
respons
demonstr
structur
prerequisit
cell
stimulatori
activ
bacteri
capsular
polysaccharid
cp
presenc
posit
neg
charg
centr
within
repeat
unit
could
recent
show
import
pathogen
factor
cell
wall
teichoic
acid
wta
aureu
similar
activ
abl
activ
cell
mhcii
present
depend
way
mechan
modul
develop
skin
abscess
format
vivo
model
interestingli
mostli
pathogen
gramposit
bacteri
speci
seem
exhibit
ribitolpi
repeat
unit
dalanin
howev
wta
structur
differ
side
chain
sugar
composit
contain
addit
repeat
unit
sugar
wherea
non
pathogen
speci
often
shorter
glycerolpi
repeat
unit
dalanin
modif
data
demonstr
glycerolpi
contain
stapyhlococcu
epidermi
wta
abl
effici
stimul
cell
prolifer
wherea
ribitolpi
wta
aureu
effici
mhcii
depend
cell
activ
polym
therefor
postul
wta
structur
express
profil
play
role
defin
pathogen
potenti
gramposit
bacteri
speci
addit
also
great
interest
understand
regulatori
event
wta
biosynthesi
pathogen
gramposit
bacteria
aureu
known
far
whether
amount
teichoic
acid
differ
develop
infect
even
bacteri
strain
interestingli
find
highli
pathogen
aureu
strain
exhibit
elev
wta
amount
cell
wall
purifi
proteinfre
cell
wall
fraction
strain
induc
cell
prolifer
cytokin
product
effici
cell
wall
less
pathogen
strain
addit
could
demonstr
cell
wall
fraction
strain
activ
skin
abscess
format
thu
regul
wta
biosynthesi
contribut
pathogen
potenti
aureu
character
highli
diverg
african
staphylococcu
aureu
isol
wild
captiv
anim
f
schaumburg
uniklinik
med
mikrobiologi
deutschland
introduct
staphylococcu
aureu
colon
human
anim
recent
report
industri
countri
describ
impact
zoonot
aureu
transmiss
livestock
companion
anim
meat
colon
infect
human
aureu
colon
undomest
subsaharan
anim
could
pose
risk
interspeci
transmiss
infect
human
therefor
character
aureu
isol
wild
captiv
anim
subsaharan
africa
obtain
data
investig
crossspeci
transmiss
aureu
area
method
screen
live
captiv
n
humanhabitu
n
anim
bushmeat
sampl
n
ivori
coast
gabon
zambia
south
africa
aureu
isol
confirm
nuc
gene
detect
sequenc
ribosom
rrna
gene
antibiot
suscept
test
use
autom
system
isol
genotyp
use
aureu
protein
spa
type
multilocu
sequenc
type
mlst
character
possess
gene
encod
virul
factor
result
aureu
found
sampl
includ
isol
human
primat
gorilla
chimpanze
nonhuman
primat
two
rumin
one
wild
cat
noteworthi
isol
nuc
pcr
neg
resist
penicillin
tetracyclin
cotrimoxazol
respect
significantli
associ
captiv
anim
inf
ci
p
mrsa
detect
preval
toxin
gene
sei
seh
seg
preval
classic
superantigenencod
gene
sease
tst
low
three
isol
contain
pantonvalentin
leukocidin
encod
gene
among
isol
found
differ
spa
type
far
confirm
differ
mlst
sequenc
type
st
preval
spa
type
predomin
st
st
st
st
st
st
st
st
form
highli
diverg
group
use
concaten
sequenc
neighborjoin
method
conclus
result
suggest
colon
human
nonhuman
primat
aureu
frequent
one
third
aureu
isol
belong
st
highli
diverg
describ
isol
colon
human
provid
excel
tool
investig
potenti
crossspeci
transmiss
futur
grisold
b
hoenigl
valentin
h
salzer
e
leitner
g
feierl
j
posch
r
kraus
g
zarfel
medic
univers
institut
hygien
graz
austria
oesterreich
max
von
pettenkof
institut
munich
germani
deutschland
medic
univers
depart
infecti
diseas
graz
austria
oesterreich
object
carbapenemresist
enterobacteriacea
emerg
major
public
health
problem
throughout
world
name
newli
describ
resist
mechan
confer
new
delhi
activ
worldwid
interest
report
emerg
carbapenemresist
enterobacteriacea
involv
carbapenem
hydrolyz
enzym
austria
method
retrospect
analysi
enterobacteriacea
resist
data
check
resist
carbapenem
detect
strain
analyz
involv
carbapenem
hydrolyz
enzym
use
pcr
method
detect
eg
mblimp
spm
vim
gim
respect
reppcr
diversilab
instrument
biomerieux
use
determin
clonal
relationship
result
tenyearperiod
carbapenemresist
enterobacteriacea
isol
hospit
patient
first
isol
year
remark
increas
involv
patient
carbapenemresist
enterobacteriacea
compris
klebsiella
pneumonia
klebsiella
oxytoca
one
escherichia
coli
strain
detect
carbapenemas
belong
vim
imp
k
pneumonia
carbapenemas
kpc
first
detect
detect
three
patient
two
case
k
pneumonia
one
patient
posit
e
coli
three
case
occur
decemb
august
detect
carbapenemresist
enterobacteriacea
strain
multiresist
exhibit
suscept
tigecyclin
colistin
amikacin
fosfomycin
gentamicin
carbapenemresist
enterobacteriacea
becom
substanti
global
health
problem
report
emerg
strain
austria
carbapenemresist
enterobacteriacea
detect
compar
low
number
patient
sinc
regard
intern
data
urgent
need
activ
surveil
carbapenemresist
enterobacteriacea
local
report
link
data
nation
intern
surveil
network
may
success
approach
effect
contain
multiresist
bacteria
analysi
popul
structur
anaplasma
phagocytophilum
c
winter
wolfsperg
n
f
von
loewenich
institut
medizinisch
mikrobiologi
freiburg
freiburg
deutschland
anaplasma
phagocytophilum
gramneg
ticktransmit
oblig
intracellular
bacterium
elicit
acut
febril
diseas
human
domest
anim
sheep
cattl
hors
dog
cat
roe
deer
red
deer
regard
potenti
reservoir
host
consider
strain
variat
suggest
occur
within
speci
isol
human
anim
differ
pathogen
heterolog
host
order
explain
host
prefer
epidemiolog
divers
use
multi
locu
sequenc
type
mlst
molecular
character
phagocytophilum
strain
sampl
human
domest
anim
potenti
reservoir
host
ixod
ricinu
tick
analyz
doubl
infect
typabilitiy
eburst
analysi
reveal
one
clonal
complex
sequenc
type
st
founder
strain
belong
clonal
complex
origin
dog
hors
human
cat
sheep
tick
sampl
us
st
might
reflect
geograph
origin
phylogenet
analysi
concaten
sequenc
show
two
main
cluster
tick
sampl
found
apart
cluster
restrict
exclus
roe
deer
phagocytophilum
strain
infect
human
dog
hors
belong
one
clonal
complex
seem
share
epidemiolog
biolog
similar
reflect
result
previou
crossinfect
experi
concaten
sequenc
ricinu
tick
found
cluster
might
involv
transmiss
cycl
phagocytophilum
strain
infect
human
domest
anim
cluster
infect
roe
deer
cluster
contrast
red
deer
roe
deer
probabl
reservoir
granulocyt
anaplasmosi
human
domest
anim
concaten
sequenc
form
clearli
separ
cluster
identif
descript
diseas
outbreak
well
improv
knowledg
popul
genet
epidemiolog
ecolog
bacteri
pathogen
begin
abil
differenti
bacteri
pathogen
via
reliabl
type
method
especi
delin
extraintestin
pathogen
escherichia
coli
expec
commens
ecoli
challeng
task
certain
expec
commens
ecoli
strain
may
genoand
phenotyp
similar
set
focu
ecoli
clonal
complex
promin
expec
lineag
harbor
phenotyp
divers
expec
asymptomat
bacteruria
also
commens
ecoli
variant
model
evalu
improv
two
alreadi
establish
system
ie
multi
locu
sequenc
type
mlst
gener
ecoli
multi
locu
vntr
analysi
mlva
test
type
system
abil
differenti
three
phenotyp
ecoli
subgroup
furthermor
evalu
addit
marker
improv
discriminatori
potenti
type
method
result
discuss
regard
advanc
type
molecular
epidemiolog
extraintestin
pathogen
escherichia
coli
evid
transmiss
septic
salmonellosi
children
ghana
water
well
h
frickmann
dekker
ng
schwarz
n
sarpong
adusarkodi
poppert
rm
hagen
j
may
bundeswehrkrankenhau
hamburg
hamburg
deutschland
rostock
institut
medizinisch
mikrobiologi
virologi
und
hygien
rostock
epidemiologi
hamburg
deutschland
kumasi
centr
collabor
research
kumasi
ghana
ghana
kwame
nkrumah
univers
scienc
technolog
kumasi
ghana
ghana
diagnostik
hamburg
deutschland
introduct
kumasi
ghana
one
model
region
epidemiolog
investig
transmiss
infecti
diseas
tropic
set
analyz
bacteri
caus
sepsi
salmonella
enterica
one
quantit
import
blood
cultur
isol
children
rural
villag
agogo
surround
area
ashanti
region
ghana
howev
exact
mode
transmiss
typic
foodborn
pathogen
particular
part
world
wide
unknown
children
region
access
bottl
drink
water
therefor
investig
contamin
drink
water
local
well
materi
method
within
studi
period
year
salmonella
enterica
blood
cultur
isol
children
year
age
isol
well
collect
partli
longitudin
salmonella
strain
repetit
isol
select
well
speci
ident
biochem
determin
api
well
synthesi
triplesugarironagar
kligler
agar
kumasi
ghana
confirm
fluorescenceinsituhybrid
pcr
hamburg
serotyp
perform
isol
ident
serotyp
identifi
within
one
villag
type
pulsedfieldgelelectrophoresi
pfge
pfge
pattern
compar
softwar
gel
compar
ii
appli
math
use
set
dice
upgma
optim
posit
toler
clonal
ident
accept
ident
result
analyz
well
colon
salmonella
enterica
serotyp
demonstr
reaction
pattern
isol
well
clearli
distinguish
blood
cultur
isol
pfgeanalysi
clinic
isol
villag
show
great
divers
differ
clone
also
endem
clone
circul
particular
region
eight
enterica
isol
isol
one
particular
well
discrimin
distinct
clone
pfge
thu
demonstr
singl
well
colon
differ
enterica
strain
individu
clone
persist
sever
week
well
discuss
pfge
data
blood
cultur
isol
indic
endem
clone
circul
within
local
popul
sourc
identifi
serotyp
gave
evid
water
well
play
major
role
transmiss
enterica
interpret
limit
differ
distinct
serotyp
may
colon
well
time
one
individu
clone
select
per
isol
event
high
number
isol
well
match
blood
cultur
isol
whole
studi
interv
like
support
hypothesi
altern
mode
transmiss
studi
address
role
food
transmiss
enterica
ghana
follow
enteroviru
surveil
germani
one
system
two
intent
diagnost
cnsinfect
polio
surveil
k
neubauer
k
beyrer
diedrich
fg
berlin
deutschland
landesgesundheitsamt
hannov
deutschland
background
sinc
global
polio
erad
initi
gpei
launch
global
incid
polio
reduc
transmiss
indigen
wild
polioviru
interrupt
four
countri
afghanistan
pakistan
india
nigeria
although
region
europ
certifi
poliofre
risk
reintroduct
remain
eg
polio
outbreak
tajikistan
spread
russian
feder
turkmenistan
kazakhstan
strategi
vaccin
surveil
polio
maintain
global
polio
erad
achiev
respons
german
programm
polio
surveil
name
enteroviru
surveil
hand
government
institut
public
health
lower
saxoni
robert
koch
institut
rki
context
enteroviru
surveil
system
extend
use
enteroviru
diagnost
patient
asept
mening
enceph
patient
acut
flaccid
paralysi
examin
one
faecal
sampl
csf
per
cn
afp
patient
offer
paediatr
neurolog
clinic
free
charg
specimen
analyz
enterovirus
use
pcr
cultur
viru
type
network
lab
establish
particip
regularli
profici
test
paediatr
hospit
neurolog
depart
germani
made
use
offer
free
enteroviru
diagnost
five
year
till
end
total
sampl
test
averag
sampl
annual
case
stool
sampl
test
remain
csf
sampl
age
distribut
patient
reflect
great
interest
paediatr
clinic
enteroviru
diagnost
overal
sampl
origin
children
year
age
median
year
season
pattern
sampl
sent
test
show
classic
domin
enterovirus
summer
month
overal
pcrposit
rate
amount
stool
sampl
csf
sampl
far
sampl
serotyp
differ
serotyp
detect
echo
common
poliovirus
detect
expect
result
demonstr
highqual
enteroviru
surveil
well
accept
clinician
b
allow
germani
meet
oblig
establish
reliabl
surveil
system
prove
poliofre
statu
furthermor
high
rate
enteroviru
posit
result
distribut
case
germani
give
good
pictur
circul
enterovirus
germani
thu
contribut
outbreak
detect
infect
control
character
extend
spectrum
lactamas
produc
escherichia
coli
comparison
phylogenet
group
diversilab
system
mononucleotid
motif
genet
marker
vollmer
c
knabb
j
dreier
bad
oeynhausen
deutschland
introduct
rapid
reliabl
method
identifi
molecular
related
clinic
isol
essenti
need
investig
potenti
rout
transmiss
randomli
amplifi
polymorph
dna
amplif
rapd
techniqu
shown
use
compar
simpl
tool
discrimin
strain
related
recent
diversilab
dl
system
releas
autom
system
analysi
microbi
fingerprint
main
advantag
compar
rapd
amplif
defin
differ
size
repetit
fragment
within
noncod
region
genom
present
studi
perform
dl
system
routin
type
tool
extendedspectrum
esbl
produc
e
coli
evalu
comparison
method
materi
method
phylogenet
related
clinic
isol
esblproduc
e
coli
compar
use
diversilab
system
dl
amplif
mononucleotid
repeat
mnr
yain
ycgw
ykge
three
candid
gene
marker
chua
yjaa
abl
distinct
main
four
phylogenet
group
isol
estim
relat
dl
system
homolog
use
pearson
correl
result
dl
system
reveal
two
larger
cluster
relat
isol
cluster
strain
cluster
ii
six
strain
well
twelv
cluster
two
three
four
relat
strain
isol
cluster
belong
phylogenet
group
none
four
mnr
isol
cluster
ii
type
show
amplif
four
mnr
dlcluster
also
show
concord
regard
phylogenet
group
mnr
amplif
pattern
esbltyp
three
differ
method
show
excel
correl
amplicon
mnr
current
sequenc
evalu
phylogenet
infer
confirm
discrimin
dl
system
discriminatori
power
dl
system
evalu
comparison
pulsefieldgelelectrophoresi
multilocu
sequenc
type
investig
includ
evalu
dl
hous
autom
rapdpcr
use
differ
establish
primer
follow
chipgelelectrophoresi
sequenc
type
express
analysi
target
capsul
null
locu
meningococci
h
clau
p
kriz
musilek
tremmel
u
vogel
institut
hygien
und
mikrobiologi
deutschland
nation
institut
public
health
nation
refer
laboratori
meningococc
infect
prag
tschechisch
republik
background
aim
multicompon
vaccin
serogroup
b
meningococci
compris
three
major
recombin
antigen
includ
neisseri
adhes
nada
factor
h
bind
protein
fhbp
neisseri
heparin
bind
antigen
nhba
well
outermembran
vesicl
especi
induc
antibodi
porin
purpos
studi
estim
effect
capsul
null
locu
cnl
meningococci
materi
method
fortyon
strain
cnl
meningococci
three
countri
burkina
faso
czech
republ
germani
belong
nine
sequenc
type
st
four
clonal
complex
antigen
sequenc
type
analys
antigen
express
genet
type
recent
publish
meningococc
antigen
type
system
mat
donnelli
et
al
result
conclus
strain
complex
harbour
fhbp
variant
includ
vaccin
express
antigen
posit
bactericid
threshold
pbt
defin
serogroup
b
strain
express
nhba
pbt
seen
strain
one
strain
harbour
nada
gene
porin
present
among
analys
cnl
strain
data
suggest
bactericid
antibodi
effect
subset
cnl
meningococci
biolog
effect
complex
depend
antibodi
level
mucos
surfac
capac
block
transmiss
data
current
avail
c
rohd
k
selezska
kazmierczak
j
sikorski
dsmz
mikrobiologi
braunschweig
deutschland
hzi
braunschweig
deutschland
dsmz
braunschweig
deutschland
deutschland
introduct
lytic
potenti
novel
pseudomona
aeruginosa
pa
phage
larg
number
novel
environment
clinic
pa
isol
challeng
studi
find
new
potenti
therapi
phage
medic
approach
fight
pa
find
possibl
relationship
lysi
phenomena
phylogenet
tree
host
alloc
cluster
lyse
strain
phylogenet
approach
use
lysi
phenotyp
latter
address
potenti
role
phage
microevolutionari
diversif
pa
strain
differ
genet
lineag
clade
phage
relev
driver
major
phylogenet
group
larg
pool
new
host
phage
offer
test
system
respond
question
materi
method
environment
pa
strain
isol
german
river
across
differ
water
qualiti
clinic
isol
came
differ
sourc
mostli
chronic
infect
strain
genet
type
use
pseudomona
arraytub
chip
phage
jg
seri
isol
sewag
courtesi
j
garb
schobert
tu
braunschweig
phage
assay
overnight
cultur
adjust
cfuml
drop
phage
suspens
ad
pattern
per
agar
plate
overlay
techniqu
result
serotyp
strain
determin
motil
phenotyp
virul
factor
biofilm
format
strain
group
acc
core
genom
similar
four
main
cluster
phage
known
infect
pa
via
lp
membran
receptor
analys
lysi
phenotyp
seven
highli
lytic
phage
set
phage
strain
pa
environment
clinic
phage
show
substanti
differ
lysi
phenotyp
set
host
proport
lyse
strain
rang
pairwis
phage
comparison
indic
high
low
phenotyp
similar
phage
result
final
suggest
two
unrel
phage
group
one
phage
seem
phenotyp
distinct
clinic
pa
sensit
phage
attack
environment
lysi
phenotyp
appear
depend
serotyp
serotyp
show
larg
proport
full
lysi
other
appear
confer
phage
resist
sensit
phage
level
intraspeci
host
divers
genet
lineag
differ
phage
sensit
emerg
host
lineag
differ
also
presenc
abund
specif
serotyp
two
phage
far
effect
lyse
clinic
environment
strain
independ
genet
host
lineag
conclus
phage
lysi
pattern
conclud
therapeut
potenti
highli
lytic
phage
broad
pa
host
spectrum
lysi
phenotyp
conclud
phage
via
divers
host
receptor
type
potenti
contribut
intraspeci
microevolutionari
diversif
within
pa
addit
studi
shown
reason
believ
popul
dynam
pa
probabl
shape
environment
forc
clinic
habitat
result
contribut
knowledg
evolutionari
dynam
pa
phage
resist
sabat
chlebowicz
h
grundmann
jm
van
dijl
aw
friedrich
univers
medic
center
groningen
medic
microbiolog
groningen
niederland
background
methicillinresist
staphylococcu
aureu
mrsa
increas
health
problem
hospit
commun
set
worldwid
mrsa
character
carriag
divers
staphylococc
cassett
chromosom
mec
sccmec
element
confer
resist
betalactam
antibiot
date
ten
major
sccmec
type
describ
basi
combin
ccr
mec
complex
although
sever
pcrbase
procedur
design
type
sccmec
cassett
often
found
limit
abil
character
mrsa
isol
goal
studi
compar
sccmec
type
result
produc
wellestablish
multiplexpcr
protocol
obtain
microarraybas
assay
method
two
hundredsix
nonrepetit
mrsa
isol
obtain
collect
previous
character
spa
type
multiplelocu
variablenumb
tandem
repeat
analysi
mlva
multiplelocu
variablenumb
tandem
repeat
fingerprint
mlvf
isol
subject
sccmectyp
use
multiplexpcr
protocol
describ
kondo
et
al
kondo
et
al
antimicrob
agent
chemoth
microarray
staphytyp
aler
technolog
gmbh
jena
germani
implement
select
mrsa
isol
result
use
multiplexpcr
protocol
mrsa
isol
typeabl
wherea
mrsa
isol
sccmec
type
could
determin
preval
sccmec
type
sccmec
type
iv
follow
sccmec
type
v
sccmec
type
sccmec
type
ii
sccmec
type
iii
sccmec
type
vi
sccmec
type
viii
analyz
microarraybas
approach
mrsa
isol
sscmec
type
iiii
vi
viii
well
nontyp
mrsa
isol
base
mlva
mlvf
spa
type
characterist
repres
preval
sccmec
type
iv
v
respect
select
microarray
character
isol
typeabl
multiplexpcr
method
perfect
agreement
result
two
method
test
among
isol
nontyp
multiplexpcr
approach
almost
typeabl
microarray
among
sccmec
type
v
preval
follow
sccmec
type
iv
sccmec
type
singl
mrsa
nontyp
base
microarray
result
conclus
microarray
approach
appear
effici
pcrbase
protocol
identif
sccmec
type
among
genet
divers
mrsa
isol
moreov
microarraybas
method
inexpens
fast
procedur
easili
implement
investig
routin
clinic
laboratori
north
branch
korea
republik
introduct
rotaviru
major
caus
sever
diarrhea
among
infant
young
children
rotavirus
belong
genu
doublestrand
rna
virus
famili
reovirida
infect
matur
villu
epitheli
cell
small
intestin
often
lead
fever
vomit
diarrhea
children
method
total
stool
specimen
collect
patient
acut
gastroenter
northern
gyeonggi
provinc
korea
year
surveil
august
juli
analyz
use
antigencaptur
enzymelink
immunosorb
assay
elisa
rtpcr
follow
sequenc
result
specimen
rotaviru
select
specimen
rotavirusposit
specimen
mean
antigencaptur
enzymelink
immunosorb
assay
elisa
streptococcu
agalactia
group
b
streptococci
gb
common
commens
femal
urogenit
tract
well
known
caus
lifethreaten
infect
neonat
sever
year
increas
infect
rate
immunocomprom
adult
patient
report
rare
case
infect
neonat
pregnant
women
immunocomprom
elderli
patient
lead
toxic
shock
syndrom
necrot
fasciiti
streptococc
toxic
shock
syndrom
stss
highli
invas
bacteri
infect
mortal
rate
rang
typic
caus
streptococcu
pyogen
mutat
gener
virul
regul
cov
report
associ
stss
case
investig
similar
mutat
found
agalactia
strain
certain
clone
respons
uncommon
cours
agalactia
infect
perform
detail
molecular
analysi
dna
sequenc
cov
virul
regul
gene
collect
agalactia
stss
strain
strain
origin
adult
children
collect
us
germani
switzerland
molecular
type
perform
multi
locu
sequenc
type
mlst
capsular
type
surfac
protein
determin
pcr
analysi
cov
gene
locu
gene
cov
covr
amplifi
pcr
subject
dna
sequenc
molecular
subtyp
mlst
show
agalactia
stss
strain
capsular
serotyp
type
v
belong
capsular
serotyp
ia
rest
strain
harbor
differ
common
mlst
type
genet
analysi
show
bp
delet
lead
frame
shift
cov
one
strain
two
compon
cov
regul
repress
hemolysi
mutat
associ
increas
hemolysi
pigment
mutat
strain
anoth
strain
harbor
bp
delet
previous
report
rest
strain
cov
allel
match
gene
sequenc
complet
sequenc
agalactia
strain
genbank
databas
harbor
silent
mutat
conclus
virul
regul
gene
mutat
strain
caus
streptococc
toxic
shock
syndrom
describ
pyogen
also
found
agalactia
detail
molecular
epidemiolog
character
stss
agalactia
strain
mlst
capsular
type
surfac
protein
determin
show
heterogen
despit
certain
predomin
strain
kalitzki
flohr
l
partnerschaftspraxi
labormedizin
mikrobiologi
hameln
deutschland
introduct
pathogen
e
coli
speci
repres
major
caus
diarrhea
variou
group
patient
wherea
enteropathogen
e
coli
epec
well
known
caus
diarrhea
babi
enterohaemorrhag
e
coli
ehec
shigatoxinproduc
e
coli
stec
known
caus
infect
especi
intak
food
contamin
bovin
faec
recent
outbreak
novel
clone
e
coli
bear
rare
serotyp
threaten
northern
germani
challeng
health
care
author
report
data
collect
routin
medic
laboratori
clinic
investig
stool
specimen
materi
method
period
three
year
stool
specimen
patient
diarrhea
enter
origin
lower
saxoni
surround
counti
screen
realtim
multiplex
pcr
presenc
pathogen
e
coli
speci
briefli
characterist
gene
ehec
stec
eaec
epec
eiac
etec
detect
inhous
realtim
multiplex
pcr
method
result
pcr
techniqu
detect
enterohaemorrhag
e
coli
shigatoxin
produc
e
coli
higher
sensit
verotoxinelisatechniqu
pathogen
e
coli
speci
found
caus
agent
age
interestingli
epec
found
young
children
adult
patient
well
ehec
stec
show
prefer
certain
age
either
e
coli
speci
respons
recent
outbreak
bear
combin
pathogen
factor
found
stool
probe
past
three
year
discuss
accord
microbiologicinfectiolog
qualiti
standard
miq
german
societi
hygien
microbiolog
screen
stool
sampl
pathogen
e
coli
speci
perform
certain
condit
follow
standard
ehec
stec
eaec
epec
would
detect
patient
exampl
miq
standard
consid
epec
caus
agent
adult
patient
immunocompromis
persist
diarrhea
three
week
data
contradict
recommend
autochthon
leishmaniasi
germani
survey
preval
sand
fli
infect
rodent
bavaria
c
bogdan
haeberlein
k
knoll
u
schleicher
erlangen
mikrobiologisch
institut
erlangen
deutschland
institut
mikrobiologi
der
bundeswehr
abteilung
virologi
und
rickettsiologi
deutschland
background
zoonot
cutan
viscer
leishmaniasi
caus
protozoan
parasit
genu
leishmania
transmit
sand
fli
vector
reservoir
anim
human
within
europ
diseas
highli
preval
countri
island
mediterranean
basin
recent
year
evid
present
argu
northward
spread
leishmaniasi
previous
nonendem
area
switzerland
slowenia
austria
within
germani
sand
fli
speci
phlebotomu
mascitii
p
pernici
detect
rhine
valley
nauck
et
al
parasitol
re
also
case
autochthon
human
leishmaniasi
bogdan
et
al
clin
infect
di
three
case
autochthon
canin
equin
leishmaniasi
recent
report
bavaria
goth
et
al
kleintierpraxi
koehler
et
al
vet
parasitol
present
studi
investig
whether
sand
fli
preval
bavaria
whether
wild
mice
carri
leishmania
parasit
therefor
might
function
reservoir
anim
univ
hosp
institut
hygien
deutschland
univ
hosp
dept
periodontolog
deutschland
ridom
gmbh
deutschland
enterohemorrhag
escherichia
coli
ehec
highli
pathogen
subgroup
shiga
toxinproduc
e
coli
stec
caus
sever
ill
includ
wateri
bloodi
diarrhea
hemolyt
urem
syndrom
common
caus
acut
renal
failur
children
worldwid
alreadi
wide
accept
ehec
branch
sorbitol
ferment
sf
hand
three
cluster
nonsf
ehec
leopold
et
al
proc
natl
acad
sci
usa
howev
involv
hypothet
intermedi
sf
clone
yet
identifi
use
publish
genom
sequenc
data
differ
strain
dna
sequencebas
approach
includ
code
region
core
genom
establish
appli
strain
collect
strain
sf
nonsf
investig
phylogeni
electopherogram
data
analyz
subsequ
phylogenet
analys
perform
use
ridom
seqspher
softwar
version
beta
ridom
gmbh
moreov
data
compar
previous
perform
multiplelocu
variablenumb
tandemrepeat
analysi
mlva
data
sequenc
analysi
total
nucleotid
per
strain
result
singl
nucleotid
polymorph
snp
discov
investig
loci
overal
variant
ratio
snp
nonsynonym
indic
certain
evolutionari
pressur
subtyp
combin
snp
result
differ
genotyp
certain
snp
snp
genotyp
could
determin
differenti
serotyp
cluster
interestingli
snp
data
enabl
us
differenti
amongst
ehec
subgroup
especi
within
ehec
contrast
snp
data
confirm
alreadi
determin
high
genotyp
conserv
within
sf
ehec
h
snp
data
investig
elabor
new
type
techniqu
use
fewer
loci
order
get
compar
rate
resolut
therefor
character
observ
snp
local
enabl
differenti
genotyp
addit
genotyp
suitabl
fit
hypothet
intermedi
clone
identifi
anim
isol
sf
phenotyp
therebi
complement
ehec
stepwis
evolutionari
model
complement
phylogenet
step
sf
either
sf
hor
nonsf
summari
snpbase
type
ehec
us
close
gap
within
evolutionari
model
ehec
identif
isol
hypothet
clone
moreov
identifi
snp
associ
genotyp
open
new
prospect
challeng
develop
altern
type
method
less
cost
compar
rate
resolut
epidemiolog
investig
phylogeni
studi
introduct
differ
studi
reveal
emerg
zoonot
behaviour
extend
host
spectrum
genotyp
ehsg
like
livestockassoci
la
mrsa
belong
clonal
complex
cc
present
mrsa
one
major
caus
wound
infect
small
anim
hors
infect
anim
may
provid
signific
threat
public
health
base
find
aim
studi
determin
proport
lamrsa
wound
swab
obtain
companion
anim
germani
materi
method
nov
may
wound
swab
origin
differ
geograph
region
germani
investig
presenc
mrsa
mrsa
character
spatyp
suscept
test
presenc
gene
encod
pantonvalentin
leukocidin
pvl
result
overal
gener
mrsa
distribut
among
clinic
sampl
companion
anim
hors
origin
regard
distribut
mrsa
among
differ
anim
speci
canin
sampl
show
distribut
n
felin
sampl
n
equin
origin
n
mrsa
respect
interestingli
proport
spatyp
frequent
associ
livestockassoci
mrsa
eg
among
strain
collect
canin
mrsa
felin
mrsa
equin
origin
contrast
previous
report
frequent
occurr
mrsa
among
clinic
isol
equin
origin
current
result
reveal
predomin
lamrsa
mrsa
posit
wound
infect
similar
trend
seen
wound
infect
due
mrsa
dog
past
frequent
associ
current
identifi
sever
case
associ
conclus
detect
proport
mrsa
hors
dog
suggest
rapid
spread
laassoci
strain
anim
livestock
rais
question
whether
ehsgmrsa
may
harbour
certain
factor
abil
genet
function
mediat
obviou
success
spread
among
differ
mammalian
speci
apart
methicillinresist
genotyp
pilu
pilu
streptococcu
pneumonia
clinic
isol
germani
g
zander
n
schade
van
der
linden
hammerschmidt
greifswald
abteilung
genetik
der
mikroorganismen
institut
genetik
und
funktionel
genomforschung
greifswald
deutschland
recent
discoveri
long
filament
piluslik
structur
extend
surfac
pneumococcu
open
new
window
research
field
pneumococci
two
pilu
region
identifi
pneumococc
genom
pilu
pilu
least
role
pneumococc
pathogenesi
suggest
analyz
distribut
pili
among
pneumococc
clinic
isol
germani
divid
three
differ
group
invas
noninvas
carrier
fortythre
pneumococc
serotyp
repres
set
sampl
includ
use
pneumococc
conjug
vaccin
pcv
pneumovax
overal
pneumococc
clinic
isol
posit
pili
pilu
islet
frequenc
within
invas
group
higher
frequenc
within
noninvas
carrier
group
pilusposit
invas
isol
posit
wherea
pilusposit
carrier
isol
posit
surprisingli
major
pilusposit
noninvas
isol
posit
pneumococc
pili
doubleposit
isol
belong
serotyp
serotyp
strongli
relat
wherea
present
mainli
serotyp
two
pneumococc
serotyp
identifi
pilusposit
studi
present
current
avail
vaccin
pneumonia
contrast
serotyp
includ
respect
clonal
piluscontain
isol
identifi
determin
mlst
analysi
correl
antibiot
resist
profil
also
establish
final
data
show
scenario
pneumococc
pili
distribut
among
pneumococc
clinic
isol
germani
may
support
potenti
constitu
vaccin
candid
background
hospitalacquir
methicillin
resist
staphylococcu
aureu
hamrsa
grow
public
health
concern
across
world
earli
detect
cluster
vital
patient
protect
pulsedfield
gel
electrophoresi
pfge
consid
gold
standard
detect
import
outbreak
event
wide
use
despit
sever
limit
limit
resolut
lack
digit
data
make
intraand
interlaboratori
comparison
difficult
spa
type
reli
sequenc
variat
within
aureu
protein
gene
spa
proven
success
tool
investig
related
strain
sequenc
data
easili
store
databas
commun
research
global
optic
map
om
creat
linear
restrict
enzym
map
singl
dna
molecul
map
distinguish
chromosom
event
kb
size
provid
higher
resolut
data
well
fragment
organ
within
genom
compar
pfge
kb
detect
limit
probabl
also
spa
type
compar
techniqu
retrospect
analysi
hamrsa
cluster
method
four
epidemiolog
relat
isol
unrel
clinic
isol
one
isol
indetermin
epidemiolog
analyz
strain
previous
character
use
spa
type
unrel
isol
chosen
base
ident
spa
type
epidemiolog
relat
strain
remain
two
isol
differ
spa
type
yet
one
sequenc
type
multilocu
sequenc
type
epidemiolog
relat
group
related
studi
strain
determin
use
pfge
om
opgen
gaithersburg
md
usa
result
pfge
result
confirm
close
relat
epidemiolog
relat
isol
three
strain
well
isol
indetermin
epidemiolog
ident
pfge
band
pattern
fourth
isol
differ
singl
band
three
unrel
isol
ident
spa
type
close
relat
epidemiologicallylink
group
though
ident
differ
spa
type
om
data
valid
pfge
data
higher
resolut
show
addit
restrict
site
strain
ident
pfge
conclus
data
illumin
vari
level
data
resolut
offer
spa
type
pfge
om
pfge
alon
abl
differenti
epidemiolog
unrel
strain
cluster
strain
share
spa
type
om
data
correspond
pfge
spa
type
result
yet
higher
resolut
provid
detail
phylogenet
inform
increas
resolut
may
use
track
progress
cluster
though
investig
need
verifi
om
alon
suffici
identifi
spread
pathogen
merker
kohl
j
kalinowski
rueschgerd
l
trueb
roetzer
niemann
forschungszentrum
borstel
molekular
mykobakteriologi
borstel
deutschland
univers
bielefeld
cebitec
bielefeld
deutschland
forschungszentrum
borstel
nation
refer
center
mycobacteria
borstel
deutschland
background
transmiss
phylogenet
background
clinic
mycobacterium
tuberculosi
complex
isol
analyz
genotyp
techniqu
dna
fingerprint
spoligotyp
miruvntr
type
although
method
discriminatori
power
high
enough
discrimin
clinic
isol
strain
level
abl
visual
microevolut
event
eg
within
one
patient
case
treatment
failur
resist
develop
methodolog
adress
question
appli
next
gener
sequenc
ng
analyz
genom
serial
isol
obtain
two
differ
patient
long
durat
treatment
time
period
first
last
isol
obtain
one
patient
month
strain
belong
beij
lineag
isol
one
patient
exhibit
rflp
loci
miruvntr
type
pattern
thu
exclud
exogen
reinfect
princip
find
isol
high
qualiti
read
mean
genom
coverag
least
obtain
read
map
refer
sequenc
identifi
singl
nucleotid
polymoph
snp
demonstr
high
qualiti
data
obtain
abl
identifi
polymorph
classic
resist
gene
confer
resist
first
line
isoniazid
rifampicin
ethambutol
pyrazinamid
streptomycin
second
line
antibiot
ofloxacin
capreomycin
interestingli
emerg
snp
resist
gene
coincid
develop
phenotyp
resist
within
cours
treatment
addit
identifi
snp
acquir
particular
isol
comparison
parent
first
strain
respect
actual
valid
classic
sequenc
conclus
result
reveal
strike
divers
serial
patient
isol
captur
standard
genotyp
function
consequ
eg
addit
resist
mechan
compensatori
evolut
current
investig
pvl
therefor
exist
two
differ
pathovar
hypothes
investig
microevolut
popul
structur
saureu
elucid
mechan
emerg
epidem
spread
investig
microevolut
mean
singl
nucleotid
polymorph
snp
snp
discoveri
perform
use
dhplc
genet
loci
bp
within
intern
strain
collect
saureu
isol
identifi
biallel
polymorph
bip
correspond
bip
per
kilobas
biallel
polymorph
use
construct
minimum
span
tree
mst
associ
haplotyp
among
strain
result
indic
two
subpopul
evolv
differ
pathovar
associ
distinct
clinic
pictur
addit
could
show
much
popul
structur
local
larg
endem
spread
countri
contin
occur
rare
occasionsfurthermor
agreement
prior
result
map
spa
type
onto
mst
reveal
sever
spa
type
whose
pattern
seem
reflect
homoplasi
recent
demonstr
mrsa
accumul
genom
divers
suffici
fast
document
pathogen
spatial
spread
long
distanc
e
g
countri
contin
current
unclear
howev
whether
genom
variat
may
also
enabl
reconstruct
transmiss
chain
individu
patient
e
g
outbreak
hospit
infect
appli
illumina
sequenc
compar
full
genom
multipl
mrsa
isol
hospit
outbreak
phylogenet
analys
indic
mark
tempor
signal
dna
sequenc
data
isol
index
patient
e
presum
start
point
outbreak
basal
posit
phylogenet
tree
isol
later
time
point
distal
tree
root
case
multipl
isol
individu
patient
avail
observ
signific
genom
divers
among
howev
everi
patient
got
infect
uniqu
mrsa
mrsa
genom
sever
patient
indistinguish
close
relat
suggest
potenti
transmiss
event
appear
genom
sequenc
hold
promis
potenti
trace
mrsa
spatial
spread
local
scale
object
identif
risk
factor
prior
hospit
central
element
prevent
control
mrsa
germani
screen
recommend
base
guidelin
robertkochinstitut
yet
screen
intens
larg
vari
institut
order
introduc
region
program
mrsa
control
detail
knowledg
mrsa
burden
requir
effect
first
time
entir
german
state
conduct
statewid
admiss
preval
screen
ap
hospit
saarland
octobernovemb
method
screen
combin
throat
nasal
swab
taken
patient
immedi
upon
admiss
use
novel
swab
eswab
copan
itali
system
enhanc
pathogen
recoveri
sampl
process
novel
fulli
autom
robot
driven
specimen
processor
wasp
copan
itali
plate
select
biplat
media
mrsa
methicillin
sensit
aureu
mssa
analys
perform
state
hygien
laboratori
univers
saarland
hospit
specimen
test
throatnos
swab
wound
swab
posit
preval
admiss
total
saureu
preval
vari
institut
figur
higher
previous
determin
german
ap
program
also
differ
previous
report
central
european
region
institut
spa
type
frequent
among
mrsa
follow
spa
type
previous
rare
report
detail
risk
assess
multivari
analysi
reveal
previou
mrsa
histori
chronic
care
presenc
skin
woundulc
significantli
associ
mrsa
carrier
statu
conduct
larg
region
ap
studi
allow
compar
determin
mrsa
colonizationinfect
upon
admiss
entir
feder
state
result
import
estim
burden
mrsa
cost
diseas
hospit
design
costeffect
continu
screen
program
region
develop
ration
approach
combat
circl
mrsa
introduct
commun
care
facil
hospit
back
commun
side
effect
gener
enhanc
attent
gener
public
institut
administr
polici
maker
toward
qualiti
goal
mrsaarnetz
observ
schoul
et
al
assess
variat
differ
vntr
loci
within
genom
date
howev
littl
known
rate
mlva
variat
henc
use
trace
transmiss
attempt
describ
extent
divers
across
epidemiolog
sampl
differ
number
transmiss
contain
within
control
similar
genet
background
compar
strain
share
finetyp
ie
strain
serogroup
pora
feta
sequenc
type
follow
sampl
order
presum
number
transmiss
within
includ
strain
long
time
carrier
strain
carrier
strain
case
invas
diseas
close
contact
strain
proxim
index
case
strain
crosssect
studi
carrier
strain
belong
finetyp
strain
cluster
invas
diseas
meningococci
strain
cluster
strain
finetypespecif
spatiotempor
cluster
invas
diseas
strain
finetypespecif
cluster
comput
satscan
version
strain
randomli
distribut
case
invas
diseas
belong
finetyp
spatiotempor
cluster
control
strain
belong
finetyp
categor
distanc
comput
mlvaprofil
strain
share
finetyp
set
variat
mlva
type
within
finetyp
differ
significantli
across
set
p
kruskalw
test
figur
variat
type
observ
within
longtim
carrier
strain
obtain
index
case
close
contact
contain
zero
one
transmiss
respect
interestingli
strain
finetypespecif
cluster
diseas
show
less
variat
strain
crosssect
carrier
sampl
contrast
mean
distanc
within
strain
spatiotempor
cluster
randomli
distribut
case
control
invas
diseas
consider
higher
figur
preliminari
analys
describ
divers
mlva
type
strain
belong
finetyp
obtain
differ
epidemiolog
set
specif
variat
seem
increas
accord
presum
number
transmiss
corrobor
find
estim
rate
variat
one
transmiss
analys
longtim
carrierand
indexcarriersampl
way
prudent
use
antibiot
major
prevent
measur
forestal
select
spread
multidrugresist
bacteria
assess
densiti
antibiot
use
hospit
cooper
within
qualiti
network
prevent
control
healthcareassoci
infect
method
within
dutchgerman
eursafeti
healthnet
project
wwweursafetyeu
german
hospit
euregio
gronauensched
provid
data
use
antibiot
intens
care
unit
icu
nonintens
care
ward
data
assess
separ
second
halfyear
first
halfyear
use
antibiot
report
hospit
pharmaci
base
anatom
therapeut
chemic
atc
code
milli
gram
transform
daili
defin
dose
ddd
defin
world
health
organ
compar
achiev
calcul
patientday
pd
result
thirtyfour
region
hospit
within
network
provid
data
use
antibiot
median
mean
densiti
antibiot
use
nonicu
ward
pd
pd
note
nonicu
set
extendedspectrum
penicillin
cephalosporin
carbapenem
quinolon
account
total
antibiot
use
respect
icu
median
mean
densiti
antibiot
use
pd
pd
differ
icu
use
broadspectrum
antibiot
vancomycin
teicoplanin
linezolid
carbapenem
tigecyclin
togeth
repres
total
use
antimicrobi
agent
discuss
total
region
use
antibiot
compar
data
region
publish
german
germap
dutch
nethmap
report
howev
hospit
observ
broad
rang
antibiot
use
respect
densiti
type
antimicrobi
agent
use
togeth
region
data
bacteri
antibioticresist
data
use
network
hospit
discuss
aim
improv
local
antibiot
polici
algorithm
empir
treatment
prudent
use
glycopeptid
hematolog
patient
tool
control
vancomycin
resist
enterococci
x
zhou
kerkhof
l
span
aw
friedrich
jp
arend
universitari
medic
centr
groningen
medic
microbiolog
groningen
niederland
universitari
medic
centr
groningen
epidemiolog
groningen
niederland
universitari
medic
centr
groningen
hematolog
groningen
niederland
introduct
enterococcu
faecium
becom
major
caus
nosocomi
infect
especi
patient
hematolog
malign
high
risk
immunocompromis
statu
therefor
adequ
antibiot
therapi
requir
howev
control
vancomycin
resist
enterococci
vre
antibiot
stewardship
focu
prudent
use
becom
necessari
aim
studi
determin
risk
factor
order
develop
algorithm
optim
empir
treatment
patient
risk
e
faecium
blood
stream
infect
bsi
method
retrospect
demograph
clinic
microbiolog
data
patient
e
faecium
bsi
compar
control
patient
studi
period
hematolog
unit
multivari
logist
regress
use
explor
independ
risk
factor
order
develop
prognost
model
determin
risk
e
faecium
bsi
result
signific
associ
e
faecium
bsi
found
age
hospit
stay
prior
blood
cultur
durat
hospit
year
admiss
fever
prior
blood
cultur
sever
durat
neutropenia
crp
creactiv
protein
time
blood
cultur
withdraw
colon
e
faecium
prior
blood
cultur
diarrhea
e
faecium
bsi
found
associ
sever
diseas
higher
mortal
rate
independ
risk
factor
e
faecium
bsi
age
year
hospit
stay
prior
blood
cultur
day
fever
day
colon
e
faecium
day
prior
blood
cultur
abdomin
pain
diarrhea
neutropenia
conclus
empir
treatment
consid
hematolog
patient
high
risk
develop
e
faecium
bsi
use
prognost
model
risk
stratif
design
studi
prudent
use
glycopeptid
becom
possibl
might
help
control
spread
vre
object
report
outbreak
klebsiella
pneumonia
carbapenem
resist
decreas
suscept
five
patient
tertiari
care
hospit
molecular
phenotyp
investig
clinic
isol
perform
method
antibiot
suscept
k
pneumonia
determin
etest
dna
k
pneumonia
isol
screen
pcr
presenc
kpc
vim
imp
betalactamas
genet
related
investig
use
enterobacteri
repetit
intergen
consensu
eric
repetit
sequenc
base
rep
pcr
result
ertapenemresist
k
pneumonia
isol
rectal
swab
urin
sampl
five
patient
outbreak
five
patient
one
colon
two
exhibit
urinari
tract
infect
two
patient
sever
ill
suffer
sepsi
andor
pneumonia
due
ertapenemresist
k
pneumonia
infect
patient
success
treat
high
dose
meropenem
gentamicin
case
pneumonia
addit
inhal
colistin
k
pneumonia
resist
penicillin
cephalosporin
ertapenem
fluoroquinolon
cotrimoxazol
strain
exhibit
elev
mic
toward
meropenem
doripenem
imipenem
still
remain
suscept
identifi
pcr
dna
sequenc
k
pneumonia
isol
five
patient
ericand
reppcr
analysi
k
pneumonia
isol
patient
show
ident
profil
suggest
clonal
spread
one
patient
produc
escherichia
coli
isol
rectal
swab
addit
produc
k
pneumonia
prior
emerg
express
e
coli
less
resist
e
coli
esbl
phenotyp
could
isol
sever
time
patient
e
coli
neg
presenc
gene
show
ident
dna
fingerprint
pattern
compar
express
e
coli
strongli
suggest
vivo
transfer
k
pneumonia
e
coli
patient
discuss
report
outbreak
produc
k
pneumonia
tertiari
care
hospit
epidemiolog
molecular
phenotyp
data
suggest
horizont
interspeci
transfer
k
pneumonia
e
coli
vivo
h
background
increas
preval
clinic
isol
vancomycinresist
enterococci
vre
patient
icu
notic
therefor
vre
screen
implement
determin
rate
colonis
icu
admiss
rate
acquisit
icu
stay
method
univers
vre
screen
introduc
interdisciplinari
icu
perian
swab
taken
patient
admiss
weekli
icu
discharg
analys
cultur
presenc
vre
preexist
vre
carriag
assum
sampl
taken
within
hour
admiss
posit
nosocomi
acquisit
defin
posit
followup
screen
neg
result
icu
admiss
vreposit
patient
characteris
detail
monitor
develop
vre
infect
hospitalis
result
patient
screen
vre
least
patient
posit
patient
could
includ
followup
screen
vreposit
patient
hospitalis
hour
first
screen
swab
distinct
commun
vs
nosocomi
acquisit
could
made
remain
patient
patient
vre
carrier
icu
admiss
patient
acquir
vre
icu
stay
mean
time
admiss
first
vre
detect
day
rang
nosocomi
case
interestingli
none
vreposit
patient
previous
known
carri
vre
total
patient
treat
vancomycin
prior
vre
detect
patient
known
colonisedinfect
methicillin
resist
aureu
vre
posit
patient
develop
definit
vre
infect
bloodstream
abdomin
infect
patient
asymptomat
bacteriuria
mortal
vre
patient
regardless
vre
infect
colonis
statu
conclus
univers
screen
reveal
substanti
vre
posit
rate
includ
high
proport
nosocomi
acquir
case
reason
high
vre
preval
may
previou
vancomycin
therapi
clinic
signific
vre
detect
low
neither
colonis
predict
consecut
infect
vre
statu
associ
mortal
therefor
implement
univers
vre
screen
subsequ
studi
period
moreov
concern
infect
control
standard
contact
isol
precaut
without
singl
room
isol
seem
justifi
studi
warrant
determin
role
environment
contamin
especi
set
moder
hand
hygien
complianc
e
e
ott
sohr
chaberni
hannov
medic
school
inst
med
microbiolog
hospit
epidemiolog
hannov
inst
hygien
environment
medicin
berlin
deutschland
background
routin
surveil
mrsa
establish
sinc
hannov
medic
school
order
identifi
nosocomi
transmiss
episod
molecular
protein
spa
type
introduc
method
mrsa
infect
inpati
analys
accord
cdc
definit
classifi
nosocomi
import
case
sequenc
repeat
region
staphylococcu
protein
gene
spa
type
perform
microbiolog
isol
mrsa
infect
result
total
mrsa
case
includ
mrsa
infect
detect
surgic
site
infect
frequent
type
mrsa
infect
follow
primari
bloodstream
infect
pneumonia
urinari
tract
infect
addit
secondari
bloodstream
infect
detect
signific
reduct
mrsa
infect
observ
p
spa
type
reveal
distinct
spa
type
spa
type
call
barnim
strain
predomin
strain
type
follow
proport
infect
secondari
bloodstream
infect
significantli
associ
spa
type
spa
type
significantli
less
associ
secondari
bloodstream
infect
conclus
molecular
spa
type
provid
addit
inform
epidemiolog
associ
routin
mrsa
surveil
spa
type
seem
invas
mrsa
strain
contrari
spa
type
studi
need
verifi
observ
juretzek
armengol
porta
r
haubold
pohl
f
schwab
w
inst
med
mikrobiologi
und
krankenhaushygien
cottbu
deutschland
last
year
preval
methicillinresist
staphylococcu
aureu
mrsa
infect
german
hospit
rais
order
know
impact
mrsa
hospit
admiss
develop
strategi
reduc
risk
spread
mrsa
insid
outsid
hospit
epidemiolog
studi
seven
german
hospit
south
brandenburg
conduct
evalu
incid
mrsa
carriag
hospit
admiss
investig
risk
factor
associ
mrsa
colonis
moreov
epidemiolog
distribut
characteris
mrsa
genotyp
analyz
method
two
month
period
onset
patient
accept
studi
clinic
ward
ask
risk
factor
screen
mrsa
nasal
wound
swab
plate
mrsa
chromogen
select
agar
incub
hour
suspect
mrsa
coloni
confirm
rapid
test
catalas
coagulas
antimicrobi
suscept
test
perform
assign
mrsa
isol
differ
clonal
complex
perform
analyz
gene
pattern
includ
virul
adhes
resist
factor
dna
chip
technolog
alereclondiag
jena
repres
predomin
multidrugresist
organ
wellknown
caus
agent
healthcareassoci
infect
hospit
howev
data
overal
preval
certain
geograph
area
yet
avail
object
determin
preval
mrsa
includ
proport
pantonvalentin
leukocidin
pvl
posit
strain
among
inpati
rural
district
hannov
germani
addit
check
patient
subgroup
may
increas
risk
mrsa
carriag
method
pointpreval
studi
conduct
hospit
octob
march
inpati
screen
cultur
nose
throat
broken
skin
patient
data
record
mrsa
isol
test
pvl
analys
staphylococc
protein
spa
type
result
mrsa
isol
consent
inpati
mrsa
preval
n
differ
hospit
rang
identifi
mrsa
carrier
detect
intern
medicin
ward
surgeri
ward
newli
identifi
mrsa
carrier
hospit
alert
system
place
spa
type
reveal
distinct
spa
type
spa
type
call
barnim
strain
predomin
strain
type
follow
commonli
known
mrsa
one
import
hospit
accquir
pathogen
within
healthcar
institut
methicillinresist
staphylococcu
aureu
mrsa
transmit
patient
patient
via
healthcar
worker
hcw
hand
cloth
equip
environ
studi
evalu
preval
mrsa
colon
among
hcw
outsid
outbreak
situat
import
staff
real
sourc
transmiss
therefor
investig
focus
mrsa
among
hospit
employe
evalu
effic
decolonis
therapi
among
healthcar
worker
staff
member
physican
nurs
person
without
direct
contact
patient
nine
hospit
within
german
part
dutchgerman
euregio
particip
investig
nasalpharyng
swab
taken
staff
member
monday
subsequ
wednesday
risk
factor
mrsa
carriership
determin
standard
questionnair
swab
microbiolog
process
spatyp
order
exclud
determin
carriership
stabl
mrsa
carrier
two
posit
swab
underw
erad
treatment
addit
skin
stabl
mrsa
posit
personnel
swab
case
skincolon
particip
releas
work
success
mrsaerad
verifi
two
day
end
antimicrobi
therapi
otherwis
first
two
day
erad
therapi
take
place
home
longterm
erad
success
control
one
six
month
erad
staff
member
mrsaposit
al
least
one
swab
posit
swab
among
physician
mrsa
preval
lower
nurs
staff
member
without
direct
contact
patient
posit
mrsa
anamnesi
acn
identifi
statist
signific
risk
factor
mrsa
colonis
stabl
mrsa
carrier
underw
decolon
therapi
parallel
normal
work
therapi
success
first
erad
cycl
case
could
verifi
followup
swap
nine
differ
spatyp
detect
frequent
one
typic
hospitalacquir
hamrsa
wherea
lifestockassoci
lamrsa
found
staff
carrier
studi
show
hospit
staff
frequent
colon
typic
hospitalaccquir
mrsa
outsid
outbreak
situat
mrsa
preval
differ
among
profession
group
notabl
livestockassoci
mrsa
found
euregio
high
pig
densiti
exist
importantli
hcw
success
decolon
matter
erad
home
parallel
work
decolonis
parallel
work
reduc
day
inabl
work
among
hcw
comparison
complet
decolonis
home
object
rate
vref
remain
constant
declin
germani
recent
year
molecular
analys
suggest
genotyp
switch
vanatyp
vanbtyp
among
hospit
vref
investig
outbreak
vanb
type
vref
involv
neonat
patient
intens
care
unit
german
hospit
resolv
emerg
spread
vanb
vref
materi
sampl
taken
singl
neonat
icu
period
enterococci
isol
nonselect
columbia
agar
speci
identifi
biochem
vancomycin
mic
determin
etest
genotyp
pcrhybrid
method
altogeth
e
faecium
sent
focal
lab
enterococci
rki
analys
includ
confirm
resist
phenotyp
genotyp
molecular
type
character
pfge
mlst
plasmid
type
rep
gene
result
confirm
vref
possess
vanb
vanb
vref
vancomycinresist
accord
eucast
criteria
mic
mgl
use
clsi
breakpoint
mgl
addit
resist
includ
ampicillin
highlevel
hl
ciprofloxacin
hl
gentamicin
hl
streptomycin
erythromycin
tetracyclin
suscept
linezolid
daptomycin
one
resist
tigecyclin
mic
pfge
analysi
reveal
one
major
clone
preval
entir
studi
period
repres
isol
anoth
vanb
vref
vana
vref
clonal
differ
major
outbreak
strain
reveal
mlst
type
hospitalassoci
strain
type
wide
preval
germani
recent
year
plasmid
type
identifi
preval
prumlik
plasmid
outbreak
strain
preliminari
molecular
character
reveal
chromosom
locat
vanb
cluster
discuss
increas
number
vanb
vref
involv
outbreak
also
report
european
countri
sweden
franc
poland
molecular
analysi
recent
outbreak
strain
sweden
reveal
vanbtyp
vref
associ
distribut
specif
cluster
prumlik
plasmid
case
correspond
vanb
cluster
plasmidloc
chromosomallyborn
although
isol
contain
sever
plasmid
includ
also
prumlik
variant
conclus
reliabl
detect
low
level
vancomycin
express
vanbtyp
vref
challeng
clinic
laboratori
delay
detect
unnot
appear
may
support
spread
vanb
vref
underestim
true
preval
among
clinic
set
molecular
screen
method
detect
strain
superior
phenotyp
assay
includ
also
screen
agar
plate
compar
high
vancomycin
inoculum
emerg
multiresist
pseudomona
aeruginosa
hidden
reservoir
hospit
molecular
studi
nosocomi
outbreak
high
risk
area
multiresist
pseudomona
p
aeruginosa
increas
problem
health
care
facil
one
import
inhabit
biofilm
nonferment
consist
differ
reservoir
clinic
siphon
trap
wash
basin
colon
differ
germ
may
underestim
sourc
pathogen
distribut
longterm
surveil
within
hematooncolog
set
isol
unit
patient
allogen
stem
cell
transplant
reveal
associ
emerg
multiresist
p
spp
infect
detect
suspici
strain
siphon
room
affect
patient
receiv
antibiot
prophylaxi
underw
treatment
multipl
daili
throat
rins
oropharyng
mucos
front
wash
basin
procedur
possibl
patient
inhal
aerosol
siphon
water
respons
outbreak
two
strain
could
detect
rapdpcr
specif
p
aeruginosa
microarray
genotyp
comparison
outbreak
strain
strain
isol
siphon
room
show
antibiot
resist
pattern
resistotyp
broad
resist
common
antibiot
suscept
polymyxin
b
wherea
resistotyp
suscept
polymyxin
b
amikacin
carbapenemresist
strain
screen
posit
vimmetallobetalactamas
outbreak
could
stop
implement
call
hygien
siphon
wash
basin
isol
unit
fa
biorec
dr
schluttig
medizinisch
apparatebau
dresden
conclus
report
molecular
studi
outbreak
multiresist
p
spp
hematooncolog
ward
optim
condit
concern
hygien
manag
even
maximum
barrier
infect
control
measur
undertaken
avoid
nosocomi
infect
hidden
reservoir
like
siphon
trap
wash
basin
sourc
pathogen
outbreak
instal
hygien
siphon
isol
unit
high
risk
patient
help
reduc
distribut
multiresist
germ
earli
molecularepidemiolog
analysi
urgent
need
verifi
outbreak
situat
essenti
implement
specif
effect
infect
control
measur
gastrointestin
tract
harbour
complex
microbi
ecosystem
engag
continu
crosstalk
host
balanc
relationship
intestin
epitheli
cell
iec
gut
microb
disturb
result
activ
mucos
immun
system
contribut
develop
inflammatori
bowel
diseas
ibd
use
cell
cultur
model
analyz
cellular
respons
iec
coincub
gramnegativ
probiot
strain
ecoli
nissl
ecn
ibd
may
develop
defect
barrier
function
base
microarray
data
obtain
coincub
iec
focuss
protein
apic
junction
complex
ajc
use
transepitheli
resist
ter
cell
readout
monitor
epitheli
barrier
function
micrornaprofil
iec
coincub
probiot
identifi
microrna
mirna
correspond
protein
ajc
qrtpcr
westernblot
barrier
function
enforc
probiot
ecoli
disrupt
epec
infect
even
barrier
disrupt
epec
barrier
function
could
restor
incub
probiot
ecn
monitor
increas
ter
confirm
particip
microrna
mirna
regul
ajc
protein
transfect
cell
mirna
mirnainhibitor
mirnamim
studi
show
mirna
involv
strengthen
probiot
effect
barrier
disrupt
effect
epec
studi
reveal
molecular
respons
iec
specif
induc
gramneg
probiot
e
coli
strain
nissl
insight
molecular
target
specif
mirna
might
foster
develop
new
strategi
treatment
gastrointestin
diseas
effect
pathogen
probiot
e
coli
immun
cell
gastrointestin
barrier
h
salia
n
kramko
schmidt
zentrum
molekularbiologi
der
infektiologi
deutschland
gut
immun
system
keep
microbiota
gastrointestin
tract
surveil
besid
commens
probiot
microorgan
also
bacteri
pathogen
enteropathogen
ecoli
caus
diarrhea
exploit
host
cell
subvers
defens
measur
pathogen
interact
subvert
immun
cell
intestin
barrier
fulli
understood
studi
address
effect
enteropathogen
e
coli
epec
strain
probiot
e
coli
nissl
ecn
strain
human
pmbc
human
monocyt
cell
dendrit
cell
deriv
human
pbmc
monocyt
cell
infect
epec
wt
epec
mutant
strain
probiot
strain
ecn
cytotox
bacteria
evalu
analyz
cell
viabil
addit
morpholog
chang
within
actin
network
analyz
via
confoc
immunofluoresc
microscopi
influenc
express
protein
involv
inflamm
via
qrtpcr
western
blot
contrast
infect
cell
e
coli
ecn
epec
infect
exhibit
dramat
increas
cytotox
threefold
analysi
actin
cytoskeleton
cell
reveal
epec
wt
well
effector
protein
delet
mutant
abl
induc
pedest
classic
actin
accumul
bacteri
attach
site
observ
epec
mutant
lack
effector
protein
tir
interestingli
pedest
format
faintli
detect
also
mutant
without
function
type
iii
secret
system
concern
express
cytokin
observ
upregul
antiinflammatori
upon
infect
dc
cell
ecn
two
fivefold
contrast
infect
epec
wt
analyz
influenc
epec
ecn
nfkb
signal
cascad
cell
observ
activ
pathway
upon
ecn
e
coli
coincub
inhibit
upon
epec
coincub
result
show
epec
exhibit
destruct
activ
immun
cell
virul
factor
effector
protein
enabl
bacteria
specif
target
host
cellular
process
comparison
effect
pathogen
probiot
bacteria
immun
cell
might
reveal
insight
molecular
mechan
impair
gastrointestin
disord
role
dendrit
cell
activ
well
tolllik
receptor
express
dss
coliti
host
live
normal
symbiosi
intestin
microbiota
due
long
coevolut
somehow
toler
abolish
ibd
patient
lead
strong
long
last
inflamm
irregularli
interrupt
short
remiss
phase
order
investig
role
dendrit
cell
express
acut
phase
inflamm
dextran
sodium
sulfat
dss
model
employ
therefor
dss
administ
mice
day
mice
display
signific
weight
loss
increas
diseas
activ
index
lamina
propria
lp
mesenter
lymph
node
mln
dc
isol
untreat
mock
dss
treat
mice
lp
dc
dss
treat
mice
own
significantli
increas
level
mhcii
repres
activ
dc
state
compar
dc
mock
mice
wherea
mln
dc
differ
concern
activ
state
furthermor
dss
mice
featur
higher
level
myeloid
dc
lp
well
mln
compar
mock
mice
well
dss
mice
significantli
increas
percentag
dc
lp
comparison
mock
mice
wherea
amount
dc
mln
vice
versa
surprisingli
lp
mln
dc
dss
mice
express
significantli
higher
amount
comparison
mock
mice
increas
appear
dc
higher
amount
like
counter
regul
host
order
suppress
develop
inflamm
hp
horz
hettlich
introduct
bacteri
inventori
human
oral
caviti
alreadi
fairli
comprehens
compos
differ
speci
mani
uncultiv
howev
dynam
variabl
oral
microflora
relat
health
diseas
still
poorli
understood
aim
test
hypothesi
develop
oral
symptom
multipl
stress
immunosystem
relat
composit
divers
initi
microflora
materi
method
model
system
analyz
oral
microbiota
healthi
individu
challeng
expedit
remot
region
himalaya
impli
hygien
diet
temperatur
physic
mental
stress
plaqu
sampl
taken
begin
bhulebhul
destin
meter
differ
altitud
seven
day
later
manang
twentyeight
individu
remain
symptomfre
group
particip
develop
dental
problem
mostli
gingiv
group
ii
oral
microbiota
monitor
via
termin
restrict
fragment
length
polymorph
trflp
analysi
amplifi
rrnagen
directli
plaqu
sampl
variat
trflp
dataset
analyz
base
addit
main
effect
multipl
interact
ammi
model
use
trex
softwar
packag
http
trexbiohpcorg
result
variat
trf
main
effect
least
indic
major
variat
trflp
profil
due
inher
differ
microbi
commun
among
individu
howev
compar
group
ii
interact
signal
consist
observ
vari
analyt
paramet
case
two
time
point
sampl
ie
sampl
start
end
trekkingtour
compar
likewis
shannonweaverindex
divers
jaccardindex
similar
indic
group
ii
differ
significantli
heterogen
oral
microbi
commun
begin
trek
tour
base
human
oral
microbiom
databas
homd
distinct
bacteri
taxa
could
elucid
keycompon
explain
observ
differ
discuss
data
indic
discern
relationship
suscept
clinic
symptom
indigen
preform
oral
microbiota
mean
initi
composit
oral
ecosystem
determin
whether
symptom
develop
upon
exposur
variou
stressparamet
role
b
induct
semimatur
dentrit
cell
mainten
intestin
homeostasi
c
klameth
k
schulzeosthoff
hildebrand
k
bode
b
member
b
protein
famili
recent
describ
regul
transcript
factor
nf
b
unlik
bs
b
seem
inhibitor
modul
nf
b
product
proinflammatori
cytokin
tnfi
inhibit
presenc
b
gene
like
gmcsf
highli
regul
hypothes
b
least
partial
contribut
dc
semimatur
process
shown
depend
presenc
absenc
tnf
furthermor
dc
differenti
type
promot
rather
tolerogen
proinflammatori
tcell
respons
due
fact
b
might
play
crucial
role
mainten
intestin
homeostasi
clarifi
role
might
lead
develop
new
strategi
treatment
inflammatori
bowl
diseas
analys
compar
first
step
b
mrna
protein
express
semimatur
matur
dc
use
quantit
pcr
western
blot
analysi
addit
express
b
restimul
semimatur
dc
investig
futur
experi
involv
b
defici
mice
gener
bmdc
analysi
impact
b
acut
dss
coliti
c
eichhorn
meltk
k
zimmermann
wassenaar
probiot
drug
symbioflor
e
coli
dsm
contain
six
escherichia
coli
genotyp
name
e
coli
function
repres
one
popul
symbioflor
liquid
prepar
contain
live
e
coli
cell
recent
classifi
biosafeti
level
organ
product
well
establish
probiot
drug
year
wide
use
especi
treatment
colon
irrit
adult
children
genom
six
genotyp
sequenc
pyrosequenc
sequenc
synthesi
technolog
overal
twelv
differ
plasmid
identifi
wholegenom
comparison
six
genotyp
allow
subdivis
four
differ
genomotyp
could
also
show
symbioflor
e
coli
clearli
belong
cluster
apathogen
e
coli
howev
larg
unknown
e
coli
genotyp
respons
product
probiot
charact
gene
protein
involv
develop
probiot
trait
e
coli
alreadi
attract
interest
due
abil
induc
defensin
product
cell
cultur
human
volunt
use
vitro
adher
assay
human
intestin
epitheli
cell
could
show
e
coli
significantli
decreas
adhes
enteropathogen
e
coli
strain
epec
host
cell
compar
probiot
strain
e
coli
nissl
epec
adher
assay
suitabl
surrog
test
system
evalu
probiot
action
given
microorgan
sequenc
genom
togeth
vitro
data
help
us
gain
insight
probiot
behavior
symbioflor
oral
biofilm
suppos
involv
number
oral
diseas
plaqu
format
dental
cari
periodont
thu
detail
knowledg
oral
microbiota
biofilm
format
import
better
understand
pathogenesi
present
pilot
studi
composit
human
microbiota
intraor
biofilm
format
analys
healthi
volunt
femal
age
use
bovin
dental
enamel
slab
harvest
minut
hour
parallel
interproxim
dental
plaqu
saliva
analys
microbi
commun
character
trflp
termin
restrict
fragment
length
polymorph
analysi
rrna
gene
appli
three
differ
restrict
enzym
haeiii
mspi
hhai
trflp
signal
phylogenet
group
assign
sequenc
data
obtain
dgge
denatur
gradient
gel
electrophoresi
analysi
silico
analysi
publish
sequenc
data
respect
initi
sampl
investig
dgge
reveal
varieti
band
restrict
signal
dental
biofilm
sampl
wherea
higher
divers
band
found
saliva
proxim
interdent
plaqu
semiquantit
analysi
trflp
confirm
lower
microbi
divers
dental
biofilm
compar
oral
compart
specif
haeiii
trf
signal
could
assign
variou
phylogenet
group
could
show
microbi
commun
structur
differ
dental
biofilm
saliva
interproxim
dental
plaqu
abund
streptococci
highest
dental
biofilm
wherea
bacteroidet
predominantli
found
saliva
rel
abund
veillonella
spp
vari
biofilm
format
lowest
frequenc
hour
biofilm
phylogenet
group
eg
group
haemophilusneisseria
detect
equal
frequenc
sampl
similar
commun
structur
differ
oral
compart
estim
calcul
similar
index
chaojaccard
reveal
lowest
similar
microbi
commun
saliva
interproxim
dental
plaqu
compar
hour
dental
biofilm
highest
similar
calcul
microbi
commun
hour
dental
biofilm
versu
hour
dental
biofilm
conclud
characterist
signatur
microbiota
found
saliva
interproxim
dental
plaqu
also
oral
biofilm
format
cultureindepend
analysi
microbiota
may
provid
new
insight
microbi
divers
variou
commun
shown
differ
oral
compart
grow
oral
biofilm
background
candida
albican
diploid
asexu
fungu
part
normal
flora
includ
vagin
surfac
healthi
individu
c
albican
normal
caus
diseas
howev
balanc
normal
flora
alter
e
g
antibiot
hormon
therapi
c
albican
caus
pain
cutan
subcutan
infect
includ
vulvovagin
germani
around
five
million
women
suffer
candid
vulvovagin
lactobacilli
belong
physiolog
flora
vagina
studi
show
benefici
effect
lactobacilli
bacteri
vaginosi
howev
role
lactobacilli
candid
vulvovagin
known
one
well
known
pathogen
factor
candida
spp
transit
yeast
hyphal
growth
therefor
analyz
far
lactobacilli
may
influenc
yeasthyph
transit
describ
factor
facilit
invas
process
method
total
use
five
differ
c
albican
strain
isol
women
present
differ
microbi
environ
vagina
differ
candida
spp
incub
distinct
lactobacillu
strain
l
gasseri
lcrispatu
und
l
jenseni
isol
vagina
well
analyz
far
differ
lactobacillu
strain
influenc
viabil
xttreduct
assay
candida
well
express
hyphaespecif
gene
result
l
crispatu
inhibit
growth
candida
albican
isol
studi
diminish
viabil
significantli
contrast
l
gasseri
led
signific
increas
viabil
candida
albican
strain
l
jensenii
exhibit
influenec
fungal
growth
effect
differ
lactobacillu
spp
yeast
hypha
transit
strongli
depend
type
respect
candida
albican
strain
conclus
result
one
may
conclud
lactobacillu
spp
may
either
favour
inhibit
pathogen
candida
albican
addit
genet
predisposit
environment
factor
commens
bacteria
contribut
develop
inflammatori
bowl
diseas
ibd
gut
mammalian
colonis
complex
flora
microorgan
contain
differ
bacteri
speci
bacteri
popul
contribut
health
host
among
thing
promot
proper
immun
system
develop
limit
pathogen
colon
bacteroid
vulgatu
mpk
shown
abil
prevent
coliti
wherea
e
coli
mpk
induc
intestin
inflamm
mice
mechan
howev
remain
unclear
current
studi
analys
composit
intestin
microbiota
tcell
transfer
rna
gene
method
want
reveal
differ
gut
microbiota
mice
develop
coliti
compar
mice
stay
healthi
composit
intestin
microbiota
develop
coliti
cystic
fibrosi
cf
recess
inherit
diseas
caus
mutat
cftr
gene
cf
patient
morbid
sever
influenc
chronic
polymicrobi
lung
infect
routin
microbiolog
test
focus
detect
typic
pathogen
use
culturebas
techniqu
thu
complex
microbi
commun
cystic
fibrosi
lung
display
howev
use
new
cultureindepend
techniqu
unbias
semiquantit
analysi
complex
bacteri
commun
avail
could
help
better
understand
role
microbiota
colonis
pathogen
cf
present
pilot
studi
respiratori
sampl
cf
patient
three
differ
age
group
year
analys
culturebas
new
cultureindepend
method
trflp
correspond
previou
studi
agedepend
infect
rate
found
culturebas
analysi
classic
cf
relat
pathogen
highest
rate
aureu
infect
year
old
group
rise
p
aeruginosa
infect
rate
older
patient
year
find
support
cultureindepend
analysi
bacteri
nucleic
acid
respiratori
sampl
use
trflp
howev
also
found
new
aspect
respiratori
infect
cultureindepend
method
increas
rate
anaerob
bacteria
cf
patient
older
age
potenti
contribut
clinic
progress
cf
lung
diseas
howev
prospect
clinic
studi
requir
confirm
new
assumpt
cultureindepend
analysi
also
provid
quantit
view
rel
abund
specif
pathogen
bacteri
commun
cf
patient
high
rel
abund
staphylococci
neisseria
haemophilu
streptococci
bacteroidet
veillonella
found
wherea
pseudomona
speci
detect
surprisingli
low
frequenc
sampl
age
group
conclud
cultureindepend
analysi
eg
trflp
fundament
chang
current
view
polymicrobi
lung
infect
cf
patient
due
unbias
detect
potenti
new
respiratori
pathogen
due
new
quantit
aspect
suppos
soon
cultureindepend
analysi
respiratori
microbiota
could
becom
new
diagnost
standard
optim
diagnost
therapi
cf
patient
introduct
commens
compris
import
compon
microecolog
epithelia
yet
opposit
upper
respiratori
tract
gut
lower
respiratori
tract
includ
lung
consid
free
foreign
microorgan
vastli
unexplor
understand
lung
microecolog
affect
host
defens
infect
essenti
identifi
lung
commens
materi
method
identifi
bacteri
speci
steril
excis
murin
lung
combin
variou
cultur
system
rdna
analysi
use
clone
pyrosequenc
method
compar
inbr
mice
maintain
specificpathogenfre
spf
inbr
wildderiv
mice
distinct
geograph
origin
nonspffacil
well
mice
caught
wild
local
bacteria
lung
fluoresc
situ
hybrid
fish
use
final
bacteri
commun
group
mice
compar
divergencebas
divers
analys
speci
level
result
isol
aerob
facult
anaerob
includ
pasteurellacea
enterobacteria
firmicut
lung
mice
addit
speci
includ
noncultivat
betaproteobacteria
enter
bacteria
identifi
rdna
clone
analysi
addit
confirm
major
speci
lung
commens
betaproteobacteria
ralstonia
sp
highthroughput
pyrosequenc
method
notabl
detect
bacteri
commun
alveolar
epithelia
eubacteria
specif
fish
absenc
inflammatori
lung
patholog
comparison
bacteri
commun
mous
group
show
overal
composit
phyla
famili
level
similar
regardless
mous
origin
rarefact
curv
divers
rich
measur
show
signific
differ
group
conclusiondiscuss
screen
mous
lung
microbiom
tradit
cultur
method
robust
genet
analysi
ultim
expect
lung
isol
major
speci
noncultur
method
introduc
mous
model
experi
lung
commens
well
coinfect
lung
pathogen
identif
commens
bacteria
murin
lung
pave
path
studi
influenc
respiratori
tract
microbiom
infect
immun
lung
salivari
microbiom
indic
humanmicrob
coevolut
introduct
humanassoci
bacteria
hold
great
potenti
shed
light
histori
ancestor
ie
migrat
pattern
concept
humanbacteri
coevolut
demonstr
helicobact
pylori
howev
analysi
requir
stomachbiopsi
current
test
hypothesi
oral
microb
may
function
chronomet
human
evolut
therebi
allow
finescal
differenti
human
popul
materi
method
saliva
sampl
ten
volunt
area
worldwid
repres
divers
ethnic
group
initi
focu
studi
variat
rdna
intern
transcrib
spacer
region
fusobacterium
nucleatum
gdh
encod
glucosedehydrogenas
gtf
encod
glycosyltransferas
mitisstreptococci
analyz
cultureindepend
method
addit
trflp
whole
commun
genet
profil
appli
result
region
f
nucleatum
gdh
mitisstreptococci
could
directli
pcramplifi
saliva
dnaextract
use
newli
design
well
publish
primer
ten
individu
test
countri
germani
turkey
poland
bolivia
congo
posit
f
nucleatum
nine
ten
individu
germani
congo
test
posit
also
gdh
sequenc
analysi
ten
clone
per
individu
show
high
intraand
interindividu
divers
gene
base
phylogenet
tree
reconstruct
cluster
consist
sequenc
type
repres
multipl
countri
howev
one
countri
typic
domin
cluster
addit
also
found
uniqu
cluster
explicitli
consist
sequenc
type
specif
one
countri
discuss
oral
microb
found
saliva
may
exhibit
clonal
structur
thu
repres
distinct
geograph
region
phylogenet
tool
unifrac
necessari
comput
distanc
within
host
order
discern
geograph
ethnic
associ
given
saliva
increasingli
prefer
sampl
human
sourc
dna
epidemiolog
popul
genet
studi
salivari
microbiom
may
hold
addit
valuabl
inform
provid
new
perspect
unsolv
human
migrat
pattern
issu
great
social
anthropolog
medic
import
introduct
clinic
studi
reveal
probiot
mixtur
vsl
protect
context
inflammatori
bowel
diseas
ibd
previous
show
reduc
cecal
inflamm
vsl
mice
correl
reduc
level
interferoninduc
protein
ip
cecal
epitheli
cell
mechanist
degrad
intestin
epitheli
cell
iec
mediat
cell
surfac
protein
vsl
lactobacillu
paracasei
lp
aim
present
studi
identifi
activ
probiot
structur
trigger
loss
proinflammatori
chemokin
method
iec
stimul
experi
cellfre
incub
assay
ileal
explant
cultur
vivo
experi
use
murin
ileiti
model
use
investig
probiot
mechan
lp
physiolog
relev
chromatograph
fraction
lcmsm
analysi
use
identifi
activ
probiot
structur
isogen
mutant
gener
proof
protect
activ
identifi
structur
result
addit
fix
bacteria
also
condit
media
lp
cm
lp
mediat
loss
iec
vitro
experi
includ
pmsf
inhibitor
studi
reveal
lp
express
secret
cell
wall
associ
serin
proteas
lp
select
directli
degrad
iecindepend
manner
besid
cm
lp
select
target
array
proinflammatori
chemokin
eg
itac
fractalkin
wherea
test
cytokin
cleav
furthermor
explant
cultur
experi
use
inflam
intestin
tissu
experiment
ibd
model
reveal
establish
gradient
tissu
also
destroy
host
cellindepend
mechan
physiolog
relev
antiinflammatori
mechan
proven
intraperiton
inject
activ
bacteri
supernat
experiment
ileiti
model
result
select
degrad
ileal
lymphocyt
recruit
ileal
inflamm
chromatograph
fraction
probiot
supernat
subsequ
lcmsm
analysi
indic
lactocepin
lp
activ
probiot
proteas
gener
lactocepinneg
mutant
similarli
activ
transform
human
lactobacillu
casei
isol
result
loss
degrad
capac
final
prove
probiot
lactocepin
activ
antiinflammatori
bacteri
structur
conclus
present
studi
reveal
select
degrad
proinflammatori
chemokin
includ
probiot
lactocepin
specif
structurerel
probiot
mechan
clinic
relev
probiot
identif
lactocepin
probiot
structur
could
enabl
structurebas
evalu
probiot
bacteria
therapeut
intervent
context
chronic
inflamm
flagellin
tcpc
essenti
factor
protect
effect
e
coli
nissl
strain
dssinduc
coliti
menz
k
gronbach
p
adam
wieser
schubert
u
dobrindt
ecn
effect
mesalazin
mainten
remiss
ulcer
coliti
shorten
durat
diarrhea
young
children
studi
preclin
model
acut
coliti
whether
ecn
protect
diseas
analys
bacteri
mechan
underli
antiinflammatori
capac
method
mice
fed
either
ecn
ecn
flic
ecn
tcpc
treat
dss
bodi
weight
diseas
activ
index
assess
daili
end
experi
colon
length
weight
measur
inflamm
determin
histolog
analys
colon
furthermor
activ
matur
lamina
propria
mesenter
lymph
node
dendrit
cell
cell
analys
result
wild
type
mice
e
coli
nissl
protect
dss
induc
coliti
wherea
protect
reduc
mice
line
flic
mutant
strain
less
effect
protect
host
diseas
compar
ecn
wild
type
strain
howev
second
bacteri
factor
tcpc
also
contribut
protect
effect
ecn
tcpc
mutant
strain
abl
protect
diseas
administr
doubl
mutant
flic
tcpc
ecn
evid
conclus
conclus
ecn
amelior
dss
induc
acut
coliti
via
flagellin
secret
protein
tcpc
howev
contribut
bacteri
factor
antiinflammatori
effect
ecn
exclud
marin
propel
flagella
probiot
escherichia
coli
strain
nissl
also
major
adhesin
mediat
bind
flagella
probiot
e
coli
strain
nissl
ecn
respons
motil
also
ecn
abil
induc
product
human
betadefensin
report
third
function
organel
ecn
ex
vivo
studi
ecn
isogen
nonflagel
mutant
ecn
flicand
complement
mutant
prove
flagella
essenti
effici
adher
cryosect
human
gut
biopsi
hyperflagel
ecn
variant
adher
even
effici
cryosect
ecn
wt
contrast
vitro
studi
show
neither
overexpress
lack
flagella
signific
effect
adhes
human
epitheli
cell
line
observ
discrep
like
due
lack
mucin
cell
line
wherea
mucu
might
still
present
cryosect
interpret
support
find
show
flagelladepend
adhes
ecn
human
epitheli
cell
line
produc
mucin
vitro
bind
ecn
flagella
mucin
demonstr
inhibit
ecn
adhes
cryosect
preincub
flagel
ecn
depend
manner
addit
abl
show
hyperflagel
ecn
variant
adher
much
effici
compar
ecn
wt
wherea
nonflagel
mutant
ecn
flicadh
bare
contrast
e
coli
strain
harbor
express
ident
flic
gene
adher
ineffici
ecn
flic
unknown
reason
final
electron
microscop
examin
ecn
reveal
e
coli
strain
express
one
flagella
one
cell
pole
contrast
gener
assumpt
e
coli
peritrich
flagel
bacteria
conclud
flagella
ecn
major
adhesin
bind
major
constitu
mucu
small
larg
human
intestin
therefor
organel
might
import
effici
transient
colon
human
gut
natur
ligand
aryl
hydrocarbon
receptor
control
intestin
lymphoid
organogenesi
ea
kiss
c
vonarbourg
kopfmann
c
esser
diefenbach
univers
freiburg
immh
freiburg
deutschland
intestin
homeostasi
prerequisit
activ
extract
metabolit
absort
intestin
epithelium
protect
intestin
pathogen
howev
underli
molecular
network
ill
defin
ror
texpress
innat
lymphocyt
ror
ilc
play
import
role
promot
intestin
homeostasi
ror
ilc
constitut
produc
interleukin
il
cytokin
instruct
epitheli
express
antimicrobi
gene
requir
protect
intestin
infect
attach
effac
ae
bacteria
furthermor
subset
ror
ilc
lymphoid
tissueinduc
lti
function
requir
postnat
develop
intestin
lymphoid
tissu
harbor
microflorareact
igaproduc
b
cell
bacteria
control
gener
b
cellcontain
isol
lymphoid
follicl
ilf
b
cellfre
cryptopatch
unknown
whether
develop
cryptopatch
program
also
instruct
environment
cue
famili
perarntsim
pa
domaincontain
protein
conserv
throughout
eukaryot
speci
believ
group
protein
evolv
control
adapt
multicellular
organ
environment
challeng
one
member
aryl
hydrocarbon
receptor
ahr
function
ligandinduc
transcript
factor
upon
bind
ligand
instruct
transcript
program
includ
induct
xenobiot
metabol
enzym
although
role
ahr
respons
environment
toxin
appreci
role
mucos
immun
system
well
defin
address
role
ahr
develop
function
ror
ilc
gener
mice
lack
ahr
ror
ilc
ahr
lti
interestingli
ahr
lti
lack
genesi
cryptopatch
ilf
ror
ilc
develop
independ
ahr
birth
requir
ahr
signal
postnat
expans
prerequisit
format
cp
ilf
postnat
mainten
ror
ilc
control
dietari
phytochem
eg
plantderiv
glucosinol
polyphenol
serv
natur
ahr
ligand
ahrmedi
signal
stabil
kit
express
ror
ilc
mice
defect
kit
signal
crippl
develop
ilf
ahrdefici
mice
highli
suscept
infect
citrobact
rodentium
mous
model
ae
infect
enterohemorrhag
strain
e
coli
result
demonstr
plantderiv
dietari
ahr
ligand
dynam
regul
postnat
develop
lymphoid
follicl
control
pool
size
ror
ilc
lti
function
thu
sens
dietari
compound
allow
dynam
adapt
immun
cell
environment
cue
requir
establish
intestin
homeostasi
resist
intestin
infect
background
proteolyt
degrad
extracellular
matrix
matrix
metalloproteas
seriou
consequ
intestin
inflamm
aim
studi
investig
whether
proteas
produc
commens
gut
bacteria
contribut
pathogenesi
ibd
purpos
focus
zinc
depend
metalloproteas
gelatinas
gele
enterococcu
faecali
e
faecali
result
order
investig
impact
bacteri
gele
develop
chronic
intestin
inflamm
monoassoci
gnotobiotc
wild
type
wt
interleukin
defici
mice
gele
express
e
faecali
strain
isogen
mutant
strain
lack
gele
express
includ
gele
delet
fsrb
delet
histolog
analysi
reveal
signific
reduct
distal
proxim
colon
tissu
patholog
mice
absenc
gele
wt
mice
develop
coliti
demonstr
commens
charact
e
faecali
strain
epitheli
barrier
function
seem
affect
gele
presenc
extracellular
ecadherin
protein
domain
significantli
reduc
mice
furthermor
use
lcmsm
analysi
could
indentifi
cleavag
site
gele
sequenc
recombin
murin
ecadherin
suggest
possibl
direct
gelemedi
degrad
stimul
distal
colon
segment
proteolyt
activ
gele
reveal
loss
barrier
function
mice
suscept
intestin
inflamm
tnf
arewt
tissu
patholog
develop
loss
barrier
integr
associ
reduc
level
extracellular
ecadherin
final
cell
exhibit
decreas
transepitheli
electr
resist
increas
transloc
permeabl
marker
stimul
gele
background
could
show
specif
gelemedi
loss
barrier
function
use
e
faecali
lipoprotein
unrel
control
broad
spectrum
mmp
inhibitor
marimastat
block
gele
activ
conclus
e
faecali
gele
impair
intestin
mucos
barrier
function
associ
degrad
extracellular
ecadherin
protein
domain
data
clearli
demonstr
role
gele
commensalderiv
proteas
develop
intestin
inflamm
diseasesuscept
host
dendrit
cell
dc
provid
differ
phenotyp
display
immatur
dc
idc
phenotyp
activ
matur
dc
mdc
phenotyp
recent
third
phenotyp
discov
term
semimatur
smdc
smdc
abl
take
antigen
process
show
reduc
express
cell
activ
costimulatori
molecul
reduc
express
mhc
class
ii
smdc
fail
polar
cell
sm
bmdc
show
reduc
cleav
invari
chain
ii
compar
mdc
major
regul
mhc
class
ii
transport
cell
surfac
lead
reduc
mhc
class
ii
surfac
express
cleav
ii
catalyz
endosom
proteas
cat
regul
endogen
inhibitor
cystatin
c
inde
mice
lack
cystatin
c
provid
signific
higher
suscept
toward
dss
induc
coliti
therefor
suggest
semimatur
play
import
role
maintain
intestin
homeostasi
regul
cathepsin
could
potenti
target
treatment
coliti
respect
averag
number
sequenc
obtain
per
tissu
sampl
mean
length
bp
sequenc
could
classifi
phyla
flora
composit
differ
markedli
mit
mhh
mice
mhh
mice
share
detect
speci
mit
mice
show
overal
lower
rich
bacteri
flora
compar
mit
mice
sever
bacteri
phyla
exclus
detect
either
mhh
mit
mice
notabl
caecum
sampl
mit
mice
yield
larg
number
sequenc
assign
deferribacter
phylum
phylum
complet
absent
mhh
mice
conclus
ko
mice
hous
spf
condit
two
differ
institut
differ
markedli
suscept
h
hepaticusinduc
intestin
patholog
differ
associ
highli
signific
differ
microbiota
composit
like
respons
attenu
respons
h
hepaticu
mice
hous
one
institut
data
highlight
import
character
intestin
microbiom
interpret
result
murin
model
ibd
use
automatis
univers
diagnost
laboratori
meet
eye
c
mackenzi
institut
medizinisch
mikrobiologi
und
krankenhaushygien
deutschland
introduct
laboratrori
automatis
made
rapid
import
advanc
past
year
increas
technolog
standardis
specimen
collect
integr
multipl
process
simpl
inocul
media
imag
identif
microorgan
use
sophist
technolog
malditof
semiautom
fashion
univers
laboratori
tradit
high
throughput
diagnost
servic
often
personel
structur
markedli
differ
counterpart
privat
sector
thu
target
mani
commerci
compani
manufactur
technolog
howev
need
effici
improv
qualiti
provid
standardis
procedur
optim
furnish
autom
system
method
univers
diagnost
laboratori
provid
servic
approxim
inpati
bed
tertiari
care
univers
set
remaind
satellit
teach
hospit
also
provid
tertiari
care
underw
trial
autom
inocul
apparatu
view
automatis
integr
advanc
technolog
result
implement
system
proceed
two
main
phase
firstli
introduct
standardis
specimen
collect
system
essenti
full
implement
automatis
thu
primari
phase
eswab
copanitalia
introduc
univers
approxim
month
second
phase
automat
inocul
specimen
processor
wasp
walk
away
specimen
processor
mastcopanitalia
set
diagnost
laboratori
initi
includ
unidirect
connect
li
test
media
plate
compatiil
train
technic
staff
system
run
parallel
manual
inocul
standard
period
order
run
comparison
qualiti
control
thereaft
system
put
onlin
run
diagnost
servic
sole
specimen
processor
staff
realloc
processng
tme
specimen
qualiti
error
document
analys
discuss
introduct
full
implement
autom
specimen
processor
microbiolog
diagnost
servic
typic
larg
univers
hospit
far
reach
consequ
workflow
staff
timealloc
especi
set
use
highli
qualifi
staff
repetit
task
demand
low
skill
ineffici
univers
laboratori
gener
unabl
employ
staff
commensur
lowskil
task
furthermor
posit
cut
cost
staff
reduct
set
automatis
great
benefit
free
technic
staff
task
appropri
train
also
demand
tertiari
care
refer
laboratori
introduct
pallidum
spp
pallidum
caus
agent
syphili
sexual
transmit
diseas
variabl
clinic
present
spirochet
resist
convent
cultiv
overcom
test
specif
limit
laboratori
diagnosi
base
stepwis
approach
use
immunolog
assay
howev
independ
clinic
evalu
test
mandatori
within
eu
current
larg
number
assay
variabl
analyt
qualiti
market
present
summari
report
result
obtain
german
profici
test
program
syphili
serolog
method
eight
profici
test
survey
conduct
germani
central
refer
laboratori
bacteriolog
serodiagnost
situat
institut
laboratori
medicin
northwest
medic
centr
frankfurt
germani
cooper
institut
standardis
medic
laboratori
ev
instand
ev
refer
laboratori
bacteriolog
infect
serolog
studi
group
germani
bissgg
test
two
sampl
obtain
infect
patient
healthi
donor
sent
particip
analysi
routin
laboratori
condit
assess
refer
test
result
perform
accord
standard
oper
procedur
instand
current
guidelin
german
chamber
physician
publish
recent
et
al
moreov
laboratori
wrongli
report
evid
activ
infect
case
past
syphili
sera
seroneg
blood
donor
discuss
liberalis
vitro
diagnost
market
eu
wide
rang
serolog
assay
syphili
diagnost
differ
diagnost
qualiti
promot
use
diagnost
laboratori
studi
confirm
previou
investig
although
posit
trend
obviou
sensit
specif
current
appli
assay
syphili
diagnost
still
vari
substanti
depend
stage
diseas
type
test
kind
manufactur
result
demonstr
ongo
extern
qualiti
control
routin
diagnost
laboratori
depth
clinic
evalu
diagnost
assay
clearli
need
monitor
test
qualiti
ensur
high
level
qualiti
syphili
diagnost
extern
qualiti
control
immunodiagnost
rare
fastidi
pathogen
bordetella
mycoplasma
coxiella
campylobact
yersinia
metaanalysi
profici
test
trial
kp
hunfeld
introduct
long
tradit
particip
medic
laboratori
extern
qualiti
control
well
establish
paramet
diagnost
procedur
medic
microbiolog
tradit
addit
enforc
new
guidelin
german
chamber
physician
evalu
profici
test
trial
indirect
detect
method
rare
fastidi
pathogen
howev
spars
importantli
particip
survey
mandatori
germani
although
lack
test
standard
data
avail
qualiti
assay
present
summari
report
result
instand
profici
test
trial
serodiagnost
bordetella
mycoplasma
coxiella
campylobact
yersinia
materi
method
twentyf
profici
test
survey
address
serodiagnost
mention
pathogen
conduct
germani
central
refer
laboratori
bacteriolog
serodiagnost
situat
institut
laboratori
medicin
northwest
medic
centr
frankfurtmain
germani
cooper
dghm
institut
standard
medic
laboratori
instand
ev
refer
laboratori
bacteriolog
infect
serolog
studi
group
germani
bissgg
survey
two
sampl
obtain
infect
patient
healthi
donor
sent
particip
analysi
routin
laboratori
condit
assess
refer
test
result
perform
accord
standard
oper
procedur
instand
current
guidelin
german
chamber
physician
publish
recent
result
studi
period
averag
follow
number
laboratori
particip
differ
serodiagnost
trial
yersinia
campylobact
bordetella
mycoplasma
coxiella
detect
specif
antibodi
yersinia
campylobact
bordetellaserolog
mainli
elisa
immunoblot
use
particip
wherea
coxiellaserolog
tradit
test
cft
ifa
predominantli
appli
rang
averag
pass
rate
diagnost
test
diagnost
comment
follow
yersinia
bordetella
mycoplasma
coxiella
campylobact
discuss
although
profici
test
trial
fulli
substitut
clinic
evalu
immunodiagnost
test
result
metaanalysi
demonstr
variabl
degre
standard
assay
qualiti
serodiagnost
rare
fastidi
bacteri
pathogen
importantli
observ
provid
interest
insight
compar
differ
assay
system
interpret
quantit
semi
quantit
test
result
correct
clinic
interpret
serolog
find
point
limit
diagnost
procedur
routin
diagnost
microbiolog
laboratori
staphylococcu
aureu
lead
caus
human
diseas
hospit
set
well
commun
shown
associ
nasal
colon
aureu
infect
strain
particular
concern
worldwid
increas
number
infect
caus
methicllinresist
aureu
mrsa
addit
longknown
healthcareassoci
clone
observ
emerg
spread
communityand
livestockassoci
mrsa
abil
clinic
import
strain
persist
within
host
larg
due
express
batteri
virul
factor
promot
adhes
acquisit
nutrient
evas
host
immunolog
respons
object
studi
determin
preval
virul
gene
among
success
sporad
mrsa
clone
dutchgerman
euregio
total
nonrepetit
mrsa
isol
recov
nasal
carriag
healthi
person
euregio
test
isol
select
base
spa
type
result
intend
includ
repres
predomin
spa
type
recov
euregio
well
repres
sporad
spa
type
virul
gene
sea
seb
sec
sed
sef
seg
seh
sei
sej
sek
sel
selm
seln
selo
seq
ser
selu
pvl
lukm
lukd
luke
sak
chp
scn
eta
etb
etd
edina
edinb
edinc
arcaacm
arcbacm
arccacm
arcdacm
detect
microarray
staphytyp
aler
technolog
gmbh
jena
germani
differ
combin
virul
gene
identifi
among
mrsa
isol
isol
carri
least
virul
gene
except
mrsa
isol
spaclon
complex
cc
spa
type
isol
spacc
carri
virul
gene
except
singl
isol
spa
type
harbour
sed
arcbacm
gene
observ
associ
predomin
mrsa
clone
virul
gene
detect
gene
sea
sed
seg
sei
sej
selm
seln
selo
ser
selu
lukd
luke
sak
chp
scn
gene
sec
sed
seg
sei
sel
selm
seln
selo
selu
sak
chp
scn
gene
sed
seg
sei
selm
seln
selo
selu
sak
chp
scn
although
lamrsa
carri
test
virul
factor
lamrsa
harbour
import
virul
factor
show
genom
plastic
mrsa
subtyp
possibl
adapt
chang
futur
diphtheria
diphtherialik
ill
caus
corynebacterium
speci
harbour
diphtheria
toxin
dt
encod
tox
gene
recent
year
diphtherialik
infect
toxigen
corynebacterium
ulceran
outnumb
caus
toxigen
c
diphtheria
mani
industri
countri
origin
associ
consumpt
raw
milk
dairi
product
contact
cattl
c
ulceran
increasingli
isol
domest
anim
pet
dog
cat
far
isol
ident
toxigen
c
ulceran
strain
anim
owner
document
dog
pig
report
first
case
proven
transmiss
toxigen
c
ulceran
strain
pet
cat
human
caus
pharyng
diphtherialik
ill
antimicrobi
resist
pattern
corynebacterium
diphtheriea
c
ulceran
c
pseudotuberculosi
strain
human
anim
origin
object
human
infect
due
corynebacterium
diphtheria
zoonot
germ
c
ulceran
c
pseudotuberculosi
rare
potenti
lifethreaten
event
requir
specif
antibiot
treatment
case
suspici
diphtheria
prompt
antitoxin
therapi
last
year
observ
increas
number
c
ulceran
strain
isol
patient
wound
infect
diphtherialik
ill
mainli
harbour
diphtheria
toxin
dt
encod
tox
gene
benzyl
penicillin
erythromycin
still
recommend
specif
antibiot
treatment
erad
pathogen
patient
prevent
infect
among
contact
although
antimicrobi
suscept
data
avail
method
studi
isol
toxigen
nontoxigen
clinic
isol
c
diphtheria
c
pseudotuberculosi
c
ulceran
human
anim
collect
nation
consiliari
laboratori
diphtheria
examin
minim
inhibitori
concentr
mic
benzyl
penicillin
ceftriaxon
erythromycin
tetracyclin
clindamycin
ciprofloxacin
determin
use
etest
system
absenc
standard
breakpoint
antibiot
suscept
determin
use
clsi
criteria
broth
microbouillon
dilut
suscept
test
corynebacterium
speci
result
benzyl
penicillin
erythromycin
ciprofloxacin
seem
highli
activ
substanc
three
corynebacterium
speci
suscept
rate
respect
c
diphtheria
tetracyclin
ceftriaxon
show
lowest
activ
vitro
suscept
rate
clindamycin
least
activ
c
ulceran
suscept
rate
contrast
c
pseudotuberculosi
strain
complet
suscept
examin
antibiot
conclus
data
emphas
need
accur
speci
identif
potenti
toxigen
corynebacteria
underscor
necess
antibiot
test
although
clindamycin
firstlin
drug
diphtheria
therapi
favour
treatment
wound
infect
due
result
c
ulceran
sure
cover
substanc
benzyl
penicillin
erythromycin
still
recommend
specif
antibiot
treatment
germani
antibiot
resist
may
occur
case
report
year
old
girl
present
persist
epigastr
pain
sinc
sever
month
hospit
treatment
omeprazol
day
show
clinic
improv
esophagogastroscopi
perform
reveal
mild
eros
gastriti
biopsi
specimen
stomach
sent
histopatholog
helicobact
cultur
suscept
test
direct
gram
stain
homogen
gastric
biopsi
specimen
long
gram
neg
corkscrewlik
rod
atyp
h
pylori
found
day
incub
agar
media
contain
human
erythrocyt
inactiv
hors
serum
first
coloni
appear
cytochrom
oxidas
catalas
ureas
test
perform
grown
bacteria
posit
strain
suscept
clarithromycin
metronidazol
amoxicillin
levofloxacin
tetracyclin
rifampicin
etest
method
speci
identif
partial
urea
ureb
gene
pcr
follow
sequenc
perform
describ
rourk
et
al
follow
phylogenet
analys
isol
identifi
helicobact
feli
helicobact
feli
belong
gastric
nonh
pylori
helicobact
formerli
also
classifi
h
heilmannii
type
ii
haesebrouck
et
al
h
feli
frequent
found
stomach
cat
dog
infect
human
report
cultur
difficult
due
fastidi
natur
organ
knowledg
two
nonh
pylori
strain
cultur
human
gastric
biopsi
specimen
far
strain
classifi
h
bizzozeronii
jalava
et
al
et
al
case
report
demonstr
direct
gram
stain
gastric
biopsi
specimen
import
identifi
gastric
nonh
pylori
helicobact
furthermor
cultur
fastidi
nonh
pylori
helicobact
use
standard
protocol
possibl
factor
interfer
metronidazol
suscept
test
h
pylori
etest
method
n
b
hobmaier
hp
e
glocker
kist
institut
medic
microbiolog
hygien
nation
refer
centr
helicobact
pylori
freiburg
deutschland
austrian
agenc
health
food
safeti
graz
oesterreich
introduct
metronidazol
part
italian
tripl
therapi
recommend
first
line
scheme
h
pylori
erad
germani
primari
resist
rate
metronidazol
data
european
multicentr
studi
antibiot
suscept
h
pylori
howev
phenotyp
suscept
test
current
approv
fda
due
varianc
test
result
lack
reproduc
clinic
relev
phenotyp
suscept
test
option
detect
resist
molecular
mechan
resist
conclus
explain
therefor
aim
studi
evalu
factor
influenc
precis
reproduc
metronidazol
suscept
test
use
etest
method
materi
method
randomli
select
h
pylori
isol
cultur
routin
gastric
biopsi
specimen
select
concern
resist
pattern
pretreat
patient
data
etc
actual
studi
etest
isol
perform
repeatedli
time
point
precis
differ
time
point
reproduc
variabl
includ
cultur
media
muellerhinton
hors
blood
vs
isosensitest
hors
blood
incub
period
hour
vs
hour
result
minim
inhibitori
concentr
mic
detect
muellerhinton
isosensitest
agar
incub
show
high
correl
small
systemat
differ
media
incub
period
found
mic
isosensitest
agar
higher
compar
muellerhinton
agar
factor
incub
led
lower
mic
incub
factor
rang
mic
significantli
broader
seri
differ
time
point
within
one
seri
discuss
small
systemat
influenc
cultur
media
incub
period
metronidazol
test
use
etest
method
correl
mic
high
evalu
reproduc
data
need
j
kolb
hillemann
j
reetz
e
richter
forschungszentrum
borstel
national
referenzzentrum
mykobakterien
borstel
deutschland
bundesinstitut
risikobewertung
berlin
deutschland
introduct
one
frequent
isol
speci
within
nontubercul
mycobacteria
avium
ubiquit
found
environ
shown
respons
varieti
human
diseas
mainli
immunocompris
patient
also
patient
obviou
immun
defici
avium
compris
subspeci
avium
subsp
avium
avium
subsp
silvaticum
avium
subsp
paratuberculosi
avium
subsp
hominissui
rout
infect
rare
known
understand
transmiss
mechan
deeper
insight
pathogen
genet
character
infecti
strain
prerequisit
therefor
aim
studi
assess
applic
mlst
miruvntr
distinguish
avium
strain
materi
method
genotyp
perform
mlst
fragment
sever
housekeep
gene
analyz
sequenc
analysi
compar
dna
sequenc
locu
estim
degre
variabl
gene
isol
differ
avium
subspeci
miru
variabl
number
tandem
repeat
loci
analyz
studi
includ
avium
isol
children
suffer
avium
lymphaden
sent
nrz
year
furthermor
strain
isol
slaughter
pig
bird
analyz
subspeci
analysi
done
pcr
target
element
result
firstli
bird
isol
proven
avium
subsp
avium
pcr
variou
singl
nucleotid
polymorph
could
detect
mlst
analysi
gene
investig
differ
gene
concern
variabl
use
decid
applic
futur
investig
miruvntr
analysi
show
great
impact
due
moder
variabl
discuss
molecular
method
subspeci
avium
identifi
mlst
enabl
type
strain
futur
may
use
exampl
analysi
transmiss
reactiv
vs
new
infect
reduct
antibiot
resist
among
pneumonia
isol
ipd
children
adult
result
german
nation
immun
program
pneumococc
conjug
vaccin
van
der
linden
rwth
aachen
medizinisch
mikrobiologi
aachen
deutschland
introduct
evalu
impact
immun
children
pneumococc
conjug
vaccin
dose
start
juli
antibiot
resist
level
among
pneumonia
isol
children
adult
invas
pneumococc
diseas
ipd
germani
materi
method
isol
ipd
case
children
year
adult
year
sent
german
nation
refer
center
streptococci
microbiolog
laboratori
germani
serotyp
perform
use
neufeld
quellung
reaction
mic
determin
use
microdilut
method
result
number
ipd
case
serotyp
includ
pneumococc
conjug
vaccin
strongli
reduc
children
two
year
start
childhood
vaccin
year
vaccin
averag
serotyp
children
year
percentag
children
year
adult
year
older
averag
case
serotyp
vaccin
vaccin
reduc
among
isol
children
macrolid
resist
reduc
averag
among
adult
macrolid
resist
reduc
vaccin
penicillin
resist
level
chang
much
vaccin
either
children
adult
howev
serotyp
distribut
among
isol
chang
consider
well
discuss
five
year
introduct
reduct
number
report
case
ipd
vaccin
serotyp
children
year
almost
observ
reduct
ipd
case
vaccin
serotyp
older
children
adult
indic
herd
protect
effect
due
disappear
vaccin
serotyp
macrolid
resist
level
reduc
consider
penicillin
resist
level
chang
sinc
disappear
penicillin
resist
vaccin
serotyp
compens
appear
penicillin
resist
serotyp
establish
red
deer
dna
banc
sourc
futur
studi
emerg
zoonot
vector
born
pathogen
c
klier
j
brenauer
b
fleischer
e
gerstmair
niedrig
schulz
sing
v
fingerl
lgl
bayern
nrz
borrelien
deutschland
bernhardnochtinstitut
national
referenzzentrum
tropisch
infektionserreg
hamburg
deutschland
robert
koch
institut
konsiliarlabor
fsme
berlin
deutschland
background
ongo
global
warm
thought
caus
environment
chang
could
foster
emerg
reemerg
zoonot
well
vectorborn
infecti
diseas
affect
human
anim
health
besid
domest
livestock
wild
anim
deer
wild
boar
serv
reservoir
infecti
diseas
date
littl
data
avail
preval
zoonot
vector
born
pathogen
anaplasma
phagocytophilum
francisella
tularensi
babesia
spp
rickettsia
spp
tbeviru
data
obtain
seropreval
studi
indic
wild
anim
suscept
sever
zoonot
vector
born
pathogen
howev
provid
inform
extend
wild
anim
serv
reservoir
studi
aim
establish
dna
banc
well
defin
materi
red
deer
perform
first
investig
preval
zoonot
vector
born
pathogen
materi
standard
collect
store
dnasampl
may
serv
materi
collect
longitudin
studi
endem
emerg
zoonot
vector
born
pathogen
method
lymph
node
red
deer
cervu
elapu
collect
directli
shoot
store
use
dna
extract
biosprint
quiagen
singl
lymph
node
store
vial
dnabanc
connect
databanc
contain
data
like
sex
age
health
statu
place
shot
regard
deer
sampl
use
screen
zoonot
vector
born
pathogen
like
anaplasma
francisella
dnavirus
pcr
result
far
around
lymph
node
red
deer
collect
deer
data
banc
establish
dna
banc
actual
consist
sampl
one
lymph
node
deer
first
screen
reveal
none
test
sampl
contain
measur
f
tularensi
dna
sampl
posit
phagocytophilum
dna
confirm
sequenc
pathogenscreen
actual
way
data
provid
moreov
tissu
sampl
subject
rnaextract
current
screen
tick
born
enceph
viru
conclus
detect
phagocytophilum
dna
screen
sampl
indic
lymph
node
red
deer
suitabl
screen
purpos
respect
phagocytophilum
absenc
f
tularensi
dna
lymph
node
howev
conclus
rule
red
deer
reservoir
due
high
mobil
broad
distribut
red
deer
might
serv
sentinel
emerg
zoonot
vectorborn
pathogen
present
dna
banc
import
prerequisit
futur
investig
emerg
pathogen
bavariensi
germani
borrelia
transmit
hard
tick
ixod
ricinu
infect
borrelia
result
clinic
manifest
skin
erythema
migran
borrelia
lymphocytoma
acrodermat
chronica
atrophican
nervou
system
neuroborreliosi
joint
lyme
arthriti
heart
lyme
carditi
current
concis
data
incid
lb
european
countri
rare
review
aim
collect
data
incid
lb
european
countri
emphasis
data
neuroborreliosi
method
data
collect
structur
literatur
search
pubm
nation
health
registri
public
health
institut
person
expertcontact
result
data
incid
lb
obtain
european
countri
report
regimen
heterogen
among
european
countri
littl
inform
reliabl
employ
report
system
eg
case
definit
geograph
distribut
show
lowest
incid
lb
southwest
europ
portug
x
along
mediteranian
coast
incid
increas
northward
sweden
x
well
western
europ
england
toward
central
europ
switzerland
highest
incid
report
slovenia
x
respect
neuroborreliosi
nb
data
european
countri
data
collect
studi
nation
registri
show
report
incid
nb
vari
x
franc
x
sweden
incid
nb
norway
x
denmark
incid
nb
germani
x
recent
data
eastern
germani
show
incid
earli
nb
longitudin
data
incid
lb
europ
indic
countri
observ
clear
increas
eg
slovenia
wherea
incid
data
countri
remain
fairli
constant
past
ten
year
countri
report
rise
lb
incid
sinc
report
data
either
remain
within
rang
norway
even
declin
germani
conclus
although
data
incid
lb
avail
mani
european
countri
current
hard
provid
reliabl
pictur
mainli
due
variou
methodolog
data
acquisit
prevent
conclus
comparison
purpos
compar
data
well
design
sentinel
prospect
studi
urgent
need
climat
chang
borrelia
tick
stricto
first
time
identifi
romania
b
spielmaniib
valaisiana
b
lusitania
case
infect
b
spielmanii
b
valaisiana
melt
curv
analysi
could
differenti
two
speci
overlap
melt
curv
mix
infect
detect
result
clinic
outcom
borrelia
serolog
individu
bitten
borreliaposit
tick
present
compar
control
group
preliminari
result
suggest
low
risk
develop
lyme
borreliosi
borreliainfect
tick
bite
romania
object
test
pertussi
serolog
perform
routin
laboratori
avail
intern
refer
prepar
method
cooper
instand
refer
prepar
use
extern
qualiti
assess
programm
eqa
two
refer
prepar
refer
reagent
prepar
nibsc
low
level
antibodi
reconstitut
central
sent
liquid
sampl
total
particip
result
report
qualit
quantit
quantit
result
convert
iuml
wherev
possibl
use
suggest
produc
diagnost
kit
result
result
report
total
particip
elisa
mix
antigen
use
measur
iggantibodi
particip
igaantibodi
measur
particip
use
mix
antigen
elisa
particip
use
elisa
measur
igmantibodi
total
particip
use
elisa
purifi
pt
measur
iggor
igaantibodi
respect
immunoblot
assay
use
estim
igg
iga
igm
antibodi
particip
respect
five
particip
use
indirect
immunofluoresc
measur
igg
iga
igm
antibodi
one
laboratori
use
complement
fixat
quantit
result
report
differ
unit
elisa
use
purifi
pt
gave
result
compar
expect
valu
iuml
conclus
mani
laboratori
use
method
recommend
eu
refer
laboratori
report
result
relat
refer
prepar
retrospect
perform
hrmpcr
discov
two
outbreak
listeriosi
austria
introduct
public
health
laboratori
charg
listeriosi
surveil
highresolut
melt
pcr
hrmpcr
analysi
promis
new
techniqu
get
low
specif
serotyp
variou
disadvantag
puls
field
gelelectrophoresi
pfge
materi
method
two
differ
outbreak
listeriosi
report
austria
outbreak
febril
gastroenter
guest
local
restaur
consumpt
contamin
homemad
jelli
pork
includ
two
case
bacteriolog
proven
invas
listeriosi
multin
outbreak
invas
listeriosi
due
contamin
acid
curd
chees
sold
supermarket
product
carri
two
genet
differ
outbreak
strain
respons
case
clone
case
clone
bacteriolog
proven
invas
listeriosi
austria
total
case
sampl
belong
outbreak
inlb
hrmpcr
product
subsequ
sequenc
verif
retrospect
studi
perform
serotyp
hrmpcr
inlb
sequencetyp
inlb
analysi
detect
outbreak
confirm
pfge
result
isol
listeria
monocytogen
patient
invas
diseas
austria
test
studi
period
serotyp
distribut
total
studi
popul
inlb
distribut
nontyp
els
type
altogeth
invas
isol
outbreak
serotyp
inlb
isol
clone
outbreak
serotyp
inlb
isol
clone
serotyp
inlb
addit
found
isol
serotyp
isol
serotyp
relat
mention
outbreak
clone
regard
hrmpcr
analysi
inlb
isol
inlb
isol
inlb
isol
belong
outbreak
conclus
hrmpcr
analysi
appear
sensit
fast
inexpens
screen
method
discov
possibl
outbreak
studi
better
distinguish
outbreak
clone
unrel
strain
serotyp
still
requir
confirm
discriminatori
method
like
pfge
popul
analysi
communityacquir
mrsa
germani
data
nation
refer
centr
staphylococci
f
layer
c
cuni
b
strommeng
w
witt
robert
koch
institut
nation
refer
centr
staphylococci
wernigerod
deutschland
introduct
commun
associ
mrsa
camrsa
emerg
worldwid
end
although
particular
clonal
lineag
associ
particular
geograph
area
eg
ocean
european
asiat
spread
lead
dynam
clonal
lineag
time
observ
report
camrsa
clonal
lineag
record
germani
past
three
year
method
respect
isol
sent
refer
centr
characteris
januari
may
n
antimicrobi
suscept
presenc
sever
resist
pathogen
associ
gene
sccmectyp
spaand
multilocu
sequencetyp
analyz
select
isol
luksfpv
sequenc
determin
pvl
sequenc
variat
pfge
smaidigest
chromosom
dna
also
perform
comparison
select
clonal
lineag
result
domin
camrsa
european
clone
isol
attribut
compar
data
last
year
observ
increas
frequenc
surprisingli
first
look
camrsa
suspici
clone
howev
consider
portion
lack
arca
mphb
isol
repres
subpopul
degener
loss
acm
cluster
resist
plasmid
initi
assum
although
find
rudimentari
invert
repeat
fosb
vicin
sek
set
suggest
related
sccmecivc
arcaneg
isol
instead
sccmeciva
typic
indic
converg
evolut
furthermor
camrsa
clone
belong
capsulespecif
synthesi
cap
region
ii
haemophilu
influenza
serotyp
c
hic
hid
unknown
studi
hic
capsul
consist
dimer
repeat
unit
oacetyl
nacetyl
dglucosamin
dglcnac
dgalactos
dgal
wherea
hid
capsul
essenti
polym
dglcnac
nacetyldmannosaminuron
acid
dmananac
dimer
polysaccharid
hid
share
common
monom
hie
capsul
high
similar
capsul
loci
hie
primarili
p
multocida
b
e
found
previous
present
analysi
cap
region
ii
hic
hid
base
similar
search
discuss
phylogenet
develop
bacteri
capsul
sequenc
cap
region
ii
hic
atcc
hid
atcc
carri
pcr
primer
walk
sequenc
hic
reveal
four
open
read
frame
orf
name
similar
search
show
phosphotransferas
function
seem
member
glycosyltransferas
famili
find
point
role
protein
synthesi
capsul
polysaccharaid
phosphodiest
linkag
connect
oacetyl
dglcnac
dgal
found
subject
phase
variat
show
similar
oacetyl
transferas
cyselacalpxanodl
famili
includ
capsul
oacetyltransferas
neisseria
meningitidi
serogroup
five
orf
found
hid
similar
search
reveal
udpnacetyldglucosamin
function
udpnacetyldmannosaminuron
acid
dehydrogenas
function
put
role
convers
dglcnac
dmananac
correspond
repetit
disaccharid
unit
dglcnac
dmananac
capsul
polysaccharid
similar
gene
gene
organ
found
hic
hid
capsul
gene
operon
actinobacillu
spp
well
distant
genera
includ
n
meningitidi
suggest
horizont
gene
transfer
capsul
evolut
across
bacteri
class
flieger
fruth
r
prager
w
rabsch
e
tietz
rki
fg
bakteriel
infektionen
wernigerod
deutschland
within
nation
refer
centr
nrc
salmonella
enter
bacteri
pathogen
locat
robert
kochinstitut
broad
spectrum
human
pathogen
bacteria
investig
salmonella
intestin
e
coli
shigella
yersinia
campylobact
addit
sinc
nrc
german
partner
binat
consilari
laboratori
listeria
locat
austrian
agenc
health
food
safeti
vienna
austria
method
labbas
surveil
mention
pathogen
develop
valid
use
monitor
chang
pathogen
occurr
alter
within
pathogen
eg
virul
gene
profil
antibiot
resist
cluster
increas
abund
diseas
case
investig
examin
epidemiolog
relationship
within
year
bacteri
sampl
human
diseas
case
analyz
among
other
follow
interest
observ
respect
type
strain
made
reduct
occurr
formerli
lead
salmonella
enterica
serovar
enteritidi
increas
occurr
monophas
salmonella
enterica
serovar
typhimurium
strain
increas
observ
salmonella
infect
children
caus
rare
serotyp
link
reptil
presenc
household
virul
gene
fingerprint
diseaseassoci
intestin
e
coli
character
intermedi
e
coli
strain
contain
virul
gene
plasmid
differ
pathotyp
work
outbreak
familyassoci
case
due
salmonella
e
coli
ehec
epec
campylobact
shigella
sonnei
listeria
task
nation
refer
centr
helicobact
pylorian
overview
e
glocker
kist
n
wueppenhorst
b
hobmaier
freiburg
institut
medizinisch
mikrobiologi
und
hygien
freiburg
deutschland
german
nation
refer
centr
nrc
helicobact
pylori
launch
resinet
german
multicentr
studi
aim
keep
resist
develop
h
pylori
surveil
collabor
microbiolog
centr
across
germani
resinet
monitor
antimicrobi
resist
rate
h
pylori
identifi
risk
factor
develop
paramount
import
sinc
resist
massiv
neg
impact
therapi
success
nrc
dedic
constrain
increas
resist
recommend
suscept
test
patient
first
treatment
failur
patient
undergon
antibiot
therapi
multipl
occas
due
unrel
bacteri
infect
note
helicobact
pylori
gastroduoden
ulcer
diseas
even
though
phenotyp
suscept
test
standardis
nrc
shown
reliabl
reproduc
may
fail
due
extralong
transport
time
incorrect
handl
gastric
tissu
sampl
contamin
overcom
shortcom
nrc
set
molecular
genet
method
examin
antimicrobi
resist
h
pylori
genotyp
identifi
resist
associ
mutat
request
genotyp
resist
test
patient
sampl
underlin
increas
demand
need
rescu
diagnost
procedur
continu
enhanc
sinc
nrc
offer
gastroenterologist
uniqu
servic
request
sent
individu
treatment
recommend
base
antimicrobi
resist
pattern
patient
h
pylori
isol
data
outcom
far
therapi
recommend
analys
provid
preciou
data
work
optimis
treatment
recommend
difficulttotreat
patient
year
found
nrc
h
pylori
establish
indispens
institut
need
improv
diagnosi
h
pylori
relat
infect
ii
control
develop
antimicrobi
resist
h
pylori
iii
standardis
antimicrobi
suscept
test
procedur
iv
give
treatment
recommend
difficulttotreat
h
pylori
infect
character
livestockassoci
methicillinresist
staphylococcu
aureu
mrsa
use
multiplelocu
variabl
number
tandem
repeat
analysi
mlva
k
brandt
mellmann
c
jenk
r
univers
hospit
institut
hygien
deutschland
staphylococcu
aureu
import
human
pathogen
emerg
methicillinresist
aureu
mrsa
becom
major
concern
especi
healthcar
set
recent
mrsa
also
emerg
livestock
e
g
swine
poultri
spread
human
reservoir
therefor
precis
type
method
unravel
transmiss
dynam
zoonot
aureu
strain
great
import
wide
use
portabl
tool
track
epidem
isol
multilocu
sequenc
type
mlst
sequenc
type
aureu
protein
spa
gene
howev
studi
shown
zoonot
mrsaisol
livestock
mainli
belong
mlst
clonal
complex
mostli
associ
limit
subset
spa
type
predominantli
assess
rang
genet
divers
among
mrsa
isol
investig
whether
multiplelocu
variabl
number
tandem
repeat
analysi
mlva
provid
greater
resolut
spatyp
studi
appli
aureusmlva
scheme
schoul
et
al
includ
eight
differ
gene
loci
base
autom
fragment
analysi
capillari
sequenc
aim
investig
divers
livestockassoci
mrsa
isol
deriv
pig
stabl
compris
locat
variou
feder
state
germani
first
result
mlva
show
spatyp
indistinguish
strain
differ
geograph
region
cluster
least
two
differ
mlvatyp
mlva
discrimin
isol
associ
spatyp
two
differ
pig
farm
assign
mlvatyp
yet
mlva
profil
identifi
far
differ
one
locu
support
theori
clonal
origin
livestockassoci
mrsa
mlva
type
zoonot
mrsa
might
therefor
contribut
better
understand
genet
divers
geograph
tempor
background
find
final
add
valuabl
inform
investig
transmiss
dynam
zoonot
pathogen
recent
overcom
speci
barrier
similar
dens
granul
protein
close
rel
gondii
n
caninum
leineweb
k
spekker
v
inc
sk
schmidt
g
schare
p
maksimov
w
institut
medizinisch
mikrobiologi
und
krankenhaushygien
deutschland
institut
epidemiologi
friedrich
institut
wusterhausen
deutschland
neospora
caninum
n
caninum
oblig
intracellular
apicomplexan
parasit
close
relat
toxoplasma
gondii
gondii
definit
host
n
caninum
dog
cattl
display
main
intermedi
host
work
deal
dens
granul
protein
known
import
role
hostparasiterelationship
previous
describ
dens
granul
protein
gondii
studi
identifi
put
homologu
n
caninum
genom
sequenc
locat
chromosom
xii
consist
two
exon
southern
blot
proven
present
singl
copi
gene
product
n
caninum
specif
antiserum
recombin
protein
could
shown
western
blot
gene
encod
kda
protein
furthermor
defin
member
excretedsecret
antigen
esa
ncaninum
confoc
microscopi
observ
extracellular
parasit
protein
accumul
dot
pattern
point
locat
dens
granul
organel
furthermor
could
show
invas
parasit
host
cell
secret
parasitophor
vacuol
pv
thu
fulfil
main
characterist
gra
protein
sum
could
verifi
studi
structur
similar
show
immunolog
cross
reactiv
similar
distribut
within
respect
parasit
indic
close
relationship
protein
interact
local
toxoplasma
gondii
protein
within
parasitophor
vacuol
apicomplexan
parasit
toxoplasma
gondii
gondii
one
success
protozoan
parasit
infect
warmblood
anim
includ
human
host
cell
parasit
develop
within
parasitophor
vacuol
pv
caus
handicap
nutrient
suppli
graand
ropprotein
main
compon
pv
deliv
secretori
organel
import
connect
parasit
host
cell
organel
describ
new
kda
gondii
protein
call
stabli
associ
network
membran
tubul
pv
membran
pvm
show
coloc
dens
granul
protein
recent
coimmunoprecipit
data
indic
major
interact
partner
found
import
nutrient
transport
host
cell
parasit
explor
secret
pv
interact
network
structur
pvm
detail
exogen
express
hatag
well
ctermin
truncat
version
rh
tachyzoit
result
indic
cterminu
essenti
suffici
correct
secret
pv
lack
last
one
hundr
amino
acid
includ
two
hydrophob
domain
show
alter
secret
behaviour
ctermin
truncat
found
exclus
within
cytoplasm
parasit
could
enter
lumen
pv
advanc
biomolecular
interact
analysi
immunoglobulinbind
protein
eibg
shiga
toxinproduc
escherichia
coli
shiga
toxinproduc
escherichia
coli
stec
caus
diarrhea
hemolyt
urem
syndrom
hu
human
belong
therefor
group
pathogen
major
interest
sever
stec
strain
express
seven
relat
immunoglobulin
ig
bind
protein
eiba
c
e
f
g
h
share
facil
bind
igg
nonimmun
manner
protein
occur
separ
combin
within
singl
strain
addit
potenti
evas
host
immun
respons
eibg
involv
bacteri
adher
host
intestin
epitheli
cell
furthermor
eibgposit
strain
show
chainlik
adher
pattern
clap
depend
differ
eibgallel
sequenc
entir
eibg
result
differ
eibgallel
alloc
three
subtyp
eibg
adhes
assay
human
bovin
epitheli
cell
show
differ
clapphenotyp
depend
eibgsubtyp
result
confirm
insert
eibg
e
coli
altern
genet
background
possibl
function
role
glycosyl
igg
harbor
nglycan
domain
fc
fragment
eibg
affin
investig
nativ
enzymat
deglycosyl
igg
peptid
nglycosidas
pngase
treatment
igg
influenc
eibgigg
interact
indic
eibg
bind
domain
differ
site
glycosyl
within
domain
igg
next
eibg
affin
igg
subtyp
differ
vertebr
speci
determin
elisa
variabl
condit
aim
identif
ig
high
bind
affin
eibg
may
facilit
effici
isol
purif
eibg
cell
lysat
pend
determin
amino
acid
sequenc
eibg
variant
perform
matrixassist
laser
desorptionion
timeofflight
mass
spectrometri
malditofm
thu
peptid
map
comparison
sequenc
eibprotein
help
unravel
molecular
mechan
iggbind
cellular
adher
furthermor
search
cellular
receptor
epitheli
cell
potenti
affin
eibg
glycosphingolipid
differ
biolog
origin
explor
thinlay
chromatographi
tlc
overlay
assay
techniqu
complement
factor
h
allotyp
predispos
typic
hemolyt
urem
syndrom
typic
hemolyt
urem
syndrom
hu
mainli
caus
infect
enterohemorrhag
escherichia
coli
wherea
atyp
nonbacteriaassoci
hu
complement
play
domin
role
recent
complement
also
shown
involv
typic
hu
studi
mostli
weakli
signific
associ
homozygos
complement
allotyp
invers
factor
h
found
suggest
allotyp
predispos
typic
hemolyt
urem
syndrom
establish
nation
giardia
intestinali
databas
biobank
function
epidemiolog
c
klotz
banik
p
gostenheinrich
aebisch
parasitologi
berlin
deutschland
giardiasi
common
worldwid
distribut
protozoan
infect
gastrointestin
tract
caus
flagel
parasit
giardia
intestinali
clinic
sign
extrem
variabl
rang
asymptomat
chronic
symptom
includ
sever
diarrhoea
abdomin
pain
contribut
factor
mechan
pathophysiolog
larg
unknown
zoonosi
potenti
distinct
giardia
intestinali
genotyp
highlight
howev
definit
specif
parasit
virul
factor
host
risk
factor
hamper
lack
function
epidemiolog
studi
aim
project
builtup
uniqu
databaselink
biobank
collect
giardia
intestinali
human
clinic
case
isol
field
domest
anim
thu
connect
epidemiolog
data
molecular
characterist
invitro
function
test
use
respect
parasit
isol
cultur
subsequ
exploit
data
clonal
parasit
collect
function
studi
eg
correl
genotypespecif
variat
potenti
virul
factor
function
characterist
current
first
phase
project
collect
character
cultiv
giardia
isol
human
anim
contribut
cooperationpartn
germani
switzerland
success
establish
invitro
cultur
protocol
expans
clonal
giardia
trophozoit
deriv
human
faecal
specimen
first
genotyp
result
clone
parasit
glutam
dehydrogenas
gene
locu
indic
success
establish
assemblag
b
subcultur
difficult
isol
assemblag
due
slower
growth
behaviour
vitro
eventu
biobank
collect
provid
uniqu
tool
function
epidemiolog
studi
virul
factor
knowledg
knowledg
knowledg
manag
microbiolog
walter
frangoulidi
helmholtzzentrum
institut
bioinformatik
und
systembiologi
neuherberg
deutschland
institut
mikrobiologi
der
bundeswehr
deutschland
introduct
rapid
expans
biolog
data
result
thousand
genom
sequenc
project
recent
develop
highthroughput
techniqu
prodigi
furthermor
number
articl
citat
public
literatur
databas
like
pubm
increas
exponenti
henc
risk
individu
specialist
lose
control
avail
inform
field
interest
rise
constantli
address
problem
databas
softwar
tool
construct
structur
consolid
data
number
databas
grow
well
qualiti
far
selfevid
show
recent
develop
use
text
data
mine
technolog
make
knowledg
access
method
detail
knowledg
store
fulltext
articl
thu
enhanc
inhous
text
mine
system
work
avail
licens
fulltext
articl
special
field
interest
extract
larg
set
entiti
relationship
creat
relat
network
addit
extend
data
mine
platform
perform
multipl
genom
analys
parallel
final
integr
text
mine
data
mine
platform
enhanc
analyt
power
complet
system
result
obtain
avail
fulltext
articl
main
research
field
regard
coxiella
burnetii
q
fever
base
select
review
articl
evalu
compar
automat
extract
relat
network
interact
network
creat
human
curat
inhous
allow
us
determin
indepth
bia
autom
approach
conclus
data
mine
techniqu
use
allow
scientist
deal
mani
speci
strain
incorpor
text
mine
abl
quickli
highlight
import
function
causal
differ
well
reveal
previous
hidden
knowledg
henc
present
tool
assist
user
strongli
studi
novel
aspect
hypothes
research
field
provid
complet
access
knowledg
fast
structur
manner
knowledg
knowledg
core
genom
determin
zoonot
pathogen
use
whole
genom
data
combin
new
web
applic
r
leopold
dj
harmsen
mellmann
institut
hygien
deutschland
periodontologi
deutschland
background
increas
access
next
gener
sequenc
tool
led
abund
genom
data
includ
fulli
finish
genom
unfinish
assembl
contig
definit
core
genom
pan
genom
andor
singleton
gene
often
necessari
perform
compar
phylogenet
analys
multipl
strain
within
speci
develop
program
facilit
compar
genom
analysi
util
annot
well
unannot
sequenc
data
also
provid
maxim
option
paramet
user
downstream
analysi
method
program
util
ncbi
blast
algorithm
queri
genom
interest
use
list
orf
sequenc
defin
user
base
upon
deriv
annot
genom
queri
user
control
paramet
core
definit
set
threshold
percent
ident
percent
overlap
etc
perl
program
pair
blast
hit
data
correspond
subject
orf
data
sort
result
separ
categor
file
queri
annot
genom
user
may
choos
variou
output
file
format
list
ortholog
core
orf
sequenc
core
orf
refer
strain
andor
core
orf
sequenc
concaten
result
perl
program
implement
web
interfac
base
java
creat
userfriendli
graphicalus
interfac
evalu
staphylococcu
aureu
escherichia
coli
genom
default
paramet
minim
sequenc
similar
similar
anoth
orf
within
chromosom
percent
ident
overlap
presenc
investig
genomessequ
yield
core
orf
aureu
e
coli
respect
noncor
orf
report
user
categor
file
eg
multicopi
orf
altern
start
andor
stop
codon
gap
align
sequenc
similar
conclus
microbi
core
genom
analysi
tool
mcgenom
use
compar
analyz
multipl
annot
genom
interrog
singl
unannot
one
process
creat
complet
transpar
give
user
control
paramet
data
maintain
userfriendli
web
interfac
sourc
code
avail
author
introduct
sparganosi
neglect
parasit
diseas
caus
plerocercoid
stage
sparganum
spirometra
sp
pseudophyllidean
tapeworm
diseas
often
found
east
asia
human
becom
infect
eat
raw
undercook
meat
fish
amphibian
reptil
contain
larval
stage
spargana
invad
brain
eye
viscera
subcuti
caus
seriou
ill
rare
complic
form
dissemin
prolif
sparganosi
caus
branch
maldifferenti
plerocercoid
provision
term
sparganum
proliferum
method
sever
cm
long
flatten
pseudoseg
helminth
extract
subcutan
nodul
infraumbil
region
femal
japanes
immigr
parasit
formalinfix
embed
paraffin
histolog
examin
addit
dna
extract
subject
cestodespecif
mitochondri
rrna
geneand
cytochrom
c
oxidas
subunit
pcr
speci
identif
result
morpholog
histolog
analysi
helminth
show
typic
aspect
cestod
ie
calcar
corpuscl
spongi
stroma
surround
aspin
tegument
characterist
featur
pseudophyllidean
cestod
larva
plerocercoid
sparganum
anterior
region
show
invagin
proper
scolex
develop
organ
pseudoseg
without
strobilar
structur
sequenc
analysi
bp
amplicon
rrna
geneand
show
ident
spirometra
erinaceieuropaei
histolog
section
parasit
also
use
set
immunofluoresc
test
incub
patient
serum
tegument
signal
detect
concentr
conclus
spirometra
erinaceieuropaei
cosmopolitan
distribut
human
case
occur
asia
possibl
due
local
eat
habit
pcr
analysi
unambigu
identifi
speci
respons
patient
diseas
thu
exclud
pathogen
sparganum
proliferum
larval
cestod
adult
strobilar
stage
unknown
popescu
tudos
b
muntau
c
giurcaneanu
poppert
elia
emerg
univers
hospit
bukarest
rumaenien
bernhardnochtinstitut
tropenmedizin
hamburg
deutschland
introduct
human
dirofilariasi
zoonot
infecti
diseas
caus
filari
nematod
dog
dirofilaria
repen
dirofilaria
immiti
depend
speci
involv
human
infect
usual
manifest
one
cutan
viscer
larva
migran
form
painless
nodul
later
cours
diseas
dirofilaria
endem
mediterranean
particularli
itali
consid
emerg
pathogen
increas
geograph
rang
case
present
one
known
case
human
dirofilariasi
caus
repen
romania
patient
develop
unusu
sever
clinic
manifest
mimick
patholog
condit
like
cellul
deep
venou
thrombosi
conclus
human
doctor
well
veterinarian
prepar
come
across
case
dirofilariasi
romania
well
european
countri
regard
nonendem
far
case
illustr
infect
even
consid
patient
sign
parasit
infect
exactli
correspond
descript
dirofilariasi
text
book
character
sorbitolfer
shiga
toxinneg
eaeposit
escherichia
coli
strain
isol
human
w
zhang
k
hansen
c
bielaszewska
character
shiga
toxin
stx
neg
sorbitolfer
sf
e
coli
strain
isol
patient
hemolyt
urem
syndrom
hu
n
diarrhea
n
asymptomat
carrier
n
germani
h
serotyp
flic
genotyp
identifi
five
differ
h
type
includ
strain
h
nonmotil
strain
carri
four
differ
eae
allel
associ
particular
serotypesfl
type
strain
h
carri
eaeg
eae
eae
eaea
h
strain
possess
sfpa
marker
gene
cluster
encod
sfp
fimbria
carri
ehechlya
cdtv
encod
ehec
hemolysin
cytoleth
distend
toxin
respect
none
virul
gene
present
isol
moreov
strain
differ
serotyp
differ
abil
adher
human
intestin
epitheli
cell
vitro
phylogenet
analysi
stxneg
sf
strain
use
multilocu
sequenc
type
demonstr
five
differ
sequenc
type
st
associ
hu
data
demonstr
group
e
coli
pathogen
human
broader
previous
thought
includ
besid
classic
nsf
stec
also
sf
e
coli
sever
serotyp
stxindepend
diagnost
strategi
involv
pcr
target
eae
method
choic
identifi
pathogen
enterohemorrhag
escherichia
coli
ehec
highli
pathogen
shiga
toxin
stx
posit
subgroup
intestin
pathogen
e
coli
ehec
infect
often
lead
diarrhea
casual
hemorrhag
coliti
hemolyt
urem
syndrom
hu
wherea
ehec
common
serotyp
hu
patient
ehec
isol
patient
diarrhea
exhibit
frequent
serotyp
among
common
serotyp
germani
contrast
wellstudi
ehec
littl
known
genom
content
genom
plastic
e
g
loss
stxencod
gene
stx
serotyp
therefor
investig
genom
two
strain
isol
interv
day
huspati
whole
genom
sequenc
use
next
gener
classic
sanger
sequenc
determin
complet
genom
sequenc
two
isol
whole
genom
comparison
use
mauv
softwar
perform
investig
differ
gene
content
detect
singl
nucleotid
polymorph
snp
snp
addit
confirm
pcr
product
sequenc
particular
region
confirm
snp
code
region
phenotyp
test
appli
confirm
impact
phenotyp
whole
genom
comparison
reveal
loss
total
gene
subsequ
isol
day
infect
major
locat
genom
island
also
includ
stx
operon
moreov
determin
three
nonsynonym
snp
three
snp
noncod
region
nonsynonym
snp
locat
rpo
rna
polymeras
sigma
factor
mreb
rod
shapedetermin
protein
malt
transcript
regul
interestingli
snp
rpo
posit
tag
tgg
resolv
stopcodon
intact
gene
rpo
play
crucial
role
surviv
stress
control
larg
regulon
among
kate
catalas
hpii
depend
rpo
reconstitut
rpo
gene
function
posit
catalas
test
detect
subsequ
isol
malt
transcript
activ
maltoseregulon
gene
may
also
involv
protect
stress
contrast
chang
mreb
involv
cell
divis
chromosom
segreg
respons
typic
rod
shape
cell
understood
yet
interestingli
synonym
snp
usual
repres
molecular
clock
normal
mutat
rate
within
chromosom
detect
indic
extern
factor
respons
chang
conclus
analysi
show
enorm
plastic
genom
infect
abl
undergo
genom
chang
phenotyp
effect
within
day
studi
focu
impact
phenotyp
chang
hostpathogen
interact
poppert
j
schmidtchanasit
e
tannich
introduct
dirofilaria
repen
filaria
dog
carnivor
transmit
variou
mosquito
repen
accident
infect
human
usual
result
subcutan
nodul
contain
singl
infertil
parasit
repen
endem
mani
tropic
subtrop
countri
well
mediterranean
recent
singl
case
infect
report
north
alp
method
result
recent
receiv
multipl
sampl
repen
worm
remov
infect
human
patient
show
variou
clinic
symptom
dermal
subconjunctiv
larva
migran
format
subcutan
nodul
divers
locat
well
format
nodul
lung
testi
case
phenotyp
diagnosi
confirm
pcr
sequenc
mitochondri
recent
year
diagnos
case
human
repen
infect
ever
suggest
increas
rate
infect
postul
climat
warm
lead
spread
repen
infect
even
region
north
alp
therefor
analyz
mosquito
captur
southwest
germani
year
presenc
filaria
use
pcr
find
evid
presenc
signific
number
repensinfect
mosquito
conclus
number
repen
infect
seem
increas
doctor
prepar
diagnos
treat
correspond
infect
travel
germani
mosquito
yet
pose
signific
risk
transmit
repen
protein
complex
brain
compos
heterogen
cellular
prion
protein
phenotyp
main
characterist
prion
diseas
accumul
patholog
prion
prp
sc
molecular
mechan
lead
prp
sc
consid
caus
convers
normal
hostencod
prion
protein
prp
c
prp
c
act
substrat
protein
transform
result
gener
distinct
prp
sc
type
howev
prp
c
compos
sever
overlap
type
brain
protein
complex
littl
known
composit
subtyp
studi
separ
prp
c
protein
obtain
human
sheep
cattl
basi
differenti
solubl
deterg
subtyp
character
immunoblot
use
variou
antibodi
recogn
differ
prp
epitop
follow
densitometr
signal
quantif
determin
glycoprotein
band
pattern
singl
serial
applic
deterg
noctyl
dglucopyranosid
chap
facilit
high
solubl
glycosyl
prp
c
isoform
wherea
high
conting
nonglycosyl
human
half
total
bovin
prp
c
remain
nonsolubl
protein
speci
becam
highli
solubl
nlauroylsarcosin
sodium
dodecyl
sulphat
furthermor
identifi
aggreg
highli
solubl
prp
c
isoform
supenat
analys
speci
find
demonstr
heterogen
prp
c
phenotyp
overlap
brain
may
separ
regard
solubl
characterist
convey
distinct
solubl
subtyp
protein
differenti
solubl
experi
therefor
facilit
separ
prp
c
type
provid
detail
inform
protein
composit
offer
new
prospect
transform
effici
prp
sc
convers
assay
conclusionsignific
conclud
gnotobiot
human
mice
repres
excel
novel
c
jejuniinfect
inflamm
model
provid
deep
insight
immunolog
molecular
interplay
c
jejuni
microbiota
innat
immun
human
campylobacteriosi
helicobact
transcrib
small
rna
recognis
hfq
ortholog
use
bioinformat
approach
identifi
gene
c
jejuni
genom
encod
protein
predict
rnabind
motif
investig
role
gene
express
colonizationvirul
use
gnotobiot
defici
mice
methodologyprincip
find
mutant
strain
gener
inactiv
gene
two
copi
gene
one
inactiv
gene
complement
tran
growth
mutant
similar
wildtyp
strain
inactiv
affect
motil
growth
phenotyp
overexpress
result
signific
decreas
autoagglutin
aag
transcriptom
proteom
characteris
strain
suggest
chang
express
flagellar
gene
may
explain
aag
phenotyp
infect
gnotobiot
defici
mice
c
jejuni
wildtyp
strain
caus
acut
bloodi
diarrhea
histopatholog
inflammatori
respons
colon
mutant
colon
mous
intestin
similar
level
wildtyp
strain
differ
potenti
induc
diarrhea
inflammatori
respons
colon
clinic
sign
diseas
level
proinflammatori
cytokin
colon
significantli
reduc
mutant
compar
wildtyp
strain
conclusionsignific
although
subtl
phenotyp
associ
put
rnabind
protein
current
proof
protein
function
gener
rnachaperon
predict
pleiotrop
phenotyp
observ
result
obtain
infect
gnotobiot
mice
indic
role
gene
cjejuni
virul
adherentinvas
escherichia
coli
aiec
associ
crohn
diseas
show
trait
similar
human
anim
extraintestin
pathogen
e
coli
expec
regard
phylogenet
origin
virul
gene
profil
howev
previou
studi
shown
human
expec
strain
rare
share
aiec
phenotyp
wherea
limit
data
avail
aieclik
phenotyp
properti
anim
e
coli
strain
extraintestin
intestin
sourc
therefor
analyz
aiec
phenotyp
expec
strain
bird
cat
dog
swine
select
respect
multi
locu
sequenc
type
st
previous
link
aiec
strain
patient
crohn
diseas
includ
addit
e
coli
enter
isol
cat
dog
case
st
complex
stc
repres
phylotyp
typic
observ
among
strain
caus
cystiti
pyelonephr
human
swine
includ
expec
strain
show
aiec
phenotyp
shown
abil
adher
invad
intestin
epitheli
cell
well
surviv
replic
within
murin
macrophag
anim
enter
strain
swine
dog
cat
phenotyp
resembl
aiec
pathotyp
interestingli
none
expec
strain
show
phenotyp
wherea
strain
enter
confirm
aieclik
strain
due
nonarbitrari
strain
select
conclus
drawn
consid
real
preval
aieclik
strain
intestin
tract
anim
frequent
detect
provid
support
lack
hostspecif
zoonot
risk
studi
includ
well
character
diseas
anim
need
order
detect
put
reservoir
aiec
strain
even
intestin
asymptomat
carrier
evalu
dimens
risk
respect
implement
prevent
control
measur
thu
public
health
enterohemorrhag
escherichia
coli
ehec
caus
hemolyt
urem
syndrom
hu
common
caus
acut
renal
failur
children
shiga
toxin
stx
key
virul
factor
ehec
endotheli
cell
major
toxin
target
perform
direct
comprehens
comparison
cellular
injuri
induc
two
major
stx
type
human
brain
microvascular
endotheli
cell
hbmec
eahi
macrovascular
endotheli
cell
scan
electron
microscopi
microcarrierbas
cultur
digit
holograph
microscopi
singl
cell
quantit
apoptosisnecrosi
assay
demonstr
caus
necrosi
apoptosi
wherea
induc
mainli
apoptosi
cell
line
moreov
microvascular
macrovascular
endotheli
cell
differ
suscept
toxin
hbmec
suscept
wherea
eahi
cell
suscept
find
implic
pathogenesi
hu
suggest
exist
yet
delin
stx
typespecif
mechan
endotheli
injuri
beyond
inhibit
protein
biosynthesi
simultan
detect
eight
potenti
bioterror
agent
real
time
pcr
bacillu
anthraci
attack
unit
state
demonstr
need
fast
reliabl
diagnost
method
detect
potenti
biolog
agent
bacillu
anthraci
also
burkholderia
pseudo
mallei
brucella
ssp
francisella
tularensi
yersinia
pesti
coxiella
burnetii
orthopoxviru
variola
major
list
biolog
agent
high
risk
misus
bioterror
attack
center
diseas
control
prevent
cdc
sinc
number
pcrbase
detect
assay
agent
publish
design
multiplex
assay
two
three
biolog
agent
howev
assay
simultan
detect
eight
differ
agent
develop
far
design
optimis
realtim
pcr
taqmanassay
detect
bacillu
anthraci
burkholderia
pseudo
mallei
brucella
ssp
francisella
tularensi
yersinia
pesti
coxiella
burnetii
orthopoxvirus
base
differ
chromosom
target
pathogen
primer
probe
lyophilizi
plate
use
total
test
dna
sampl
includ
minimum
dna
sampl
eight
biolog
agent
respect
assay
test
specif
limit
detect
lod
find
show
posit
pcr
result
respect
target
bacteria
cross
reaction
close
relat
speci
clinic
relev
bacteri
pathogen
sensit
experi
show
detect
limit
copi
per
reaction
assay
total
design
realtim
pcr
taqman
assay
combin
detect
eight
differ
potenti
bioterror
specimen
one
realtim
pcr
run
assay
easili
handl
lyophilizi
primer
probe
first
time
possibl
detect
highli
virul
pathogen
time
good
detect
limit
analysi
antibiot
toler
staphylococcu
toward
character
aureu
persist
cell
lechner
vulic
k
lewi
r
bertram
imit
lehrbereich
mikrobiel
genetik
eberhard
karl
antimicrobi
discoveri
center
depart
biolog
northeastern
univers
boston
usa
bacteri
cultur
contain
subpopul
dormant
cell
call
persist
nongrow
cell
phenotyp
variant
wild
type
capabl
surviv
kill
bactericid
antibiot
persist
state
revers
dormant
cell
might
expect
form
stochast
growth
cultur
prior
antibiot
exposur
aim
studi
mechan
govern
persist
format
cellular
physiolog
genet
properti
staphylococcu
aureu
toler
differ
plankton
grown
aureu
strain
two
small
coloni
variant
scv
hemb
mend
well
variou
antibiot
test
exponentialor
stationaryphas
antibiot
appli
daptomycin
ciprofloxacin
tobramycin
rifampicin
penicillin
rang
mic
biphas
kill
kinet
highli
indic
persist
cell
observ
stationaryphas
upon
treatment
mic
daptomycin
mend
challeng
mic
tobramycin
timedepend
cfu
analys
reveal
strong
kill
effect
daptomycin
exponenti
grow
scv
kill
retard
tobramycin
treatment
appear
erad
less
effici
scv
cell
challeng
tobramycin
result
scvlike
cell
upon
cultiv
solid
media
result
indic
stationaryphas
cell
antibiot
toler
exponentialphas
cell
due
elev
level
persist
thu
growth
phase
well
strain
background
genotyp
appear
import
factor
format
aureu
persist
cell
crohn
diseas
relev
enterococcu
faecali
trigger
differenti
host
respons
germfre
convent
defici
mice
ig
sava
hrncir
ocvirk
haller
technisch
chair
biofunction
cdd
center
diet
diseas
ziel
research
centr
nutrit
food
scienc
freisingweihenstephan
germani
institut
microbiolog
vvi
dept
immunolog
gnotobiolog
academi
scienc
czech
republ
novi
hradek
czech
republ
background
pattern
recognit
molecul
play
import
role
maintain
intestin
homeostasi
mutat
gene
associ
human
increas
suscept
crohn
diseas
mice
defici
molecul
show
symptom
spontan
intestin
inflamm
underscor
multifactori
etiolog
crohn
diseas
howev
sever
studi
mice
shown
play
import
role
control
composit
intestin
microbiota
regul
express
antimicrobi
peptid
host
defens
sever
intestin
pathogen
yersinia
pseudotuberculosi
citrobact
rodentium
helicobact
hepaticu
involv
enterococci
common
member
intestin
microbiota
develop
intestin
inflamm
alreadi
prove
use
monocolon
enterococcu
faecali
method
one
new
enterococcu
faecali
strain
identifi
screen
fecal
sampl
patient
crohn
diseas
gelatinolyt
activ
specif
pathogen
free
germ
free
oral
infect
either
enterococcu
faecali
wellcharacter
fulli
sequenc
strain
age
week
result
specif
pathogen
free
highli
suscept
oral
inocul
strain
die
within
week
post
infect
mice
infect
strain
well
monocolon
mice
protect
mortal
shortterm
experi
week
mice
infect
follow
signific
weight
loss
elev
level
serumamyloid
blood
high
regul
tnf
gut
conclus
result
clearli
demonstr
link
e
faecali
stain
specif
abil
commens
trigger
diseas
genet
suscept
host
